From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Sarilumab (Anti-Human IL6Rα, HumanAntibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
Anti-PVRIG Antibody (COM701) is a CHO-expressed humanantibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-c-Kit Antibody (LMJ729) (LOP628 antibody) is a CHO-expressed humanantibody that targets SCFR/c-Kit/CD117. The predicted molecular weight (MW) of Anti-c-Kit Antibody (LMJ729) is 150 kDa. The isotype control for Anti-c-Kit Antibody (LMJ729) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PCSK9 Antibody is a humanantibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-BACE1 Antibody is a CHO-expressed humanantibody that targets BACE1. The predicted molecular weight (MW) of Anti-BACE1 Antibody is 145 kDa. The isotype control for Anti-BACE1 Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Hepsin Antibody is a CHO-expressed humanantibody that targets Hepcidin. Anti-Hepsin Antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR20 Antibody (DS-6157 antibody) is a humanantibody expressed in CHO, targeting GPR20. Anti-GPR20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFB Antibody (CSL346) is a CHO-expressed humanantibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-EphB2 Antibody is a CHO expressed humanantibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ABCB5 Antibody is a CHO-expressed humanantibody that targets ABCB5. The Anti-ABCB5 Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ABCB5 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GOLM1 Antibody is a CHO-expressed humanantibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-NOTCH1 Antibody is a CHO-expressed humanantibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-RAMP3 Antibody is a CHO expressed humanantibody that targets RAMP3. The Anti-RAMP3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RAMP3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR7 Antibody is a CHO-expressed humanantibody that targets TLR7. Anti-TLR7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TLR7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-MMP9 Antibody is a CHO-expressed humanantibody that targets MMP9. The Anti-MMP9 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.76 kDa. For the isotype control of the Anti-MMP9 Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-STOP1 Antibody is a humanantibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SLC40A1 Antibody is a human-derived antibody expressed in CHO, targeting SLC40A1. The predicted molecular weight (MW) of Anti-SLC40A1 Antibody is 150 kDa.
Anti-SERPINE1 Antibody is a human-derived antibody expressed in CHO, targeting SERPINE1. The Anti-SERPINE1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SERPINE1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LIF Antibody (MSC-1) is a CHO-expressed humanantibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPSAB1 Antibody is a CHO-expressed humanantibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-PACAP38 Antibody is a humanantibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Hepcidin/HAMP Antibody (LY2787106) is a CHO-expressed humanantibody that targets Hepcidin/HAMP.Anti-Hepcidin/HAMP Antibody (LY2787106) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody (LY2787106) can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-TSHR Antibody (K1-70) is a CHO-expressed humanantibody that targets TSHR. Anti-TSHR Antibody (K1-70) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.54 kDa. For the isotype control of Anti-TSHR Antibody (K1-70), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PTPRC/CD45 Antibody is a CHO-expressed humanantibody that targets PTPRC/CD45. Anti-PTPRC/CD45 Antibody has a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PTPRC/CD45 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed humanantibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL4 Antibody is a CHO expressed humanantibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed humanantibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL8 Antibody is a CHO expressed humanantibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-TNFSF2/TNFa Antibody is a CHO-expressed humanantibody that targets TNFSF2/TNFa. The Anti-TNFSF2/TNFa Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TNFSF2/TNFa Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MSPR/RON/CD136 Antibody is a humanantibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ACVR2B Antibody is a humanantibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CHI3L1 Antibody is a humanantibody expressed in CHO that targets CHI3L1. The Anti-CHI3L1 Antibody contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CHI3L1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed humanantibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-GPR73/PROKR1 Antibody is a CHO-expressed humanantibody that targets GPR73/PROKR1. Anti-GPR73/PROKR1 Antibody features a huIgG4SP heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR73/PROKR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ICAM3/CD50 Antibody is a humanantibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR4/CD184 Antibody is a CHO-expressed humanantibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFSF2/TNFa Antibody (hMAK195) is a humanantibody expressed in CHO cells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL8/IL-8 Antibody is a humanantibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed humanantibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed humanantibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-INHBB/Activin B Antibody is a humanantibody expressed in CHO, targeting INHBB/Activin B. The Anti-INHBB/Activin B Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-INHBB/Activin B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANO1/TMEM16A Antibody is a CHO-expressed humanantibody that targets ANO1/TMEM16A. The Anti-ANO1/TMEM16A Antibody consists of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-ANO1/TMEM16A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed humanantibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CXCL4/PF4 Antibody is a humanantibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CEACAM1/CD66a Antibody is a humanantibody expressed in CHO cells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-DDR1/CD167a Antibody is a CHO-expressed humanantibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHO cells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed humanantibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed humanantibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SCN9a/Nav1.7 Antibody is a humanantibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL12/SDF1a Antibody is a CHO-expressed humanantibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a CHO-expressed humanantibody that targets IL-3Ra/CD123. The predicted molecular weight (MW) of Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is 146.14 kDa. The isotype control for Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-LY75/CD205 Antibody (MEN1309) is a humanantibody expressed in CHO cells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-OX2R/CD200R1 Antibody is a CHO-expressed humanantibody that targets OX2R/CD200R1. The predicted molecular weight (MW) of Anti-OX2R/CD200R1 Antibody is 146.58 kDa. The isotype control for Anti-OX2R/CD200R1 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed humanantibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-B7-H3/CD276 Antibody is a CHO-expressed humanantibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed humanantibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LY2928057 is a CHO-expressed humanantibody that targets SLC40A1/Ferroportin. The predicted molecular weight (MW) of LY2928057 is 150 kDa. The isotype control for LY2928057 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 (TRU-015) is a single-chain Fv antibody, and its predicted molecular weight (MW) is 54.6 kDa. The isotype control for PF-5212374 (TRU-015) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a CHO-expressed humanantibody targeting F3/Factor III/Tissue Factor/CD142. The Anti-F3/Factor III/Tissue Factor/CD142 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-F3/Factor III/Tissue Factor/CD142 Antibody can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CDP-484 is a CHO-expressed humanantibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Adakitug (BMS-986253) is a CHO-expressed humanantibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
R707 is a humanantibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VB1-050 is a humanantibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). For other indications, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MDX-1105 is a humanantibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Alpitatug (IMC 3C5) is a CHO-expressed humanantibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases .
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) .
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
Canakinumab (ACZ885) is a recombinant humananti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
Patritumab (HumanAnti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
FG-3019 (Pamrevlumab) is a recombinant humanantibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
Sonepcizumab (LT 1009) is a fully humananti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
Balekafusp alfa is an IgG1K humanantibody against IL-2 with anti-tumor activity. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration (EC50s for 105 and 253 nM for human tonsillar and pre-B-697-hCXCR5 cells, respectively). VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonal antibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against humandeath receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/humanTYRP1. Anti-Mouse/Human TYRP1 Antibody (TA99) binds to Tyrp1 (tyrosinase related protein-1) on tumor. Anti-Mouse/Human TYRP1 Antibody (TA99) enhances infiltration of the tumor by CD8+ T cells. Anti-Mouse/Human TYRP1 Antibody (TA99) can be used for the research of melanoma .
DCBY02 is a monoclonal antibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
Anti-CLEC4C Antibody is a CHO-expressed humanized antibody that targets CLEC4C. The Anti-CLEC4C Antibody carries a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 150 kDa.
PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .
TRX585 is a humanised anti-immunoglobulin-like transcript 5 (ILT5) monoclonal antibody. TRX585 has a potent immunoregulatory activity. TRX585 significantly activates human T cells and upregulates NKG2D and Fas ligand, followed by enhancing antitumor activity with potent cytotoxicity. TRX585 can be used for viral infections and malignancies research .
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b antibody inhibitor, targeting to GRP78. Anti-Human/Mouse GRP78 Antibody (C38) inhibits RhoA, ROCK and AKT activation. Anti-Human/Mouse GRP78 Antibody (C38) can be used for the researches of cancer and metabolic disease, such as melanoma and diabetes .
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/humanKLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatory T-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to monkey/humanCD28. Anti-Monkey/Human CD28 Antibody (CD28.2) can block CD28 signaling. Anti-Monkey/Human CD28 Antibody (CD28.2) can be used for the research of immunology .
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody. Anti-Mouse/Human CD44 Antibody (IM7) relieves inflammation and induces cell apoptosis by blocking the interaction between CD44 and hyaluronic acid. Anti-Mouse/Human CD44 Antibody (IM7) can be used for research on inflammation conditions and cancer such as arthritis and osteosarcoma .
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/humanCD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically deplete B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis .
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/humanv-H-Ras IgG2a monoclonal antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation .
Anti-Mouse/Human IL-7 Antibody (M25) is an anti-mouse IL-7 IgG2b monoclonal antibody. Anti-Mouse/Human IL-7 Antibody (M25) alleviates inflammation by blocking IL-7 signaling and inhibiting innate lymphoid cells (ILC2s) activation. Anti-Mouse/Human IL-7 Antibody (M25) can reduce the number of B cell precursors. Anti-Mouse/Human IL-7 Antibody (M25) can be used for research on inflammation conditions such as airway inflammation .
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) selectively binds to proteolyzed collagen type I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) reduces PD L1 levels in tumor cells. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) can be used for the researches of cancer and inflammation, such as such as ovarian tumor .
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/humanCD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for research on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/humanMHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for research on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived Osteopontin/SPP1 IgG1, κ type antibody inhibitor. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) blocks Angiotensin II (HY-13948)-induced DNA synthesis and collagen gel contraction in cardiac fibroblasts. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) significantly inhibits tumor growth in CT26 or MC38 tumors mice models .
Anti-Dysadherin Antibody is a humanantibody expressed in CHO cells, targeting dysadherin. Anti-Dysadherin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/humanCD40L/CD154. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) blocks the interactionbetween CD154 and CD40. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) can be used for the researches of inflammation and immunology, such as colitis and transplant .
Anti-EFNA4 Antibody (PF-06647263 antibody) is a humanantibody expressed in CHO cells, targeting EFNA4. Anti-EFNA4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonal antibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a humanantibody expressed in CHO cells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
Anti-MUC17 Antibody is a humanantibody expressed in CHO cells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/humanVLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse/rat/human LRP1/CD91. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) binds to the β chain of LRP1. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) affects intracellular signaling, lipid homeostasis, and clearance of apoptotic cells by blocking LRP1. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) can be used for western blot (WB), immunofluorescence (IF) and other detections .
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
Anti-Clathrin Heavy Chain Antibody is a humanantibody expressed in CHO cells, targeting Clathrin Heavy Chain. Anti-Clathrin Heavy Chain Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TrkB/NTRK2 Antibody is a humanantibody expressed in CHO cells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-EMMPRIN/CD147 Antibody is a humanantibody expressed in CHO cells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-25 Antibody is a humanantibody expressed in CHO cells, targeting IL-25. Anti-IL-25 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (scFv59) is a humanantibody expressed in CHO cells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/humanCCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for research on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
Anti-GLP1R Antibody is a humanantibody expressed in CHO cells, targeting GLP1R. Anti-GLP1R Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody; ADCT-401 antibody) is a human monoclonal antibody (mAb) targeting PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research .
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CD27 Antibody (M2177) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CD27 Antibody (M2191) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-IL11 Antibody (X203) is a human-derived IgG1, κ type antibody inhibitor, targeting to human IL-11 . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
Anti-IL11RA Antibody (X209) is a human-derived IgG4, κ type antibody inhibitor, targeting to human IL-11RA. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CDH17/Cadherin-17 Antibody (10C12) is a humanantibody expressed in CHO cells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24. Anti-CD24 Antibody (SWA11) has anticancer effects, such as lung cancer and ovarian cancer. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. AntibodyAnti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-IL-13 Antibody (C836) is a murine IgG1κ chimeric antibody targeting humanIL-13. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .
Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
KWAR23 is an anti-human SIRPαantibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody (mAb) targeting TROP2. Anti-TROP2 Antibody has an inhibitory effect on multiple tumor cell lines in vitro. Anti-TROP2 Antibody has anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX models .
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for humanActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-LGR5/GPR49 Antibody (18G7H6A3) is a human monoclonal antibody (mAb) targeting LGR5/GPR49. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonal antibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-NGF/bNGF Antibody (AS2886401-00) is a human monoclonal antibody (mAb) targeting NGF/bNGF. Anti-NGF/bNGF Antibody (AS2886401-00) inhibits cytosolic Ca 2+ influx. Anti-NGF/bNGF Antibody (AS2886401-00) produces a long-lasting analgesic effect on pain during exercise in a rat model of OA. Anti-NGF/bNGF Antibody (AS2886401-00) can be used in Osteoarthritis research .
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
MDX-1411 is a fully human monoclonal antibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .
Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody that targets Dectin-1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD133/PROM1 Antibody (CMab-43) is a human IgG2a monoclonal antibody (mAb) targeting PROM1/CD133. Anti-CD133/PROM1 Antibody (CMab-43) can be used in colon cancer research .
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
Anti-CD4 Antibody (Hu5A8) is a humanized IgG4 monoclonal antibody that targets CD4. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Secukinumab (Anti-Human IL-17A) is a fully humananti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis .
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Cergutuzumab is a fully human IgG1 antibody that targets CEACAM5. The isotype control for Cergutuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanAnti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets humanCD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
x
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes .
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
VIS-410 is a fully human IgG1 antibody that targets influenza A virus. The isotype control for VIS-410 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) targeting CDH3/P-cadherin. CQY684 stabilizes the X-dimer of P-cadherin, promoting its endocytosis and directing it to lysosomal degradation. CQY684 can be used in Breast, esophageal, and head and neck cancers research .
Cilgavimab (AZD-1061; COV2-2130) is a humanSARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonal antibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
GB-0895 is a human monoclonal antibody (mAb) targeting TSLP. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
FF-21101 is a human IgG1 monoclonal antibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
NI-301 is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research .
Relatlimab (BMS-986016) is a human monoclonal antibodyanti-LAG-3antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind to FcγRIa and FcγRIIa, leading to the formation of antidrug antibodies (ADA). AMG-966 can be used in Crohn's disease and Ulcerative colitis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
Gimsilumab (MORAb-022) is a humananti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
Golocdacimab (MEDI6570) is a fully humananti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential to be used in the treatment of type 2 diabetes .
TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .
GSK-315234 is a human IgG1 monoclonal antibody (mAb) targeting OSM . GSK-315234 can be used in the study of atherosclerosis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
hCBE-11 is a human monoclonal antibody (mAb) targeting TNFRSF3. hCBE-11 can be used in solid tumors research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
Carlumab (CNTO 888) is a humananti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
Libivirumab (17.1.41) is a humananti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
Evinacumab (REGN1500) is a humananti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Lafuvitug (3BNC-117) is a fully human IgG1 antibody that targets envelope glycoprotein gp120 protein. The isotype control for Lafuvitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
ASN-500 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. ASN-500 can be used in respiratory syncytial virus infection research .
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
Lucatumumab (HCD122) is a fully humananti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
BIIB023 is a human monoclonal antibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research .
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4)human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
Botensilimab (AGEN 1181), a humananti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
Garetatug is a humanized monoclonal antibody targeting humanCLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
Brodalumab (AMG 827) is a humananti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
EVO-46135 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratory syncytial virus infections and Metapneumovirus infections research.
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Lerdelimumab (CAT-152) is an IgG4 humananti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the humanICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
MEDI-8852 is a human IgG1 monoclonal antibody (mAb) targeting influenza A virus hemagglutinin HA. MEDI-8852 can be used in influenza A virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPαantibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
TGTB227 is a human monoclonal antibody (mAb) targeting TIGIT. TGTB227 inhibits the immunosuppressive function of Tregs by reducing the expression of Foxp3 in Tregs. TGTB227 can be used in tumor immunity research .
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
Barecetamab (ISU-104) is a fully humananti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Meplazumab is a human IgG2 monoclonal antibody (mAb) targeting Basigin/CD147. Meplazumab can be used in COVID-19 pneumonia, Coronary artery disease and Malaria research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Bleselumab (ASKP 1240) is a humananti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
ABM-125 is a human IgG anti-IL-25 monoclonal antibody. The isotype control of ABM-125 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 can be used in research related to viral asthma .
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
TATX-21 is a human monoclonal antibody (mAb) targeting ACVRL1/ALK-1. TATX-21 can be used in arterial sclerosis and heart disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .
XmAb-7195 (AIMab-7195) is a human monoclonal antibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
AK-001 is a fully human IgG1 antibody that targets Siglec-8. VRC-01 can be used for the study of chronic rhinosinusitis with nasal polyps. The isotype control for AK-001 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1 .
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
MEDI-1912 is a human monoclonal antibody (mAb) targeting NGF/bNGF. MEDI-1912 inhibits signaling through TrkA and p75 receptors. MEDI-1912 can be used in chronic pain research .
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
Ixotatug is a monoclonal antibody targeting humanCLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .
Laventatug is a humanized monoclonal antibody targeting humanSLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D. Tesnatilimab can be studied in research for diseases such as Crohn’s disease (CD) and Inflammatory Bowel Disease (IBD). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
BAT6026 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. BAT6026 significantly reduces Treg cells and increased CD8+ T cells in tumor .
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
Aprutumab (BAY 1179470) is a fully humanFGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Stromab (DS9231; TS-23; CSL-301) is a human IgG1 monoclonal antibody (mAb) targeting Serpin F2. Stromab can be used in schaemic stroke, Pulmonary embolism, Myocardial infarction and Thrombosis research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
Ramucirumab (anti-VEGFR) is a humanVEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
CHS-114 (SRF-114) is a fully human IgG1 antibody that targets CCR8. CHS-114 has the potential for the study of head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Cosibelimab (CK-301) is a high-affinity, fully humanPD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
GS-8588 is a human bispecific antibody (bsAb) targeting gp120/Glycoprotein 120. GS-8588 induces T cell activation and cytokine secretion in PWH. GS-8588 can be used in AIDS research .
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
Rapaprutug is a monoclonal antibody targeting humanKARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
AMG-211 (MEDI-565) is a human monoclonal antibody (mAb) targeting CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .
ABT-110 is a human monoclonal antibody (mAb) targeting NGF/bNGF. ABT-110 reduces established thermal and mechanical hypersensitivity in the CFA rat model. ABT-110 can be used in persistent/chronic inflammatory pain research .
Claseprubart is a monoclonal antibody targeting humancomplement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases .
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
BTH1704 is a human monoclonal antibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .
AX-202 is a human monoclonal antibody (mAb) targeting S100A4. AX-202 has antifibrotic effects in the mouse Tsk-1 model. AX-202 can be used in Plaque psoriasis and Systemic scleroderma research .
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of diseases related to transthyretin amyloidosis, such as certain neurological and cardiovascular diseases .
Lomtegovimab (BI 767551) is a humananti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
Vixarelimab (KPL-716) is a humananti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
Inlecitug is a chimeric monoclonal antibody targeting humanKDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) .
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
Tabalumab (LY2127399) is a humananti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
PE0116 is a fully humanCD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
VRC-01 is a fully human IgG1 antibody that targets envelope glycoprotein gp120 Protein. VRC-01 blocks viral entry by partially mimicking the interaction of the CD4 receptor with HIV-1 gp120 envelope glycoprotein. The isotype control for VRC-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RSM-01 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. RSM-01 has anti-respiratory syncytial virus (RSV) activity. VIR-7229 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .
Iratumumab (MDX-060) a humananti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
Durvalumab (MEDI 4736) is an humananti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
Robatumumab (Sch 717454) is an anti-humanIGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
Cudarolimab (IBI101) is a completely humananti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
HFB-100204 is a human monoclonal antibody (mAb) targeting CXCR5. HFB-100204 reduces CXCR5+ immune cells, including B cells and Tfh cells, in the blood and spleen of hCXCR5 knockout mice. HFB-100204 can be used in autoimmune diseases research .
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream signaling cascades and increases neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 can be used in Alzheimer's disease (AD) research .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
Briakinumab (ABT-874) is a fully humananti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
ST2485 is a monoclonal antitenascinantibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
Latozinemab (AL001) is a recombinant humananti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to humanTrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for research on inflammatory and chronic pain .
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Ofatumumab is a fully humananti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
LASN01 is a human IgG1 monoclonal antibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PLGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
S-531011 is a human IgG1 monoclonal antibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
NP137 is a human IgG1 monoclonal antibody (mAb) targeting Netrin-1. NP137 inhibits the binding of netrin-1 to its receptor UNC5H2 (IC50: 0.5 nM). NP137 activates caspase 3 to induce apoptosis. NP137 can be used in solid tumors and hematologic malignancies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
FB-825 is a human monoclonal antibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research .
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 attenuates pulmonary neutrophilia, inflammatory cytokine release and signs of endothelial injury in bronchoalveolar lavage and serum samples. GSK1995057 can be used in Acute lung injury and Adult respiratory distress syndrome research. Recommended isotype control: dAb (VHH-His) .
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
CR-8020 is a human IgG1 antibody that targets influenza A virus H3N2. CR-8020 binds to hemagglutinin (HA) of H3N2 strains with IC50s of 3.36 nM and 0.06 nM for A/Brisbane/10/2007 and A/Wyoming/3/2003, respectively. The isotype control for CR-8020 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
TXB4 (PPMX-T003) is a human monoclonal antibody (mAb) targeting CD71. JST-TfR09 can induce ferroptosis by reducing ferritin levels in ATLL cell lines, increasing the generation of ferrous iron and reactive oxygen species (ROS), and inducing lipid peroxidation via malondialdehyde. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
SBT-100 is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 has tumor growth inhibitory effects on MDA-MB-231 .
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity .
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) .
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used in Multiple sclerosis and Sjogren's syndrome research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to humanmyostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
Eldelumab (BMS-936557) is a humananti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Durvalumab (anti-PD-L1)(MEDI 4736) is a humananti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting humanDll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
Ogalvibart (C-135-LS) is a humananti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
Cixutumumab (IMC-A12) is a humananti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
Suvratoxumab (MEDI4893) is a long-acting, high-affinity humananti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
NI-1201 is a monoclonal antibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R .
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
HGS101 is a fully human CCR5 monoclonal antibody with high affinity to CCR5. HGS101 binds to the 2nd extracellular loop (ECL-2) and acts as a signal antagonist. HGS101 restores Maraviroc (HY-13004) inhibition of Maraviroc-resistant HIV-1 infection of PBMCs. HGS101 shows anti-HIV activity by inhibiting CCR5 signaling in simian immunodeficiency virus-uninfected RMs models .
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies .
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA)antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibit the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (Ki: 0.9 nM). KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3). KD014 can be used in breast cancer research .
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting PRLR/Prolactin Receptor. XOMA-213 inhibits hPRL-dependent growth of BaF3/hPRLR cells (EC50: 0.5 μg/mL). XOMA-213 inhibits PRLR signaling and tumor growth in the Nb2-11-luc xenograft mouse model and the DMBA-induced rat breast cancer model. XOMA-213 can be used in Breast cancer, Hyperprolactinaemia and Prostate cancer research .
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
Anti-IGFBP2 Antibody (M14) is an humananti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
1D09C3 is a fully humananti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) [1] [2] [3] .
GC1118 (GC-1118A) is a fully humananti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).
Azintuxizumab is an anti-SLAMF7human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines .
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
Amivantamab (JNJ-61186372) is a humanEGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanE-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to humanc-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to humanCD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanBRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to humanCD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease .
Semzuvolimab is a human IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Human CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to humanIFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGlycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to humanCD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanTROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanIL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanCD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanMHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanCD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a κ chimeric antibody, targeting to humanCD44. Anti-CD44 Antibody (Hermes-1) blocks the binding of hyaluronan to CD44. Anti-CD44 Antibody (Hermes-1) restores (Platelet-derived Growth Factor-BB)-induced β-receptor activation and motility in fibroblasts. Anti-CD44 Antibody (Hermes-1) causes partial loss of the anti-aging effect of hyaluronic .
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17Fantibodies, IL-17A/Fantibodies, and serum albumin VHHantibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanc-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets humanCD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to humanIL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
Cusatuzumab is a humanαCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
Anti-IL-12 p70 Antibody (20C2) is an anti-humanIL-12 p70 IgG1 monoclonal antibody. Anti-IL-12 p70 Antibody (20C2) can inhibit the production of IFN-γ. Anti-IL-12 p70 Antibody (20C2) can be used for research on inflammation conditions. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to humanMUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC)(Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
Codrituzumab (GC33) is a humanized monoclonal antibody targeting humanGPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
Anti-CD8α Antibody (OKT-8) is an anti-humanCD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for research on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific humananti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-humanCD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully humananti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a humananti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
Glembatumumab vedotin (CDX-011) is an ADC(antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
Ozuriftamab is a humanIgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to humanCD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
Vilamakitug (XB-2001) is an anti-IL-1αhuman IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Ciduvectamig is an anti-CD3E/TMEFF2human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Motavizumab (MEDI-524) is an anti-humanRSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domainantibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).
Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
Miptenalimab (BI-754111) is an anti-humanLAG-3antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ADC Control Human IgG1-SN-38 is an isotype control of ADC Human IgG1-SN-38. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946).
Mecbotamab vedotin (BA301) is an IgG1 antibody inhibitor of anti-(human tyrosine kinase receptor AXL) (human-Mus musculus monoclonal BA301 γ1-chain). Mecbotamab vedotin can be used to make immunoconjugates for Methods of Axl-expressing cancers research .
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
Palverafusp alfa is an VEGFA/PDCD1-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the humananti-guanylate cyclase C (GCC)antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
Iparomlimab is an anti-humanPD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the humancomplement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
(R)-TCB2 is the R-enantiomer of TCB2. TCB2 is a potent anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity .
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528) .
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Teplizumab (MGA-031) is a Fc receptor non-binding anti-humanCD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
Trastuzumab vedotin (MRG002) is an anti-humanepidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer .
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer .
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells .
5-Lipoxygenase blocking peptide (Human/rat 5-LO 130-149) is a specific sequence fragment of 5-lipoxygenase (5-LOX), which can be utilized to prepare an antibody against 5-LOX .
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of humanIL-17A to IL-17R.
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes .
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting humanEGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
Ramantamig is a humanized monoclonal antibody targeting humanCD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
Olinvacimab (TTAC-0001) is a fully humananti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
HY-P990983 is an IL4RA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of humanHER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Human IL10 mRNA encodes the human interleukin 10 (IL10) protein, a cytokine that produces primarily by monocytes and to a lesser extent by lymphocytes. IL10 has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production.
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
Osemitamab is an IgG1 antibody targeting to humanclaudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to humanEpCAM and humanCD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully humananti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Glucocorticoid receptor agonist-4 Ala-Ala-Mal (Compound Preparation 9) is an anti-humanTNFαantibody-glucocorticoid receptor agonist (GC) conjugate. Glucocorticoid receptor agonist-4 Ala-Ala-Mal can be used in the study of autoimmune and inflammatory diseases .
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
Glucocorticoid receptor agonist-3 Ala-Ala-Mal (Compound Preparation 8) is an anti-humanTNFαantibody-glucocorticoid receptor agonist (GC) conjugate. Glucocorticoid receptor agonist-3 Ala-Ala-Mal can be used in the study of autoimmune and inflammatory diseases .
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
JNJ-70218902 is a bispecific antibody that binds to humanTMEFF2 on cancer cells and to humanCD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
ISB2001 is a human trispecific antibody (tsAb) targeting CD38 & CD3 & BCMA. BI-765423 can be used in relapsed/refractory multiple myeloma (RRMM) research. Recommended isotype control: IgG1-kappa-IgG1-Fab .
NLRP3 agonist 3 (Compound Payload 5) is an antibody-drug conjugate (ADC). NLRP3 agonist 3 is a NLRP3 agonist that induces IL-1β secretion in primary human monocytes. NLRP3 agonist 3 can be used in cancer research .
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting humanGPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to humanCD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
VTSEGAGLQLQK- 13C6, 15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research .
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912). ORM-5029 can be used for study of cancer .
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a humanantibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes .
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
Runimotamab (RG-6194) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ABI793 is a human IgG1 antihuman CD154 (CD40 ligand) monoclonal antibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 74.5 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against humanCD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
Atrosab is a humanized IgG1 antagonistic anti-TNFR1antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for humanIL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
AM-0687 is a selective inhibitor for PI3Kδ with an IC50 of 2.9 nM. AM-0687 decreases the levels of IgG and IgM specific antibodies, inhibits the anti-IgM/CD40L-induced proliferation of human B cell (IC50=0.8 nM) and the phosphorylation of AKT (IC50=0.7 nM), and exhibits anti-inflammatory efficacy .
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a humananti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully humanC4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κantibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and humanTFR1 .
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .
HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody .
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonal antibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
Retavibart is a human respiratory syncytial virus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
2141-V11 is an anti-CD40 agonist antibody with enhanced binding to FcγRIIB. 2141-V11 results in effective tumor-specific T-cell responses in vivo. 2141-V11 can be used for the study of BCG-unresponsive non-muscle invasive bladder cancer .
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
Lyt-200 is a humanized monoclonal antibody targeting Galectin-9. Lyt-200 exhibits potent inhibitory effects on hematological cancer cells and can also be used in combination with methotrexate (HY-14519) for research purposes .
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers .
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection .
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
DS-8895 is an anti-EphA2 monoclonal antibody. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. DS-8895 can be studied in research for advanced solid cancers positive to EphA2 .
SSGJ-608 is a humanized monoclonal antibody targeting IL-17A. SSGJ-608 can be used in the research of autoimmune and inflammatory diseases, such as moderate-to-severe plaque psoriasis .
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
MP196 is a cationic hexapeptide antibiotic targeting the bacterial cytoplasmic membrane, which exerts rapid bactericidal activity by disrupting membrane integrity, inhibiting cell respiration and cell wall synthesis. MP196 is promising for research of drug-resistant bacterial infections .
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. HMBD-001 inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. HMBD-001 is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .
Anti-UNC5B Antibody (YW88) is a monoclonal antibody against UNC5B. Anti-UNC5B Antibody (YW88) can inhibit the binding of Netrin-1 to Unc5B. Anti-UNC5B Antibody (YW88) can be used in research on angiogenesis .
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
ASP5094 is a humanized monoclonal antibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
BTI-322 is a rat monoclonal IgG2b directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
NM-02 is an antibody targeting HER2 with an EC50 value of 1.2 nM. NM-02 binds to domains I and II of HER2-ECD, blocking HER2-related signaling pathways. NM-02 is promising for research of HER2-positive breast cancer .
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric mAbs directed against nonoverlapping EGFR epitopes (mAb992 and mAb1024). Sym004 is ability to mediate rapid EGFR internalization and subsequent degradation of internalized receptors via EGFR cross-linking. Sym004 can be used for the study of metastatic colorectal cancer, head and neck (H&N) and lung cancer .
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA) .
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH). ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels .
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM). Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer .
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer .
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .
RFB4 is a anti-CD22 monoclonal antibody. RFB4 can construct recombinant immunotoxins by fusing with copper green pseudomonas exotoxin (PE38) through disulfide bonds such as RFB4(dsFv)-PE38. RFB4 can be used for research on cancer such as lymphoma .
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for research on cancer or infection such as Malignant Mesothelioma and MERS .
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
Anti-HER3 Antibody (Ab562) is an anti-HER3 monoclonal antibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia .
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study .
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis .
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma .
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer .
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
LAE-102, a monoclonal antibody, is an activin receptor type II-A (ACTRIIA/ACVR2) antagonist. LAE-102 is promising for research of endocrine and metabolic diseases, tumors, and respiratory system diseases .
M701 is a humanized bispecific CD3/EpCAM T-cell engager antibody. M701 effectively kill high EpCAM expressing cancer cells. M701 can be used for the study of malignant ascites and gastric cancer .
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
MHES0488A is a selective humanized antibody that targets HER2 with a KD value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer .
Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury.
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
CM101 is an anti-pathoangiogenic polysaccharide that can be derived from group B streptococcus. CM101 can inhibit inflammatory angiogenesis and accelerate wound healing in mouse models as well as minimizing scarring after spinal cord injury. CM101 also causes rapid tumor neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth and tumor apoptosis .
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for research on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37 monoclonal antibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia .
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis .
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
Enapotamab (Anti-AXL/UFO Reference Antibody) is an AXL/UFO-related antibody that can be used for synthesis of ADC molecule Enapotamab vedotin (HY-P99921) .
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease . The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .
QX-004N (HS-20137) is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). QX-004N is promising for research of immune system diseases and diseases of digestive system .
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
HS-20093 Antibody is an antibody-drug conjugate (ADC) targeting B7-H3. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
Gancotamab (MM-302) is a HER2-targeted antibody with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
TRS-005 Antibody is an antibody that targets CD20-positive tumor cells. TRS-005 Antibody can be used in the synthesis of antibody-drug conjugates (ADCs). TRS-005 Antibody can be used in the study of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) .
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .
FM-303 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). FM-303 is promising for research of immune system diseases and diseases of digestive system .
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc . Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA) .
AMG-529 is a humanized anti-ASGR1 monoclonal antibody that binds to ASGR1 and blocks ligand binding, resulting in dose-induced increases in ALP, a biomarker of ASGR1 inhibition .
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI) .
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .
Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiens monoclonal antibody .
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
Anti-EGFR Antibody (D2C7) is a monoclonal antibody against EGFR. The recombinant immunotoxin D2C7-(scdsFv)-PE38KDEL constructed based on Anti-EGFR Antibody (D2C7) has antineoplastic activity in glioblastoma models .
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
LM-108 is an anti-CCR8 monoclonal antibody. LM-108 selectively depletes tumor-infiltrating targeting tumor-infiltrating regulatory T cells (Tregs). LM-108 can be used for the study of gastric cancer .
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) .
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
MM-111 is a bispecific antibody fusion protein targeting the ErbB2/ErbB3 oncogenic unit. MM-111 blocks activation of the PI3K pro-survival pathway. MM-111 binds to the ErbB2 receptor, which localizes the bispecific molecule to ErbB2 over-expressing tumor cells and promotes binding of the anti-ErbB3 arm to the ErbB3 receptor. MM-111 binding to ErbB3 results in inhibition of ErbB3 signaling by blocking the binding of the ErbB3 physiological ligand heregulin. MM-111 can be used for the study of ErbB2 over-expressing breast tumors .
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models [1] [2] [3] [4] [5] .
BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. BI-836858 is Fc-engineered for increased binding to FcγRIIIa (CD16). BI-836858 has antibody-dependent cellular cytotoxicity (ADCC) activities. BI-836858 can be used for the study of acute myeloid leukemia (AML) .
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). ZL-1102 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
EBI-031 is a humanized antibody inhibitor targeting IL-6. EBI-031 is a nonsteroidal anti-inflammatory inhibitor. EBI-031 has superior biological efficacy in the management of ocular diseases, such as non-infectious uveitis (NIU) and retinal vascular diseases, and other disease including non-uveitic macular edema and diabetic macular edema .
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
Anti-STEAP2 Antibody (AZD0516 antibody) is a selective six-transmembrane epithelial antigen of prostate 2 (STEAP2) inhibitor. Anti-STEAP2 Antibody inhibits the proliferation, migration and invasion of prostate cancer cells by blocking the STEAP2-mediated ERK/MAPK signaling pathway. Anti-STEAP2 Antibody is promising for research of prostate cancer .
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 + macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .
CNTO-860 is a humanized anti-tissue factor monoclonal antibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
AT008 is an anti-GPCR monoclonal antibody that blocks the binding of chemokine ligands to its cell surface receptor CCR4. AT008 can be studied in research for certain haematological and solid cancers.
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer .
CNTO4088 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
Davutamig (REGN-5093) is a humanIgG4-kappa, anti-MET bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .
Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
Eflepedocokin alfa is a recombinant fusion protein. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
Ledelabricin alfa is a human proteoglycan 4 (PRG4) isoform A variant. PRG4 is a joint/boundary lubricant. Ledelabricin Alfa can be used for the research arthropathy .
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
DSTYSLSSTLTLSK TFA is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection . Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .
5-Lipoxygenase blocking peptide (Human/rat 5-LO 130-149) is a specific sequence fragment of 5-lipoxygenase (5-LOX), which can be utilized to prepare an antibody against 5-LOX .
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a humananti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .
HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .
Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .
MCE Protein A Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein A, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG, IgE, IgM.
MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting humanEpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .
Sarilumab (Anti-Human IL6Rα, HumanAntibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
Anti-PVRIG Antibody (COM701) is a CHO-expressed humanantibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Matriptase Antibody is a human-derived antibody expressed in CHO, targeting Matriptase. The Anti-Matriptase Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Matriptase Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-c-Kit Antibody (LMJ729) (LOP628 antibody) is a CHO-expressed humanantibody that targets SCFR/c-Kit/CD117. The predicted molecular weight (MW) of Anti-c-Kit Antibody (LMJ729) is 150 kDa. The isotype control for Anti-c-Kit Antibody (LMJ729) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-BACE1 Antibody is a CHO-expressed humanantibody that targets BACE1. The predicted molecular weight (MW) of Anti-BACE1 Antibody is 145 kDa. The isotype control for Anti-BACE1 Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-EphB4 Antibody is a humanantibody expressed in CHO that targets EphB4. The predicted molecular weight (MW) of the Anti-EphB4 Antibody is 150 kDa. For the isotype control of Anti-EphB4 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-EphA2 Antibody is a human-derived antibody expressed in CHO cells, targeting EphA2. The predicted molecular weight (MW) of the Anti-EphA2 Antibody is 150 kDa. The isotype control for the Anti-EphA2 Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Hepsin Antibody is a CHO-expressed humanantibody that targets Hepcidin. Anti-Hepsin Antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR20 Antibody (DS-6157 antibody) is a humanantibody expressed in CHO, targeting GPR20. Anti-GPR20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PCSK9 Antibody is a humanantibody expressed in CHO, targeting PCSK9. Anti-PCSK9 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PCSK9 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFB Antibody (CSL346) is a CHO-expressed humanantibody that targets VEGFB. Anti-VEGFB Antibody (CSL346) contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-VEGFB Antibody (CSL346) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-EphB2 Antibody is a CHO expressed humanantibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-DLL4 Antibody is a CHO-expressed humanantibody targeting DLL4. The Anti-DLL4 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-DLL4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ABCB5 Antibody is a CHO-expressed humanantibody that targets ABCB5. The Anti-ABCB5 Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ABCB5 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GOLM1 Antibody is a CHO-expressed humanantibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-NOTCH3 Antibody is a CHO-expressed humanantibody that targets NOTCH3. The Anti-NOTCH3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-NOTCH3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-NOTCH1 Antibody is a CHO-expressed humanantibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-ROBO1 Antibody is a CHO-expressed humanantibody that targets ROBO1. The Anti-ROBO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ROBO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-RAMP3 Antibody is a CHO expressed humanantibody that targets RAMP3. The Anti-RAMP3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RAMP3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR7 Antibody is a CHO-expressed humanantibody that targets TLR7. Anti-TLR7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TLR7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-EPOR Antibody is a humanized antibody expressed in CHO, targeting EPOR. The predicted molecular weight (MW) of Anti-EPOR Antibody is 150 kDa. The isotype control for Anti-EPOR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-CXC-ELR Antibody is a human-derived antibody expressed in CHO, targeting CXC-ELR. Anti-CXC-ELR Antibody is equipped with huIgG4SP type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXC-ELR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-MMP9 Antibody is a CHO-expressed humanantibody that targets MMP9. The Anti-MMP9 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.76 kDa. For the isotype control of the Anti-MMP9 Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-PDGFB Antibody (MOR-8457) is a CHO-expressed humanantibody that targets PDGFB. Anti-PDGFB Antibody (MOR-8457) is composed of a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-PDGFB Antibody (MOR-8457) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-PAR2 Antibody is a human-derived antibody expressed in CHO cells, targeting PAR2. The Anti-PAR2 Antibody contains a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-PAR2 Antibody can be referred to as Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-STOP1 Antibody is a humanantibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSPAN8 Antibody is a human source antibody expressed in CHO cells, targeting TSPAN8. The Anti-TSPAN8 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TSPAN8 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SLC40A1 Antibody is a human-derived antibody expressed in CHO, targeting SLC40A1. The predicted molecular weight (MW) of Anti-SLC40A1 Antibody is 150 kDa.
Anti-SERPINE1 Antibody is a human-derived antibody expressed in CHO, targeting SERPINE1. The Anti-SERPINE1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SERPINE1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LIF Antibody (MSC-1) is a CHO-expressed humanantibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPSAB1 Antibody is a CHO-expressed humanantibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-PACAP38 Antibody is a humanantibody expressed in CHO cells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-Hepcidin/HAMP Antibody (LY2787106) is a CHO-expressed humanantibody that targets Hepcidin/HAMP.Anti-Hepcidin/HAMP Antibody (LY2787106) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Anti-Hepcidin/HAMP Antibody (LY2787106) can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CD163 Antibody (OR2805) is a human-origin antibody expressed in CHO, targeting CD163. Anti-CD163 Antibody (OR2805) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CD163 Antibody (OR2805), please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PAR2 Antibody (PAR650097) is a CHO-expressed humanantibody that targets PAR2. Anti-PAR2 Antibody (PAR650097) has a huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 144.1 kDa. The isotype control for Anti-PAR2 Antibody (PAR650097) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSHR Antibody (K1-70) is a CHO-expressed humanantibody that targets TSHR. Anti-TSHR Antibody (K1-70) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.54 kDa. For the isotype control of Anti-TSHR Antibody (K1-70), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PTPRC/CD45 Antibody is a CHO-expressed humanantibody that targets PTPRC/CD45. Anti-PTPRC/CD45 Antibody has a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PTPRC/CD45 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed humanantibody that targets IL-13. Anti-IL-13 Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL4 Antibody is a CHO expressed humanantibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed humanantibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANGPTL8 Antibody is a CHO expressed humanantibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-CD5 Antibody is a human-derived antibody expressed in CHO, targeting CD5. The Anti-CD5 Antibody contains huIgG2 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa.
The Anti-TNFSF2/TNFa Antibody is a CHO-expressed humanantibody that targets TNFSF2/TNFa. The Anti-TNFSF2/TNFa Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TNFSF2/TNFa Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-MSPR/RON/CD136 Antibody is a humanantibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ACVR2B Antibody is a humanantibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IGF-2 Antibody (DX-2647) is a CHO-expressed humanantibody that targets IGF-2. Anti-IGF-2 Antibody (DX-2647) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.78 kDa. The isotype control for Anti-IGF-2 Antibody (DX-2647) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-13 Antibody (M1295) is a human-derived antibody expressed in CHO, targeting IL-13. Anti-IL-13 Antibody (M1295) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-IL-13 Antibody (M1295) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DLL3 Antibody is a humanized antibody expressed in CHO, targeting DLL3. The predicted molecular weight (MW) of the Anti-DLL3 Antibody is 146.36 kDa. The isotype control for the Anti-DLL3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-oxLDL Antibody is a humanized antibody expressed in CHO cells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MUSK Antibody is a humanized antibody expressed in CHO that targets MUSK. The Anti-MUSK Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-MUSK Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Haptoglobin Antibody is a humanized antibody expressed in CHO cells that targets Haptoglobin. The Anti-Haptoglobin Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Haptoglobin Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ERG Antibody is a humanized antibody expressed in CHO, targeting ERG. The Anti-ERG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ERG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXADR Antibody is a humanized antibody expressed in CHO, targeting CXADR. The Anti-CXADR Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXADR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-Mesothelin Antibody is a humanized antibody expressed in CHO that targets Mesothelin. The Anti-Mesothelin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-Mesothelin Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFA Antibody is a humanized antibody expressed in CHO cells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CHI3L1 Antibody is a humanantibody expressed in CHO that targets CHI3L1. The Anti-CHI3L1 Antibody contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CHI3L1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-RGMC/HFE2 Antibody (DISC-0974) is a CHO-expressed humanantibody that targets RGMC/HFE2. The Anti-RGMC/HFE2 Antibody (DISC-0974) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.66 kDa. For the isotype control of the Anti-RGMC/HFE2 Antibody (DISC-0974), please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed humanantibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TM4SF1 Antibody is a CHO-expressed humanantibody that targets TM4SF1. The Anti-TM4SF1 Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TM4SF1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SLAMF6 Antibody (h20F3ec) (SGN-CD352A antibody) is a human-derived antibody expressed in CHO targeting SLAMF6/CD352. Anti-SLAMF6 Antibody (h20F3ec) has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.9 kDa. The isotype control for Anti-SLAMF6 Antibody (h20F3ec) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LAP Antibody is a humanized antibody expressed in CHO cells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Meflin Antibody is a humanized antibody expressed in CHO cells, targeting Meflin. The Anti-Meflin Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Meflin Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLEC7A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-CSF3R/G-CSFR Antibody is a CHO-expressed humanantibody that targets CSF3R/G-CSFR. Anti-CSF3R/G-CSFR Antibody contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CSF3R/G-CSFR Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-TMEFF1/Tomoregulin-1 Antibody is a CHO-expressed humanantibody that targets TMEFF1/Tomoregulin-1. Anti-TMEFF1/Tomoregulin-1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TMEFF1/Tomoregulin-1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GPR73/PROKR1 Antibody is a CHO-expressed humanantibody that targets GPR73/PROKR1. Anti-GPR73/PROKR1 Antibody features a huIgG4SP heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. The isotype control for Anti-GPR73/PROKR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ICAM3/CD50 Antibody is a humanantibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IL-6/IFNb2 Antibody is a CHO-expressed humanantibody that targets IL-6/IFNb2. The Anti-IL-6/IFNb2 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.46 kDa. The isotype control for Anti-IL-6/IFNb2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR4/CD184 Antibody is a CHO-expressed humanantibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFSF2/TNFa Antibody (hMAK195) is a humanantibody expressed in CHO cells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL8/IL-8 Antibody is a humanantibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed humanantibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-BST2/CD317 Antibody is a CHO-expressed humanantibody that targets BST2/CD317. The Anti-BST2/CD317 Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-BST2/CD317 Antibody can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed humanantibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFRSF5/CD40 Antibody is a CHO-expressed humanantibody that targets TNFRSF5/CD40. The Anti-TNFRSF5/CD40 Antibody contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-TNFRSF5/CD40 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CYR61/CCN1 Antibody is a CHO-expressed humanantibody that targets CYR61/CCN1. The Anti-CYR61/CCN1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CYR61/CCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Histone H4 Antibody is a CHO-expressed humanantibody that targets Histone H4. Anti-Histone H4 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Histone H4 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Nogo Receptor/NgR Antibody is a CHO-expressed humanantibody targeting Nogo Receptor/NgR. The Anti-Nogo Receptor/NgR Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-Nogo Receptor/NgR Antibody, you may refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-TMPRSS2 Antibody is a CHO-expressed humanized antibody that targets TMPRSS2. The Anti-TMPRSS2 Antibody features a huIgG1 heavy chain and a huκ light chain, with an expected molecular weight (MW) of 150 kDa. For the isotype control of the Anti-TMPRSS2 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TCR Antibody (NKTT320) is a humanized antibody expressed in CHO, targeting TCR. Anti-TCR Antibody (NKTT320) features huIgG4 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TCR Antibody (NKTT320) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHO cells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD33 Antibody (IMGN-779 antibody) is a CHO-expressed humanized antibody targeting Siglec-3/CD33. Anti-CD33 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.6 kDa. The isotype control for Anti-CD33 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-INHBB/Activin B Antibody is a humanantibody expressed in CHO, targeting INHBB/Activin B. The Anti-INHBB/Activin B Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-INHBB/Activin B Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ANO1/TMEM16A Antibody is a CHO-expressed humanantibody that targets ANO1/TMEM16A. The Anti-ANO1/TMEM16A Antibody consists of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-ANO1/TMEM16A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed humanantibody that targets SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CXCL4/PF4 Antibody is a humanantibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CEACAM1/CD66a Antibody is a humanantibody expressed in CHO cells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CTLA-8/IL-17a Antibody is a humanantibody expressed in CHO, targeting CTLA-8/IL-17a. The Anti-CTLA-8/IL-17a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTLA-8/IL-17a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TNFRSF18/GITR/CD357 Antibody is a CHO-expressed humanantibody targeting TNFRSF18/GITR/CD357. The Anti-TNFRSF18/GITR/CD357 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TNFRSF18/GITR/CD357 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-DDR1/CD167a Antibody is a CHO-expressed humanantibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHO cells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed humanantibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-IGF1R/CD221 Antibody is a CHO-expressed humanantibody that targets IGF1R/CD221. Anti-IGF1R/CD221 Antibody contains huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IGF1R/CD221 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ERBB1/EGFR/HER1 Antibody is a CHO-expressed humanantibody that targets ERBB1/EGFR/HER1. The Anti-ERBB1/EGFR/HER1 Antibody consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-ERBB1/EGFR/HER1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SCN9a/Nav1.7 Antibody is a humanantibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL12/SDF1a Antibody is a CHO-expressed humanantibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD7 Antibody is a humanized antibody expressed in CHO cells, targeting CD7. The Anti-CD7 Antibody is comprised of huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFR/c-Met Antibody is a humanized antibody expressed in CHO, targeting HGFR/c-Met. The Anti-HGFR/c-Met Antibody contains huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFR/c-Met Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD48 Antibody is a humanized antibody expressed in CHO cells that targets CD48. The Anti-CD48 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-CD48 Antibody, you can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-GAD65 Antibody is a humanized antibody expressed in CHO cells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD83 Antibody is a humanized antibody expressed in CHO cells that targets CD83. The Anti-CD83 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.8 kDa. The isotype control for Anti-CD83 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-MAGEA3 Antibody is a humanized antibody expressed in CHO cells that targets MAGEA3. The Anti-MAGEA3 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-MAGEA3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHO cells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-IFNa1 Antibody is a humanized antibody expressed in CHO cells that targets IFNa1. The Anti-IFNa1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.82 kDa. The isotype control for the Anti-IFNa1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (DLX212) is a CHO-expressed humanantibody that targets Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (DLX212) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Amyloid Beta Antibody (DLX212) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHO cells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-21 Antibody is a humanized antibody expressed in CHO cells that targets IL-21. The Anti-IL-21 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.32 kDa. The isotype control for Anti-IL-21 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CAPRIN1 Antibody is a humanized antibody expressed in CHO, targeting CAPRIN1. The Anti-CAPRIN1 Antibody comes with a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CAPRIN1 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHO cells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHO cells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Complement C5aR1 Antibody is a human recombinant antibody expressed in CHO cells, targeting C5AR/C5AR1 /C5R1. Anti-Complement C5aR1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-Complement C5aR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TIE2/CD202b Antibody is a CHO-expressed humanantibody that targets TIE2/CD202b. Anti-TIE2/CD202b Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TIE2/CD202b Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a CHO-expressed humanantibody that targets IL-3Ra/CD123. The predicted molecular weight (MW) of Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is 146.14 kDa. The isotype control for Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CDCP1/CD318 Antibody (38 E11) is a CHO-expressed humanantibody targeting CDCP1/CD318. The Anti-CDCP1/CD318 Antibody (38 E11) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CDCP1/CD318 Antibody (38 E11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-AXL/UFO Antibody (ORY012) is a humanized antibody expressed in CHO cells, targeting AXL/UFO. Anti-AXL/UFO Antibody (ORY012) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.78 kDa. The isotype control for Anti-AXL/UFO Antibody (ORY012) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGF/SF Antibody (TAK-701) is a humanized antibody expressed in CHO, targeting HGF/SF. Anti-HGF/SF Antibody (TAK-701) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 153.8 kDa. The isotype control for Anti-HGF/SF Antibody (TAK-701) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD20 Antibody is a humanized antibody expressed in CHO that targets CD20/MS4A1. The Anti-CD20 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD20 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-IL-20 Antibody is a Chinese hamster ovary (CHO) expressed humanized antibody that targets IL-20. The Anti-IL-20 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-20 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Sphingosine-1-phosphate Antibody is a humanized antibody expressed in CHO cells that targets Sphingosine-1-phosphate. Anti-Sphingosine-1-phosphate Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Sphingosine-1-phosphate Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CRTAM/CD355 Antibody is a humanized antibody expressed in CHO cells, targeting CRTAM/CD355. The Anti-CRTAM/CD355 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CRTAM/CD355 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHO cells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-LY6E Antibody (MLYE4489A) (RG-7841 antibody) is a humanized antibody expressed in CHO targeting Ly6E. Anti-LY6E Antibody (MLYE4489A) contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-LY6E Antibody (MLYE4489A) can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-LY75/CD205 Antibody (MEN1309) is a humanantibody expressed in CHO cells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-OX2R/CD200R1 Antibody is a CHO-expressed humanantibody that targets OX2R/CD200R1. The predicted molecular weight (MW) of Anti-OX2R/CD200R1 Antibody is 146.58 kDa. The isotype control for Anti-OX2R/CD200R1 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-ERBB1/EGFR/HER1 Antibody (7A7) is a human-derived antibody expressed in CHO cells, targeting ERBB1/EGFR/HER1. Anti-ERBB1/EGFR/HER1 Antibody (7A7) has a muIgG1 heavy chain and an mκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ERBB1/EGFR/HER1 Antibody (7A7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-13 Antibody (H2L6) is a humanized antibody expressed in CHO cells that targets IL-13. Anti-IL-13 Antibody (H2L6) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.16 kDa. The isotype control for Anti-IL-13 Antibody (H2L6) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-DC-SIGN/CD209 Antibody is a CHO-expressed humanized antibody that targets DC-SIGN/CD209. Anti-DC-SIGN/CD209 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DC-SIGN/CD209 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHO cells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-GREM1/Gremlin Antibody is a humanized antibody expressed in CHO that targets GREM1/Gremlin. The Anti-GREM1/Gremlin Antibody has a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GREM1/Gremlin Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
BMS-986021 (BMS-986148 antibody) is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986021 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986021, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-KLK5/Kallikrein 5 Antibody is a CHO-expressed humanantibody that targets KLK5/Kallikrein 5. The Anti-KLK5/Kallikrein 5 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-KLK5/Kallikrein 5 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-B7-H3/CD276 Antibody is a CHO-expressed humanantibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-B7-H4/VTCN1 Antibody is a CHO-expressed humanantibody that targets B7-H4/VTCN1. The Anti-B7-H4/VTCN1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H4/VTCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-100 (Human IgG1) is a humanized IgG1 monoclonal antibody that targets NAMPT. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
The Anti-TNFSF9/4-1BBL Antibody is a CHO-expressed humanized antibody that targets TNFSF9/4-1BBL. The Anti-TNFSF9/4-1BBL Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-TNFSF9/4-1BBL Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHO cells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-VCAM1/CD106 Antibody is a humanized antibody expressed in CHO cells, targeting VCAM1/CD106. The Anti-VCAM1/CD106 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.4 kDa. For the isotype control of the Anti-VCAM1/CD106 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed humanantibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Integrin a11/ITAG11 Antibody is a CHO-expressed humanantibody targeting Integrin a11/ITAG11. The Anti-Integrin a11/ITAG11 Antibody is composed of huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Integrin a11/ITAG11 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-Histone H3 Antibody is a CHO-expressed humanized antibody that targets Histone H3. The Anti-Histone H3 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-Histone H3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHO cells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHO cells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized antibody expressed in CHO cells, targeting ENPP3/CD203c. Anti-ENPP3/CD203c Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 154.04 kDa. The isotype control for Anti-ENPP3/CD203c Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-CEACAM5/CEA/CD66e Antibody is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. The Anti-CEACAM5/CEA/CD66e Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5/CEA/CD66e Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Siglec-2/CD22 Antibody (NCI m971) is a humanized antibody expressed in CHO cells that targets Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (NCI m971) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.64 kDa. The isotype control for Anti-Siglec-2/CD22 Antibody (NCI m971) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-2/CD22 Antibody (NCI m972) is a humanized antibody expressed in CHO, targeting Siglec-2/CD22. The Anti-Siglec-2/CD22 Antibody (NCI m972) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.3 kDa. The isotype control for Anti-Siglec-2/CD22 Antibody (NCI m972) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-PDGFRB/CD140b Antibody (IMC-2C5) is a humanized antibody expressed in CHO cells that targets PDGFRB/CD140b. Anti-PDGFRB/CD140b Antibody (IMC-2C5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.54 kDa. The isotype control for Anti-PDGFRB/CD140b Antibody (IMC-2C5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-B7-H6/NCR3LG1 Antibody is a CHO-expressed humanantibody that targets B7-H6/NCR3LG1. The Anti-B7-H6/NCR3LG1 Antibody features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa.
The Anti-TPBG Antibody (PF-06263507) is a humanized antibody expressed in CHO cells that targets TPBG. PF-06263507 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for PF-06263507 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LY2928057 is a CHO-expressed humanantibody that targets SLC40A1/Ferroportin. The predicted molecular weight (MW) of LY2928057 is 150 kDa. The isotype control for LY2928057 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
GSK-4381562 is a CHO-expressed humanantibody that targets PVRIG. GSK-4381562 carries a huIgG1 heavy chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-4381562 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Integrin b7/ITGB7 Antibody is a CHO-expressed humanized antibody that targets Integrin b7/ITGB7. Anti-Integrin b7/ITGB7 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Integrin b7/ITGB7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Complement Factor P/Properdin Antibody is a humanized antibody expressed in CHO, targeting Complement Factor P/Properdin. Anti-Complement Factor P/Properdin Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Complement Factor P/Properdin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BNC-101 is a human-derived antibody expressed in CHO cells that targets GPR49/LGR5. The predicted molecular weight (MW) of BNC-101 is 150 kDa. The isotype control for BNC-101 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 (TRU-015) is a single-chain Fv antibody, and its predicted molecular weight (MW) is 54.6 kDa. The isotype control for PF-5212374 (TRU-015) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CLN-619 is a humanantibody expressed in CHO that targets MICA. CLN-619 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.06 kDa. The isotype control for CLN-619 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Apamistamab is a CHO-expressed humanantibody that targets PTPRC/CD45. Apamistamab carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.52 kDa. The isotype control for Apamistamab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-578 is a CHO-expressed humanantibody that targets NGF/bNGF. MEDI-578 has a huIgG2a heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-578 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
ANX005 is a human-derived antibody expressed in CHO cells, targeting C1q. ANX005 contains huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for ANX005 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NGM-120 is a CHO-expressed humanantibody that targets GFRAL. NGM-120 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.7 kDa. The isotype control for NGM-120 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AMG-811 is a CHO expressed humanantibody that targets IFNg. AMG-811 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for AMG-811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a CHO-expressed humanantibody targeting F3/Factor III/Tissue Factor/CD142. The Anti-F3/Factor III/Tissue Factor/CD142 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-F3/Factor III/Tissue Factor/CD142 Antibody can be referred to as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHO cells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CDP-484 is a CHO-expressed humanantibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Adakitug (BMS-986253) is a CHO-expressed humanantibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
R707 is a humanantibody expressed in CHO cells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VB1-050 is a humanantibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LY3022855 is a CHO-expressed humanantibody that targets CSF1R/M-CSFR/CD115. LY3022855 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LY3022855 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Atinumab (NG-101) is a CHO-expressed humanantibody that targets RTN4/NOGO. Atinumab (NG-101) carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.62 kDa. The isotype control for Atinumab (NG-101) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Radretumab is a CHO-expressed humanized antibody that targets Fibronectin. Radretumab has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.2 kDa. The isotype control for Radretumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ALT-100 (Human IgG4) is a humanized antibody expressed in CHO, targeting NAMPT. ALT-100 (Human IgG4) consists of a huIgG1/huIgG4 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For inflammatory or fibrotic diseases, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003). For other indications, the isotype control for ALT-100 (Human IgG4) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
CDX-1401 is a CHO-expressed human-derived antibody targeting LY75/CD205/DEC-205. CDX-1401 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CDX-1401 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MDX-1105 is a humanantibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
IMC-C103C is a humanantibody expressed in CHO cells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LY3022859 (IMC-TR1) is a CHO-expressed humanantibody that targets TBFbR2. LY3022859 (IMC-TR1) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 143 kDa. The isotype control for LY3022859 (IMC-TR1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
FR104 is a humanized antibody expressed in CHO cells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
NGM-313 is a CHO-expressed humanantibody targeting Klotho Beta. NGM-313 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for NGM-313 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
DFRF4539A (RG-7598) is a human-derived antibody expressed in CHO that targets FcRH5/IRTA2/CD307e. DFRF4539A (RG-7598) carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DFRF4539A (RG-7598) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NGM-621 is a CHO-expressed humanantibody that targets Complement C3. NGM-621 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.04 kDa. The isotype control for NGM-621 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LY2525623 is a humanized antibody expressed in CHO targeting IL-23. LY2525623 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for LY2525623 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Torudokimab is a humanized antibody expressed in CHO, targeting IL-33. Torudokimab has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Torudokimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Senlizumab is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Icatolimab is a CHO-expressed humanized antibody targeting BTLA/CD272. Icatolimab contains huIgG4SP type heavy chains and huκ type light chains, with a predicted molecular weight (MW) of 146 kDa. The isotype control for Icatolimab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
ASK-8007 is a humanized antibody expressed by CHO, targeting Osteopontin. ASK-8007 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for ASK-8007 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
KHK-2898 is a humanized antibody expressed in CHO targeting CD98. KHK-2898 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for KHK-2898 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Alpitatug (IMC 3C5) is a CHO-expressed humanantibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
RG-7652 is a humanized antibody expressed in CHO cells, targeting PCSK9. RG-7652 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.88 kDa. The isotype control for RG-7652 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CMAB008 is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. CMAB008 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CMAB008 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ATH3G10 is a humanized antibody expressed in CHO that targets Phosphorylcholine. ATH3G10 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for ATH3G10 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
TOL-101 is a humanized antibody expressed in CHO cells that targets TCR. TOL-101 is composed of huIgG2 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 125.6 kDa. The isotype control for TOL-101 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
RGX-019 is a humanized antibody expressed in CHO cells, targeting MER/MERTK. RGX-019 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for RGX-019 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NTX-1088 is a CHO-expressed humanized antibody that targets PVR/CD155. NTX-1088 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.86 kDa. The isotype control for NTX-1088 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0701 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
ELB-031 is a humanized antibody expressed in CHO, targeting TYRO3. ELB-031 contains a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 143.64 kDa. The isotype control for ELB-031 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ESBA-105 is a humanized antibody expressed in CHO cells, targeting TNFSF2/TNFa. ESBA-105 carries a huIgG1 heavy chain and a huκ light chain, with an anticipated molecular weight (MW) of 145.14 kDa. The isotype control for ESBA-105 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NC-318 (5G-12) is a human-derived antibody expressed by CHO, targeting Siglec-15/CD33L3. NC-318 (5G-12) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.98 kDa. The isotype control for NC-318 (5G-12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
FG-3246 (FOR46) is a humanized antibody expressed in CHO cells that targets CD46. FG-3246 (FOR46) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for FG-3246 (FOR46) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
U3-1784 is a humanized antibody expressed in CHO that targets FGFR4/CD334. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BI-765063 is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4PE type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.36 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
PF-03732010 is a humanized antibody expressed in CHO, targeting CDH3/P-cadherin. PF-03732010 has a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 142.7 kDa. The isotype control for PF-03732010 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
APX-007 is a CHO-expressed humanized antibody that targets IL-6Ra/CD126. APX-007 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for APX-007 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
TTX-030 is a humanized antibody expressed in CHO cells, targeting ENTPD1/CD39. TTX-030 contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for TTX-030 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
PF-06342674 is a CHO-expressed humanized antibody that targets IL-7Ra/CD127. PF-06342674 carries a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.14 kDa. The isotype control for PF-06342674 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-2045 is a humanized antibody expressed in CHO cells that targets IL-4Ra/CD124. MEDI-2045 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-2045 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
BMS-986178 is a humanized antibody expressed in CHO, targeting TNFRSF4/OX40/CD134. BMS-986178 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for BMS-986178 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-3617 is a humanized antibody expressed in CHO cells, targeting Ang2/ANGPT2/Angiopoietin2. MEDI-3617 has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-3617 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
AGS-67E is a humanized antibody expressed by CHO, targeting TSPAN26/CD37. AGS-67E has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.44 kDa. The isotype control for AGS-67E can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MVT-5873 is a humanized antibody expressed in CHO cells, targeting Sialyl-Lewis A. MVT-5873 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for MVT-5873 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases .
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
AMG-820 is a fully human IgG2 antibody that targets CSF-1R. AMG-820 inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-induced receptor activation. The isotype control for AMG-820 can refer to Human IgG2 kappa, Isotype Control (HY-P99002) .
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects .
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
CTX-2026 is a fully humanantibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .
Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
Canakinumab (ACZ885) is a recombinant humananti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
Patritumab (HumanAnti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
FG-3019 (Pamrevlumab) is a recombinant humanantibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
Derlotuximab is a CHO-expressed, scFv-Fc (huIgG1) type chimeric antibody that targets Histone H1. The predicted molecular weight (MW) of Derlotuximab is 145.1 kDa. The isotype control for Derlotuximab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
Sonepcizumab (LT 1009) is a fully humananti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
Balekafusp alfa is an IgG1K humanantibody against IL-2 with anti-tumor activity. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
Mapatumumab (HGS-ETR1) is a fully human IgG2 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration (EC50s for 105 and 253 nM for human tonsillar and pre-B-697-hCXCR5 cells, respectively). VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
Anti-Human/Rat/Fish AChR Antibody (Mab35) is an anti-human/rat/fish AChR IgG1 monoclonal antibody. Anti-Human/Rat/Fish AChR Antibody (Mab35) can attack the AChR of neuromuscular junctions. Anti-Human/Rat/Fish AChR Antibody (Mab35) can be used for the construction of myasthenia gravis models .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against humandeath receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/humanTYRP1. Anti-Mouse/Human TYRP1 Antibody (TA99) binds to Tyrp1 (tyrosinase related protein-1) on tumor. Anti-Mouse/Human TYRP1 Antibody (TA99) enhances infiltration of the tumor by CD8+ T cells. Anti-Mouse/Human TYRP1 Antibody (TA99) can be used for the research of melanoma .
ATN-658 is a mouse-derived IgG antibody expressed in CHO cells that targets PLAUR/uPAR/CD87. ATN-658 contains muIgG1 heavy chain and mκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for ATN-658 can be referenced as Mouse IgG1 kappa, Isotype Control (HY-P99977).
DCBY02 is a monoclonal antibody targeting CD93 expressed in CHO cells. DCBY02 has a heavy chain of the mlgG type and a light chain of the mkappa type, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DCBY02 can be referenced as Mouse IgG1 kappa, Isotype Control.
The Anti-IL-20Ra Antibody is a humanized antibody expressed in CHO that targets IL-20Ra. The predicted molecular weight (MW) of the Anti-IL-20Ra Antibody is 150 kDa.
Anti-CLEC4C Antibody is a CHO-expressed humanized antibody that targets CLEC4C. The Anti-CLEC4C Antibody carries a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 150 kDa.
Anti-LILRB4/ILT3/CD85k Antibody is a CHO-expressed humanized antibody that targets LILRB4/ILT3/CD85k. The predicted molecular weight (MW) of Anti-LILRB4/ILT3/CD85k Antibody is 144.36 kDa.
PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .
TRX585 is a humanised anti-immunoglobulin-like transcript 5 (ILT5) monoclonal antibody. TRX585 has a potent immunoregulatory activity. TRX585 significantly activates human T cells and upregulates NKG2D and Fas ligand, followed by enhancing antitumor activity with potent cytotoxicity. TRX585 can be used for viral infections and malignancies research .
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b antibody inhibitor, targeting to GRP78. Anti-Human/Mouse GRP78 Antibody (C38) inhibits RhoA, ROCK and AKT activation. Anti-Human/Mouse GRP78 Antibody (C38) can be used for the researches of cancer and metabolic disease, such as melanoma and diabetes .
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/humanKLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatory T-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to monkey/humanCD28. Anti-Monkey/Human CD28 Antibody (CD28.2) can block CD28 signaling. Anti-Monkey/Human CD28 Antibody (CD28.2) can be used for the research of immunology .
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody. Anti-Mouse/Human CD44 Antibody (IM7) relieves inflammation and induces cell apoptosis by blocking the interaction between CD44 and hyaluronic acid. Anti-Mouse/Human CD44 Antibody (IM7) can be used for research on inflammation conditions and cancer such as arthritis and osteosarcoma .
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/humanCD20. Anti-Monkey/Human CD20 Antibody (2H7) specifically deplete B cells. Anti-Monkey/Human CD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis .
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/humanv-H-Ras IgG2a monoclonal antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation .
Anti-Mouse/Human IL-7 Antibody (M25) is an anti-mouse IL-7 IgG2b monoclonal antibody. Anti-Mouse/Human IL-7 Antibody (M25) alleviates inflammation by blocking IL-7 signaling and inhibiting innate lymphoid cells (ILC2s) activation. Anti-Mouse/Human IL-7 Antibody (M25) can reduce the number of B cell precursors. Anti-Mouse/Human IL-7 Antibody (M25) can be used for research on inflammation conditions such as airway inflammation .
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) selectively binds to proteolyzed collagen type I. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) reduces PD L1 levels in tumor cells. Anti-Human/Mouse denatured collagen type-I Antibody (XL313) can be used for the researches of cancer and inflammation, such as such as ovarian tumor .
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/humanCD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for research on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/humanMHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .
Anti-Mouse/Human CD11b Antibody (M1/70) is an anti-mouse CD11b IgG2b monoclonal antibody. Anti-Mouse/Human CD11b Antibody (M1/70) can significantly inhibit the adhesion between dendritic cells (DCs) and platelets. Anti-Mouse/Human CD11b Antibody (M1/70) can kill ovarian cancer cells and inhibit their migration. Anti-Mouse/Human CD11b Antibody (M1/70) can alleviate renal fibrosis and inflammation. Anti-Mouse/Human CD11b Antibody (M1/70) can be used for research on inflammation conditions and cancer such as ischemia-reperfusion injury (IRI), thrombotic inflammatory conditions and ovarian cancer .
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc) .
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived Osteopontin/SPP1 IgG1, κ type antibody inhibitor. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) blocks Angiotensin II (HY-13948)-induced DNA synthesis and collagen gel contraction in cardiac fibroblasts. Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) significantly inhibits tumor growth in CT26 or MC38 tumors mice models .
Anti-Dysadherin Antibody is a humanantibody expressed in CHO cells, targeting dysadherin. Anti-Dysadherin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/humanCD40L/CD154. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) blocks the interactionbetween CD154 and CD40. Anti-Monkey/Human CD40L/CD154 Antibody (5C8) can be used for the researches of inflammation and immunology, such as colitis and transplant .
Anti-EFNA4 Antibody (PF-06647263 antibody) is a humanantibody expressed in CHO cells, targeting EFNA4. Anti-EFNA4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
Anti-Tenascin C Antibody (Neuradiab antibody) is a human monoclonal antibody (mAb) targeting Tenascin C. Anti-Tenascin C Antibody can be used in Glioblastoma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a humanantibody expressed in CHO cells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1, κ humanantibody, targeting to humanpan-Glypican. The recommend isotype control of Anti-pan-Glypican Antibody (HS20): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-MUC17 Antibody is a humanantibody expressed in CHO cells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/humanVLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia .
Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse/rat/human LRP1/CD91. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) binds to the β chain of LRP1. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) affects intracellular signaling, lipid homeostasis, and clearance of apoptotic cells by blocking LRP1. Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) can be used for western blot (WB), immunofluorescence (IF) and other detections .
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
Anti-Clathrin Heavy Chain Antibody is a humanantibody expressed in CHO cells, targeting Clathrin Heavy Chain. Anti-Clathrin Heavy Chain Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TrkB/NTRK2 Antibody is a humanantibody expressed in CHO cells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-EMMPRIN/CD147 Antibody is a humanantibody expressed in CHO cells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-25 Antibody is a humanantibody expressed in CHO cells, targeting IL-25. Anti-IL-25 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (scFv59) is a humanantibody expressed in CHO cells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/humanCCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for research on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
Anti-GLP1R Antibody is a humanantibody expressed in CHO cells, targeting GLP1R. Anti-GLP1R Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody; ADCT-401 antibody) is a human monoclonal antibody (mAb) targeting PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research .
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
Anti-PSMA Antibody is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CD27 Antibody (M2177) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2177) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2177) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CD27 Antibody (M2191) is a human monoclonal antibody (mAb) targeting TNFRSF7/CD27. Anti-CD27 Antibody (M2191) inhibits the binding of sCD70 to human CD27 ECD-Fc. Anti-CD27 Antibody (M2191) can be used in the study of anti-tumor immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-IL11 Antibody (X203) is a human-derived IgG1, κ type antibody inhibitor, targeting to human IL-11 . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD71/TfR1 Antibody (JR-141 antibody (uncoupled from iduronate 2-sulfatase)) is a humanized anti-human transferrin receptor (CD71; TfR) antibody. Anti-CD71/TfR1 Antibody is the antibody part of the fusion protein Pabinafusp alfa (HY-P99797). The recommend isotype control of Anti-CD71/TfR1 Antibody: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
Anti-IL11RA Antibody (X209) is a human-derived IgG4, κ type antibody inhibitor, targeting to human IL-11RA. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CDH17/Cadherin-17 Antibody (10C12) is a humanantibody expressed in CHO cells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24. Anti-CD24 Antibody (SWA11) has anticancer effects, such as lung cancer and ovarian cancer. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is an anti-LAMP1 humanized monoclonal antibody. Anti-LAMP1/CD107a Antibody can be used for the antibody part of SAR-428926. AntibodyAnti-LAMP1/CD107a Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-IL-13 Antibody (C836) is a murine IgG1κ chimeric antibody targeting humanIL-13. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .
Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
KWAR23 is an anti-human SIRPαantibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
Anti-F8/Factor VIII Antibody is a CHO-expressed humanantibody that targets F8/Factor VIII. Anti-F8/Factor VIII Antibody has a huIgG4 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-F8/Factor VIII Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody (mAb) targeting TROP2. Anti-TROP2 Antibody has an inhibitory effect on multiple tumor cell lines in vitro. Anti-TROP2 Antibody has anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX models .
Anti-TSHR Antibody (M22) is a humanized IgG1 monoclonal antibody that targets thyrotropin receptor (TSHR). Anti-TSHR Antibody (M22) inhibits the binding of TSH and TSHR. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for humanActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. PF-06478924 can be used in the study of advanced and metastatic solid tumors .
Anti-VSIR/VISTA Antibody (SG7) is a human monoclonal antibody (mAb) targeting VISTA/B7-H5. Anti-VSIR/VISTA Antibody (SG7) inhibits VISTA function and prevents PSGL-1 and VSIG3 from binding to VISTA. Anti-VSIR/VISTA Antibody (SG7) has anti-tumor activity in the mouse B16F10 melanoma model. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-LGR5/GPR49 Antibody (18G7H6A3) is a human monoclonal antibody (mAb) targeting LGR5/GPR49. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD371/CLEC12A Antibody (H6e7) is a human monoclonal antibody (mAb) targeting CD371/CLEC12A. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MB-66 (MAPP-66) is a fully human IgG1 antibody that targets HSV and HIV. MB-66 is a monoclonal antibody film for vaginal application. The isotype control for MB-66 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-NGF/bNGF Antibody (AS2886401-00) is a human monoclonal antibody (mAb) targeting NGF/bNGF. Anti-NGF/bNGF Antibody (AS2886401-00) inhibits cytosolic Ca 2+ influx. Anti-NGF/bNGF Antibody (AS2886401-00) produces a long-lasting analgesic effect on pain during exercise in a rat model of OA. Anti-NGF/bNGF Antibody (AS2886401-00) can be used in Osteoarthritis research .
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody against FGFR3. IMC-D11 can be used for the antibody part of LY3076226. IMC-D11 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors .
MDX-1411 is a fully human monoclonal antibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .
Anti-Dectin-1 Antibody (2M24) is a humanized IgG1 monoclonal antibody that targets Dectin-1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody that targets MST1R. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD133/PROM1 Antibody (CMab-43) is a human IgG2a monoclonal antibody (mAb) targeting PROM1/CD133. Anti-CD133/PROM1 Antibody (CMab-43) can be used in colon cancer research .
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
Anti-CD4 Antibody (Hu5A8) is a humanized IgG4 monoclonal antibody that targets CD4. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Secukinumab (Anti-Human IL-17A) is a fully humananti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis .
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody that targets TREM2. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Cergutuzumab is a fully human IgG1 antibody that targets CEACAM5. The isotype control for Cergutuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Amrecibart is an anti-coagulation factor 11 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanAnti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets humanCD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
x
Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody that targets TM4SF1. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Iluzanebart is a human monoclonal IgG1 antibody and is the agonist antibody for human TREM2 (hTREM2). Iluzanebart improves the survival and function of microglia by activating the TREM2 signaling pathway to compensate for the loss of CSF1R function. Iluzanebart can be used for research of adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP) .
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects .
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes .
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease .
HY-P991007 is an gp120 envelope glycoprotein-targeting IgG1κ type humanantibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
VIS-410 is a fully human IgG1 antibody that targets influenza A virus. The isotype control for VIS-410 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
HY-P990944 is an influenza A virus hemagglutinin HA-targeting IgG1κ type humanantibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) targeting CDH3/P-cadherin. CQY684 stabilizes the X-dimer of P-cadherin, promoting its endocytosis and directing it to lysosomal degradation. CQY684 can be used in Breast, esophageal, and head and neck cancers research .
Cilgavimab (AZD-1061; COV2-2130) is a humanSARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
Anti-CD200R1/OX2R Antibody (I-4P) is a human monoclonal antibody (mAb) targeting CD200R1/OX2R. Anti-CD200R1/OX2R Antibody (I-4P) can be used in solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
GB-0895 is a human monoclonal antibody (mAb) targeting TSLP. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
FF-21101 is a human IgG1 monoclonal antibody (mAb) targeting CDH3/P-cadherin. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
NI-301 is a human monoclonal antibody (mAb) targeting Transthyretin/TTR. NI-301 can be used in Cardiomyopathies and Familial amyloid neuropathy research .
Relatlimab (BMS-986016) is a human monoclonal antibodyanti-LAG-3antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind to FcγRIa and FcγRIIa, leading to the formation of antidrug antibodies (ADA). AMG-966 can be used in Crohn's disease and Ulcerative colitis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CEACAM5 Antibody (A5B7) is a humanized antibody expressed in CHO cells, targeting CEACAM5/CEA/CD66e. Anti-CEACAM5 Antibody (A5B7) consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CEACAM5 Antibody (A5B7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
Gimsilumab (MORAb-022) is a humananti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA) .
BAT5906 is a human monoclonal antibody (mAb) targeting VEGFA. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
Golocdacimab (MEDI6570) is a fully humananti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential to be used in the treatment of type 2 diabetes .
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
TBL-100 is a human monoclonal antibody (mAb) targeting Tau. TBL-100 can be used in Alzheimer's disease (AD) and Progressive supranuclear palsy research .
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .
GSK-315234 is a human IgG1 monoclonal antibody (mAb) targeting OSM . GSK-315234 can be used in the study of atherosclerosis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
hCBE-11 is a human monoclonal antibody (mAb) targeting TNFRSF3. hCBE-11 can be used in solid tumors research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer .
Carlumab (CNTO 888) is a humananti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
Libivirumab (17.1.41) is a humananti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
Evinacumab (REGN1500) is a humananti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Lafuvitug (3BNC-117) is a fully human IgG1 antibody that targets envelope glycoprotein gp120 protein. The isotype control for Lafuvitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
IMP-761 is a human IgG4 monoclonal antibody (mAb) targeting CD223/LAG3. IMP-761 binds to D1 of human LAG32. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Linavonkibart (SRK 181) is a high-affinity, fully humanantibody that selectively binds to latent TGFβ1 and inhibits its activation. Linavonkibart plays an important role in cancer .
XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
ASN-500 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. ASN-500 can be used in respiratory syncytial virus infection research .
UBX2050 is a human monoclonal antibody (mAb) targeting TIE2. UBX2050 can be used in Age-related macular degeneration, Diabetic macular oedema and Diabetic retinopathy research .
IN-002 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. IN-002 can be used in respiratory syncytial virus (RSV) infections research.
AGEN-1571 is a human IgG1 monoclonal antibody (mAb) targeting ILT2. AGEN-1571 promotes adaptive and innate immune responses. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001)
NMC-001 is a human IgG1 monoclonal antibody (mAb) targeting MDM2. NMC-001 can be used in pancreatic cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research .
Lucatumumab (HCD122) is a fully humananti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
BIIB023 is a human monoclonal antibody (mAb) targeting TNFRSF12A/TWEAKR/CD266. BIIB023 can be used in lupus nephritis and rheumatoid arthritis research .
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4)human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
EVO-46120 is a human monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. EVO-46120 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research.
Botensilimab (AGEN 1181), a humananti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
Garetatug is a humanized monoclonal antibody targeting humanCLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
Brodalumab (AMG 827) is a humananti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
EVO-46135 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. EVO-46135 can be used in Respiratory syncytial virus infections and Metapneumovirus infections research.
AT-1413 is a human monoclonal antibody (mAb) targeting CD43. AT-1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) in melanoma cell lines and acute myeloid leukemia (AML) cells. AT-1413 has antitumor activity in AML mouse models. AT-1413 can be used in Acute myeloid leukaemia, Breast cancer, Malignant melanoma and Myelodysplastic syndromes research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ADI-65534 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65534 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ADI-15878 is a human IgG monoclonal antibody (mAb) targeting Envelope glycoprotein, GP2. ADI-15878 can be used in Ebola virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
19G9 is a humanantibody expressed in CHO, targeting RG1. The predicted molecular weight (MW) of 19G9 is 145 kDa. The isotype control for 19G9 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ADI-65533 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-65533 can be used in Hantavirus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
IDB-002 is a human monoclonal antibody (mAb) targeting F/Fusion glycoprotein F0. IDB-002 can be used in respiratory syncytial virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Lerdelimumab (CAT-152) is an IgG4 humananti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors) .
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the humanICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
GSK2831781 is a human IgG1 monoclonal antibody (mAb) targeting CD223/LAG3. GSK2831781 can be used in the study of ulcerative colitis Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
KHK2823 is a humanized monoclonal anti-human CD123/IL3RA antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). KHK2823 can be used in research related to leukemia .
MEDI-8852 is a human IgG1 monoclonal antibody (mAb) targeting influenza A virus hemagglutinin HA. MEDI-8852 can be used in influenza A virus infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPαantibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
TGTB227 is a human monoclonal antibody (mAb) targeting TIGIT. TGTB227 inhibits the immunosuppressive function of Tregs by reducing the expression of Foxp3 in Tregs. TGTB227 can be used in tumor immunity research .
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
Barecetamab (ISU-104) is a fully humananti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
DNL-919 (TAK-920) is a human IgG1 monoclonal antibody (mAb) targeting TREM-2. DNL-919 can be used in Alzheimer's disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Meplazumab is a human IgG2 monoclonal antibody (mAb) targeting Basigin/CD147. Meplazumab can be used in COVID-19 pneumonia, Coronary artery disease and Malaria research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Bleselumab (ASKP 1240) is a humananti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets NKG2A. Zimistobart can be used for the study of non-small cell lung cancer (NSCLC). The isotype control for Zimistobart can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
ABM-125 is a human IgG anti-IL-25 monoclonal antibody. The isotype control of ABM-125 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 can be used in research related to viral asthma .
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
TATX-21 is a human monoclonal antibody (mAb) targeting ACVRL1/ALK-1. TATX-21 can be used in arterial sclerosis and heart disease research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
PD-360324 is a human monoclonal antibody (mAb) targeting CSF1/M-CSF. PD-360324 can be used in cutaneous lupus erythematosus, pulmonary sarcoidosis and rheumatoid arthritis research .
XmAb-7195 (AIMab-7195) is a human monoclonal antibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
BIIB036 is a human IgG1 monoclonal antibody (mAb) targeting TNFRSF12A/Fn14. BIIB036 inhibits the growth of patient-derived primary colorectal tumors in SCID mice .
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
AK-001 is a fully human IgG1 antibody that targets Siglec-8. VRC-01 can be used for the study of chronic rhinosinusitis with nasal polyps. The isotype control for AK-001 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
VIR-8190 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. VIR-8190 can be used in respiratory syncytial virus (RSV) and metapneumovirus infections research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .
Daretabart is a humanized IgG1K antibody targeting GD2, which can be used for anti-tumor research. The corresponding isotype control is: Human lgG1 kappa, lsotype Control (HY-P99001) .
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1 .
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
MEDI-1912 is a human monoclonal antibody (mAb) targeting NGF/bNGF. MEDI-1912 inhibits signaling through TrkA and p75 receptors. MEDI-1912 can be used in chronic pain research .
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
Ixotatug is a monoclonal antibody targeting humanCLDN6 (claudin-6). Ixotatug specifically binds to CLDN6, interfering with relevant signaling pathways in tumor cells and exerting antitumor activity. Ixotatug is promising for research of cancers .
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .
Laventatug is a humanized monoclonal antibody targeting humanSLC39A6. Laventatug specifically binds to SLC39A6, interfering with the intracellular zinc ion transport process and thus exerting antitumor activity. Laventatug is promising for research of cancers .
Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
ADI-42898 is a human IgG1 monoclonal antibody (mAb) targeting Envelopment polyprotein, M polyprotein. ADI-42898 binds to the Gn/Gc complex and blocks the cell entry of seven HCPS- and HFRS-associated hantaviruses. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D. Tesnatilimab can be studied in research for diseases such as Crohn’s disease (CD) and Inflammatory Bowel Disease (IBD). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
RG-7258 is a human monoclonal antibody (mAb) targeting CRLF2. RG-7258 blocks dendritic cell activation and mast cell cytokine release. RG-7258 reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. RG-7258 can be used in asthma research .
BAT6026 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. BAT6026 significantly reduces Treg cells and increased CD8+ T cells in tumor .
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
Aprutumab (BAY 1179470) is a fully humanFGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
SEA-TGT is a human monoclonal antibody (mAb) targeting TIGIT. SEA-TGT enhances binding to the activating FcγRIIIA while reducing binding to the inhibitory FcγRIIb. SEA-TGT can be used in advanced solid tumors and Lymphoma research .
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Stromab (DS9231; TS-23; CSL-301) is a human IgG1 monoclonal antibody (mAb) targeting Serpin F2. Stromab can be used in schaemic stroke, Pulmonary embolism, Myocardial infarction and Thrombosis research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
Ramucirumab (anti-VEGFR) is a humanVEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
CHS-114 (SRF-114) is a fully human IgG1 antibody that targets CCR8. CHS-114 has the potential for the study of head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
W0180 is a human IgG1 monoclonal antibody (mAb) targeting VISTA/B7-H5. W0180 has the potential to activate T cells. W0180 can be used in solid tumors research .
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Cosibelimab (CK-301) is a high-affinity, fully humanPD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
GS-8588 is a human bispecific antibody (bsAb) targeting gp120/Glycoprotein 120. GS-8588 induces T cell activation and cytokine secretion in PWH. GS-8588 can be used in AIDS research .
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 + T cells .
Rapaprutug is a monoclonal antibody targeting humanKARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases .
AMG-211 (MEDI-565) is a human monoclonal antibody (mAb) targeting CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .
ABT-110 is a human monoclonal antibody (mAb) targeting NGF/bNGF. ABT-110 reduces established thermal and mechanical hypersensitivity in the CFA rat model. ABT-110 can be used in persistent/chronic inflammatory pain research .
Claseprubart is a monoclonal antibody targeting humancomplement C1s. Claseprubart specifically binds to complement C1s to inhibit the activation of the complement system, exerting immunosuppressive activity. Claseprubart is promising for research of autoimmune diseases and inflammation-related diseases .
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
BTH1704 is a human monoclonal antibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research .
VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-β signaling. VPI-2690B can be used in Diabetic nephropathies research .
AX-202 is a human monoclonal antibody (mAb) targeting S100A4. AX-202 has antifibrotic effects in the mouse Tsk-1 model. AX-202 can be used in Plaque psoriasis and Systemic scleroderma research .
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research .
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of diseases related to transthyretin amyloidosis, such as certain neurological and cardiovascular diseases .
Lomtegovimab (BI 767551) is a humananti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
Bocunebart is a humanized monoclonal antibody targeting human adenylate cyclase-activating polypeptide (ADCYAP1). Bocunebart exerts anti-inflammatory activity by specifically binding to ADCYAP1 and inhibiting related inflammatory signaling pathways. Bocunebart is promising for research of inflammation-related diseases .
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .
Firsekibart is an immunoglobulin G4-λ2 monoclonal antibody targeting human interleukin 1β (IL-1β). Firsekibart is promising for research of inflammation-related diseases, such as rheumatoid arthritis and inflammatory bowel disease .
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
Vixarelimab (KPL-716) is a humananti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
Inlecitug is a chimeric monoclonal antibody targeting humanKDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BI-1910 enhances T cell activation and induces CD8 T cell-dependent anti-tumor effects. BI-1910 can be used in solid tumors research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992) .
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
Adezkibart is a human monoclonal antibody immunosuppressant targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Adezkibart is found in the Chinese hamster ovary cell line CHO-K1, which binds to FLT3LG to block the relevant signaling pathway, inhibits the immune response, and exerts immunosuppressive activity. Adezkibart is promising for research of immune-related diseases .
AR-201 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. AR-201 has anti-respiratory syncytial virus (RSV) activity. AR-201 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
Mik-Beta-1 is a human IgG1-kappa anti-IL2RB monoclonal antibody. The isotype control of Mik-Beta-1 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). Mik-Beta-1 can be used in research related to the prevention of allograft rejection .
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR) .
QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases .
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research .
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
MEDI-6469 is a human monoclonal antibody (mAb) targeting TNFRSF4/OX40/CD134. MEDI-6469 targets the OX40 receptor on activated T cells to enhance the immune response against cancer cells. .
Tabalumab (LY2127399) is a humananti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
PE0116 is a fully humanCD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
VRC-01 is a fully human IgG1 antibody that targets envelope glycoprotein gp120 Protein. VRC-01 blocks viral entry by partially mimicking the interaction of the CD4 receptor with HIV-1 gp120 envelope glycoprotein. The isotype control for VRC-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RSM-01 is a human IgG1 monoclonal antibody (mAb) targeting F, Fusion glycoprotein F0. RSM-01 has anti-respiratory syncytial virus (RSV) activity. VIR-7229 can be used in lower respiratory tract illness (LRTI) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VRDN-002 is a human monoclonal antibody (mAb) targeting IGF1R/CD221. VRDN-002 reduces inflammation and proptosis in thyroid eye disease (TED). VPI-2690B can be used in Graves ophthalmopathy research .
Iratumumab (MDX-060) a humananti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
Durvalumab (MEDI 4736) is an humananti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
Robatumumab (Sch 717454) is an anti-humanIGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
Cudarolimab (IBI101) is a completely humananti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
HFB-100204 is a human monoclonal antibody (mAb) targeting CXCR5. HFB-100204 reduces CXCR5+ immune cells, including B cells and Tfh cells, in the blood and spleen of hCXCR5 knockout mice. HFB-100204 can be used in autoimmune diseases research .
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream signaling cascades and increases neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 can be used in Alzheimer's disease (AD) research .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research .
Briakinumab (ABT-874) is a fully humananti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc .
BC011 is a human monoclonal antibody (mAb) targeting TNFRSF1B. BC011 promotes CD8+T cell proliferation and depletes Treg cells, thereby increasing the proportion of effector T cells in the tumor microenvironment. BC011 can be used in tumor Immunity research.
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
Crusekitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A). Crusekitug specifically binds to IL-17A, blocking its signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Crusekitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
ST2485 is a monoclonal antitenascinantibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .
Latozinemab (AL001) is a recombinant humananti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research .
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to humanTrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for research on inflammatory and chronic pain .
TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
REGN-7257 is a humanized monoclonal antibody targeting IL2RG that effectively blocks signaling of all γ-c cytokines. REGN-7257 can be used in the study of aplastic anemia. The corresponding isotype control is: Human IgG4 kappa, Isotype Control (HY-P99003) .
BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Ofatumumab is a fully humananti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. BIIB022 blocks IGF-1 and IGF-2-induced phosphorylation of IGF-1R and downstream substrates. BIIB022 can be used in lung, pancreatic, and colon cancer research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
LASN01 is a human IgG1 monoclonal antibody (mAb) targeting IL-11RA. LASN01 inhibits IGF-1 and IL-11-induced hyaluronic acid (HA) release and TGFβ-stimulated procollagen in orbital fibroblasts. LASN01 can be used in thyroid eye disease (TED) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PLGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity .
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
S-531011 is a human IgG1 monoclonal antibody (mAb) targeting CCR8. S-531011 reduces tumor-infiltrating CCR8+ Tregs and has anti-tumor activity in CT26.WT and EMT6 tumor-bearing mouse tumor models. S-531011 can be used in the study of cancer immunity. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
NP137 is a human IgG1 monoclonal antibody (mAb) targeting Netrin-1. NP137 inhibits the binding of netrin-1 to its receptor UNC5H2 (IC50: 0.5 nM). NP137 activates caspase 3 to induce apoptosis. NP137 can be used in solid tumors and hematologic malignancies research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
RG7287 is an activating antibody inhibitor targeting humanCDCP1. RG7287 prevents the loss of contact inhibition caused by the co-transformation of NIH3T3 cells with CDCP1 and Src in focus formation assays. RG7287 inhibits tumor cell proliferation and leads to a significant reduction in CDCP1 levels .
Anti-MSLN/Mesothelin (h7D9.v3) is a human monoclonal antibody (mAb) targeting MSLN. Anti-MSLN/Mesothelin (h7D9.v3) can be used in ovarian cancer, mesothelioma, and pancreatic cancer research .
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research .
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
AMG 317 is a humanized monoclonal anti-CD124/IL4R/IL-4Rα antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002). AMG 317 can be used in research related to asthma .
FB-825 is a human monoclonal antibody (mAb) targeting IGHE. FB-825 targets the CεmX domain of membrane IgE (mIgE), resulting in the downregulation of mIgE-positive B cells and the production of IgE. FB-825 can be used in Allergic asthma, Atopic dermatitis, Job syndrome and Allergic rhinitis research .
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 attenuates pulmonary neutrophilia, inflammatory cytokine release and signs of endothelial injury in bronchoalveolar lavage and serum samples. GSK1995057 can be used in Acute lung injury and Adult respiratory distress syndrome research. Recommended isotype control: dAb (VHH-His) .
Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
CR-8020 is a human IgG1 antibody that targets influenza A virus H3N2. CR-8020 binds to hemagglutinin (HA) of H3N2 strains with IC50s of 3.36 nM and 0.06 nM for A/Brisbane/10/2007 and A/Wyoming/3/2003, respectively. The isotype control for CR-8020 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
TXB4 (PPMX-T003) is a human monoclonal antibody (mAb) targeting CD71. JST-TfR09 can induce ferroptosis by reducing ferritin levels in ATLL cell lines, increasing the generation of ferrous iron and reactive oxygen species (ROS), and inducing lipid peroxidation via malondialdehyde. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
SBT-100 is a human monoclonal antibody (mAb) targeting STAT3. SBT-100 inhibits IL-6-mediated P-STAT3 nuclear translocation in HEp-2 and PANC-1 cells. SBT-100 has tumor growth inhibitory effects on MDA-MB-231 .
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .
AT002 (CBAS-173, EJ212/007-Cl2-5) is a recombinant human IgG1 monoclonal antibody. AT002 targets the cell surface protein activated leukocyte adhesion molecule (ALCAM)/CD166. AT002 can be used in the research of cancer, autoimmune diseases and inflammatory diseases.
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity .
Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity .
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) .
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used in Multiple sclerosis and Sjogren's syndrome research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to humanmyostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
Eldelumab (BMS-936557) is a humananti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
PF-06835375 is a humanized IgG1 antibody selective against CXCR5 expressed on B cells, Tfh cells, and circulating Tfh-like (cTfh) cells. PF-06835375 can be used for the study of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1].
Durvalumab (anti-PD-L1)(MEDI 4736) is a humananti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
Lecankitug is a humanized monoclonal antibody targeting human interleukin 17A (IL-17A) and interleukin 17F (IL-17F). Lecankitug specifically binds to IL-17A and IL-17F, blocking their signal transduction, thus exerting immunosuppressive and anti-inflammatory activities. Lecankitug is promising for research of autoimmune and inflammatory diseases, such as psoriasis and rheumatoid arthritis .
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting humanDll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
Ogalvibart (C-135-LS) is a humananti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
Cixutumumab (IMC-A12) is a humananti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
Suvratoxumab (MEDI4893) is a long-acting, high-affinity humananti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
NI-1201 is a monoclonal antibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R .
Anti-ERBB3/HER3 (SGP1) is a human monoclonal antibody (mAb) targeting ERBB3/HER3. Anti-ERBB3/HER3 (SGP1) inhibits Neuregulin stimulated growth of cultured breast cancer cells. Anti-ERBB3/HER3 (SGP1) can be used in breast cancer research .
HGS101 is a fully human CCR5 monoclonal antibody with high affinity to CCR5. HGS101 binds to the 2nd extracellular loop (ECL-2) and acts as a signal antagonist. HGS101 restores Maraviroc (HY-13004) inhibition of Maraviroc-resistant HIV-1 infection of PBMCs. HGS101 shows anti-HIV activity by inhibiting CCR5 signaling in simian immunodeficiency virus-uninfected RMs models .
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
Human IgG1 lambda2, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1λ antibody. Isotype control antibodies can help remove non-specific signals from experimental results and assess the accuracy and reliability of the experiment .
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
OM-7D3-B3 is a monoclonal antibody targeting human claudin-1 (CLDN1) (Kd = 4 nM). OM-7D3-B3 blocks the process in which CLDN1 is involved in the entry of hepatitis C virus (HCV) into cells. OM-7D3-B3 is promising for research of HCV infection .
DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research .
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
MAb604.107 is a human monoclonal antibody (mAb) targeting NOTCH1. MAb604.107 inhibits the proliferation and CD34/CD44 expression of primary T-ALL cells. MAb604.107 has anti-tumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. MAb604.107 can be used in T acute lymphoblastic leukemia research .
Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies .
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA)antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (KD = 200 pM, IC50 = 466 pM) in A549 cells and cyno c-Met (KD = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibit the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .
KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (Ki: 0.9 nM). KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3). KD014 can be used in breast cancer research .
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting PRLR/Prolactin Receptor. XOMA-213 inhibits hPRL-dependent growth of BaF3/hPRLR cells (EC50: 0.5 μg/mL). XOMA-213 inhibits PRLR signaling and tumor growth in the Nb2-11-luc xenograft mouse model and the DMBA-induced rat breast cancer model. XOMA-213 can be used in Breast cancer, Hyperprolactinaemia and Prostate cancer research .
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
Anti-IGFBP2 Antibody (M14) is an humananti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .
MP-RM-1 is a selective murine monoclonal antibody inhibitor targeting human epidermal growth factor receptor 3 (ErbB-3). MP-RM-1 blocks the activation of ErbB-3 induced by neuregulin 1 (NRG-1β) and promotes the internalization and degradation of ErbB-3, inhibiting downstream signaling pathways such as PI3K-Akt. MP-RM-1 is promising for research of ErbB-3 highly expressed solid tumors such as breast cancer, melanoma, and prostate cancer .
MSB-0254 is a human monoclonal antibody (mAb) targeting VEGFR2/KDR/CD309. MSB-0254 inhibits the invasion, migration, and vascular mimetic (VM) formation of U251 and primary glioma cells. MSB-0254 inhibits the growth of U251 and GL261 cell transplanted tumors. MSB-0254 reduces the expression of CD34, VEGFR2, Ki67, MMP2, MMP9, and CD34/PAS. MSB-0254 can be used in advanced solid tumors research .
KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .
M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers .
HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
1D09C3 is a fully humananti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL) [1] [2] [3] .
GC1118 (GC-1118A) is a fully humananti-EGFR monoclonal antibody with binding affinity of 0.16 nM (KD) to EGFR. GC1118 displays potent inhibitory effects on high- and low-affinity EGFR ligand-induced signaling. GC1118 shows potent anti proliferative activity in KRAS wild-type and KRAS mutant cells. GC1118 can reach the tumor by crossing both BBB (blood-brain barrier) and BTB (brain-tumor barrier) and shows superior anti-tumor effects in various mice xenograft models. GC1118 can be used for the researches of cancer, such as colorectal cancer .
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
Azintuxizumab is an anti-SLAMF7human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines .
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
Amivantamab (JNJ-61186372) is a humanEGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanE-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to humanc-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to humanCD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-MUC16 Antibody (VK8) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanMUC16. The recommend isotype control of Anti-MUC16 Antibody (VK8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-YB-1 Antibody (21A3) is a kind of mouse IgG1 chimeric antibody, targeting to humanYB-1. The recommend isotype control of Anti-YB-1 Antibody (21A3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanBRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to humanCD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease .
Semzuvolimab is a human IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Human CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to humanIFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD1a Antibody (OKT-6) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD1a. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGlycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to humanCD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-Fy3 Antibody (MIMA-29) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanFy3. The recommend isotype control of Anti-Fy3 Antibody (MIMA-29): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-Ganglioside GD2 Antibody (14G2a) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanGanglioside GD2. The recommend isotype control of Anti-Ganglioside GD2 Antibody (14G2a): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-CD59 Antibody is a CHO-expressed humanized antibody that targets CD59. The Anti-CD59 Antibody has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD59 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADChuman IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanTROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanIL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanCD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanMHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCD40. The recommend isotype control of Anti-CD40 Antibody (G28.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanCD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a κ chimeric antibody, targeting to humanCD44. Anti-CD44 Antibody (Hermes-1) blocks the binding of hyaluronan to CD44. Anti-CD44 Antibody (Hermes-1) restores (Platelet-derived Growth Factor-BB)-induced β-receptor activation and motility in fibroblasts. Anti-CD44 Antibody (Hermes-1) causes partial loss of the anti-aging effect of hyaluronic .
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCEACAM5. The recommend isotype control of Anti-CEACAM5 Antibody (4H11-8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17Fantibodies, IL-17A/Fantibodies, and serum albumin VHHantibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanc-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets humanCD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer .
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).
Anti-CA19-9 Antibody (1116-NS-19-9) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCA19-9. The recommend isotype control of Anti-CA19-9 Antibody (1116-NS-19-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody, targeting to humanCD32/FcγRIIA. The recommend isotype control of Anti-CD32/FcγRIIA Antibody (IV.3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanCTLA-4/CD152. The recommend isotype control of Anti-CTLA-4/CD152 Antibody (BN13): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Bemarituzumab (FUT8-KO) is an anti-FGFR2b monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to humanIL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
Cusatuzumab is a humanαCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
Tacatuzumab is an anti-AFP (alpha-fetoprotein protein) human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-IL-12 p70 Antibody (20C2) is an anti-humanIL-12 p70 IgG1 monoclonal antibody. Anti-IL-12 p70 Antibody (20C2) can inhibit the production of IFN-γ. Anti-IL-12 p70 Antibody (20C2) can be used for research on inflammation conditions. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979) .
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanCEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to humanMUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC)(Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
Codrituzumab (GC33) is a humanized monoclonal antibody targeting humanGPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanNKG2D/CD314. The recommend isotype control of Anti-NKG2D/CD314 Antibody (1D11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-MAGEC2/CT10 Antibody (LX-CT10.5) is a kind of mouse IgG2a, κ chimeric antibody, targeting to humanMAGEC2/CT10. The recommend isotype control of Anti-MAGEC2/CT10 Antibody (LX-CT10.5): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
Anti-CD8α Antibody (OKT-8) is an anti-humanCD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for research on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific humananti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-humanCD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully humananti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a humananti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
Ozuriftamab is a humanIgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-CSF1R/CD115 Antibody (2-4A5-4) is a kind of rat IgG1, κ chimeric antibody, targeting to humanCSF1R/CD115. The recommend isotype control of Anti-CSF1R/CD115 Antibody (2-4A5-4): Rat IgG1 kappa, Isotype Control (HY-P99979).
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to humanCD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to humanGC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to humanCD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Blosozumab (LY2541546) is an anti-Humansclerostin (SOST)antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
Vilamakitug (XB-2001) is an anti-IL-1αhuman IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
Ciduvectamig is an anti-CD3E/TMEFF2human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Motavizumab (MEDI-524) is an anti-humanRSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
Efclarofusp alfa is a CHO-expressed humanized antibody consisting of VEGFR-1 and VEGFR-2 regions fused to human IgG1 Fc. Efclarofusp alfa is an angiogenesis inhibitor .
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
Anti-CD25/IL-2Rα Antibody (7G7B6) is a kind of mouse IgG2a chimeric antibody, targeting to humanCD25/IL-2Rα. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a kind of mouse IgG1 chimeric antibody, targeting to humanLFA-1α/CD11a. The recommend isotype control of Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13): Mouse IgG1 kappa, Isotype Control (HY-P99977).
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domainantibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft .
Anti-TNFRSF21/DR6/CD358 Antibody is a CHO-expressed humanized antibody that targets TNFRSF21/DR6/CD358. The Anti-TNFRSF21/DR6/CD358 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TNFRSF21/DR6/CD358 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
Miptenalimab (BI-754111) is an anti-humanLAG-3antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
Palverafusp alfa is an VEGFA/PDCD1-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the humananti-guanylate cyclase C (GCC)antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .
Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
Iparomlimab is an anti-humanPD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
HY-P990960 is an TIGIT-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the humancomplement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b, κ chimeric antibody, targeting to humanPD-L1/B7-H1. The recommend isotype control of Anti-PD-L1/B7-H1 Antibody (29E.2A3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Teplizumab (MGA-031) is a Fc receptor non-binding anti-humanCD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
HY-P990934 is an KAAG1-targeting IgG1κ type chimeric humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
HY-P990916 is an ganglioside GD2-targeting IgG1κ type chimeric humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells .
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of humanIL-17A to IL-17R.
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
GEN-1053 (BNT-313) is a fully human IgG1 antibody that targets CD27. GEN-1053 binds to CD27 and forms a hexamer upon binding. The isotype control for GEN-1053 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes .
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting humanEGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
Ramantamig is a humanized monoclonal antibody targeting humanCD3ε, GPRC5D, and TNFRSF17 (tumor necrosis factor receptor superfamily member 17)。Ramantamig is promising for research of cancers, especially hematological malignancies such as multiple myeloma .
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
Olinvacimab (TTAC-0001) is a fully humananti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human netrin-5 (NTS5) and programmed death-1 (PD-1). Ledostomig is promising for research of various cancers .
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
HY-P991032 is an TACSTD2/TROP2-targeting IgG1κ type bispecific antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
HY-P990952 is an MASP3-targeting IgG4κ type chimeric humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
HY-P990983 is an IL4RA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of humanHER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer .
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
HY-P990948 is an ITGA4_ITGB7-targeting IgG1κ type chimeric humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
Osemitamab is an IgG1 antibody targeting to humanclaudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to humanEpCAM and humanCD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
Sigvotatug (Biotinylated) is a biotinylated derivative of Sigvotatug (HY-P990764). Sigvotatug (Biotinylated) is a humanized IgG1 κ monoclonal antibody inhibitor against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
Etuptamig is a chimeric monoclonal antibody of immunoglobulin λ-chain-γ1, λ-chain-γ3 targeting human natural killer cell cytotoxicity receptor 1 (NCR1). Etuptamig is promising for research of various cancers .
Procizumab (AK-1967) is a humanized IgG1 antibody that targets dipeptidyl peptidase 3 (DPP3). Procizumab has the potential for the study of sepsis. The isotype control for Procizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully humananti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Ociperlimab is a humanized IgG1 anti-TIGITantibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer .
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
Nesfrotamig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2) and human tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Nesfrotamig is promising for research of cancers, especially in ERBB2-positive related tumor diseases, such as breast cancer and gastric cancer .
JNJ-70218902 is a bispecific antibody that binds to humanTMEFF2 on cancer cells and to humanCD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
ISB2001 is a human trispecific antibody (tsAb) targeting CD38 & CD3 & BCMA. BI-765423 can be used in relapsed/refractory multiple myeloma (RRMM) research. Recommended isotype control: IgG1-kappa-IgG1-Fab .
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
BHQ-880 is a humanized antibody expressed in CHO cells, targeting DKK1. The predicted molecular weight (MW) of BHQ-880 is 142.96 kDa. The isotype control for BHQ-880 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to humanCD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
GSK-2330811 is a humanized IgG1 antibody that targets Oncostatin M (OSM). GSK-2330811 has the potential for the study of diffuse cutaneous systemic sclerosis (dcSSc). The isotype control for GSK-2330811 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
CM-24 is a humanized antibody expressed in CHO cells, targeting CEACAM1/CD66a. The predicted molecular weight (MW) of CM-24 is 145 kDa. The isotype control for CM-24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-3174998 is a humanized IgG1 OX40/TNFRSF4 agonistic monoclonal antibody. GSK-3174998 has the potential for the study of advanced solid tumors. The isotype control for GSK-3174998 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
PY314 is a humanized antibody expressed in CHO, targeting TREM2. PY314 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for PY314 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
ARGX-119 is a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase (MuSK). ARGX-119 can be used for the study of neuromuscular diseases. The isotype control for ARGX-119 can refer to Human IgG1 lambda1, Isotype Control (HY-P99992) .
LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research .
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a humanantibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
Sapelizumab is a CHO-expressed humanized antibody targeting IL-6Ra/CD126. Sapelizumab has a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Sapelizumab can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
Oportuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Oportuzumab contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Oportuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
HY-P990958 is an T cell receptor germline-encoded variable chain Vβ6/β10-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
HY-P990902 is an Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer . The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001)
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
Runimotamab (RG-6194) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
GSK-679586 is a CHO-expressed humanized antibody that targets IL-13. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
IMMU-114 is a CHO expressed humanized antibody that targets HLA-DR. IMMU-114 is composed of huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.1 kDa. The isotype control for IMMU-114 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
ABI793 is a human IgG1 antihuman CD154 (CD40 ligand) monoclonal antibody. ABI793 inhibits immune response by blocking the CD154-CD40 (IC50 = 75 nM) signaling pathway. ABI793 effectively prevents kidney transplant rejection. ABI793 can be used for research on immunological rejection .
SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-570 is a humanized antibody expressed in CHO that targets ICOS/CD278. MEDI-570 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-570 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
Ibritumomab is a mouse antibody expressed in CHO, targeting CD20/MS4A1. Ibritumomab is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Ibritumomab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Galiximab (IDEC-114) is a primatized monoclonal IgG1 antibody targeting CD80. Galiximab variable regions are primatized, and the constant regions are humanized. Galiximab induces antibody-dependent cellular cytotoxicity by blocking CD80-CD28 binding. Galiximab has antitumor activity and can induce apoptosis in tumor cells. Galiximab can be used in the research of relapsed Hodgkin lymphoma and solid tumors .
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
Erlizumab is a CHO-expressed humanized antibody that targets Integrin b2/ITGB2/CD18. Erlizumab is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Erlizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002) .
Vonlerizumab is a CHO-expressed humanized antibody targeting TNFRSF4/OX40/CD134. Vonlerizumab carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. The isotype control for Vonlerizumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 74.5 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
PY159 is a humanized antibody expressed in CHO cells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .
IMA-026 is a humanized antibody expressed in CHO cells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
ICT-01 is a humanized antibody expressed by CHO that targets BTN1A1. ICT-01 has an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.2 kDa. The isotype control for ICT-01 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against humanCD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
Citatuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Citatuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.4 kDa. The isotype control for Citatuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Atrosab is a humanized IgG1 antagonistic anti-TNFR1antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for humanIL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
Hersintuzumab is a CHO-expressed humanized antibody targeting ERBB2/HER2/CD340. Hersintuzumab is equipped with a huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Hersintuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
PDL-241 is a humanized antibody expressed in CHO that targets SLAMF7/CS1. PDL-241 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.38 kDa. The isotype control for PDL-241 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GFB-024 is a CHO-expressed humanized antibody that targets CB1/CNR1. GFB-024 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GFB-024 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
RG-6125 is a humanized antibody expressed in CHO, targeting CDH11/Cadherin-11. RG-6125 has a huIgG2 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for RG-6125 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
STX-100 is a humanized antibody expressed in HEK293 cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully humanC4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κantibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and humanTFR1 .
NEO-201 is a humanized antibody expressed in CHO cells that targets CEACAM6/CD66c. NEO-201 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.48 kDa. The isotype control for NEO-201 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
GSK-3050002 (E-6071) is a CHO-expressed humanized antibody that targets CCL20. GSK-3050002 (E-6071) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GSK-3050002 (E-6071) can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
AB-25E9 is a humanized antibody expressed in CHO, targeting Siglec-15/CD33L3. The predicted molecular weight (MW) of AB-25E9 is 150 kDa. The isotype control for AB-25E9 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHO cells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
ALT-836 (TNX-832) is a humanized antibody expressed in CHO cells, targeting F3/Factor III/Tissue Factor/CD142. ALT-836 (TNX-832) has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for ALT-836 (TNX-832) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research .
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .
Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonal antibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody against the protein F of respiratory syncytial virus (RSV) with an extended half-life. Clesrovimab can bind to the conserved site IV of the RSV F glycoprotein and neutralize various strains containing RSV F. Clesrovimab can be used in the research of RSV diseases .
Retavibart is a human respiratory syncytial virus (RSV) fusion glycoprotein F. Retavibart can be used for antiviral research. Isotype control: Human IgG1 kappa .
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .
TQB2916 is a humanized IgG2 monoclonal antibody agonist targeting CD40. TQB2916 has a significant antitumor activity with CD40 occupancy and immune activation. TQB2916 can be used for advanced solid tumors and lymphomas research .
2141-V11 is an anti-CD40 agonist antibody with enhanced binding to FcγRIIB. 2141-V11 results in effective tumor-specific T-cell responses in vivo. 2141-V11 can be used for the study of BCG-unresponsive non-muscle invasive bladder cancer .
Belantamab (FUT-8 KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT-8 KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
NGM-438 is a humanized IgG1 monoclonal antibody targeting LAIR1. NGM438 reversed collagen-induced immune suppression in myeloid cells and promoted anti-PD1 mAb-driven T cell responses in immune cell-based functional assays .
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
Lyt-200 is a humanized monoclonal antibody targeting Galectin-9. Lyt-200 exhibits potent inhibitory effects on hematological cancer cells and can also be used in combination with methotrexate (HY-14519) for research purposes .
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .
TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers .
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a Kd of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma .
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .
Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection .
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .
Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody targeting EGFR with a KD value of 0.21 nM. Nimotuzumab (powder) is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab (powder), a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
DS-8895 is an anti-EphA2 monoclonal antibody. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. DS-8895 can be studied in research for advanced solid cancers positive to EphA2 .
SSGJ-608 is a humanized monoclonal antibody targeting IL-17A. SSGJ-608 can be used in the research of autoimmune and inflammatory diseases, such as moderate-to-severe plaque psoriasis .
EU-103 is a humanized monoclonal antibody targeting V-Set And Immunoglobulin Domain Containing 4 (VSIG4) with a KD value ranging from 10 −7 and 10 −9. EU-103 blocks the interaction between VSIG4 and CD8+ T cells, promotes the conversion of M2 macrophages into M1 macrophages, induces the proliferation of CD8+ T cells and the secretion of pro-inflammatory cytokines, thereby inhibiting tumor growth. EU-103 is promising for research of cancers, such as bladder cancer, breast cancer, and colon cancer .
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases .
RO-5429083 is a humanized monoclonal antibody inhibitor targeting CD44. RO-5429083 can be used for acute myeloid leukemia (AML) and solid tumors research .
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
MP196 is a cationic hexapeptide antibiotic targeting the bacterial cytoplasmic membrane, which exerts rapid bactericidal activity by disrupting membrane integrity, inhibiting cell respiration and cell wall synthesis. MP196 is promising for research of drug-resistant bacterial infections .
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. HMBD-001 inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. HMBD-001 is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer .
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases .
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .
VIS954 is an anti-APRIL monoclonal antibody. VIS954 can be studied in research for anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA Vasculitis) and IgA nephrophathy .
Anti-UNC5B Antibody (YW88) is a monoclonal antibody against UNC5B. Anti-UNC5B Antibody (YW88) can inhibit the binding of Netrin-1 to Unc5B. Anti-UNC5B Antibody (YW88) can be used in research on angiogenesis .
Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
ASP5094 is a humanized monoclonal antibody against integrin alpha-9. ASP5094 has good safety and tolerability. ASP5094 can be used in the research of diseases such as rheumatoid arthritis .
BTI-322 is a rat monoclonal IgG2b directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .
NM-02 is an antibody targeting HER2 with an EC50 value of 1.2 nM. NM-02 binds to domains I and II of HER2-ECD, blocking HER2-related signaling pathways. NM-02 is promising for research of HER2-positive breast cancer .
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric mAbs directed against nonoverlapping EGFR epitopes (mAb992 and mAb1024). Sym004 is ability to mediate rapid EGFR internalization and subsequent degradation of internalized receptors via EGFR cross-linking. Sym004 can be used for the study of metastatic colorectal cancer, head and neck (H&N) and lung cancer .
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .
BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
BI-655064, a humanised anti-CD40 antibody with has fragment crystallisable (Fc) regions with two mutations that prevent Fc-mediated antibody-dependent or complement-mediated cellular cytotoxicity and platelet activation. BI-655064 can be used for the study of autoimmune disease, such as lupus nephritis and rheumatoid arthritis (RA) .
ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research .
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
ALD1613 is a potent neutralizing monoclonal antibody against adrenocorticotropic hormone (ACTH). ALD1613 neutralizes ACTH-induced signaling and inhibits ACTH-induced cyclic AMP accumulation in a mouse adrenal cell line (Y1) via all five melanocortin receptors. ALD1613 significantly reduces plasma corticosterone levels in wild-type rats. ALD1613 can be used in the study of diseases associated with elevated ACTH levels .
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM). Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer .
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis .
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer .
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma .
RFB4 is a anti-CD22 monoclonal antibody. RFB4 can construct recombinant immunotoxins by fusing with copper green pseudomonas exotoxin (PE38) through disulfide bonds such as RFB4(dsFv)-PE38. RFB4 can be used for research on cancer such as lymphoma .
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for research on cancer or infection such as Malignant Mesothelioma and MERS .
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
Anti-HER3 Antibody (Ab562) is an anti-HER3 monoclonal antibody. Anti-HER3 Antibody (Ab562) can be used to synthesize the antibody-drug conjugate (ADC) AMT-562 (HY-171747) .
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia .
Atigotatug (FUT8-KO) is an anti-fuc-GM1 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out, and fucose deficiency enhances the ADCC effect of the antibody. Atigotatug (HY-P990902) is a Fucosyl ganglioside GM1 (fuc-GM1)-targeting IgG1κ type humanized antibody. Atigotatug can induce immune-mediated tumor cell death, such as small cell lung cancer .
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
MK-4830 is a fully humanized monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to ILT4 and blocks its interaction with HLA-G and other ligands. MK-4830 inhibits tumor growth in humanized mouse cancer models .
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study .
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis .
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma .
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research . The component ratio of this product is Active ingredient: Excipients = 1:1.0-1:1.2.
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
ASKG-712 (AM712) is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein. ASKG-712 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
Ianalumab (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF .
Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer .
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
LAE-102, a monoclonal antibody, is an activin receptor type II-A (ACTRIIA/ACVR2) antagonist. LAE-102 is promising for research of endocrine and metabolic diseases, tumors, and respiratory system diseases .
M701 is a humanized bispecific CD3/EpCAM T-cell engager antibody. M701 effectively kill high EpCAM expressing cancer cells. M701 can be used for the study of malignant ascites and gastric cancer .
OSE-703 is a humanized monoclonal antibody inhibitor targeting interleukin-7 receptor α subunit (IL-7Rα). OSE-703 is promising for research of tumors and respiratory diseases .
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
Alefacept (BG 9273) is a human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein. Alefacept can be used for the research of chronic plaque psoriasis .
MHES0488A is a selective humanized antibody that targets HER2 with a KD value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer .
Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury.
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
ABX-MA1 is a humanized IgG2 monoclonal antibody inhibitor targeting MCAM/MUC18. ABX-MA1 significantly decreases homotypic aggregation and heterotypic adhesion to HUVECs, and the formation of experimental lung metastasis. ABX-MA1 potently inhibits tumor growth, angiogenesis, and MMP-2 expression in A375SM/WM2664 xenograft mice model, promising for melanoma research .
MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
CM101 is an anti-pathoangiogenic polysaccharide that can be derived from group B streptococcus. CM101 can inhibit inflammatory angiogenesis and accelerate wound healing in mouse models as well as minimizing scarring after spinal cord injury. CM101 also causes rapid tumor neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth and tumor apoptosis .
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for research on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
BI-836826 is a IgG1 chimerized and Fc-engineered anti-CD37 monoclonal antibody. BI 836826 displays both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic activities. BI-836826 can be used for the study of chronic lymphocytic leukemia .
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis .
IMM-20059 is humanized IgG1 monoclonal antibody targeting EPN1. IMM-20059 in combination with Atezolizumab (HY-P9904) significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy .
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes .
Enapotamab (Anti-AXL/UFO Reference Antibody) is an AXL/UFO-related antibody that can be used for synthesis of ADC molecule Enapotamab vedotin (HY-P99921) .
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer .
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases .
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies .
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
SM-17 is a humanized monoclonal antibody inhibitor targeting interleukin 25 (IL-25) and interleukin-17 receptor B (IL17RB). SM-17 is promising for research of immune system diseases .
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease . The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .
QX-004N (HS-20137) is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). QX-004N is promising for research of immune system diseases and diseases of digestive system .
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env). VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection .
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
HS-20093 Antibody is an antibody-drug conjugate (ADC) targeting B7-H3. HS-20093 Antibody exhibits anti-tumor activity. HS-20093 Antibody can be studied in research for small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors .
KB002 is a humanized monoclonal antibody inhibitor targeting GM-CSF. KB002 has significant immune activity and can be used for asthma, rheumatoid arthritis and chronic Idiopathic thrombocytopenia purpura (ITP) research .
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
Gancotamab (MM-302) is a HER2-targeted antibody with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
TRS-005 Antibody is an antibody that targets CD20-positive tumor cells. TRS-005 Antibody can be used in the synthesis of antibody-drug conjugates (ADCs). TRS-005 Antibody can be used in the study of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) .
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .
FM-303 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). FM-303 is promising for research of immune system diseases and diseases of digestive system .
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research .
Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc . Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA) .
AMG-529 is a humanized anti-ASGR1 monoclonal antibody that binds to ASGR1 and blocks ligand binding, resulting in dose-induced increases in ALP, a biomarker of ASGR1 inhibition .
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI) .
S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research .
Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
MORAb-028 is a humanized IgG1 monoclonal antibody inhibitor targeting GD2. MORAb-028 has a potent antitumor activity and kills GD2-expressing target cells via complement-mediated cytotoxicity (CDC). MORAb-028 significantly inhibits tumor growth in EL-4-luc xenograft mice model. MORAb-028 can be used for melanoma cancer research .
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)) .
Eflapegrastim is a composite protein consisting of a genetically modified granulocyte-colony stimulating factor (GCSF) molecule linked via a chemical bond to an IgG4 Fc fragment (LAPS-carrier). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiens monoclonal antibody .
SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. SFN68 significantly inhibits HGF/c-Met interaction, c-Met activation, and, cell scattering and proliferation mediated by HGF. SFN68 can be used for cancers research .
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research .
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
Anti-EGFR Antibody (D2C7) is a monoclonal antibody against EGFR. The recombinant immunotoxin D2C7-(scdsFv)-PE38KDEL constructed based on Anti-EGFR Antibody (D2C7) has antineoplastic activity in glioblastoma models .
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .
LM-108 is an anti-CCR8 monoclonal antibody. LM-108 selectively depletes tumor-infiltrating targeting tumor-infiltrating regulatory T cells (Tregs). LM-108 can be used for the study of gastric cancer .
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research .
huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) .
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
MM-111 is a bispecific antibody fusion protein targeting the ErbB2/ErbB3 oncogenic unit. MM-111 blocks activation of the PI3K pro-survival pathway. MM-111 binds to the ErbB2 receptor, which localizes the bispecific molecule to ErbB2 over-expressing tumor cells and promotes binding of the anti-ErbB3 arm to the ErbB3 receptor. MM-111 binding to ErbB3 results in inhibition of ErbB3 signaling by blocking the binding of the ErbB3 physiological ligand heregulin. MM-111 can be used for the study of ErbB2 over-expressing breast tumors .
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models [1] [2] [3] [4] [5] .
BI-836858 is a fully humanized IgG1 anti-CD33 monoclonal antibody. BI-836858 is Fc-engineered for increased binding to FcγRIIIa (CD16). BI-836858 has antibody-dependent cellular cytotoxicity (ADCC) activities. BI-836858 can be used for the study of acute myeloid leukemia (AML) .
IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). ZL-1102 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascular endothelial growth factor (VEGF) inhibitor .
Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
EBI-031 is a humanized antibody inhibitor targeting IL-6. EBI-031 is a nonsteroidal anti-inflammatory inhibitor. EBI-031 has superior biological efficacy in the management of ocular diseases, such as non-infectious uveitis (NIU) and retinal vascular diseases, and other disease including non-uveitic macular edema and diabetic macular edema .
CDX-3379 is a humanized monoclonal antibody inhibitor targeting ErbB3. CDX-3379 binds to ErbB3, blocking the dimerization of ErbB3 with other receptors, thereby inhibiting the phosphorylation of ErbB3. CDX-3379 can inhibit the growth and proliferation of tumor cells. CDX-3379 is promising for research of tumors expressing ErbB3 and NRG1, such as HNSCC .
Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
Anti-STEAP2 Antibody (AZD0516 antibody) is a selective six-transmembrane epithelial antigen of prostate 2 (STEAP2) inhibitor. Anti-STEAP2 Antibody inhibits the proliferation, migration and invasion of prostate cancer cells by blocking the STEAP2-mediated ERK/MAPK signaling pathway. Anti-STEAP2 Antibody is promising for research of prostate cancer .
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 + macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5) .
CNTO-860 is a humanized anti-tissue factor monoclonal antibody. CNTO-860 can improve tumor control when combined with Paclitaxel (HY-B0015) in colon cancer model and significantly increase tumor-free survival .
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
AT008 is an anti-GPCR monoclonal antibody that blocks the binding of chemokine ligands to its cell surface receptor CCR4. AT008 can be studied in research for certain haematological and solid cancers.
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of FGFR2 in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer .
CNTO4088 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). CNTO4088 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
Riliprubart (SAR 445088) is an anti-C1s humanized IgG4 monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a. Riliprubart can be used to study complement-mediated diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
Briquilimab (JSP-191 or AMG-191) is a humanized IgG1 monoclonal antibody that binds human CD117 (c-Kit). Briquilimab blocks the interaction between CD117 receptor and stem cell factor on various CD117 expressing tissues. Briquilimab can lead to inhibition of SCF/c-Kit signaling and MC apoptosis. Briquilimab is a non-toxic approach to target and deplete HSC, enabling blood and immune reconstitution with minimal toxicity with the other agents being used for transient immune suppression to prevent immunologic rejection. Briquilimab can be used in various disease research such as severe combined immunodeficiency (SCID), myelodyplastic syndromes (MDS), acute myeloid leukemia (AML), chronic spontaneous urticarial (CSU), chronic inducible urticarial (CIndU) and asthema .
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
Davutamig (REGN-5093) is a humanIgG4-kappa, anti-MET bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .
Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
Efanesoctocog alfa is a B domain-deleted single-chain Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Efanesoctocog alfa has an extended half-life. Efanesoctocog alfa can be used for the study of inherited hemophilia A .
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
Eflepedocokin alfa is a recombinant fusion protein. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
Ledelabricin alfa is a human proteoglycan 4 (PRG4) isoform A variant. PRG4 is a joint/boundary lubricant. Ledelabricin Alfa can be used for the research arthropathy .
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
Ki67/MKI67 is localized on mitotic chromosomes and maintains its dispersion during nuclear envelope disassembly. It covers a large portion of the chromosome surface and prevents chromatin from collapsing into clumps. Ki67/MKI67 Protein, Human (His) is the recombinant mouse-derived Ki-67(MKI67) protein, expressed by E. coli , with N-6*His labeled tag.
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
VTSEGAGLQLQK- 13C6, 15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .
Myoglobin Antibody (YA925) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA925), targeting Myoglobin, with a predicted molecular weight of 17 kDa. Myoglobin Antibody (YA925) can be used for WB,IHC-P,ICC/IF,IP experiment in human, mouse, rat background.
Parvalbumin Antibody (YA1249) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1249), targeting Parvalbumin. Parvalbumin Antibody (YA1249) can be used for WB, IHC-P, IP experiment in human background.
CATE antibody; CATE_humanantibody; Cathepsin E antibody; Cathepsin E form II antibody; CTSE antibody; Erythrocyte membrane aspartic proteinase antibody; Slow moving proteinase antibody;
WB, IHC-P
Human, Mouse, Rat
CTSE Antibody is a rabbit-derived non-conjugated IgG antibody, targeting CTSE, with a predicted molecular weight of 43 kDa (observed band size: 48 kDa). CTSE Antibody can be used for WB, IHC-P experiments in human, mouse, rat backgrounds.
human IgG Antibody (YA4605) is a mouse-derived and non-conjugated IgG1 antibody, targeting to IgG. It can be applicated for WB, ELISA assays, in the background of human.
Human IgG Antibody (YA4898) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IgG. It can be applicated for WB, ELISA assays, in the background of human.
Human IgM Antibody (YA4900) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IgM. It can be applicated for ELISA assays, in the background of human.
CBP Tag Antibody (YA1314) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1314), targeting CBP tag, with a predicted molecular weight of 4 kDa. CBP Tag Antibody (YA1314) can be used for WB experiment.
BDNF Antibody (YA5778) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BDNF. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Claudin 18.1 Antibody (YA5683) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Claudin 18.1. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Human IgG Fc Antibody (YA4899) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IgG (Fc Specific). It can be applicated for WB, ICC/IF, ELISA assays, in the background of human.
HLA class I antigen antibody;
FLJ36918 antibody;
FLJ60820 antibody;
MGC111087 antibody;
MGC21250 antibody;
MHC class I chain related gene A protein antibody;
MIC A antibody;
micA antibody;
MICA_humanantibody;
OTTHUMP00000029088 antibody;
PERB11.1 antibody;
Stress inducible class I homolog antibody;
MHC class I chain related protein B antibody;
MICB antibody
MICB_humanantibody
PERB11.2 antibody
Stress inducible class I homolog antibody
WB, IP, FC
Human
MICA+MICB Antibody (YA3560) is a rabbit-derived non-conjugated IgG antibody, targeting MICA. MICA+MICB Antibody (YA3560) can be used for WB, FC, IP experiment in human background.
Natriuretic Peptides A Antibody (YA1381) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1381), targeting Natriuretic Peptides A, with a predicted molecular weight of 16 kDa (observed band size: 16 kDa). Natriuretic Peptides A Antibody (YA1381) can be used for WB, IP experiment in human background.
DKFZp686O09161 antibody; MCPH7 antibody; OTTHUMP00000009566 antibody; SCL interrupting locus protein antibody; SCL-interrupting locus protein antibody; SCL/TAL1 interrupting locus antibody; SIL antibody; STIL antibody; STIL_humanantibody; TAL 1 interrupting locus protein antibody; DKFZp686O09161 antibody; MCPH7 antibody; OTTHUMP00000009566 antibody; SCL interrupting locus protein antibody; SCL-interrupting locus protein antibody; SCL/TAL1 interrupting locus antibody; SIL antibody; STIL antibody; STIL_humanantibody; TAL 1 interrupting locus protein antibody; TAL-1-interrupting locus protein antibody
DNA-directed DNA polymerase mu antibody; DNA-directed DNA/RNA polymerase mu antibody; DPOLM_humanantibody; FLJ35482 antibody; Pol iota antibody; Pol Mu antibody; Polm antibody; POLM protein antibody; Polymerase (DNA directed) mu antibody; Polymerase DNA directed mu antibody; DNA-directed DNA polymerase mu antibody; DNA-directed DNA/RNA polymerase mu antibody; DPOLM_humanantibody; FLJ35482 antibody; Pol iota antibody; Pol Mu antibody; Polm antibody; POLM protein antibody; Polymerase (DNA directed) mu antibody; Polymerase DNA directed mu antibody; Tdt N antibody; Tdt-N antibody; TdtN antibody; Terminal transferase antibody
SP7/Osterix Antibody is an unconjugated, approximately 45 kDa, rabbit-derived, anti-SP7/Osterix monoclonal antibody. SP7/Osterix Antibody can be used for: WB, IHC-P, IF-Tissue, IHC-Fr expriments in human, mouse, and rat background without labeling.
human IgG(Fc Specific) Antibody (YA4613) is a mouse-derived and non-conjugated IgG1 antibody, targeting to IgG (Fc Specific). It can be applicated for WB, ICC/IF, ELISA assays, in the background of human.
human IgG (Fc Specific) Antibody (YA4614) is a mouse-derived and non-conjugated IgG1 antibody, targeting to IgG (Fc Specific). It can be applicated for WB, ELISA assays, in the background of human.
Cortactin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 62 kDa, targeting to Cortactin. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.
CXCR3 Antibody (YA3444) is a mouse-derived and phycoerythrin (PE) IgG1 monoclonal antibody, targeting to CD138. It can be applicated for FC assays, in the background of human.
MPO Antibody (YA5574) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MPO. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
ARHG antibody; Ras homolog family member G antibody; Rho G antibody; Rho related GTP binding protein RhoG precursor antibody; Rho-related GTP-binding protein RhoG antibody; RHOG antibody; RHOG_humanantibody
IGCJ antibody;
IGJ_humanantibody;
Immunoglobulin J chain antibody;
Immunoglobulin J polypeptide linker protein for immunoglobulin alpha and mu polypeptides antibody;
immunoglobulin joining chain antibody;
JCH antibody;
JCHAIN antibody;
Joining chain of multimeric IgA and IgM antibody
WB, IHC-P, ICC/IF, FC
Human, Mouse
IGJ Antibody (YA1290) is a non-conjugated IgG antibody, targeting IGJ. IGJ Antibody (YA1290) can be used for WB, IF-Cell, IHC-P, FC experiment in human, mouse background.
AKT 1 antibody; AKT antibody; AKT1 antibody; AKT1_humanantibody; MGC99656 antibody; PKB antibody; PKB-ALPHA antibody; PRKBA antibody; Protein Kinase B Alpha antibody; Protein kinase B antibody; Proto-oncogene c-Akt antibody; RAC Alpha antibody; RAC antibody; RAC-alpha serine/threonine-protein kinase antibody; RAC-PK-alpha antibody
WB, ICC/IF, IHC-P
Human, Mouse, Rat, Dog
Phospho-Akt1(Ser473) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to Phospho-Akt1(Ser473). It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Mouse, Rat, Dog.
372 kDa Golgi complex-associated protein antibody;
GCP antibody;
GCP372 antibody;
Giantin antibody;
GOGB1_humanantibody;
GOLGB1 antibody;
Golgin B1 antibody;
Golgin B1, golgi integral membrane protein antibody;
Golgin subfamily B member 1 antibody;
GOLIM1 antibody;
Macrogolgin antibody;
MGC33154 antibody
WB, IHC-P, ICC/IF, FC
Human, Mouse, Rat, Monkey
Giantin Antibody (YA6864) is a Rabbit-derived and non-conjugated IgG antibody, targeting to Giantin. It can be applicated for WB, IF-Cell, IHC-P, FC assays, in the background of Human, Mouse, Rat, Monkey.
COI antibody; COX I antibody; COX1 antibody; COX1_humanantibody; COXI antibody; Cytochrome c oxidase polypeptide I antibody; Cytochrome c oxidase subunit 1 antibody; Cytochrome C Oxidase subunit I antibody; Mitochondrially encoded cytochrome c oxidase I antibody; MT CO1 antibody; COI antibody; COX I antibody; COX1 antibody; COX1_humanantibody; COXI antibody; Cytochrome c oxidase polypeptide I antibody; Cytochrome c oxidase subunit 1 antibody; Cytochrome C Oxidase subunit I antibody; Mitochondrially encoded cytochrome c oxidase I antibody; MT CO1 antibody; MT-CO1 antibody; MTCO 1 antibody; MTCO1 antibody
Osteoprotegerin Antibody (YA3535) is an unconjugated, approximately 46 kDa,mouse-derived, anti-OPG monoclonal antibody. OPG Antibody can be used for: WB, IF-Cell, IHC-P expriments in human, mouse, rat background without labeling.
ABC42 antibody; Abcd1 antibody; ABCD1_humanantibody; Adrenoleukodystrophy protein antibody; ALD antibody; Aldgh antibody; ALDP antibody; AMN antibody; ATP binding cassette, sub family D (ALD), member 1 antibody; ATP-binding cassette sub-family D member 1 antibody; ABC42 antibody; Abcd1 antibody; ABCD1_humanantibody; Adrenoleukodystrophy protein antibody; ALD antibody; Aldgh antibody; ALDP antibody; AMN antibody; ATP binding cassette, sub family D (ALD), member 1 antibody; ATP-binding cassette sub-family D member 1 antibody; OTTHUMP00000025960 antibody; OTTMUSP00000019283 antibody; RGD1562128 antibody; RP23 373N8.2 antibody; X linked adrenoleukodystrophy (ALD) gene homolog antibody
Myosin heavy chain Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 224 kDa, targeting to Myosin heavy chain. It can be used for WB,IHC-P,IF-Tissue assays with tag free, in the background of Human, Mouse, Rat.
Cofilin Antibody (YA1311) is a non-conjugated IgG antibody, targeting Cofilin 1, with a predicted molecular weight of 19 kDa (observed band size: 19 kDa). Cofilin Antibody (YA1311) can be used for WB, IF-Cell, FC experiment in Human, Mouse, Rat, Monkey background.
FLJ33404 antibody; OTTHUMP00000028777 antibody; Target of myb 1 antibody; Target of Myb protein 1 antibody; Target of myb1 antibody; TOM 1 antibody; TOM1 antibody; TOM1_humanantibody
CD4 Antibody is a non-conjugated and mouse origined monoclonal antibody about 51 kDa, targeting to CD4. It can be used for IHC-P assays with tag free, in the background of Human.
beta Granin antibody; betagranin; N-terminal fragment of chromogranin A; antibody; catestatin antibody; CgA antibody; CHG A antibody; Chga antibody; chromofungin antibody; Chromogranin A antibody; Chromogranin A parathyroid secretory protein 1 antibody; Chromogranin A precursor antibody; ChromograninA antibody; CMGA_humanantibody; ER-37 antibody; Pancreastatin antibody; Parastatin antibody; Parathyroid secretory protein 1 antibody; Pituitary secretory protein I antibody; Secretory protein I antibody; SP I antibody; SP-I antibody; SP1 antibody; SPI antibody; vasostatin 2 antibody; Vasostatin antibody; Vasostatin I antibody; Vasostatin II antibody; vasostatin-2 antibody;
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Chromogranin A Antibody (YA5572) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Chromogranin A. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
PGC1 alpha+beta Antibody (YA3458) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3458), targeting PGC1 alpha+beta , with a predicted molecular weight of 91/113 kDa (observed band size:110 kDa). PGC1 alpha+beta Antibody (YA3458) can be used for WB experiment in human, mouse, rat background.
Caspase-12 Antibody is an unconjugated, approximately 48 kDa, rabbit-derived, anti-Caspase-12 monoclonal antibody. Caspase-12 Antibody can be used for: WB, IHC-P expriments in human, mouse, rat, background without labeling.
NGFB Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-NGFB monoclonal antibody. NGFB Antibody can be used for: WB, IF-Cell, IF-Tissue, IHC-P, IHC-Fr expriments in human, rat, mouse ,Zebrafish background without labeling.
Alpha-dystroglycan Antibody is an unconjugated, approximately 97 kDa, rabbit-derived, anti-Alpha-dystroglycan polyclonal antibody. Alpha-dystroglycan Antibody can be used for: WB, IHC-P, IF-Cell, FC expriments in human,mouse and rat background without labeling.
Nephrin Antibody (YA3472) is a non-conjugated IgG antibody, targeting Nephrin, with a predicted molecular weight of 135 kDa (observed band size: 200 kDa). Nephrin Antibody (YA3472) can be used for WB, IHC-P, IF-Tissue, IHC-Fr experiment in human, Mouse and Rat background.
Jagged1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Jagged1. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.
CD339 Antibody (YA4135) is a mouse-derived and non-conjugated IgG1 antibody, targeting to CD339. It can be applicated for WB, FC, ELISA assays, in the background of human.
bHLHb39 antibody;
C-HAIRY1 antibody;
Class B basic helix-loop-helix protein 39 antibody;
FLJ20408 antibody;
Hairy and enhancer of split 1 antibody;
Hairy homolog (Drosophila) antibody;
Hairy homolog antibody;
Hairy like antibody;
Hairy, Drosophila, homolog of antibody;
Hairy-like protein antibody;
HAIRY1 antibody;
HES-1 antibody;
HES1_humanantibody;
HHL antibody;
HL antibody;
HRY antibody;
MGC129109 antibody;
OTTHUMP00000209031 antibody;
RHL antibody;
Transcription factor HES-1 antibody
WB, ICC/IF, IHC-P, FC
Human, Mouse, Rat
Hes1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 30 kDa, targeting to Hes1. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
IRG1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 54 kDa, targeting to IRG1. It can be used for WB assays with tag free, in the background of human, Mouse.
CD 68 antibody;
CD68 antibody;
CD68 antigen antibody;
CD68 molecule antibody;
CD68_humanantibody;
DKFZp686M18236 antibody;
gp11 antibody;
Gp110 antibody;
LAMP4 antibody;
Macrophage antigen CD68 (microsialin) antibody;
MACROPHAGE ANTIGEN CD68 antibody;
Macrosialin antibody;
SCARD1 antibody;
Scavenger receptor class D member 1 antibody
WB, IHC-P, FC
Human
CD68 Antibody (YA798) is a non-conjugated and Mouse origined monoclonal antibody about 37 kDa., targeting to CD68. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human.
IMD42 antibody;
MGC129539 antibody;
NR1F3 antibody;
Nuclear receptor ROR gamma antibody;
Nuclear receptor subfamily 1 group F member 3 antibody;
RAR related orphan receptor C antibody;
Retinoic acid binding receptor gamma antibody;
Retinoid related orphan receptor gamma antibody;
Rorc antibody;
RORG antibody;
RORG_humanantibody;
RZR GAMMA antibody;
RZRG antibody;
TOR antibody
WB, IHC-P
Human, Rat
ROR gamma T Antibody (YA3559) is an unconjugated,, rabbit-derived, anti-ROR gamma T antibody. Cytokeratin 19 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, chicken, dog, pig, cow, horse, rabbit background without labeling.
Stanniocalcin 2 antibody; Stanniocalcin related protein antibody; Stanniocalcin-2 antibody; Stanniocalcin-related protein antibody; Stanniocalcin2 antibody; STC 2 antibody; STC related protein antibody; STC-2 antibody; STC-related protein antibody; STC2 antibody; Stanniocalcin 2 antibody; Stanniocalcin related protein antibody; Stanniocalcin-2 antibody; Stanniocalcin-related protein antibody; Stanniocalcin2 antibody; STC 2 antibody; STC related protein antibody; STC-2 antibody; STC-related protein antibody; STC2 antibody; STC2_humanantibody; STCRP antibody
3 hydroxy 3 methylglutaryl CoA reductase antibody;
3 hydroxy 3 methylglutaryl Coenzyme A reductase antibody;
3 hydroxymethylglutaryl CoA reductase antibody;
3-hydroxy-3-methylglutaryl CoA reductase (NADPH) antibody;
3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody;
3H3M antibody;
HMDH_humanantibody;
HMG CoA reductase antibody;
HMG CoAR antibody;
HMG-CoA reductase antibody;
Hmgcr antibody;
Hydroxymethylglutaryl CoA reductase antibody;
LDLCQ3 antibody;
MGC103269 antibody;
Red antibody
WB, IP
Human, Mouse
HMGCR Antibody is an unconjugated, approximately 97 kDa, rabbit-derived, anti-HMGCR monoclonal antibody. HMGCR Antibody can be used for: WB,IP expriments in human, mouse background without labeling.
Wilms Tumor Protein Antibody (YA2277) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2277), targeting Wilms Tumor Protein, with a predicted molecular weight of 49 kDa (observed band size: 55 kDa). Wilms Tumor Protein Antibody (YA2277) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse background.
CD4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 51 kDa, targeting to CD4. It can be used for WB, IF-Cell, IHC-P, mIHC assays with tag free, in the background of Mouse.
deltaTubulin Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 51 kDa, targeting to delta Tubulin. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.
ACAD 6 antibody; ACAD6 antibody; ACADV_humanantibody; Acadvl antibody; Acyl CoA dehydrogenase very long chain antibody; Acyl Coenzyme A dehydrogenase very long chain antibody; LCACD antibody; mitochondrial antibody; Very long chain specific acyl CoA dehydrogenase antibody; Very long chain specific acyl CoA dehydrogenase mitochondrial antibody; ACAD 6 antibody; ACAD6 antibody; ACADV_humanantibody; Acadvl antibody; Acyl CoA dehydrogenase very long chain antibody; Acyl Coenzyme A dehydrogenase very long chain antibody; LCACD antibody; mitochondrial antibody; Very long chain specific acyl CoA dehydrogenase antibody; Very long chain specific acyl CoA dehydrogenase mitochondrial antibody; Very long-chain specific acyl-CoA dehydrogenase antibody; VLCAD antibody
ATOX1 antibody; ATOX1_humanantibody; ATX1 antibody; ATX1 antioxidant protein 1 homolog (yeast) antibody; ATX1 antioxidant protein 1 homolog antibody; Copper transport protein antibody; Copper transport protein ATOX1 antibody; HAH1 antibody; Metal transport protein antibody; Metal transport protein ATX1 antibody; ATOX1 antibody; ATOX1_humanantibody; ATX1 antibody; ATX1 antioxidant protein 1 homolog (yeast) antibody; ATX1 antioxidant protein 1 homolog antibody; Copper transport protein antibody; Copper transport protein ATOX1 antibody; HAH1 antibody; Metal transport protein antibody; Metal transport protein ATX1 antibody; MGC138453 antibody; MGC138455 antibody
COX antibody; COX VA antibody; COX5A antibody; COX5A_humanantibody; Cytochrome c oxidase polypeptide Va antibody; Cytochrome c oxidase polypeptide, mitochondrial antibody; Cytochrome c oxidase subunit 5A antibody; Cytochrome c oxidase subunit 5A, mitochondrial antibody; Cytochrome c oxidase subunit Va antibody; mitochondrial antibody; COX antibody; COX VA antibody; COX5A antibody; COX5A_humanantibody; Cytochrome c oxidase polypeptide Va antibody; Cytochrome c oxidase polypeptide, mitochondrial antibody; Cytochrome c oxidase subunit 5A antibody; Cytochrome c oxidase subunit 5A, mitochondrial antibody; Cytochrome c oxidase subunit Va antibody; mitochondrial antibody; Mitochondrial cytochrome c oxidase subunit Va antibody; VA antibody
CD21 Antibody (YA1307) is a non-conjugated IgG antibody, targeting CD21, with a predicted molecular weight of 113 kDa (observed band size: 155 kDa). CD21 Antibody (YA1307) can be used for WB,IF-Cell,IHC-P,FC,IF-Tissue, IP experiment in human, mouse, rat background.
adult 1 antibody;
MYH1 antibody;
MYH1_humanantibody;
MyHC-2x antibody;
MyHC-IIx/d antibody;
Myosin heavy chain 1 antibody;
Myosin heavy chain 2x antibody;
Myosin heavy chain antibody;
Myosin heavy chain IIx/d antibody;
Myosin-1 antibody;
skeletal muscle antibody
IHC-P, IF-Tissue
Human, Mouse, Rat
Fast Myosin Skeletal Heavy chain Antibody(YA3479) is a non-conjugated and Rabbit origined monoclonal antibody , targeting to Fast Myosin Skeletal Heavy chain . It can be used for IHC-P, IF-Tissue assays with tag free, in the background of Human, Mouse, Rat.
Phospho-Hormone sensitive lipase (Ser853) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 117 kDa, targeting to Phospho-Hormone sensitive lipase (S853). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.
CD44 Antibody (YA6155) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD44. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Lea1 antibody; RU2A_humanantibody; Small nuclear ribonucleoprotein polypeptide A antibody; SNRPA1 antibody; U2 small nuclear ribonucleoprotein A'' antibody; U2 small nuclear ribonucleoprotein polypeptide A' antibody; U2 snRNP A antibody; U2 snRNP A'' antibody
Cellular retinaldehyde binding protein 1 antibody;
Cellular retinaldehyde binding protein antibody;
Cellular retinaldehyde-binding protein antibody;
MGC3663 antibody;
Retinaldehyde binding protein 1 antibody;
Retinaldehyde-binding protein 1 antibody;
RLBP 1 antibody;
RLBP1 antibody;
RLBP1_humanantibody;
WB, IHC-P
Human, Mouse, Rat
CRALBP Antibody (YA1306) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1306), targeting CRALBP, with a predicted molecular weight of 36 kDa (observed band size: 34 kDa). CRALBP Antibody (YA1306) can be used for WB, IHC-P experiment in mouse background.
K Cadherin Antibody(YA3564) is a rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to K-Cadherin. It can be applicated for WB, IHC-P, IF-Tissue assays, in the background of human, mouse, rat.
IRG1 Antibody (YA4642) is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to IRG1. It can be used for WB,IF-Cell assays with tag free, in the background of Mouse.
SOD-1 Antibody (YA3541) is an unconjugated, approximately 17 kDa, rabbit-derived, anti-SOD1 monoclonal antibody. SOD1 Antibody can be used for: WB, IF-Cell, IF-Tissue, IHC-P, FC expriments in human, mouse, rat background without labeling.
CD31 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to CD31. It can be used for WB,IHC-P,FC,IP,IF assays with tag free, in the background of Human.
CAMEO antibody;
heart odd homeobox 1 protein antibody;
HOD antibody;
Homeodomain-only protein antibody;
HOP antibody;
HOP homeobox antibody;
HOP_humanantibody;
HOPX antibody;
LAGY antibody;
Lung cancer-associated Y protein antibody;
NECC1 antibody;
Not expressed in choriocarcinoma clone 1 antibody;
Not expressed in choriocarcinoma protein 1 antibody;
OB1 antibody;
odd homeobox 1 protein antibody;
Odd homeobox protein 1 antibody;
OTTHUMP00000158970 antibody;
SMAP31 antibody;
TOTO antibody
WB, IP
Human
HOPX Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 8 kDa, targeting to HOPX. It can be used for WB, IP assays with tag free, in the background of Human.
FLJ13556 antibody; N myc downstream regulated gene 3 antibody; N-myc downstream-regulated gene 3 protein antibody; NDRG family member 3 antibody; NDRG3 antibody; NDRG3_humanantibody; Protein Ndr3 antibody; Protein NDRG3 antibody
Human IgM Antibody (YA3610) is a mouse-derived and non-conjugated IgG1 antibody, targeting to IGHM. It can be applicated for WB, IHC-P, FC, ELISA assays, in the background of human.
CJS antibody; Gli 2 antibody; GLI family zinc finger 2 antibody; GLI Kruppel family member GLI2 antibody; GLI2 antibody; GLI2_humanantibody; Glioma associated oncogene family zinc finger antibody; HPE9 antibody; Oncogene GLI2 antibody; PHS2 antibody; CJS antibody; Gli 2 antibody; GLI family zinc finger 2 antibody; GLI Kruppel family member GLI2 antibody; GLI2 antibody; GLI2_humanantibody; Glioma associated oncogene family zinc finger antibody; HPE9 antibody; Oncogene GLI2 antibody; PHS2 antibody; Tax helper protein 1 antibody; Tax helper protein 2 antibody; Tax helper protein antibody; Tax responsive element 2 holding protein antibody; Tax responsive element 25 bp sequence binding protein antibody; THP antibody; THP1 antibody; THP2 antibody; Zinc finger protein GLI2 antibody
beta Amyloid 1-40 Antibody (YA3554) is an unconjugated, approximately 4 kDa, rabbit-derived, anti-beta Amyloid 1-40 monoclonal antibody.beta Amyloid 1-40 Antibody (YA3554) can be used for: WB, IHC-P, IF-Tissue expriments in human, mouse background without labeling. beta Amyloid 1-40 Antibody (YA3554) recognizes Aβ-40 peptide. This antibody does not cross-react with other β-amyloid peptides.
beta Amyloid 1-42 Antibody (YA3555) is an unconjugated, approximately 4 kDa, rabbit-derived, anti-beta Amyloid 1-42 monoclonal antibody.beta Amyloid 1-42 Antibody (YA3555) can be used for: WB, IHC-P, IF-Tissue expriments in human, mouse background without labeling.
beta Amyloid Antibody (YA3556) is an unconjugated, approximately 4 kDa, rabbit-derived, anti-beta Amyloid monoclonal antibody.beta Amyloid Antibody (YA3555) can be used for: WB, IHC-P, IF-Tissue, Dot Blot expriments in human, mouse background without labeling.
G-CSF Receptor Antibody (YA3373) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3373), targeting G-CSF Receptor, with a predicted molecular weight of 92 kDa (observed band size: 92 kDa). G-CSF Receptor Antibody (YA3373) can be used for WB, FC experiment in human background.
CMT2B antibody;
PRO2706 antibody;
PSN antibody;
RAB7, member RAS oncogene family antibody;
RAB7A antibody;
RAB7A, member RAS oncogene family antibody;
RAB7A_humanantibody;
Ras associated protein RAB7 antibody;
Ras related protein Rab7 antibody;
Ras related protein Rab7a antibody
WB, ICC/IF, IHC-P, FC
Human, Mouse
RAB7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 23 kDa, targeting to RAB7. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.
APG 5 antibody;
APG 5L antibody;
APG5 antibody;
APG5 autophagy 5 like antibody;
APG5 like antibody;
APG5-like antibody;
APG5L antibody;
Apoptosis specific protein antibody;
Apoptosis-specific protein antibody;
ASP antibody;
ATG 5 antibody;
Atg5 antibody;
ATG5 autophagy related 5 homolog antibody;
ATG5_humanantibody;
Autophagy protein 5 antibody;
Autophagy related 5 antibody;
hAPG5 antibody;
Homolog of S Cerevisiae autophagy 5 antibody;
OTTHUMP00000040507 antibody
WB, IHC-P, ICC/IF, IP, FC, IF-Tissue
Human, Rat, Mouse, Monkey
ATG5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 32 kDa, targeting to ATG5. It can be used for WB,ICC/IF,IHC-P,IP, FC, IF-Tissue assays with tag free, in the background of Human, Rat, Mouse, Monkey.
DKFZp686B09108 antibody; Homeo box protein PBX1 antibody; Homeo box protein PRL antibody; Homeobox protein PBX 1 antibody; Homeobox protein PBX1 antibody; Homeobox protein PRL antibody; MGC126627 antibody; PBX 1 antibody; Pbx1 antibody; PBX1_humanantibody; DKFZp686B09108 antibody; Homeo box protein PBX1 antibody; Homeo box protein PRL antibody; Homeobox protein PBX 1 antibody; Homeobox protein PBX1 antibody; Homeobox protein PRL antibody; MGC126627 antibody; PBX 1 antibody; Pbx1 antibody; PBX1_humanantibody; Pre B cell leukemia homeobox 1 antibody; Pre B cell leukemia transcription factor 1 antibody; Pre-B-cell leukemia transcription factor 1 antibody; PRL antibody
HOME1_humanantibody; Homer antibody; HOMER 1A antibody; HOMER 1B antibody; HOMER 1C antibody; Homer homolog 1 (Drosophila) antibody; homer homolog 1 antibody; Homer protein homolog 1 antibody; homer scaffolding protein 1 antibody; Homer, Drosophila, homolog of, 1 antibody; HOME1_humanantibody; Homer antibody; HOMER 1A antibody; HOMER 1B antibody; HOMER 1C antibody; Homer homolog 1 (Drosophila) antibody; homer homolog 1 antibody; Homer protein homolog 1 antibody; homer scaffolding protein 1 antibody; Homer, Drosophila, homolog of, 1 antibody; Homer, neuronal immediate early gene, 1 antibody; Homer-1 antibody; Homer1 antibody; HOMER1A antibody; HOMER1B antibody; HOMER1C antibody; SYN47 antibody; Ves 1 antibody
CD44 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 82 kDa, targeting to CD44. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human, Mouse.
F Box G - Domain 3 antibody; F box only protein 3 antibody; F box protein 3 antibody; F box protein FBX3 antibody; F-box only protein 3 antibody; FBA antibody; FBX3 antibody; FBX3_humanantibody; FBXO3 antibody
FLJ96580 antibody; HDGF antibody; HDGF_humanantibody; Hepatoma derived growth factor antibody; Hepatoma-derived growth factor antibody; High mobility group protein 1 like 2 antibody; High mobility group protein 1-like 2 antibody; HMG-1L2 antibody; HMG1L2 antibody
FLJ13874 antibody; Heat shock 70 kDa protein 12A antibody; heat shock 70kD protein 12A antibody; heat shock 70kDa protein 12A antibody; HS12A_humanantibody; Hspa12a antibody; KIAA0417 antibody
WB, IHC-P, ICC/IF, IP
Human, Mouse, Rat
HspA12A Antibody (YA2947) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2947), targeting HspA12A, with a predicted molecular weight of 75 kDa (observed band size: 75 kDa). HspA12A Antibody (YA2947) can be used for WB, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
Beta Actin Antibody is a non-conjugated and Mouse origined monoclonal antibody about 42 kDa, targeting to Beta Actin. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse, Rat.
CD169 Antibody (YA1293) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1293), targeting CD169. CD169 Antibody (YA1293) can be used for WB, FC experiment in human,Mouse background.
GTP binding protein RAB 1A antibody; mKIAA3012 antibody; RAB 1 antibody; Rab 1A antibody; RAB1 antibody; RAB1, member RAS oncogene family antibody; Rab1A antibody; RAB1A member RAS oncogene family antibody; RAB1A_humanantibody; Ras related protein Rab 1A antibody; GTP binding protein RAB 1A antibody; mKIAA3012 antibody; RAB 1 antibody; Rab 1A antibody; RAB1 antibody; RAB1, member RAS oncogene family antibody; Rab1A antibody; RAB1A member RAS oncogene family antibody; RAB1A_humanantibody; Ras related protein Rab 1A antibody; Ras-associated protein RAB1 antibody; Ras-related protein Rab-1A antibody; YPT1 antibody; YPT1 related protein antibody; YPT1-related protein antibody
ABC 35 antibody
ABC35 antibody
ABCC 7 antibody
ABCC7 antibody
ATP binding cassette sub family C member 7 antibody;
cAMP dependent chloride channel antibody;
cAMP-dependent chloride channel antibody;
CF antibody;
CFTR antibody;
CFTR/MRP antibody;
CFTR_humanantibody;
Channel conductance controlling ATPase antibody;
Channel conductance-controlling ATPase antibody;
Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub family C, member 7) antibody;
Cystic fibrosis transmembrane conductance regulator antibody;
Cystic Fibrosis Transmembrane Regulator antibody;
dJ760C5.1 antibody;
MRP 7 antibody;
MRP7 antibody;
TNR CFTR antibody
WB, IP
Human
CFTR Antibody(YA3569) is a rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to CFTR. It can be applicated for WB, IP assays, in the background of human.
CD27 Antibody (YA4673) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD27. It can be applicated for FC, ELISA assays, in the background of human.
CD27 Antibody (YA5551) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD27. It can be applicated for FC, ELISA assays, in the background of human.
Baron antibody; Beclin 1 associated RUN domain containing protein antibody; Beclin-1 associated RUN domain containing protein antibody; hypothetical protein LOC9711 antibody; Kiaa0226 antibody; OTTHUMP00000208021 antibody; OTTHUMP00000208023 antibody; OTTHUMP00000208024 antibody; RUBIC_humanantibody; Rubicon antibody; Baron antibody; Beclin 1 associated RUN domain containing protein antibody; Beclin-1 associated RUN domain containing protein antibody; hypothetical protein LOC9711 antibody; Kiaa0226 antibody; OTTHUMP00000208021 antibody; OTTHUMP00000208023 antibody; OTTHUMP00000208024 antibody; RUBIC_humanantibody; Rubicon antibody; RUN domain and cysteine rich domain containing, Beclin 1 interacting protein antibody; Run domain Beclin 1 interacting and cystein rich containing protein antibody; Run domain Beclin-1 interacting and cysteine-rich containing protein antibody; RUN domain protein as Beclin 1 interacting and cysteine rich containing antibody
Complement receptor of the immunoglobulin superfamily antibody; CRIg antibody; Ig superfamily protein antibody; Protein Z39Ig antibody; UNQ317/PRO362 antibody; V set and immunoglobulin domain containing 4 antibody; V-set and immunoglobulin domain-containing protein 4 antibody; VSIG4 antibody; VSIG4_humanantibody; Z39IG antibody
EIF2S1 Antibody(YA3562) is a rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to EIF2S1. It can be applicated for WB, ICC/IF, IHC-P, FC, IP assays, in the background of human, mouse, rat, monkey.
Calgranulin-A antibody;
Calprotectin L1L subunit antibody;
CFAG antibody;
Cystic fibrosis antigen antibody;
Leukocyte L1 complex light chain antibody;
Migration inhibitory factor-related protein 8 antibody;
MRP-8 antibody;
N-terminally processed antibody;
p8 antibody;
Protein S100-A8 antibody;
S100 calcium-binding protein A8 antibody;
S100A8 antibody;
S10A8_humanantibody;
Urinary stone protein band A antibody
WB, IHC-P, ICC/IF, IP, FC, IF-Tissue
Human
S100 A8 Antibody (YA1170) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1170), targeting S100A8. S100 A8 Antibody (YA1170) can be used for WB, IHC-P, IF-Cell, FC, IF-Tissue, IP experiment in human background.
NKp32 Antibody (YA4682) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD337. It can be applicated for ELISA, FC assays, in the background of human.
PSMB1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 26 kDa, targeting to PSMB1. It can be used for WB, IF-Cell, IHC-P, FC assays with tag free, in the background of Human,Mouse, Rat.
CD107 antigen like family member A antibody;
CD107 antigen-like family member A antibody;
CD107a antibody;
CD107a antigen antibody;
LAMP 1 antibody;
LAMP-1 antibody;
LAMP1 antibody;
LAMP1_humanantibody;
LAMPA antibody;
LGP120 antibody;
lgpA antibody;
Lysosomal membrane glycoprotein 120KD antibody;
Lysosomal Associated Membrane Protein 1 antibody;
Lysosome associated membrane glycoprotein 1 antibody;
Lysosome-associated membrane glycoprotein 1 antibody;
Lysosome-associated membrane protein 1 antibody;
OTTHUMP00000040663 antibody
WB, IHC-P
Human
LAMP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 45 kDa, targeting to LAMP1. It can be used for WB,IHC-P assays with tag free, in the background of Human.
FLJ43224 antibody;
MGC104393 antibody;
MGC125896 antibody;
MGC125897 antibody;
NED8 antibody;
NEDD 8 antibody;
NEDD-8 antibody;
Nedd8 antibody;
NEDD8_humanantibody;
Neddylin antibody;
Neural precursor cell expressed developmentally down regulated 8 antibody;
Neural precursor cell expressed developmentally down regulated gene 8 antibody;
Neural precursor cell expressed developmentally down-regulated protein 8 antibody;
Rub1 antibody;
Ubiquitin like protein Nedd 8 antibody;
Ubiquitin like protein Nedd8 antibody;
Ubiquitin-like protein Nedd8 antibody
WB, ICC/IF, IHC-P, IP
Human, Rat
NEDD8 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 9 kDa, targeting to NEDD8. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Rat.
ELKL motif kinase 1 antibody;
ELKL motif kinase antibody;
EMK-1 antibody;
EMK1 antibody;
MAP/microtubule affinity regulating kinase 2 antibody;
MAP/microtubule affinity-regulating kinase 2 antibody;
Mark2 antibody;
MARK2_humanantibody;
MGC99619 antibody;
PAR 1 antibody;
Par 1b antibody;
PAR1 homolog antibody;
Par1b antibody;
Ser/Thr protein kinase PAR 1B antibody;
Serine/threonine protein kinase EMK antibody;
Serine/threonine protein kinase MARK2 antibody;
Serine/threonine-protein kinase MARK2 antibody;
WB, FC
Human, Mouse, Rat
MARK2 Antibody (YA2104) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2104), targeting MARK2, with a predicted molecular weight of 88 kDa (observed band size: 78, 82 kDa). MARK2 Antibody (YA2104) can be used for WB, FC experiment in human, mouse, rat background.
Cardiac Troponin T Antibody (YA2719) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2719), targeting Cardiac Troponin T, with a predicted molecular weight of 36 kDa (observed band size: 40 kDa). Cardiac Troponin T Antibody (YA2719) can be used for WB, IHC-P experiment in human, mouse, rat background.
CD107 antigen like family member A antibody;
CD107 antigen-like family member A antibody;
CD107a antibody;
CD107a antigen antibody;
LAMP 1 antibody;
LAMP-1 antibody;
LAMP1 antibody;
LAMP1_humanantibody;
LAMPA antibody;
LGP120 antibody;
lgpA antibody;
Lysosomal membrane glycoprotein 120KD antibody;
Lysosomal Associated Membrane Protein 1 antibody;
Lysosome associated membrane glycoprotein 1 antibody;
Lysosome-associated membrane glycoprotein 1 antibody;
Lysosome-associated membrane protein 1 antibody;
OTTHUMP00000040663 antibody;
WB, IHC-P, IHC-F, ICC/IF, IP, IF-Tissue
Human, Mouse, Rat
LAMP1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 45 kDa, targeting to LAMP1. It can be used for WB, IHC-P, IF-Tissue, IHC-Fr, IP assays with tag free, in the background of Human,Mouse,Rat.
Ctip2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 96 kDa, targeting to Ctip2. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.
39.1 antibody;
CK 17 antibody;
CK17 antibody;
CK-17 antibody;
Cytokeratin-17 antibody;
K17 antibody;
K1C17_humanantibody;
Keratin 17 antibody;
keratin 17 epitope S1 antibody;
keratin 17 epitope S2 antibody;
keratin 17 epitope S4 antibody;
Keratin 17, type I antibody;
Keratin antibody;
Keratin type I cytoskeletal 17 antibody;
keratin, type i cytoskeletal 17 [version 1] antibody;
Keratin-17 antibody;
KRT17 antibody;
PC antibody;
PC2 antibody;
PCHC1 antibody;
type I cytoskeletal 17 antibody;
WB, IHC-P, ICC/IF
Human, Mouse, Rat
Cytokeratin 17 Antibody (YA3438) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3438), targeting Cytokeratin 17, with a predicted molecular weight of 48 kDa (observed band size: 48 kDa). Cytokeratin 17 Antibody (YA3438) can be used for WB, IF-Cell, IF-Tissue, IHC-P experiment in human, Mouse, Rat background.
N Cadherin Antibody (YA4680) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD325. It can be applicated for FC, ELISA assays, in the background of human.
PSMB5/MB1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 26 kDa, targeting to PSMB5/MB1. It can be used for WB, IHC-P, IF-Cell, FC assays with tag free, in the background of Human,Mouse, Rat.
CAP E antibody; CAPE antibody; Chromosome associated protein E antibody; Chromosome-associated protein E antibody; FLJ10093 antibody; hCAP E antibody; hCAP-E antibody; hCAPE antibody; PRO0324 antibody; SMC 2 antibody; CAP E antibody; CAPE antibody; Chromosome associated protein E antibody; Chromosome-associated protein E antibody; FLJ10093 antibody; hCAP E antibody; hCAP-E antibody; hCAPE antibody; PRO0324 antibody; SMC 2 antibody; SMC protein 2 antibody; SMC-2 antibody; SMC2 antibody; SMC2 L1 antibody; SMC2_humanantibody; SMC2L1 antibody; Structural maintenance of chromosomes (SMC) family member chromosome associated protein E antibody; Structural maintenance of chromosomes 2 antibody; Structural maintenance of chromosomes 2 like 1 antibody; Structural maintenance of chromosomes 2 yeast like 1 antibody; Structural maintenance of chromosomes protein 2 antibody; XCAP E homolog antibody; XCAP-E homolog antibody; XCAPE homolog antibody
Human IgM Antibody (YA1062) is a mouse-derived non-conjugated IgG2a antibody (Clone NO.: YA1062), targeting Human IgM. Human IgM Antibody (YA1062) can be used for ELISA, IHC-P experiment in human background.
Myoglobin Antibody (YA5614) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Myoglobin. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
1110008L20Rik antibody; EF hand domain containing family member A1 antibody; EF hand domain family A1 antibody; EF hand domain family member A1 antibody; EF-hand domain-containing family member A1 antibody; EFHA1 antibody; EFHA1 EF hand domain family member A1 antibody; EFHA1_humanantibody; FLJ25016 antibody; FLJ34588 antibody; 1110008L20Rik antibody; EF hand domain containing family member A1 antibody; EF hand domain family A1 antibody; EF hand domain family member A1 antibody; EF-hand domain-containing family member A1 antibody; EFHA1 antibody; EFHA1 EF hand domain family member A1 antibody; EFHA1_humanantibody; FLJ25016 antibody; FLJ34588 antibody; Smhs2 homolog antibody
NGFR Antibody (YA2774) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2774), targeting NGFR, with a predicted molecular weight of 45 kDa (observed band size: 75 kDa). NGFR Antibody (YA2774) can be used for WB, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
CD146 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 72 kDa, targeting to CD146. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Rat.
Islet 1 Antibody (YA1244) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1244), targeting Islet 1. Islet 1 Antibody (YA1244) can be used for WB, IF-Cell, IHC-P, FC,IP, IHC-Fr experiment in human, mouse, rat background.
Alpha 1 (VI) chain (61 AA) antibody; CO6A1_humanantibody; COL6A1 antibody; Collagen alpha-1(VI) chain antibody; Collagen type VI alpha 1 antibody; Collagen VI alpha 1 polypeptide antibody; Collagen VI antibody; human mRNA for collagen VI alpha 2 C terminal globular domain antibody; OPLL antibody; PP3610 antibody
WB, ICC/IF, IHC-P
Human, Mouse, Rat
Collagen VI A1+A2+A3 Antibody (YA893) is an unconjugated, approximately 109 kDa, rabbit-derived, anti-Collagen VI (YA893) monoclonal antibody. Collagen VI A1+A2+A3 Antibody (YA893) can be used for: WB, IF-Cell, IF-Tissue, IHC-P expriments in human, mouse, rat background without labeling.
BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_humanantibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_humanantibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody
CD63 Antibody (YA5577) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD63. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
JNK Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to JNK. It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.
JNK1 (1A4) Antibody is a non-conjugated and Mouse origined monoclonal antibody about 48 kDa, targeting to JNK1 (1A4). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.
C21KG antibody; G 22K antibody; G-22K antibody; GTP binding protein smg p21A antibody; GTP-binding protein smg p21A antibody; KREV 1 antibody; KREV1 antibody; OTTHUMP00000013741 antibody; RAP 1A antibody; RAP1 antibody; C21KG antibody; G 22K antibody; G-22K antibody; GTP binding protein smg p21A antibody; GTP-binding protein smg p21A antibody; KREV 1 antibody; KREV1 antibody; OTTHUMP00000013741 antibody; RAP 1A antibody; RAP1 antibody; RAP1A antibody; RAP1A member of RAS oncogene family antibody; RAP1A_humanantibody; Ras related protein Krev 1 antibody; Ras related protein Rap 1A antibody; RAS related protein RAP1A antibody; Ras-related protein Krev-1 antibody; Ras-related protein Rap-1A antibody; SMGP21 antibody; GTP-binding protein smg p21B antibody; K-REV antibody; OK/SW-cl.11 antibody; RAL1B antibody; rap1b antibody; RAP1B member of RAS oncogene family antibody; RAP1B_humanantibody; Ras family small GTP binding protein RAP1B antibody; RAS related protein RAP1B antibody; Ras-related protein Rap-1b antibody; Small GTP binding protein antibody
Calcium/calmodulin dependent protein kinase II alpha antibody;
Calcium/calmodulin dependent protein kinase II beta antibody;
Calcium/calmodulin dependent protein kinase II delta antibody;
Calcium/calmodulin dependent protein kinase II gamma antibody;
Calcium/calmodulin-dependent protein kinase type II subunit alpha antibody;
CaM kinase II alpha antibody;
CaM kinase II antibody;
CaM kinase II beta antibody;
CaM kinase II delta antibody;
CaM kinase II gamma antibody;
CaM kinase II subunit alpha antibody;
CaMK-II subunit alpha antibody;
CAMK2 antibody;
Camk2a antibody;
CAMK2B antibody;
CAMK2D antibody;
CAMK2G antibody;
CAMKA antibody;
KCC2A_humanantibody;
CaMKⅡ
WB, IHC-P, IHC-F, ICC/IF, FC, IF-Tissue
Human, Mouse, Rat, Monkey, Pig
CaMKII Antibody (YA4627) is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to CaMKII . It can be used for WB, IF-Cell, IF-Tissue, IHC-P, IHC-Fr, FC assays with tag free, in the background of Human, Mouse, Rat, monkey, pig.
MAP kinase activated protein Kinase 2 antibody;
MAP kinase-activated protein kinase 2 antibody;
MAPK activated protein kinase 2 antibody;
MAPK-activated protein kinase 2 antibody;
MAPK2_humanantibody;
MAPKAP K2 antibody;
MAPKAP kinase 2 antibody;
MAPKAPK 2 antibody;
MAPKAPK-2 antibody;
MAPKAPK2 antibody;
Mitogen activated protein kinase activated protein kinase 2 antibody;
MK 2 antibody;
MK2 antibody
WB, IP
Human, Mouse, Rat
MAPKAPK2 Antibody (YA304) is a non-conjugated and Rabbit origined monoclonal antibody about 46 kDa, targeting to MAPKAP Kinase 2. It can be used for WB,IP assays with tag free, in the background of Human, Mouse,Rat.
Leukocyte L1 complex heavy chain antibody; 60B8AG antibody; CAGB antibody; Calgranulin B antibody; Calgranulin-B antibody; Calprotectin L1H subunit antibody; CFAG antibody; CGLB antibody; Cystic fibrosis antigen B antibody; L1AG antibody;
Leukocyte L1 complex heavy chain antibody; LIAG antibody; MAC387 antibody; MIF antibody; Migration inhibitory factor related protein 14 antibody; Migration inhibitory factor-related protein 14 antibody; MRP 14 antibody; MRP-14 antibody; MRP14 antibody; Myeloid-related protein 14 antibody; NIF antibody; OTTHUMP00000015331 antibody; p14 antibody; Protein S100-A9 antibody; S100 A9 antibody; S100 calcium binding protein A9 antibody; S100 calcium binding protein A9 calgranulin B antibody;
S100 calcium-binding protein A9 antibody; S100A9 antibody; S10A9_humanantibody;
WB, IHC-P, IF-Tissue, mIHC
Human
S100A9 Antibody(YA3464) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3464), targeting S100A8. S100A9 Antibody (YA1170) can be used for WB, IHC-P, mIHC, IF-Tissue experiment in human background.
CD 74 antibody; CD74 antibody; CD74 antigen; invariant polypeptide of major histocompatibility complex; class II antigen-associated; antibody; CD74 antigen antibody; CD74 molecule antibody; CD74 molecule; major histocompatibility complex; class II invariant chain antibody; CLIP antibody; DHLAG antibody; Gamma chain of class II antigens antibody; HG2A_humanantibody; HLA class II histocompatibility antigen gamma chain antibody; HLA DR antigens associated invariant chain antibody; HLA DR gamma antibody; HLA-DR antigens-associated invariant chain antibody; HLA-DR-gamma antibody; HLADG antibody; HLADR antigens associated invariant chain antibody; Ia antigen associated invariant chain antibody; Ia antigen-associated invariant chain antibody; Ia associated invariant chain antibody; Ia gamma antibody; Ii antibody; Invariant polypeptide of major histocompatibility complex class II antigen associated antibody; la-gamma antibody; Major histocompatibility complex class II invariant chain antibody; MHC HLA DR gamma chain antibody; MHC HLA-DR gamma chain antibody; p33 antibody; p35 antibody; Protein 41 antibody;
IHC-P, WB, ICC/IF, ELISA
Human
CD74 Antibody (YA5590) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD74. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
EGFR Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to EGFR. It can be used for WB,ICC/IF,mIHC,IP, FC assays with tag free, in the background of Human, Mouse, Rat.
95 alpha chain antibody;
95 antibody;
CD 11c antibody;
CD11 antigen like family member C antibody;
CD11 antigen-like family member C antibody;
CD11c antibody;
CD11c antigen antibody;
Complement component 3 receptor 4 subunit antibody;
CR4 antibody;
Integrin alpha X antibody;
Integrin alpha X chain antibody;
Integrin alpha-X antibody;
Integrin aX antibody;
Integrin subunit alpha X antibody;
integrin, alpha X (antigen CD11C (p150), alpha polypeptide) antibody;
integrin, alpha X (complement component 3 receptor 4 subunit antibody;
ITAX_humanantibody;
ITGAX antibody;
LEU M5 alpha subunit antibody;
Leu M5 antibody
WB, IHC-P, IHC-F, IF-Tissue
Mouse
CD11c Antibody(YA3565) is a rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to CD11c. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of mouse.
cytoplasmic 1 antibody;
MGC138448 antibody;
NF ATc antibody;
NF ATc1 antibody;
NF-ATc antibody;
NF-ATc1 antibody;
NF-ATc1.2 antibody;
NFAC1_humanantibody;
NFAT 2 antibody;
NFAT transcription complex cytosolic component antibody;
NFATC 1 antibody;
NFATc antibody;
NFATc1 antibody;
Nuclear factor of activated T cells cytoplasmic 1 antibody;
Nuclear factor of activated T cells cytoplasmic calcineurin dependent 1 antibody;
Nuclear factor of activated T cells cytosolic component 1 antibody;
nuclear factor of activated T-cells 'c' antibody;
Nuclear factor of activated T-cells antibody
WB, IHC-P, FC
Human
NFAT2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 101 kDa, targeting to NFAT2. It can be used for WB, IHC-P, FC assays with tag free, in the background of Human.
Antigen Presenting Molecule antibody;
Cw*1701 antibody;
D6S204 antibody;
FLJ27082 antibody;
HLA A antibody;
HLA B antibody;
HLA C antibody;
HLA class 1 A antibody;
HLA class 1 B antibody;
HLA class 1 C antibody;
HLA JY3 antibody;
HLAA antibody;
HLAB antibody;
HLAC antibody;
HLC C antibody;
human Leucocyte Antigen C antibody;
Major Histocompatibility Complex Class I A antibody;
Major Histocompatibility Complex Class I B antibody;
Major Histocompatibility Complex Class I C antibody;
Major histocompatibility complex, class I, A + B + C antibody;
MHC class I antigen A*1 antibody;
MHC Class I Antigen antibody;
MHC class I antigen B*7 antibody;
MHC class I antigen Cw*1 antibody;
MHC class I HLA A antibody;
MHC class I HLA B antibody;
MHC class I HLA C antibody;
MHC HLA ABC antibody;
PSORS1 antibody
ICC/IF, FC
Human
HLA Class 1 ABC Antibody (YA4638) is a mouse-derived non-conjugated IgG antibody (Clone NO.: YA4638), targeting HLA Class 1 ABC. HLA Class 1 ABC Antibody (YA4638) can be used for ICC, FC experiment in human background.
ABC30 antibody;
abcC2 antibody;
ATP binding cassette sub family C (CFTR/MRP) member 2 antibody;
ATP binding cassette subfamily C member 2 antibody;
ATP-binding cassette sub-family C member 2 antibody;
Canalicular multidrug resistance protein antibody;
Canalicular multispecific organic anion transporter 1 antibody;
CMOAT antibody;
CMOAT1 antibody;
cMRP antibody;
DJS antibody;
KIAA1010 antibody;
MRP 2 antibody;
MRP2_humanantibody;
Multidrug resistance associated protein 2 antibody;
Multidrug resistance-associated protein 2 antibody;
WB, ICC/IF, FC
Human
MRP2/ABCC2 Antibody is an unconjugated, approximately 174 kDa, rabbit-derived, anti-MRP2/ABCC2 monoclonal antibody. MRP2/ABCC2 Antibody can be used for: WB, ICC/IF, FC expriments in human background without labeling.
18A2 antibody;
42A antibody;
calcium Placental protein antibody;
Calvasculin antibody;
CAPL antibody;
Fibroblast specific protein 1 (FSP1) antibody;
Fibroblast specific protein 1 antibody;
Fibroblast specific protein antibody;
FSP1 antibody;
Leukemia multidrug resistance associated protein antibody;
Malignant transformation suppression 1 (MTS1) antibody;
Malignant transformation suppression 1 antibody;
Metastasin antibody;
MTS1 antibody;
OTTHUMP00000015467 antibody;
OTTHUMP00000015468 antibody;
P9KA antibody;
PEL98 antibody;
Placental calcium-binding protein antibody;
Protein Mts1 antibody;
Protein S100 A4 antibody;
Protein S100-A4 antibody;
S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog) antibody;
S100 calcium binding protein A4 antibody;
S100 calcium-binding protein A4 antibody;
S100a4 antibody;
S10A4_humanantibody
WB, ICC/IF, IHC-P, IP, FC
Human, Mouse
S100A4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 12 kDa, targeting to S100A4. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.
70 kDa androgen receptor activator antibody; 70 kDa androgen receptor coactivator antibody; 70 kDa AR activator antibody; 70 kDa AR-activator antibody; Androgen receptor coactivator 70 kD antibody; Androgen receptor coactivator 70 kDa protein antibody; Androgen receptor-associated protein of 70 kDa antibody; ARA 70 antibody; ARA70 antibody; DKFZp762E1112 antibody; ELE 1 antibody; ELE1 antibody; ELE1/ret TK antibody; NCOA 4 antibody; NCoA-4 antibody; NCOA4 antibody; NCOA4_humanantibody; Nuclear receptor coactivator 4 antibody; Papillary thyroid carcinoma 3 antibody; PTC 3 antibody; PTC3 antibody; RET activating gene ELE1 antibody; Ret activating protein ELE1 antibody; Ret-activating protein ELE1 antibody; RFG antibody
WB
Human
NCOA4 Antibody (YA4630) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA4630), targeting NCOA4. NCOA4 Antibody (YA4629) can be used for WB experiment in human background.
70 kDa androgen receptor activator antibody; 70 kDa androgen receptor coactivator antibody; 70 kDa AR activator antibody; 70 kDa AR-activator antibody; Androgen receptor coactivator 70 kD antibody; Androgen receptor coactivator 70 kDa protein antibody; Androgen receptor-associated protein of 70 kDa antibody; ARA 70 antibody; ARA70 antibody; DKFZp762E1112 antibody; ELE 1 antibody; ELE1 antibody; ELE1/ret TK antibody; NCOA 4 antibody; NCoA-4 antibody; NCOA4 antibody; NCOA4_humanantibody; Nuclear receptor coactivator 4 antibody; Papillary thyroid carcinoma 3 antibody; PTC 3 antibody; PTC3 antibody; RET activating gene ELE1 antibody; Ret activating protein ELE1 antibody; Ret-activating protein ELE1 antibody; RFG antibody
IHC-P, IF-Tissue
Human, Mouse, Rat
NCOA4 Antibody (YA4631) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA4631), targeting NCOA4. NCOA4 Antibody (YA4631) can be used for IHC-P, IF-Tissue experiment in Human, Mouse, Rat background.
Phospho-JNK1 (Thr183/Tyr185) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to Phospho-JNK1 (Thr183/Tyr185). It can be used for WB,IP assays with tag free, in the background of Human, Rat.
Caudal type homeo box 2 antibody;
Caudal type homeo box transcription factor 2 antibody;
Caudal type homeobox 2 antibody;
Caudal type homeobox protein 2 antibody;
Caudal type homeobox transcription factor 2 antibody;
Caudal-type homeobox protein 2 antibody;
CDX 2 antibody;
CDX 3 antibody;
CDX-3 antibody;
Cdx2 antibody;
CDX2_humanantibody;
CDX3 antibody;
Homeobox protein CDX 2 antibody;
Homeobox protein CDX-2 antibody;
WB, IHC-P, ICC/IF, FC
Human, Mouse, Rat
CDX2 Antibody is an unconjugated, approximately 34 kDa, rabbit-derived, anti-CDX2 monoclonal antibody. CDX2 Antibody can be used for: WB, IHC-P, ICC/IF, FC expriments in human, mouse, rat background without labeling.
BSC1 antibody;
Bumetanide sensitive sodium 3 antibody;
Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 antibody;
Kidney specific Na K Cl symporter antibody;
Kidney-specific Na-K-Cl symporter antibody;
MGC48843 antibody;
Na K 2Cl cotransporter antibody;
NKCC2 antibody;
potassiumchloride cotransporter 2 antibody;
S12A1_humanantibody;
Slc12a1 antibody;
sodium potassium chloride cotransporter 2 antibody;
solute carrier family 12 (sodium/potassium/chloride transporters) antibody;
Solute carrier family 12 member 1 antibody
WB, IHC-P, ICC/IF
Human, Mouse, Rat
SLC12A1 Antibody (YA3471) is a non-conjugated IgG antibody, targeting SLC12A1, with a predicted molecular weight of 121 kDa (observed band size: 150 kDa). SLC12A1 Antibody (YA3471) can be used for WB, IHC-P, IF-Cell, mIHC experiment in human, Mouse and Rat background.
ATF2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 52 kDa, targeting to ATF2. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
DASS-397D15.1 antibody; DR alpha chain antibody; DR alpha chain precursor antibody; DRA_humanantibody; DRB1 antibody; DRB4 antibody; FLJ51114 antibody; Histocompatibility antigen HLA DR alpha antibody; Histocompatibility antigen HLA-DR alpha antibody; HLA class II histocompatibility antigen antibody; HLA class II histocompatibility antigen DR alpha chain antibody; HLA DR1B antibody; HLA DR3B antibody; HLA DRA antibody; HLA DRA1 antibody; HLA DRB1 antibody; HLA DRB3 antibody; HLA DRB4 antibody; HLA DRB5 antibody; HLA-DR histocompatibility type antibody; HLA-DRA antibody; HLADR4B antibody; HLADRA1 antibody; HLADRB antibody; Major histocompatibility complex class II DR alpha antibody; Major histocompatibility complex class II DR beta 1 antibody; Major histocompatibility complex class II DR beta 3 antibody; Major histocompatibility complex class II DR beta 4 antibody; Major histocompatibility complex class II DR beta 5 antibody; MGC117330 antibody; MHC cell surface glycoprotein antibody; MHC class II antigen DRA antibody; MHC II antibody; MLRW antibody; OTTHUMP00000029406 antibody; OTTHUMP00000029407 antibody; HLA-DRA nanobody;
ELISA
Human
HLA-DR Antibody (YA4707) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HLA-DRA. It can be applicated for ELISA assays, in the background of human.
C-TAK1 antibody;
Cdc25C associated protein kinase 1 antibody;
Cdc25C-associated protein kinase 1 antibody;
cTAK1 antibody;
ELKL motif kinase 2 antibody;
EMK-2 antibody;
Emk2 antibody;
ETK 1 antibody;
KIAA4230 antibody;
KP78 antibody;
MAP microtubule affinity regulating kinase 3 antibody;
MAP/microtubule affinity-regulating kinase 3 antibody;
Mark3 antibody;
MARK3_humanantibody;
Par 1a antibody;
PAR1A antibody;
Protein kinase STK10 antibody;
Ser/Thr protein kinase PAR-1 antibody;
Serine threonine protein kinase p78 antibody;
Serine/threonine-protein kinase p78 antibody;
SerThr protein kinase PAR 1 antibody;
WB, ICC/IF, IP, FC
Mouse, Human
MARK3 Antibody (YA2150) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2150), targeting MARK3, with a predicted molecular weight of 84 kDa (observed band size: 84 kDa). MARK3 Antibody (YA2150) can be used for WB, ICC/IF, IP, FC experiment in mouse, human background.
Transcription factor AP2 alpha Antibody is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3441), targeting Transcription factor AP2 alpha, with a predicted molecular weight of 48 kDa (observed band size: 48 kDa). Transcription factor AP2 alpha Antibody (YA3441) can be used for WB, IF-Cell, IHC-P experiment in human, Mouse, Rat background.
C C chemokine receptor type 2 antibody;
C C CKR 2 antibody;
C-C chemokine receptor type 2 antibody;
C-C CKR-2 antibody;
CC chemokine receptor type 2 antibody;
CC CKR 2 antibody;
CC-CKR-2 antibody;
CCCKR2 antibody;
CCR 2 antibody;
CCR-2 antibody;
CCR1L antibody;
CCR2 antibody;
CCR2_humanantibody;
CCR2A antibody;
CCR2B antibody;
CCR5L antibody;
CD192 antibody;
CD192 antigen antibody;
Chemokine C C motif receptor 2 antibody;
Chemokine CC Motif Receptor 2 antibody;
CKR 2 antibody;
CKR2 antibody;
CKR2A antibody;
CKR2B antibody;
CMKBR2 antibody;
MCP 1 R antibody;
MCP-1-R antibody;
MCP1 RECEPTOR antibody;
MCP1R antibody;
Monocyte chemoattractant protein 1 receptor antibody;
Monocyte Chemotactic Protein 1 Receptor antibody;
Monocyte Chemotactic Protein 1 Receptor antibody
WB, IHC-P, IP, FC
Human
CCR2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 42 kDa, targeting to CCR2. It can be used for WB,IHC-P,IP,FC assays with tag free, in the background of Human.
c Ki ras2 antibody; c Kirsten ras protein antibody; c-K-ras antibody; c-Ki-ras antibody; Cellular c Ki ras2 proto oncogene antibody; Cellular transforming proto oncogene antibody; CFC2 antibody; cK Ras antibody; GTPase KRas antibody; K RAS p21 protein antibody; c Ki ras2 antibody; c Kirsten ras protein antibody; c-K-ras antibody; c-Ki-ras antibody; Cellular c Ki ras2 proto oncogene antibody; Cellular transforming proto oncogene antibody; CFC2 antibody; cK Ras antibody; GTPase KRas antibody; K RAS p21 protein antibody; K RAS2A antibody; K RAS2B antibody; K RAS4A antibody; K RAS4B antibody; K-Ras 2 antibody; KI RAS antibody; Ki-Ras antibody; KIRSTEN MURINE SARCOMA VIRUS 2 antibody; Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog antibody; Kirsten rat sarcoma viral oncogene homolog antibody; KRAS antibody; KRAS proto oncogene, GTPase antibody; KRAS1 antibody; KRAS2 antibody; N-terminally processed antibody; NS antibody; NS3 antibody; Oncogene KRAS2 antibody; p21ras antibody; PR310 c K ras oncogene antibody; PR310 cK ras oncogene antibody; RALD antibody; RASK_humanantibody; RASK2 antibody; Transforming protein p21 antibody; v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog antibody; v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
4F9 antibody; Antigen detected by monoclonal and antibody IA4 antibody; C33 antibody; C33 antigen antibody; CD 82 antibody; CD82 antibody; CD82 antigen antibody; CD82 molecule antibody; CD82_humanantibody; GR 15 antibody; GR15 antibody; IA 4 antibody; IA4 antibody; Inducible membrane protein antibody; Inducible membrane protein R2 antibody; KAI 1 antibody; KAI1 antibody; Kangai 1; suppression of tumorigenicity 6; prostate; CD82 antigen; R2 leukocyte antigen; antigen detected by monoclonal and antibody IA4; antibody; Kangai 1 antibody; Kangai1 antibody; Leukocyte surface antigen R2 antibody; Metastasis suppressor Kangai 1 antibody; Metastasis suppressor Kangai-1 antibody; Metastasis suppressor Kangai1 antibody; Prostate cancer antimetastasis gene KAI1 antibody; R2 antibody; R2 leukocyte antigen antibody; SAR 2 antibody; SAR2 antibody; ST 6 antibody; ST6 antibody; Suppression of tumorigenicity 6 antibody; Suppression of tumorigenicity 6 prostate antibody; Suppressor of tumorigenicity 6 antibody; Suppressor of tumorigenicity 6 protein antibody; Tetraspanin 27 antibody; Tetraspanin-27 antibody; Tetraspanin27 antibody; Tspan 27 antibody; Tspan-27 antibody; Tspan27 antibody; CD82 nanobody
ELISA, FC
Human
CD82 Antibody (YA4701) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD82. It can be applicated for ELISA, FC assays, in the background of human.
FLJ23286 antibody; IL5 promoter REII region binding protein antibody; KIAA1090 antibody; MGC176638 antibody; MMSET antibody; MMSET type II antibody; Multiple myeloma SET domain containing protein type III antibody; Multiple myeloma SET domain protein antibody; Multiple myeloma SET domain-containing protein antibody; NSD 2 antibody; FLJ23286 antibody; IL5 promoter REII region binding protein antibody; KIAA1090 antibody; MGC176638 antibody; MMSET antibody; MMSET type II antibody; Multiple myeloma SET domain containing protein type III antibody; Multiple myeloma SET domain protein antibody; Multiple myeloma SET domain-containing protein antibody; NSD 2 antibody; NSD2 antibody; NSD2_humanantibody; Nuclear receptor binding SET domain protein 2 antibody; Nuclear SET domain-containing protein 2 antibody; Probable histone-lysine N-methyltransferase NSD2 antibody; Protein trithorax-5 antibody; REIIBP antibody; Trithorax/ash1 related protein 5 antibody; TRX5 antibody; TRX5 protein antibody; WHS antibody; Whsc1 antibody; Wolf Hirschhorn syndrome candidate 1 antibody; Wolf Hirschhorn syndrome candidate 1 protein antibody; Wolf-Hirschhorn syndrome candidate 1 protein antibody
FBP1 Antibody (YA1264) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1264), targeting FBP1. FBP1 Antibody (YA1264) can be used for WB, IF-Cell, IHC-P experiment in human,mouse,rat background.
Caudal type homeo box 2 antibody; Caudal type homeo box transcription factor 2 antibody; Caudal type homeobox 2 antibody; Caudal type homeobox protein 2 antibody; Caudal type homeobox transcription factor 2 antibody; Caudal-type homeobox protein 2 antibody; CDX 2 antibody; CDX 3 antibody; CDX-3 antibody; Cdx2 antibody; CDX2/AS antibody; CDX2_humanantibody; CDX3 antibody; Homeobox protein CDX 2 antibody; Homeobox protein CDX-2 antibody;
IHC-P, ICC/IF, ELISA
Human
CDX1+CDX2+CDX4 Antibody (YA5488) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CDX2. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.
CD366 antibody;
FLJ14428 antibody;
HAVcr-2 antibody;
Havcr2 antibody;
HAVR2_humanantibody;
Hepatitis A virus cellular receptor 2 antibody;
Kidney injury molecule 3 antibody;
KIM 3 antibody;
KIM3 antibody;
T cell immunoglobulin and mucin domain containing 3 antibody;
T cell immunoglobulin mucin 3 antibody;
T-cell immunoglobulin and mucin domain-containing protein 3 antibody;
T-cell immunoglobulin mucin family member 3 antibody;
T-cell immunoglobulin mucin receptor 3 antibody;
T-cell membrane protein 3 antibody;
Tim 3 antibody;
TIM-3 antibody;
TIM3 antibody;
TIMD-3 antibody;
TIMD3 antibody;
WB, IHC-P, ICC/IF, FC
Human
TIM3 Antibody (YA1448) is a mouse-derived non-conjugated IgG antibody (Clone NO.: YA1448), targeting TIM3. TIM3 Antibody (YA1448) can be used for WB, IHC-P, IF-Cell, FC experiment in human background.
CD66b Antibody (YA4695) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD66b. It can be applicated for ELISA, FC assays, in the background of human.
3-1 antibody; 6-alpha-mannosidase antibody; Alpha mannosidase 2 antibody; alpha Mannosidase II antibody; Alpha-mannosidase 2 antibody; AMAN II antibody; Golgi alpha mannosidase II antibody; Golgi alpha-mannosidase II antibody; Golgi integral membrane protein 7 antibody; GOLIM7 antibody; 3-1 antibody; 6-alpha-mannosidase antibody; Alpha mannosidase 2 antibody; alpha Mannosidase II antibody; Alpha-mannosidase 2 antibody; AMAN II antibody; Golgi alpha mannosidase II antibody; Golgi alpha-mannosidase II antibody; Golgi integral membrane protein 7 antibody; GOLIM7 antibody; MA2A1_humanantibody; MAN II antibody; Man2a1 antibody; MANA 2 antibody; MANA2 antibody; MANII antibody; Mann II antibody; Mannosidase alpha class 2A member 1 antibody; Mannosidase Two antibody; Mannosidase, alpha type II antibody; Mannosidase, alpha, II antibody; Mannosyl oligosaccharide 1 3 1 6 alpha mannosidase antibody; Mannosyl oligosaccharide 1,3 1,6 alpha mannosidase antibody; Mannosyl-oligosaccharide 1 antibody
BHE40_humanantibody; bHLHB2 antibody; bHLHe40 antibody; Class B Basic Helix Loop Helix Protein 2 antibody; Class B basic helix-loop-helix protein 2 antibody; Class E basic helix loop helix protein 40 antibody; Class E basic helix-loop-helix protein 40 antibody; Clast5 antibody; DEC1 antibody; Differentially expressed in chondrocytes protein 1 antibody; BHE40_humanantibody; bHLHB2 antibody; bHLHe40 antibody; Class B Basic Helix Loop Helix Protein 2 antibody; Class B basic helix-loop-helix protein 2 antibody; Class E basic helix loop helix protein 40 antibody; Class E basic helix-loop-helix protein 40 antibody; Clast5 antibody; DEC1 antibody; Differentially expressed in chondrocytes protein 1 antibody; E47 interaction protein 1 antibody; EIP1 antibody; Enhancer of split and hairy related protein 2 antibody; Enhancer-of-split and hairy-related protein 2 antibody; SHARP 2 antibody; SHARP-2 antibody; Stimulated by retinoic acid gene 13 protein antibody; STRA13 antibody
DAP1 antibody;
GAP modifying protein 1 antibody;
GMP 1 antibody;
OFC10 antibody;
PIC 1 antibody;
PIC1 antibody;
SENP2 antibody;
Sentrin 1 antibody;
Sentrin antibody;
Small ubiquitin related modifier 1 antibody;
Small ubiquitin-like modifier 1 antibody;
Small ubiquitin-related modifier 1 antibody;
SMT3 antibody;
SMT3 homolog 3 antibody;
SMT3 suppressor of mif two 3 homolog 1 antibody;
SMT3, yeast, homolog 3 antibody;
Smt3C antibody;
SMT3H3 antibody;
SUMO-1 antibody;
SUMO1 antibody;
SUMO1_humanantibody;
Ubiquitin homology domain protein PIC1 antibody;
Ubiquitin Like 1 antibody;
Ubiquitin like protein SMT3C antibody;
Ubiquitin like protein UBL1 antibody;
Ubiquitin-homology domain protein PIC1 antibody;
Ubiquitin-like protein SMT3C antibody;
Ubiquitin-like protein UBL1 antibody;
UBL 1 antibody;
UBL1 antibody
WB, ICC/IF, IHC-P, IP, FC, ChIP
Human, Mouse
SUMO1 Antibody (YA046) is a non-conjugated and Rabbit origined monoclonal antibody about 12 kDa, targeting to SUMO-1. It can be used for WB,ICC/IF,IHC-P,IP,FC,ChIP assays with tag free, in the background of Human, Mouse.
DCT 1 antibody;
dct-1 antibody;
DCT1 antibody;
Divalent cation transporter 1 antibody;
Divalent metal transporter 1 antibody;
DMT 1 antibody;
DMT-1 antibody;
DMT1 antibody;
FLJ37416 antibody;
Natural resistance associated macrophage protein 2 antibody;
Natural resistance-associated macrophage protein 2 antibody;
NRAM2_humanantibody;
NRAMP 2 antibody;
NRAMP2 antibody;
OK/SW-cl.20 antibody;
Slc11a2 antibody;
Solute carrier family 11 (proton coupled divalent metal ion transporters) member 2 antibody;
Solute carrier family 11 member 2 antibody
WB, IHC-P, FC
Human
DMT1 Antibody (YA4629) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA4629), targeting DMT1. DMT1 Antibody (YA4629) can be used for WB, IHC-P, FC experiment in human background.
COAA1_humanantibody;
Col10a 1 antibody;
COL10A1 antibody;
Collagen alpha 1(X) chain antibody;
Collagen alpha-1(X) chain antibody;
Collagen type X alpha 1 (Schmid metaphyseal chondrodysplasia) antibody;
Collagen type X alpha 1 antibody;
Collagen X alpha 1 polypeptide antibody;
CollagenX antibody;
fa66d11 antibody;
fb10c08 antibody;
OTTHUMP00000040411 antibody;
Procollagen type X alpha 1 antibody;
Schmid metaphyseal chondrodysplasia antibody;
wu:fa66d11 antibody;
wu:fb10c08 antibody;
WB
Human, Mouse, Rat
Collagen X Antibody is an unconjugated, approximately 66 kDa, rabbit-derived, anti-Collagen X monoclonal antibody. Collagen X Antibody can be used for: WB expriments in mouse, rat, human background without labeling.
CD32 antibody; CD32 antigen antibody; CD32B antibody; CDw32 antibody; Fc fragment of IgG; low affinity II; receptor for; CD32; antibody; Fc fragment of IgG; low affinity IIb; receptor antibody; Fc fragment of IgG; low affinity IIb; receptor; CD32; antibody; Fc fragment of IgG; low affinity IIb; receptor for; CD32; antibody; Fc fragment of IgG; low affinity IIb; receptor for antibody; Fc gamma receptor IIB antibody; Fc gamma RII antibody; Fc gamma RIIB antibody; Fc-gamma RII antibody; Fc-gamma RII-b antibody; Fc-gamma-RIIb antibody; FCG2 antibody; FCG2B_humanantibody; Fcgr2 antibody; FCGR2B antibody; FCRII antibody; FcRII-b antibody; IGFR2 antibody; IgG Fc receptor II beta antibody; IgG Fc receptor II-b antibody; Low affinity immunoglobulin gamma Fc region receptor II antibody; Low affinity immunoglobulin gamma Fc region receptor II-b antibody; Ly-17 antibody; Lym 1 antibody; Lymphocyte antigen 17 antibody; CD32 nanobody;
ELISA, FC
Human
CD32B Antibody (YA4679) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD32. It can be applicated for ELISA, FC assays, in the background of human.
CYP11A1 Antibody is an unconjugated, approximately 53 kDa, rabbit-derived, anti-CYP11A1 polyclonal antibody. CYP11A1 Antibody can be used for: WB,IHC-F,IHC-P,ICC/IF expriments in human, mouse, rat background without labeling.
Human, Mouse, Monkey, Goat, Hamster, Rat, Chlamydomonas Reinhardtii
Beta Tubulin Antibody (YA839) is a non-conjugated and Mouse origined monoclonal antibody about 50-55 kDa, targeting to Tubulin beta chain (TUBB). It can be used for WB,ICC/IF assays in the background of Human, Mouse, Monkey, Goat, Hamster, Rat, Chlamydomonas Reinhardtii.
Endo G Antibody (YA1529) is a non-conjugated IgG antibody, targeting Endo G, with a predicted molecular weight of 33 kDa (observed band size: 30 kDa). Endo G Antibody (YA1529) can be used for WB experiment in human, mouse, rat background.
SMURF2 Antibody (YA2372) is a non-conjugated IgG antibody, targeting SMURF2, with a predicted molecular weight of 86 kDa (observed band size: 86 kDa). SMURF2 Antibody (YA2372) can be used for WB experiment in human, mouse, rat background.
HGNC:17793 antibody; V SNARE antibody; v-SNARE antibody; Vesicle associated soluble NSF attachment protein receptor antibody; Vesicle transport through interaction with t SNAREs 1B antibody; Vesicle transport through interaction with t SNAREs homolog 1B (yeast) antibody; Vesicle transport through interaction with t-SNAREs homolog 1B antibody; Vesicle transport v-SNARE protein Vti1-like 1 antibody; VTI1 antibody; VTI1 like antibody; HGNC:17793 antibody; V SNARE antibody; v-SNARE antibody; Vesicle associated soluble NSF attachment protein receptor antibody; Vesicle transport through interaction with t SNAREs 1B antibody; Vesicle transport through interaction with t SNAREs homolog 1B (yeast) antibody; Vesicle transport through interaction with t-SNAREs homolog 1B antibody; Vesicle transport v-SNARE protein Vti1-like 1 antibody; VTI1 antibody; VTI1 like antibody; Vti1 rp1 antibody; VTI1-LIKE antibody; Vti1-rp1 antibody; VTI1B antibody; VTI1B_humanantibody; VTI1L antibody; VTI1L1 antibody; VTI2 antibody
Blast 2 antibody; BLAST-2 antibody; Blast2 antibody; C type lectin domain family 4 member J antibody; C-type lectin domain family 4 antibody; C-type lectin domain family 4 member J antibody; C-type lectin domain family 4; member J antibody; CD 23 antibody; CD 23A antibody; CD23 antibody; CD23 antigen antibody; CD23A antibody; CLEC 4J antibody; CLEC4J antibody; Fc epsilon receptor II antibody; Fc epsilon RII antibody; Fc fragment of IgE antibody; Fc fragment of IgE low affinity II receptor for antibody; Fc fragment of IgE receptor II antibody; Fc fragment of IgE; low affinity II; receptor for; CD23; antibody; Fc of IgE antibody; Fc of IgE; low affinity II; receptor for; CD23; antibody; Fc receptor IgE low affinity II alpha polypeptide antibody; Fc receptor; IgE; low affinity II; alpha polypeptide; isoform CRA_a antibody; Fc-epsilon-RII antibody; FCE 2 antibody; FCE2 antibody; FCER 2 antibody; Fcer2 antibody; FCER2_humanantibody; FCER2A antibody; FceRII antibody; IgE binding factor antibody; IgE receptor lymphocyte antibody; IgE-binding factor antibody; IGEBF antibody; Immunoglobulin E binding factor antibody; Immunoglobulin E receptor antibody; Immunoglobulin E receptor; low affinity II antibody; Immunoglobulin E-binding factor antibody; Immunoglobulin epsilon chain antibody; LEUKOCYTE ANTIGEN CD23 antibody; Low Affinity IgE Receptor antibody; Low affinity immunoglobulin epsilon Fc receptor antibody; Low affinity immunoglobulin epsilon Fc receptor membrane bound form antibody; Low affinity immunoglobulin epsilon Fc receptor soluble form antibody; Ly-42 antibody; Ly42 antibody; Lymphocyte antigen CD23 antibody; Lymphocyte IgE receptor antibody; MGC93219 antibody; CD23 nanobody
ELISA, FC
Human
CD23 Antibody (YA4669) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD23. It can be applicated for ELISA, FC assays, in the background of human.
DKFZp686C01211 antibody;
DNA binding factor KBF1 antibody;
DNA binding factor KBF1 EBP1 antibody;
DNA-binding factor KBF1 antibody;
EBP 1 antibody;
EBP-1 antibody;
EBP1 antibody;
KBF1 antibody;
MGC54151 antibody;
NF kappa B antibody;
NF kappaB antibody;
NF kappabeta antibody;
NF kB1 antibody;
NFkappaB antibody;
NFKB 1 antibody;
NFKB p105 antibody;
NFKB p50 antibody;
Nfkb1 antibody;
NFKB1_humanantibody;
Nuclear factor kappa B DNA binding subunit antibody;
Nuclear factor kappa-B, subunit 1 antibody;
Nuclear factor NF kappa B p105 subunit antibody;
Nuclear factor NF kappa B p50 subunit antibody;
Nuclear factor NF-kappa-B p50 subunit antibody;
Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody;
Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody;
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody;
p105 antibody;
p50 antibody;
p84/NF-kappa-B1 p98 antibody;
Transcription factor NFKB1 antibody
WB, ICC/IF, IHC-P
Human, Mouse
NF-κB p105/p50 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 50 kDa, targeting to NF-κB p105/p50. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.
MDM2 Antibody (YA3442) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA3442), targeting MDM2, with a predicted molecular weight of 55 kDa (observed band size: 90 kDa). MDM2 Antibody (YA3442) can be used for WB, ICC/IF, IHC-P experiment in human, monkey background.
CXCR5 Antibody (YA4714) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD185. It can be applicated for FC, ELISA assays, in the background of human.
Mouse-anti-human-Kappa-Light-Chain-antibody; Mouse Anti-human Ig kappa chain; Mouse Anti human Ig kappa chain
ELISA
Human
Mouse anti Human Kappa Light Chain is a mouse-derived and non-conjugated IgG1 recombinant monoclonal antibody, targeting to κ-Light Chain. It can be applicated for ELISA assays, in the background of human.
"Basic helix loop helix domain containing class B protein 7 antibody; Basic helix-loop-helix domain-containing protein, class B, 7 antibody; bHLHB7 antibody; bHLHe20 antibody; Class B basic helix loop helix protein 7 antibody; Class B basic helix-loop-helix protein 7 antibody; Class E basic helix loop helix protein 20 antibody; Class E basic helix-loop-helix protein 20 antibody; Olig3 antibody; OLIG3_humanantibody; "Basic helix loop helix domain containing class B protein 7 antibody; Basic helix-loop-helix domain-containing protein, class B, 7 antibody; bHLHB7 antibody; bHLHe20 antibody; Class B basic helix loop helix protein 7 antibody; Class B basic helix-loop-helix protein 7 antibody; Class E basic helix loop helix protein 20 antibody; Class E basic helix-loop-helix protein 20 antibody; Olig3 antibody; OLIG3_humanantibody; Oligo3 antibody; Oligodendrocyte lineage transcription factor 3 antibody; Oligodendrocyte specific bHLH transcription factor 3 antibody; Oligodendrocyte transcription factor 3 antibody; "
Activin binding protein; Follistatin; FS; fst; human follistatin gene
WB
Rat
Follistatin Antibody (YA2847) is a non-conjugated IgG antibody, targeting Follistatin, with a predicted molecular weight of 38 kDa (observed band size: 38 kDa). Follistatin Antibody (YA2847) can be used for WB experiment in rat background.
12S1644 antibody; D12S1644 antibody; IL 4 STAT antibody; IL-4 Stat antibody; IL4 STAT antibody; Interleukin 4 Induced antibody; Interleukin 4 Induced Transcription Factor IL4 STAT antibody; Signal transducer and activator of transcription 6 antibody; Signal Transducer And Activator Of Transcription 6 Interleukin 4 Induced antibody; Signal Transducer And Activator Of Transcription 6 Nirs Variant 1 antibody; Signal transducer and activator of transcription 6, interleukin 4 induced antibody;
STAT 6 antibody; STAT interleukin4 induced antibody; STAT, interleukin4 induced antibody; Stat6 antibody; STAT6_humanantibody; STAT6B antibody; STAT6C antibody; Transcription factor IL 4 STAT antibody;
WB, ICC/IF, IHC-P, IP
Human, Mouse
STAT6 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 94 kDa, targeting to STAT6. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse.
SRD5A2 Antibody is an unconjugated, approximately 28 kDa, rabbit-derived, anti-SRD5A2 monoclonal antibody. SRD5A2 Antibody can be used for: WB, IP expriments in human, rat background without labeling.
S6K1 Antibody is an unconjugated, approximately 59 kDa, rabbit-derived, anti-S6K1 monoclonal antibody. S6K1 Antibody can be used for: WB, ICC/IF, IP expriments in human, rat, mouse background without labeling.
DNA topoisomerase 2 binding protein 1 antibody; DNA topoisomerase 2-binding protein 1 antibody; DNA topoisomerase II binding protein 1 antibody; DNA topoisomerase II binding protein antibody; DNA topoisomerase II-beta-binding protein 1 antibody; DNA topoisomerase II-binding protein 1 antibody; DNA topoisomerase IIbeta binding protein 1 antibody; Hypothetical protein KIAA0259 [Fragment] antibody; KIAA0259 antibody; TOP2BP1 antibody; DNA topoisomerase 2 binding protein 1 antibody; DNA topoisomerase 2-binding protein 1 antibody; DNA topoisomerase II binding protein 1 antibody; DNA topoisomerase II binding protein antibody; DNA topoisomerase II-beta-binding protein 1 antibody; DNA topoisomerase II-binding protein 1 antibody; DNA topoisomerase IIbeta binding protein 1 antibody; Hypothetical protein KIAA0259 [Fragment] antibody; KIAA0259 antibody; TOP2BP1 antibody; TOPB1_humanantibody; TOPBP 1 antibody; TopBP1 antibody; Topoisomerase (DNA) II binding protein 1 antibody; Topoisomerase II binding protein 1 antibody
Basic domain helix loop helix protein class B 1 antibody; Basic helix loop helix protein class B 1 antibody; BHLHB antibody; bHLHB1 antibody; bHLHe19 antibody; Class B basic helix loop helix protein 1 antibody; Class B basic helix-loop-helix protein 1 antibody; class E basic helix loop helix protein 19 antibody; Class E basic helix-loop-helix protein 19 antibody; human protein kinase C binding protein RACK17 antibody; Basic domain helix loop helix protein class B 1 antibody; Basic helix loop helix protein class B 1 antibody
EPX Antibody is an unconjugated, approximately 79 kDa, rabbit-derived, anti-EPX polyclonal antibody. EPX Antibody can be used for: IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat background without labeling.
Human IgG4 Antibody (YA3327) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3327), targeting Human IgG4, with a predicted molecular weight of 36 kDa (observed band size: 36 kDa). Human IgG4 Antibody (YA3327) can be used for WB, IHC-P experiment in human background.
LRRK2 Antibody (YA2821) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2821), targeting LRRK2, with a predicted molecular weight of 286 kDa (observed band size: 286 kDa). LRRK2 Antibody (YA2821) can be used for WB, IHC-P, ICC/IF experiment in human, mouse background.
IRS-1 Antibody is an unconjugated, approximately 137 kDa, rabbit-derived, anti-IRS1 polyclonal antibody. IRS-1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat and predicted: chicken background without labeling.
OCLN_human; Occludin; Ocl; BLCPMG; PPP1R115; PTORCH1; Tight junction protein occludin;
WB, IHC-P, ICC/IF
Human, Mouse, Rat
OCLN Antibody is an unconjugated, approximately 59 kDa, rabbit-derived, anti-OCLN polyclonal antibody. OCLN Antibody can be used for: WB,IHC-P,ICC/IF expriments in human, mouse, rat background without labeling.
HCAK1; Ig kappa chain C region; IGKC; IMMUNOGLOBULIN InV; Km
WB, IHC-P, ICC/IF
Human
Human kappa Light Chain Antibody (YA1996) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1996), targeting Human kappa Light Chain, with a predicted molecular weight of 12 kDa (observed band size: 26 kDa). Human kappa Light Chain Antibody (YA1996) can be used for WB, IHC-P, ICC/IF experiment in human background.
Claudin 11 Antibody (YA2334) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2334), targeting Claudin 11, with a predicted molecular weight of 22 kDa (observed band size: 22 kDa). Claudin 11 Antibody (YA2334) can be used for WB, FC experiment in human, mouse, rat background.
Phospho-LRRK2(Ser935) Antibody is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3424), targeting LRRK2, with a predicted molecular weight of 286 kDa (observed band size: 286 kDa). Phospho-LRRK2(Ser935) Antibody can be used for WB,ICC/IF experiment in human, mouse background.
FLJ14301; OODD; Protein Wnt-10a ; SSPS; STHAG4; Wingless type MMTV integration site family member 10A antibody; WN10A_human; wnt10a
WB, ELISA
Human, Mouse, Goat
Wnt10a Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Wnt10a, with a predicted molecular weight of 46 kDa. Wnt10a Antibody can be used for WB, ELISA experiments in human, mouse, goat backgrounds.
Growth hormone receptor Antibody is an unconjugated, approximately 68 kDa, rabbit-derived, anti-Growth hormone receptor polyclonal antibody. Growth hormone receptor Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, sheep background without labeling.
MPO Antibody is an unconjugated, approximately 84 kDa, rabbit-derived, anti-MPO polyclonal antibody. MPO Antibody can be used for: ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, and predicted: rat, dog, horse, rabbit, guinea pig background without labeling.
Cdc2 related protein kinase; CDC28; CDC2A; Cdk 2; CDK1; CDK2; CDK2_human ; CDKN2; MPF; p33(CDK2) antibody;
WB, ICC/IF, IHC-P, IP, FC
Human, Mouse, Rat
CDK2 Antibody (YA514) is a non-conjugated and Rabbit origined monoclonal antibody about 34 kDa, targeting to Cdk2. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse,Rat.
Oxytocin Receptor Antibody is an unconjugated, approximately 43 kDa, rabbit-derived, anti-Oxytocin R polyclonal antibody. Oxytocin Receptor Antibody can be used for: WB, ELISA, IHC-P expriments in human, mouse, rat, and predicted: dog, pig, cow, horse background without labeling.
ERp28; ERP29_human; ERp31; HEL S 107; PDI-DB; PDIA9
WB, IHC-P, ICC/IF
Human, Mouse, Rat
ERp29 Antibody (YA1793) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1793), targeting ERp29, with a predicted molecular weight of 29 kDa (observed band size: 29 kDa). ERp29 Antibody (YA1793) can be used for WB, IHC-P, ICC/IF experiment in human, mouse, rat background.
FPR3 Antibody (YA3905) is a mouse-derived and non-conjugated IgG1 antibody, targeting to FPR3. It can be applicated for IHC-P, FC, ELISA assays, in the background of human.
lamin B1 Antibody (YA6359) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to lamin B1. It can be applicated for WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC assays, in the background of human, mouse, rat.
Aquaporin 5 Antibody is an unconjugated, approximately 29 kDa, rabbit-derived, anti-Aquaporin 5 polyclonal antibody. Aquaporin 5 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, sheep background without labeling.
CD220; HHF5; human insulin receptor; Insr; Insulin receptor subunit beta; IR 1; IR
WB, ICC/IF
Human, Rat
Insulin Receptor Antibody (YA1540) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1540), targeting Insulin Receptor, with a predicted molecular weight of 156 kDa (observed band size: 95 kDa). Insulin Receptor Antibody (YA1540) can be used for WB, ICC/IF experiment in human, rat background.
MPO Antibody is an unconjugated, approximately 84 kDa, mouse-derived, anti-MPO monoclonal antibody. MPO Antibody can be used for: WB, IHC-P, IF-Cell, IF-Tissue expriments in human, mouse, rat background without labeling.
LDLR Antibody is an unconjugated, approximately 92 kDa, rabbit-derived, anti-LDLR monoclonal antibody. LDLR Antibody can be used for: WB, IHC-P expriments in human, mouse background without labeling.
MPO Antibody is an unconjugated, approximately 84 kDa, mouse-derived, anti-MPO monoclonal antibody. MPO Antibody can be used for: WB, IHC-P, FC, IF-Cell, IF-Tissue expriments in human, mouse, rat background without labeling.
Major synaptic vesicle protein p38; MRX96; MRXSYP; Syn p38; Synaptophysin; Syp; SYPH; SYPH_human; SypI
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Synaptophysin Antibody (YA5802) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Synaptophysin. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_human; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_human; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa Cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_humanantibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 5/6 Antibody (YA5599) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 5/6. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
58 kDa cytokeratin; CK-5; CK5; Cytokeratin-5; Cytokeratin5; DDD; DDD1; EBS2; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K2C5_human; K5; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; Keratin 5; Keratin; keratin complex 2, basic, gene 5; keratin, type II cytoskeletal 5; Keratin-5; Keratin5; KRT 5; Krt5; KRT5A; type II cytoskeletal 5; Type-II keratin Kb5; CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_human; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12; 58 kDa cytokeratin antibody; CK-5 antibody; CK5 antibody; Cytokeratin-5 antibody; Cytokeratin5 antibody; DDD antibody; DDD1 antibody; EBS2 antibody; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types antibody; K2C5_humanantibody; K5 antibody; keratin 5; epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types; antibody; Keratin 5 antibody; Keratin antibody; keratin complex 2, basic, gene 5 antibody; keratin, type II cytoskeletal 5 antibody; Keratin-5 antibody; Keratin5 antibody; KRT 5 antibody; Krt5 antibody; KRT5A antibody; type II cytoskeletal 5 antibody; Type-II keratin Kb5 antibody
IHC-P, ELISA
Human
Cytokeratin 5/6 Antibody (YA5676) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 5/6. It can be applicated for IHC-P, ELISA assays, in the background of human.
IGHG2; immunoglobulin Gm2; immunoglobulin heavy constant gamma 2 (G2m marker)
WB, IHC-P, ICC/IF
Human
Human IgG2 Antibody (YA2196) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2196), targeting Human IgG2, with a predicted molecular weight of 36 kDa (observed band size: 53 kDa). Human IgG2 Antibody (YA2196) can be used for WB, IHC-P, ICC/IF experiment in human background.
DRD2 Antibody is an unconjugated, approximately 51 kDa, rabbit-derived, anti-DRD2 polyclonal antibody. DRD2 Antibody can be used for: WB expriments in rat, mouse and predicted: human background without labeling.
Bone morphogenetic protein 2; BMP 2; BMP 2A; BMP2A; BMP-2; BMP2_human.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse, Rat
BMP-2 Antibody is an unconjugated, approximately 13/44 kDa, rabbit-derived, anti-BMP2 polyclonal antibody. BMP-2 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, cow, horse, rabbit, sheep background without labeling.
DHCR7 Antibody is a rabbit-derived non-conjugated IgG antibody, targeting DHCR7, with a predicted molecular weight of 54 kDa (observed band size: 54 kDa). DHCR7 Antibody can be used for WB,
ELISA experiments in mouse backgrounds.
CD34 Antibody is an unconjugated, approximately 39 kDa, rabbit-derived, anti-CD34 polyclonal antibody. CD34 Antibody can be used for: WB, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, dog, pig, cow, rabbit background without labeling.
Lamin B1 Antibody (YA5329) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Lamin B1. It can be applicated for WB assays, in the background of human, mouse, monkey.
Leptin Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Leptin, with a predicted molecular weight of 16 kDa . Leptin Antibody can be used for IHC-P, IHC-F, ICC/IF, ELISA experiments in human, mouse, rat, pig, sheep backgrounds.
CD34 Antibody (YA6360) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD34. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue, IP assays, in the background of human, mouse, rat.
Calponin-1 Antibody (YA6377) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CNN1. It can be applicated for WB, IHC-P, IF-Tissue, IHC-F assays, in the background of human, mouse, rat.
IL-23R Antibody is a non-conjugated IgG antibody, targeting IL-23R, with a predicted molecular weight of 72 kDa (observed band size: 72 kDa). IL-23R Antibody can be used for WB, IHC-P experiment in human background.
Desmin Antibody (YA5603) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Desmin. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Desmin Antibody (YA5746) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Desmin. It can be applicated for IHC-P, ELISA assays, in the background of human, mouse, rat.
Desmin Antibody (YA5806) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Desmin. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
hCG beta Antibody (YA5743) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to hCG β. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.
Neutrophil Elastase Antibody is an unconjugated, approximately 26 kDa, rabbit-derived, anti-Neutrophil Elastase monoclonal antibody. Neutrophil Elastase Antibody can be used for: WB,IHC-P,ICC/IF,FC expriments in human background without labeling.
Occludin Antibody is an unconjugated, approximately 59 kDa, rabbit-derived, anti-Occludin polyclonal antibody. Occludin Antibody can be used for: IHC-P, IHC-F, Flow-Cyt, IF, ELISA expriments in human, mouse, rat, and predicted: dog, pig, cow, sheep background without labeling.
PTPRC; CD45; Receptor-type tyrosine-protein phosphatase C; Leukocyte common antigen; L-CA; T200; CD antigen CD45
FC
Human
Purified Mouse Anti-Human CD45RA Antibody (YA3628) is a non-conjugated and Mouse origined monoclonal antibody , targeting to CD45RA. It can be used for FC assays, in the background of Human.
AKT 1; AKT; AKT1; AKT1_human ; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha ; Proto-oncogene c-Akt; RAC Alpha;
IHC-P, IHC-F, ICC/IF, IP, FC
Human, Mouse
AKT1 Antibody (YA634) is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to AKT1. It can be used for IHC-P, IP, FC, IHC-Fr, IF-Cell assays with tag free, in the background of Human, Mouse.
Zinc finger BED domain containing 4; Zinc finger BED domain containing protein 4; Zinc finger BED type containing 4; ZBED4_human.
WB
Human
ZBED4 Antibody is a rabbit-derived non-conjugated IgG antibody , targeting ZBED4 Antibody , with a predicted molecular weight of 130 kDa (observed band size:135 kDa). ZBED4 Antibody can be used for WB experiment in human background.
KIAA1936; SET and MYND domain containing 4; SET and MYND domain-containing protein 4; SMYD4; SMYD4_human; ZMYND21.
WB
Human
SMYD4 Antibody (YA5282) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SMYD4. It can be applicated for WB assays, in the background of human.
CLDN1 Antibody is an unconjugated, approximately 23 kDa, rabbit-derived, anti-CLDN1 monoclonal antibody. CLDN1 Antibody can be used for: WB, IHC-P expriments in Human, Mouse, Rat background without labeling.
PTPRC; CD45; Receptor-type tyrosine-protein phosphatase C; Leukocyte common antigen; L-CA; T200; CD antigen CD45
FC
Human
Mouse Anti-Human CD45RA Antibody (PE/Cy7) is a non-conjugated and Mouse origined monoclonal antibody , targeting to CD45RA. It can be used for FC assays, in the background of Human.
Toll-Like Receptor 3 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 105 kDa, targeting to Toll-Like Receptor 3 . It can be used for WB, IHC-P, IHC-F, IF, ELISA assays with tag free, in the background of Human, Mouse, Rat.
AFP Antibody (YA914) is an unconjugated, approximately 65 kDa, mouse-derived, anti-AFP (YA914) monoclonal antibody. AFP Antibody (YA914) can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, rat, background without labeling.
AFP Antibody (YA915) is an unconjugated, approximately 69 kDa, rabbit-derived, anti-AFP (YA915) monoclonal antibody. AFP Antibody (YA915) can be used for: WB,IHC-P,ICC/IF,FC expriments in human background without labeling.
Lysozyme Antibody (YA5480) is a mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to Lysozyme. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Ah receptor; Aromatic hydrocarbon receptor; Aryl hydrocarbon receptor; Aryl hydrocarbon receptor precursor; BHLHE76; Class E basic helix loop helix protein 76; HGNC:348; AHR_human.
WB, ICC/IF
Human
Aryl hydrocarbon Receptor Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 96 kDa, targeting to Aryl hydrocarbon Receptor. It can be used for WB,ICC/IF assays with tag free, in the background of Human.
BNSP Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 35 kDa, targeting to IBSP. It can be used for WB, IHC-P assays with tag free, in the background of Human, Mouse.
IFNG; IFG; IFI; IFN Gamma; IFN Immune; IFN-gamma; IFNG; IFNG_human; Immune Interferon; Interferon gamma; Interferon Gamma Precursor; Macrophage Activating Factor; MAF; T Cell Interferon; Type II Interferon.
WB, ICC/IF, FC
Human, Mouse, Rat
IFN gamma Antibody is an unconjugated, approximately 19 kDa, rabbit-derived, anti-IFN gamma monoclonal antibody. IFN gamma Antibody can be used for: WB,ICC/IF,FC expriments in human, mouse,rat background without labeling.
Toll-like Receptor 7 Antibody (YA5330) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TLR7. It can be applicated for WB assays for exogenous protein in transfected cells.
Thrombomodulin Antibody (YA5534) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD141. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Toll-Like Receptor 7 Antibody (YA6381) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TLR7. It can be applicated for FC, WB assays, in the background of human.
LRP2_human; Low-density lipoprotein receptor-related protein 2; LDL receptor related protein 2; DBS; GP330; LRP-2; Glycoprotein 330(gp330); Megalin;
IHC-P, WB, IF-Tissue, IHC-F, ICC/IF
Mouse, Rat, Human
LRP2 Antibody (YA6390) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LRP2. It can be applicated for IHC-P, WB, IF-Tissue, IHC-F, ICC/IF assays, in the background of mouse, rat, human.
beta Arrestin 1 Antibody (YA822) is a non-conjugated and Mouse origined monoclonal antibody about 47 kDa, targeting to beta Arrestin 1 (6A1). It can be used for WB assays with tag free, in the background of Human.
MTR1A_human; Melatonin receptor type 1A; Melatonin Receptor 1A; Mel-1A-R; Mel1a receptor; MT1; MT 1; Mel 1A R
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse, Rat
MTNR1A Antibody is an unconjugated, approximately 39 kDa, rabbit-derived, anti-MTNR1A polyclonal antibody. MTNR1A Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, sheep, guinea pig background without labeling.
Toll-Like Receptor 3 Antibody (YA5327) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TLR3. It can be applicated for WB assays for exogenous protein in transfected cells.
Cell Death Activator; Cell death activator CIDE-3; Cell death inducing DFFA like effector protein C; CIDE 3; CIDE C; CIDEC_human; FLJ20871; FPLD5; FSP27; CIDE-3
WB, ELISA, IHC-P, IHC-F, FC, ICC/IF
Human, Mouse, Rat
FSP27/CIDEC Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-CIDEC/FSP27 polyclonal antibody. FSP27/CIDEC Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: pig backgrounds without labeling.
MYOG_human; MYOG; BHLHC3; MYF4; Class C basic helix-loop-helix protein 3 (bHLHc3); Myogenic factor 4 (Myf-4); BHLHC3; MYF4; MYF 4
WB, IHC-P, FC
Human, Mouse, Rat
Myogenin Antibody is an unconjugated, approximately 25 kDa, rabbit-derived, anti-Myogenin monoclonal antibody. Myogenin Antibody can be used for: WB, IHC-P, FC expriments in human, mouse, rat background without labeling.
hnRNP U Antibody (YA979) is a non-conjugated IgG1 antibody, targeting hnRNP U, with a predicted molecular weight of 91 kDa (observed band size: 110 kDa). hnRNP U Antibody (YA979) can be used for WB experiment in human background.
hnRNP U Antibody (YA980) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA980), targeting hnRNP U, with a predicted molecular weight of 91 kDa (observed band size: 120 kDa). hnRNP U Antibody (YA980) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat background.
Elongation factor 2 Antibody (YA5227) is a mouse-derived and non-conjugated monoclonal antibody, targeting to eEF2. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.
hnRNP U Antibody (YA5235) is a mouse-derived and non-conjugated monoclonal antibody, targeting to hnRNP U. It can be applicated for WB assays, in the background of human.
TERT Antibody is an unconjugated, approximately 125 kDa, rabbit-derived, anti-TERT polyclonal antibody. TERT Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, background without labeling.
Cyclin D2/CCND2 Antibody (YA5215) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Cyclin D2. It can be applicated for WB assays, in the background of human.
Lamin B2 Antibody (YA5332) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Lamin B2. It can be applicated for WB assays, in the background of human, mouse.
Cell Death Activator; Cell death activator CIDE-3; Cell death inducing DFFA like effector protein C; CIDE 3; CIDE C; CIDEC_human; FLJ20871; FPLD5; FSP27; CIDE-3
WB, ICC/IF, FC
Human
FSP27/CIDEC Antibody (YA911) is an unconjugated, approximately 27 kDa, mouse-derived, anti-CIDEC (YA911) monoclonal antibody. FSP27/CIDEC Antibody (YA911) can be used for: WB, ICC/IF, FC expriments in human background without labeling.
Mannose Phosphate Isomerase Antibody (YA5198) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Mannose Phosphate Isomerase. It can be applicated for WB, ICC assays, in the background of human, rat.
GATA6 Antibody (YA5199) is a mouse-derived and non-conjugated monoclonal antibody, targeting to GATA6. It can be applicated for WB assays, in the background of human.
CKM; CKMM; Creatine kinase M; Creatine kinase M chain; Creatine kinase M type; Creatine kinase M-type; Creatine kinase muscle; Creatine kinase, muscle type; KCRM_human; M-CK; MCK; Muscle creatine kinase.
ELISA
Human
Creatine Kinase MM Antibody (YA5317) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CK-MM. It can be applicated for ELISA assays, in the background of human.
Prostatic Acid Phosphatase Antibody (YA5619) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Prostatic Acid Phosphatase. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Calumenin Antibody (YA813) is a non-conjugated and Mouse origined monoclonal antibody about 37 kDa, targeting to Calumenin (4C6). It can be used for WB assays with tag free, in the background of Human, Mouse.
TERT Antibody is an unconjugated, approximately 125 kDa, rabbit-derived, anti-TERT monoclonal antibody. TERT Antibody can be used for: WB, IHC-P, Flow-Cyt expriments in human background without labeling.
CHL; chordin like 1; Chordin-like protein 1; CHRDL1; CRDL1_human; dA141H5.1; neuralin 1; Neuralin-1; Neurogenesin-1; NRLN1; Ventroptin; VOPT.
WB, IHC-P, ICC
Human
CHRDL1 Antibody (YA5233) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CHRDL1. It can be applicated for WB, IHC-P, ICC assays, in the background of human.
Calumenin Antibody (YA5246) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Calumenin. It can be applicated for WB assays, in the background of human, mouse.
MGC2648; Protein Wnt-5b; Wingless type MMTV integration site family, member 5B; WNT 5B; WNT 5B protein; Wnt5b; WNT5B protein; WNT5B_human.
WB
Transfected
Wnt5b Antibody (YA5323) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Wnt5b. It can be applicated for WB assays for exogenous protein in transfected cells.
HDAC4 Antibody (YA741) is a non-conjugated and Mouse origined monoclonal antibody about 119 kDa, targeting to HDAC4 (4A3). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat, Monkey.
CSDD1; FLJ12457; LIN 28; Lin-28A; LIN28; LIN28A; LN28A_human; Protein lin-28 homolog A; ZCCHC1; Zinc finger CCHC domain-containing protein 1.
WB
Human, Mouse
LIN28A Antibody (YA711) is a non-conjugated and Mouse origined monoclonal antibody about 23 kDa, targeting to LIN28A (2C1). It can be used for WB assays with tag free, in the background of Human, Mouse.
ACAN Antibody is an unconjugated, rabbit-derived, anti-ACAN monoclonal antibody. ACAN Antibody can be used for:IHC-P expriments in human background without labeling.
IL-10 Antibody is an unconjugated, approximately 18 kDa, rabbit-derived, anti-IL-10 monoclonal antibody. IL-10 Antibody can be used for: WB, ICC, FC expriments in human background without labeling.
MMP-7 Antibody is an unconjugated, approximately 30 kDa, rabbit-derived, anti-MMP7 polyclonal antibody. MMP-7 Antibody can be used for: ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat background without labeling.
CD166 Antibody is an unconjugated, approximately 65 kDa, rabbit-derived, anti-CD166 monoclonal antibody. CD166 Antibody can be used for: WB,IHC-F,IHC-P,ICC/IF,IP expriments in human, mouse, rat background without labeling.
Ferritin L chain; Ferritin L subunit; Ferritin light chain; Ferritin light polypeptide; Ferritin light polypeptide like 3; FRIL; FRIL_human; FTL; L apoferritin; LFTD; MGC71996; NBIA 3; NBIA3.
ELISA
Human
Ferritin Light Chain Antibody (YA971) is a mouse-derived non-conjugated IgG2b antibody (Clone NO.: YA971), targeting Ferritin Light Chain. Ferritin Light Chain Antibody (YA971) can be used for ELISA experiment in human background.
Ferritin L chain; Ferritin L subunit; Ferritin light chain; Ferritin light polypeptide; Ferritin light polypeptide like 3; FRIL; FRIL_human; FTL; L apoferritin; LFTD; MGC71996; NBIA 3; NBIA3.
ELISA
Human
Ferritin Light Chain Antibody (YA972) is a mouse-derived non-conjugated IgG2a antibody (Clone NO.: YA972), targeting Ferritin Light Chain. Ferritin Light Chain Antibody (YA972) can be used for ELISA experiment in human background.
ALB; ALBU_human; Albumin (32 AA); Albumin (AA 34); Albumin; Analbuminemia; Bisalbuminemia; Cell growth inhibiting protein 42; DKFZp779N1935; Dysalbuminemic hyperthyroxinemia; Growth inhibiting protein 20; HSA; Hyperthyroxinemia dysalbuminemic; Serum albumin.
ELISA
Human
Albumin Antibody (YA984) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA984), targeting Human Serum Albumin. Albumin Antibody (YA984) can be used for ELISA experiment in human background.
ALB; ALBU_human; Albumin (32 AA); Albumin (AA 34); Albumin; Analbuminemia; Bisalbuminemia; Cell growth inhibiting protein 42; DKFZp779N1935; Dysalbuminemic hyperthyroxinemia; Growth inhibiting protein 20; HSA; Hyperthyroxinemia dysalbuminemic; Serum albumin.
WB, ELISA
Human
Albumin Antibody (YA985) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA985), targeting Human Serum Albumin, with a predicted molecular weight of 69 kDa (observed band size: 69 kDa). Albumin Antibody (YA985) can be used for WB, ELISA experiment in human background.
IL-10 Antibody is an unconjugated, approximately 21 kDa, rabbit-derived, anti-IL-10 monoclonal antibody. IL-10 Antibody can be used for: WB, IF-Cell, IHC-P expriments in human, mouse, rat background without labeling.
CSDD1; FLJ12457; LIN 28; Lin-28A; LIN28; LIN28A; LN28A_human; Protein lin-28 homolog A; ZCCHC1; Zinc finger CCHC domain-containing protein 1.
WB
Human, Mouse
LIN28A Antibody (YA5266) is a mouse-derived and non-conjugated monoclonal antibody, targeting to LIN28A. It can be applicated for WB assays, in the background of human, mouse.
Ferritin L chain; Ferritin L subunit; Ferritin light chain; Ferritin light polypeptide; Ferritin light polypeptide like 3; FRIL; FRIL_human; FTL; L apoferritin; LFTD; MGC71996; NBIA 3; NBIA3.
ELISA
Human
Ferritin Light Chain Antibody (YA5300) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Ferritin Light Chain. It can be applicated for ELISA assays, in the background of human.
VE-Cadherin Antibody (YA3491) is an unconjugated, approximately 88 kDa, rabbit-derived, anti-CD144/VE Cadherin monoclonal antibody. VE-Cadherin Antibody (YA3491) can be used for: WB, IF-Cell, FC expriments in human, mouse, rat, background without labeling.
Vitamin D3 receptor; 125 dihydroxyvitamin D3 receptor; 1 antibody 1,25-@dihydroxyvitamin D3 receptor; 125 dihydroxyvitamin D3 receptor; 25-dihydroxyvitamin D3 receptor; NR1I1; Nuclear receptor subfamily 1 group I member 1; VDR; VDR_human; Vitamin D (1,25- dihydroxyvitamin D3) receptor; Vitamin D hormone receptor; Vitamin D receptor; Vitamin D3 receptor,
IHC-P, IHC-F, ICC/IF
Human, Rat
Vitamin D Receptor Antibody is an unconjugated, approximately 47 kDa, rabbit-derived, anti-Vitamin D Receptor polyclonal antibody. Vitamin D Receptor Antibody can be used for: IHC-P, IHC-F, ICC, IF expriments in human, rat, and predicted: mouse, chicken, pig, cow, horse, rabbit background without labeling.
Cellular oncogene fos; FBJ murine osteosarcoma viral v fos oncogene homolog antibody FBJ Osteosarcoma Virus; FOS; FOS protein; G0 G1 switch regulatory protein 7; G0S7; Oncogene FOS; Proto oncogene protein c fos; v fos FBJ murine osteosarcoma viral oncogene homolog; AP-1; p55; FOS_human; Proto-oncogene c-Fos; G0/G1 switch regulatory protein 7.
FC
Human
c-Fos Antibody (YA6349) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to c-Fos. It can be applicated for FC assays, in the background of human.
CEA Antibody (YA917) is an unconjugated, approximately 150-200 kDa, rabbit-derived, anti-CEA (YA917) monoclonal antibody. CEA Antibody (YA917) can be used for: WB,IHC-P,ICC/IF expriments in human, background without labeling.
CXCR4 Antibody is an unconjugated, approximately 40 kDa, rabbit-derived, anti-CXCR4 polyclonal antibody. CXCR4 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: cow, rabbit background without labeling.
Choline O acetyltransferase; Choline O acetyltransferase; Acetyl CoA choline O acetyltransferase; Acetyl CoA:choline O acetyltransferase; ChAT; CHOACTase; Choline acetylase; choline acetyltransferase; CMS1A; CMS1A2; EC 2.3.1.6; OTTHUMP00000019583; OTTHUMP00000019584; CLAT_human.
WB, IHC-P, ICC/IF, IP, FC
Human, Mouse, Rat
ChAT Antibody is an unconjugated, approximately 82 kDa, rabbit-derived, anti-ChAT monoclonal antibody. ChAT Antibody can be used for: WB,IHC-P,ICC/IF,FC,IPexpriments in human, mouse, rat background without labeling.
SCF Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-SCF monoclonal antibody. SCF Antibody can be used for: WB, IHC-P, ICC/IF, FC expriments in human background without labeling.
SNAI1_human; Zinc finger protein SNAI1; SNAI1; SNAH; SNAI 1; SNA; SNAIL1; dJ710H13.1; Protein snail homolog 1 (Protein sna); Protein snail homolog 1; Protein sna
WB, IHC-P, ICC/IF, ELISA
Human, Mouse
SNAI1 Antibody is an unconjugated, approximately 29 kDa, rabbit-derived, anti-SNAI1 polyclonal antibody. SNAI1 Antibody can be used for: WB,IHC-P,ICC/IF,ELISA expriments in human,and mouse background without labeling.
ApoA-I Antibody (YA3481) is an unconjugated, approximately 31 kDa, rabbit-derived, anti-APOA1 monoclonal antibody. ApoA-I Antibody (YA3481) can be used for: WB,IHC-P,ICC/IF,IP expriments in human, mouse background without labeling.
Scavenger receptor cysteine-rich type 1 protein M130; CD 163; CD163 antigen; CD163 molecule; Hemoglobin Scavenger Receptor; M130; M130 antigen precursor; Macrophage associated antigen; MM130; C163A_human.
WB, IHC-P, IHC-F, ICC/IF
Human, Mouse
CD163 Antibody is an unconjugated, approximately 130 kDa, rabbit-derived, anti-CD163 polyclonal antibody. CD163 Antibody can be used for: WB, IHC-P, IHC-F, ICC/IF expriments in human, mouse, and predicted: rat, dog, pig, horse background without labeling.
K1C18_human; Keratin, type I cytoskeletal 18; KRT18; CYK18; Cell proliferation-inducing gene 46 protein; Cytokeratin-18 (CK-18); Keratin-18 (K18); PIG46; Keratin 18;
WB, ELISA, IHC-P, IHC-F, FC, ICC/IF
Human, Mouse, Rat
Cytokeratin 18 Antibody is an unconjugated, approximately 48 kDa, rabbit-derived, anti-CK18 polyclonal antibody. Cytokeratin 18 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, rabbit background without labeling.
Osteocalcin Propeptide; Gamma-carboxyglutamic acid-containing protein; Bone Gla-protein; BGLAP; Bone gamma carboxyglutamate protein; BGLAP; BGP; Bone gamma carboxyglutamate gla protein osteocalcin; Bone gamma carboxyglutamate protein; Bone Gla protein; Gamma carboxyglutamic acid containing protein; OC; PMF1; OSTCN_human.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse
Osteocalcin Antibody is an unconjugated, approximately 11 kDa, rabbit-derived, anti-Osteocalcin polyclonal antibody. Osteocalcin Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat background without labeling.
F2 Antibody is a non-conjugated IgG antibody, targeting F2, with a predicted molecular weight of 70 kDa (observed band size: 76 kDa). F2 Antibody can be used for WB, IP experiment in human background.
TGFBI Antibody (YA2268) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2268), targeting TGFBI, with a predicted molecular weight of 75 kDa (observed band size: 68 kDa). TGFBI Antibody (YA2268) can be used for WB, IHC-P experiment in human, mouse, rat background.
DAK1; DAP K1; DAP kinase 1; DAPK 1; DAPK; DAPK1; DAPK1_human; Death Associated Protein Kinase 1; Death-associated protein kinase 1
WB, IHC-P, ICC/IF
Human, Mouse, Rat
DAP Kinase 1 Antibody (YA2798) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2798), targeting DAP Kinase 1, with a predicted molecular weight of 160 kDa (observed band size: 160 kDa). DAP Kinase 1 Antibody (YA2798) can be used for WB, IHC-P, ICC/IF experiment in human, mouse, rat background.
Myelin Protein Zero Rabbit pAb; peripheral myelin prothein Zero; MPZ; MPP; Myelin P0 protein; CHM; CMT1; CMT1B; DSS; MYELIN GLYCOPROTEIN P-ZERO; MYELIN PROTEIN PERIPHERAL; Myelin protein zero; P0; MYP0_human.
WB
Rat
Myelin Protein Zero Antibody (YA4637) is a rabbit-derived non-conjugated IgG antibody, targeting MPZ, with a predicted molecular weight of 28 kDa (observed band size: 28 kDa). MPZ Antibody can be used for WB experiments in rat backgrounds.
ZO1_human; Tight junction protein ZO-1; TJP1; ZO1; Tight junction protein 1; Zona occludens protein 1; Zonula occludens protein 1; ZO1 tight junction protein;
WB, IHC-P, ICC/IF
Human, Mouse, Rat, Monkey
ZO-1/TJP1 Antibody is an unconjugated, approximately 191 kDa, rabbit-derived, anti-ZO-1/TJP1 monoclonal antibody. ZO-1/TJP1 Antibody can be used for: WB, IF-Cell, IHC-P expriments in Human, Mouse, Rat, Monkey background without labeling.
AGM1; Constant region of heavy chain of IgM; DKFZp686I15196; DKFZp686I15212; FLJ00385; Ig mu chain C region; IGHM; Immunoglobin heavy constant mu; Immunoglobulin mu; MGC104996; MGC52291; MU; VH.
ELISA
Human
Human IgM Antibody (YA5304) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IgM. It can be applicated for ELISA assays, in the background of human.
Perforin Antibody (YA5638) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Perforin. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CD19 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 61 kDa, targeting to CD19. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human.
General transcription factor IIB; General transcription factor TFIIB; gtf2b; RNA polymerase II transcription factor IIB; S300 II; S300-II; TF IIB; TF2B; TF2B_human; TFIIB; Transcription initiation factor IIB.
WB
Human, Mouse, Monkey
Transcription Initiation Factor IIB Antibody (YA1054) is a non-conjugated IgG2b antibody, targeting Transcription Initiation Factor IIB, with a predicted molecular weight of 35 kDa (observed band size: 35 kDa). Transcription Initiation Factor IIB Antibody (YA1054) can be used for WB experiment in human, mouse, monkey background.
General transcription factor IIB; General transcription factor TFIIB; gtf2b; RNA polymerase II transcription factor IIB; S300 II; S300-II; TF IIB; TF2B; TF2B_human; TFIIB; Transcription initiation factor IIB.
WB, IP
Human, Mouse, Rat
Transcription Initiation Factor IIB Antibody (YA1055) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1055), targeting Transcription Initiation Factor IIB, with a predicted molecular weight of 35 kDa (observed band size: 31 kDa). Transcription Initiation Factor IIB Antibody (YA1055) can be used for WB, IP experiment in human, mouse, rat background.
Aquaporin 4 Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Aquaporin 4, with a predicted molecular weight of 36 kDa (observed band size: 34 kDa). Aquaporin 4 Antibody can be used for WB, IHC-P, IHC-F, FC, ICC/IF experiments in human, mouse, rat, pig, cow, rabbit, sheep backgrounds.
General transcription factor IIB; General transcription factor TFIIB; gtf2b; RNA polymerase II transcription factor IIB; S300 II; S300-II; TF IIB; TF2B; TF2B_human; TFIIB; Transcription initiation factor IIB.
WB
Human, Mouse, Monkey
Transcription Initiation Factor IIB Antibody (YA5179) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TFIIB. It can be applicated for WB assays, in the background of human, mouse, monkey.
FLJ36922; FLJ55954; OTTHUMP00000165834; PP-T; PP5; PPP5; PPP5_human; PPP5C; PPT; Protein phosphatase 5, catalytic subunit; Protein phosphatase T; Serine/threonine protein phosphatase 5; Serine/threonine-protein phosphatase 5.
WB
Human
PP5 Antibody (YA5211) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PP5. It can be applicated for WB assays, in the background of human.
Musashi 1/Msi1 Antibody (YA5255) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Musashi-1. It can be applicated for WB assays, in the background of human, mouse, rat.
MGC119418; MGC119419; MGC119420; Protein Wnt 3a Precursor; Protein Wnt-3a; Wingless type MMTV integration site family member 3A; Wnt 3a; wnt3a; WNT3A protein; WNT3A_human.
WB
Human
Wnt3a Antibody (YA5319) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Wnt3a. It can be applicated for WB assays, in the background of human.
DnaJ homolog subfamily B member 1; DnaJ protein homolog 1; Heat shock 40 kDa protein 1; HSP40; Heat shock protein 40; human DnaJ protein 1; hDj-1;
IHC-P, WB
Human, Mouse, Rat
Hsp40 Antibody (YA5395) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HSP40. It can be applicated for IHC-P, WB assays, in the background of human, mouse, rat.
Uroplakin III Antibody (YA5622) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Uroplakin III. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
Tyrosinase Antibody (YA5658) is a mouse-derived and non-conjugated IgA monoclonal antibody, targeting to Tyrosinase. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
Tyrosinase Antibody (YA5745) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Tyrosinase. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.
Granzyme B Antibody (YA5992) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Granzyme B. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.
Beclin-1; ATG6; beclin1; VPS30; Beclin 1 like protein 1; 4921513J16Rik; 5430417M23Rik; ATG6; BECLIN 1; BECN1; MGC6843; BECN1_human.
IHC-P, WB, IF-Tissue, IHC-F
Human, Mouse, Rat
Beclin 1 Antibody (YA6368) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Beclin 1. It can be applicated for IHC-P, WB, IF-Tissue, IHC-F assays, in the background of human, mouse, rat.
K1C18_human; Keratin, type I cytoskeletal 18; KRT18; CYK18; Cell proliferation-inducing gene 46 protein; Cytokeratin-18(CK-18); Keratin-18(K18); PIG46; Keratin 18;
WB, IHC-P, IHC-F, ICC/IF, IF-Tissue
Human, Mouse, Rat
Cytokeratin 18 Antibody (YA6415) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to CK18. It can be applicated for WB, IHC-P, IHC-F, ICC/IF, IF-Tissue assays, in the background of human, mouse, rat.
beta Catenin Antibody (YA6422) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Beta catenin. It can be applicated for WB assays, in the background of human, mouse, rat.
14-3-3 protein eta; 1433F_human; Brain protein 14-3-3; eta isoform; HGNC:12853; Protein AS1; Tyrosine 3/tryptophan 5 monooxygenase activation protein eta polypeptide; YWHA 1; YWHA1; Ywhah.
WB
Human, Mouse, Rat
14-3-3 eta Antibody (YA838) is a non-conjugated and Mouse origined monoclonal antibody about 28 kDa, targeting to 14-3-3 eta (5F2). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
CBR1 Antibody (YA810) is a non-conjugated and Mouse origined monoclonal antibody about 30 kDa, targeting to CBR1 (2C9). It can be used for WB,ICC/IF assays with tag free, in the background of Human.
Myogenic differentiation 1; AI503393; bHLHc1; MD1; MGC156574; MYF3; MYOD; MYOD1; PUM; MYOD1_human; Class C basic helix-loop-helix protein 1; bHLHc1; Myogenic factor 3; Myf-3.
WB, ELISA
Human, Mouse, Rat, Chicken
MyoD1/Myf3 Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-MyoD1/Myf3 polyclonal antibody. MyoD1/Myf3 Antibody can be used for: WB, ELISA expriments in human, mouse, rat, and chicken background without labeling.
StARD1; Cholesterol trafficker; Luteinizing hormone induced protein; Mitochondrial steroid acute regulatory protein; StAR related lipid transfer (START) domain containing 1; StARD1; START domain containing protein 1; Steroidogenic Acute Regulatory Protein; Steroidogenic acute regulatory protein mitochondrial; STAR_human.
WB
Human, Mouse
StAR Antibody is an unconjugated, approximately 32 kDa, rabbit-derived, anti-StAR monoclonal antibody. StAR Antibody can be used for: WB expriments in human, mouse background without labeling.
Adhesion related kinase; AI323647; Ark; Axl; AXL oncogene; AXL receptor tyrosine kinase; AXL transforming gene; AXL transforming sequence/gene; EC 2.7.10.1; JTK11; Oncogene AXL; Tyro7; Tyrosine protein kinase receptor UFO; Tyrosine-protein kinase receptor UFO; UFO; UFO_human.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse
Axl Antibody is an unconjugated, approximately 95 kDa, rabbit-derived, anti-AXL polyclonal antibody. Axl Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, dog, horse, rabbit background without labeling.
FLJ36922; FLJ55954; OTTHUMP00000165834; PP-T; PP5; PPP5; PPP5_human; PPP5C; PPT; Protein phosphatase 5; catalytic subunit; Protein phosphatase T; Serine/threonine protein phosphatase 5; Serine/threonine-protein phosphatase 5.
WB
Human
PP5 Antibody (YA1069) is a non-conjugated IgG2a antibody, targeting PPP5C, with a predicted molecular weight of 57 kDa (observed band size: 57 kDa). PP5 Antibody (YA1069) can be used for WB experiment in human background.
FEN1 Antibody (YA5294) is a mouse-derived and non-conjugated monoclonal antibody, targeting to FEN-1. It can be applicated for WB, ICC assays, in the background of human, mouse, rat, monkey, hamster.
FEN1 Antibody (YA5295) is a mouse-derived and non-conjugated monoclonal antibody, targeting to FEN-1. It can be applicated for WB, IP assays, in the background of human, mouse, rat.
ACDCR1; ADIPO R1; Adiponectin receptor protein 1; ADIPOR 1; ADIPOR1; CGI-45; CGI-45 protein; FLJ25385; PAQR1; Progestin and adipoQ receptor family member I; TESBP1A; ADR1_human.
ICC/IF, IHC-P, FC
Human, Mouse
Adiponectin receptor protein 1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to Adiponectin receptor protein 1. It can be used for ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.
Endothelial Kruppel like zinc finger protein; Epithelial zinc finger protein EZF; EZF; GKLF; Gut-enriched krueppel-like factor; KLF; KLF4; KLF4_human; Krueppel-like factor 4; Kruppel like factor 4; Epithelial zinc finger protein EZF; Gut enriched Krueppel
WB
Human, Mouse, Rat
KLF4 Antibody (YA716) is a non-conjugated and Mouse origined monoclonal antibody about 55 kDa, targeting to KLF4 (3B3). It can be used for WB assays with tag free, in the background of Transfected.
alpha pal; alpha palindromic binding protein; Alpha palindromic-binding protein; Alpha-pal; locus control region factor 1; NFE2 related factor 1; NRF-1; Nrf1; NRF1_human; Nuclear respiratory factor 1; transcription factor 11.
WB, IHC-F, IHC-P, ICC/IF, IP
Human, Mouse, Rat
NRF-1 Antibody (YA260) is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to Nrf1. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.
ANM 1; ANM1; ANM1_human; complete cds; HCP 1; HCP1; Heterogeneous nuclear ribonucleoprotein methyltransferase 1 like 2; Heterogeneous nuclear ribonucleoproteins methyltransferase like 2; Heterogeneous nuclear ribonucleoproteins methyltransferase like2; Hi
WB
Human
PRMT1 Antibody (YA686) is a non-conjugated and Mouse origined monoclonal antibody about 42 kDa, targeting to PRMT1 (4E9). It can be used for WB assays with tag free, in the background of Human.
Calponin 1 Antibody is an unconjugated, approximately 33 kDa, rabbit-derived, anti-Calponin 1 monoclonal antibody. Calponin 1 Antibody can be used for: WB,IHC-P,ICC/IF expriments in human, mouse, rat, and predicted: dog, pig background without labeling.
CPT1A Antibody is an unconjugated, approximately 86 kDa, rabbit-derived, anti-CPT1A polyclonal antibody. CPT1A Antibody can be used for: IHC-P, IHC-F, ICC/IF expriments in human，mouse, and predicted: rat background without labeling.
BRICD4; BRICHOS domain containing 4; CHM1 LIKE; CHM1L; Chondromodulin I like; Chondromodulin I like protein; Chondromodulin-1-like protein; Chondromodulin-I-like protein; hChM1L; hTeM; Myodulin; TEM; Tendin; Tenomodulin; Tenomodulin protein; TNMD; TNMD_human; UNQ771/PRO1565.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse, Rat
TNMD Antibody is an unconjugated, approximately 37 kDa, rabbit-derived, anti-TNMD polyclonal antibody. TNMD Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, rabbit, sheep background without labeling.
alpha pal; alpha palindromic binding protein; Alpha palindromic-binding protein; Alpha-pal; locus control region factor 1; NFE2 related factor 1; NRF-1; Nrf1; NRF1_human; Nuclear respiratory factor 1; transcription factor 11.
WB
Human
NRF-1 Antibody (YA5263) is a mouse-derived and non-conjugated monoclonal antibody, targeting to NRF-1. It can be applicated for WB assays, in the background of human.
IL18BP Antibody (YA5271) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IL18BP. It can be applicated for WB assays, in the background of human.
Leptin Antibody (YA5310) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Leptin. It can be applicated for ELISA assays, in the background of human.
CD5 Antibody (YA5588) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD5. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Wilms Tumor Protein Antibody (YA5623) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Wilms' Tumor 1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat, pig.
Calretinin Antibody (YA5634) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Calretinin. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
FLJ39988; FLJ40036; FLJ40253; FLJ40587; FLJ40789; FLJ40834; G1m marker; G2m marker; G3m marker; G4m marker; HDC; Heavy chain disease protein; human immunglobulin G; Ig gamma 1 chain C region; Ig gamma 2 chain C region; Ig gamma 3 chain C region.
ELISA
Human
Human IgG Antibody (YA5301) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IgG. It can be applicated for ELISA assays, in the background of human.
OPGL; CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_human.
WB, IHC-P, ELISA
Human, Mouse, Rat
RANKL Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-RANKL/CD254 polyclonal antibody. RANKL Antibody can be used for: WB, IHC-P, ELISA expriments in human, mouse, rat background without labeling.
Cytokeratin 5 Antibody (YA953) is a non-conjugated IgG1 antibody, targeting Cytokeratin pan, with a predicted molecular weight of 62 kDa (observed band size: 62 kDa). Cytokeratin 5 Antibody (YA953) can be used for WB experiment in human, mouse, rat background.
Cytokeratin 5 Antibody (YA954) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA954), targeting Cytokeratin pan. Cytokeratin 5 Antibody (YA954) can be used for IHC-P, ICC/IF experiment in human background.
GCDFP-15 Antibody (YA5607) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GCDFP-15. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
MIG9; Migration inducing gene 9; Protein S100-E; Protein S100-P; Protein S100P; S100 calcium binding protein P; S100 calcium-binding protein P; S100 P; S100E; S100P; S100P_human
IHC-P, ICC/IF, ELISA
Human
S100P Antibody (YA5748) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to S100P. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.
GCCR; GCR; GCR_human; GCRST; glucocorticoid nuclear receptor variant 1; Glucocorticoid receptor; GR; GRL; Grl1; nr3c1; Nuclear receptor subfamily 3 group C member 1; nuclear receptor subfamily 3, group C, member 1; glucocorticoid receptor;
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Glucocorticoid Receptor Antibody (YA6231) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glucocorticoid Receptor. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
C20orf21; DACA 1; DACA-1; Dermatomyositis associated with cancer putative autoantigen 1; YTH domain family 1; YTH domain family member 1; YTH domain family protein 1; YTHD1; YTHD1_human; Ythdf1;
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
YTHDF1 Antibody (YA6237) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to YTHDF1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
DNAJB1; DNAJ1; HDJ1; HSPF1; DnaJ homolog subfamily B member 1; DnaJ protein homolog 1; Heat shock 40 kDa protein 1; HSP40; Heat shock protein 40; human DnaJ protein 1; hDj-1
WB
Human
Hsp40 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 38 kDa, targeting to Hsp40. It can be used for WB assays with tag free, in the background of Human.
High temperature requirement protein A2; HTRA 2; HtrA like serine protease; HtrA serine peptidase 2; HtrA; E. coli; homolog of; 2; HtrA2; HTRA2_human; mitochondrial; Omi stress regulated endoprotease; Omi stress-regulated endoprotease; PARK 13; PARK13; Pr
WB, IP
Human
HtrA2/Omi Antibody (YA726) is a non-conjugated and Mouse origined monoclonal antibody about 49 kDa, targeting to HtrA2 (8G11). It can be used for WB,IP assays with tag free, in the background of Human.
Thioredoxin Reductase 2 Antibody (YA661) is a non-conjugated and Mouse origined monoclonal antibody about 57 kDa, targeting to Thioredoxin Reductase 2 (3F2). It can be used for WB assays with tag free, in the background of Human.
CD11c Antibody is an unconjugated, approximately 126 kDa, rabbit-derived, anti-CD11c polyclonal antibody. CD11c Antibody can be used for: ELISA, Flow-Cyt expriments in human, rat, and predicted: mouse, dog background without labeling.
EphA3 Antibody (YA1517) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1517), targeting EPHA3. EphA3 Antibody (YA1517) can be used for FC, ELISA experiment in human background.
NR0B2; NR0B2_human; Nr0b2a; Nuclear receptor subfamily 0 group B member 2; Nuclear receptor subfamily 0, group B, member 2a; Orphan nuclear receptor SHP; SHP; SHP-1; Shp1; Small heterodimer partner.
WB, IHC-P, ICC/IF
Mouse, Rat
NR0B2 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 28 kDa, targeting to NR0B2. It can be used for WB,IHC-P,IF assays with tag free, in the background of Mouse, Rat.
Thioredoxin Reductase 2 Antibody (YA5251) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TXNRD2. It can be applicated for WB assays, in the background of human.
Myelin Basic Protein Antibody (YA5613) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MBP. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Cytokeratin 20; CK 20; Cytokeratin20; K20; Keratin 20; Keratin type I cytoskeletal 20; Keratin20; KRT 20; KRT 21; KRT20; KRT21; MGC35423; Protein IT; K1C20_human.
WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC
Human, Rat
Cytokeratin 20 Antibody (YA6352) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CK20. It can be applicated for WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC assays, in the background of human, rat.
Metalloproteinase inhibitor 2 precursor; Tissue inhibitor of metalloproteinases 2; Collagenase inhibitor; CSC 21K; CSC21K; TIMP2; TIMP 2; TIMP 2; TIMP metallopeptidase inhibitor 2; TIMP2_human; Metalloproteinase inhibitor 2; CSC-21K; TIMP-2.
WB, IHC-P, FC
Human
TIMP2 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 24 kDa, targeting to TIMP2. It can be used for WB, IHC-P,Flow-Cytassays with tag free, in the background of Human.
Cdk 5; Cdk5; CDK5_human; Cell division protein kinase 5; Crk6; Cyclin dependent kinase 5; Cyclin-dependent kinase 5; Protein kinase CDK5 splicing; PSSALRE; Serine threonine protein kinase PSSALRE; Serine/threonine-protein kinase PSSALRE; Tau protein kinas
WB, ICC/IF
Human, Mouse, Rat, Monkey
CDK5 Antibody (YA796) is a non-conjugated and Mouse origined monoclonal antibody about 33 kDa, targeting to CDK5 (2E8). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat, Monkey.
ADRB2 Antibody is an unconjugated, approximately 46 kDa, rabbit-derived, anti-ADRB2 polyclonal antibody. ADRB2 Antibody can be used for: WB expriments in human, mouse, rat, and predicted: dog, rabbit background without labeling.
GPR43 Antibody is an unconjugated, approximately 37 kDa, rabbit-derived, anti-GPR43 polyclonal antibody. GPR43 Antibody can be used for: ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, and predicted: rat background without labeling.
DNAJA1; DNAJ2; HDJ2; HSJ2; HSPF4; DnaJ homolog subfamily A member 1; DnaJ protein homolog 2; HSDJ; Heat shock 40 kDa protein 4; Heat shock protein J2; HSJ-2; human DnaJ protein 2; hDj-2
WB, IP, FC
Human, Mouse, Rat
DNAJA1 Antibody (YA2748) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2748), targeting DNAJA1, with a predicted molecular weight of 45 kDa (observed band size: 45 kDa). DNAJA1 Antibody (YA2748) can be used for WB, IP, FC experiment in human, mouse, rat background.
Gli 1; Gli1; Gli-1; GLI; GLI Kruppel family member 1; Glioma associated oncogene; Glioma associated oncogene homolog 1 (zinc finger protein); Oncogene GLI; Zfp 5; Zfp5; Zinc finger protein GLI 1; Zinc finger protein GLI1; GLI1_human.
WB, IHC-P, IHC-F, ICC/IF, FC
Human, Mouse, Rat
Gli1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 118 kDa, targeting to Gli1. It can be used for WB,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.
BOP; CD8 beta opposite; CD8b opposite; Histone lysine N methyltransferase SMYD1; KMT3D; SET and MYND domain-containing protein 1; SMYD1; SMYD1_human; Zinc finger MYND domain containing 18; ZMYND18; ZMYND22; zinc finger, MYND domain containing 18.
WB
Rat
SMYD1 Antibody (YA5193) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SMYD1. It can be applicated for WB assays, in the background of rat.
Cyclin H Antibody (YA5224) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Cyclin H. It can be applicated for WB, IP assays, in the background of human.
Switch Associated Protein 70 Antibody (YA5257) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SWAP70. It can be applicated for WB, IP assays, in the background of human, mouse, rat, monkey.
SOX9 Antibody (YA6367) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SOX9. It can be applicated for WB, IHC-P, IF-Tissue, IHC-F assays, in the background of human, mouse, rat.
PI3 Kinase p85 beta Antibody (YA688) is a non-conjugated and Mouse origined monoclonal antibody about 82 kDa, targeting to PI3 Kinase p85 beta (8D9). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
mitochondrial; ODPA_human; PDH; PDHA; PDHA1; PDHCE1A; PDHE1 A type I; PDHE1-A type I; PHE1A; Pyruvate Dehydrogenase (lipoamide) alpha 1; Pyruvate dehydrogenase complex; E1 alpha polypeptide 1; Pyruvate Dehydrogenase E1 alpha; Pyruvate dehydrogenase E1 com
WB, ICC/IF
Human, Mouse
Pyruvate Dehydrogenase E1 alpha Antibody (YA681) is a non-conjugated and Mouse origined monoclonal antibody about 43 kDa, targeting to Pyruvate Dehydrogenase E1 alpha (3H2). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse.
Substance P Antibody is an unconjugated, approximately 1.4/13 kDa, rabbit-derived, anti-Substance P polyclonal antibody. Substance P Antibody can be used for: IHC-P, Flow-Cyt, ICC expriments in human, mouse, rat, guinea pig, and predicted: pig, cow, horse, rabbit, sheep background without labeling.
CD16 Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-CD16 polyclonal antibody. CD16 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: pig, cow, rabbit, sheep background without labeling.
FABP 1; FABP1; FABP1; FABPL; FABPL_human; Fatty Acid Binding Protein 1; Fatty acid binding protein 1 liver; Fatty Acid Binding Protein; Fatty acid-binding protein 1; Fatty acid-binding protein; Fatty acid-binding protein liver; L FABP; L-FABP; liver; Liver-type fatty acid-binding protein.
ELISA
Human
liver FABP Antibody (YA965) is a non-conjugated IgG1 antibody, targeting FABP1, with a predicted molecular weight of 14 kDa. liver FABP Antibody (YA965) can be used for ELISA experiment in human background.
FABP 1; FABP1; FABP1; FABPL; FABPL_human; Fatty Acid Binding Protein 1; Fatty acid binding protein 1 liver; Fatty Acid Binding Protein; Fatty acid-binding protein 1; Fatty acid-binding protein; Fatty acid-binding protein liver; L FABP; L-FABP; liver; Liver-type fatty acid-binding protein.
WB, IHC-F, IHC-P, ICC/IF
Mouse
liver FABP Antibody (YA967) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA967), targeting FABP1, with a predicted molecular weight of 14 kDa (observed band size: 14 kDa). liver FABP Antibody (YA967) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in mouse background.
NUP98 Antibody (YA1010) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1010), targeting NUP98, with a predicted molecular weight of 198 kDa (observed band size: 98 kDa). NUP98 Antibody (YA1010) can be used for WB, IP experiment in human background.
NUP98 Antibody (YA1011) is a non-conjugated IgG antibody, targeting NUP98, with a predicted molecular weight of 198 kDa (observed band size: 98 kDa). NUP98 Antibody (YA1011) can be used for WB experiment in human background.
Hexokinase I Antibody (YA5220) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HXK I. It can be applicated for WB assays, in the background of human, mouse, rat.
SAFB1 Antibody (YA5230) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SAFB1. It can be applicated for WB, ICC assays, in the background of human.
NUP98 Antibody (YA5241) is a mouse-derived and non-conjugated monoclonal antibody, targeting to NUP98. It can be applicated for WB, IP assays, in the background of human.
CKMT2 Antibody (YA5252) is a mouse-derived and non-conjugated monoclonal antibody, targeting to sMtCK. It can be applicated for WB assays, in the background of rat.
HDAC3 Antibody (YA5254) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HDAC3. It can be applicated for WB assays, in the background of human, mouse, rat.
Cell cycle checkpoint control protein; Cell cycle checkpoint control protein RAD9A; DNA repair exonuclease rad9 homolog A; hRAD 9; hRAD9; Rad 9; RAD 9A; RAD9; S pombe; homolog; RAD9 homolog A; RAD9 homolog; RAD9A; RAD9A_human.
WB, IP
Human, Mouse, Rat, Monkey
Rad9 Antibody (YA5262) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RAD9A. It can be applicated for WB, IP assays, in the background of human, mouse, rat, monkey.
High temperature requirement protein A2; HTRA 2; HtrA like serine protease; HtrA serine peptidase 2; HtrA, E. coli, homolog of, 2; HtrA2; HTRA2_human; mitochondrial; Omi stress regulated endoprotease; Omi stress-regulated endoprotease; PARK 13; PARK13; Protease serin
WB
Human
HtrA4/Omi Antibody (YA5287) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HTRA2. It can be applicated for WB assays, in the background of human.
Int 4; INT4; MGC131950; MGC138321; MGC138323; Proto-oncogene Int-4 homolog; Proto-oncogene Wnt-3; wingless type MMTV integration site family member 3; Wnt 3 proto oncogene protein; WNT 3 proto oncogene protein precursor; wnt3; WNT3_human.
WB
Transfected
Wnt3 Antibody (YA5324) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Wnt3. It can be applicated for WB assays for exogenous protein in transfected cells.
FABP 1; FABP1; FABP1; FABPL; FABPL_human; Fatty Acid Binding Protein 1; Fatty acid binding protein 1 liver; Fatty Acid Binding Protein; Fatty acid-binding protein 1; Fatty acid-binding protein; Fatty acid-binding protein liver; L FABP; L-FABP; liver; Liver-type fatty acid-binding protein.
ELISA
Human
liver FABP Antibody (YA5325) is a mouse-derived and non-conjugated monoclonal antibody, targeting to L-FABP. It can be applicated for ELISA assays, in the background of human.
OTTHUMP00000020114; OTTHUMP00000020115; OTTHUMP00000020116; Plasma retinol binding protein 4; Plasma retinol-binding protein; Plasma retinol-binding protein; 1-176; PRBP; PRO2222; RBP; RBP4; RDCCAS; RET4_human; Retinol binding protein 4; Retinol binding protein 4 interstitial; Retinol binding protein 4 plasma.
ELISA
Human
RBP4 Antibody (YA5326) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RBP4. It can be applicated for ELISA assays, in the background of human.
Basic calponin; Calponin 1; Calponin 1 basic smooth muscle; Calponin H1; Calponin H1 smooth muscle; Calponin-1; Calponin1; Calponins basic; CNN 1; Cnn1; CNN1_human; Epididymis secretory protein Li 14; HEL S 14; Sm Calp; SMCC; smooth muscle
IHC-P, WB, ICC/IF, ELISA
Human
Calponin-1 Antibody (YA5530) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Calponin-1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Glycophorin A Antibody (YA5608) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Glycophorin A. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Endothelial Kruppel like zinc finger protein; EZF; GKLF; KLF; Kruppel like factor 4(Epithelial zinc finger protein EZF)(Gut enriched Krueppel like factor); Kruppel like factor 4(gut); Krueppel-like factor 4; EZF; GKLF; KLF 4; KLF-4; Krueppel like factor 4; KLF4_human.
WB, IHC-P, IHC-F, ICC/IF, FC
Human, Mouse, Rat
KLF4 Antibody (YA6358) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KLF4. It can be applicated for WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC assays, in the background of human, mouse, rat.
phospho-HSF1 (Ser326) Antibody (YA6363) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to phosphorylated HSF1 (Ser326). It can be applicated for WB, IHC-P, IHC-F, IF-Tissue, FC assays, in the background of human, mouse.
IL17A Antibody is an unconjugated, approximately 15 kDa, rabbit-derived, anti-IL17A polyclonal antibody. IL17A Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in mouse, rat, background without labeling.
Sonic hedgehog; Vhh-1; Sonic hedgehog protein; SHH; HHG 1; HHG1; HLP 3; HLP3; Holoprosencephaly 3; HPE 3; HPE3; MCOPCB5; SMMC I; SMMCI; Sonic Hedgehog (Drosophila) homolog; sonic hedgehog homolog (Drosophila); Sonic hedgehog homolog; Sonic hedgehog protein; TPT; TPTPS; Sonic hedgehog protein N-product; SHH_human.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse, Rat
Shh Antibody is an unconjugated, approximately 19/47 kDa, rabbit-derived, anti-Shh polyclonal antibody. Shh Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, cow, horse, rabbit background without labeling.
Ferroportin 1; Ferroportin-1; FPN1; HFE4; IREG1; Iron regulated transporter 1; Iron-regulated transporter 1; MTP1; S40A1_human; SLC40A1; Solute carrier family 40 member 1; MST079; MSTP079; MTP1; SLC11A3.
WB, ELISA
Human
SLC40A1 Antibody is an unconjugated, approximately 63 kDa, rabbit-derived, anti-SLC40A1 polyclonal antibody. SLC40A1 Antibody can be used for: WB, ELISA expriments in human, and predicted: mouse, rat, dog, pig, rabbit background without labeling.
Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_human; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.
WB, IHC-P, ICC/IF, FC
Human
PD-1 Antibody is an unconjugated, approximately 32 kDa, rabbit-derived, anti-PD-1 monoclonal antibody. PD-1 Antibody can be used for: WB, IHC-P, Flow-Cyt, IF/ICC expriments in human background without labeling.
carm1; CARM1_human; Coactivator associated arginine methyltransferase 1; Coactivator-associated arginine methyltransferase 1; Histone arginine methyltransferase CARM 1; Histone arginine methyltransferase CARM1; Histone-arginine methyltransferase CARM1; PRMT 4; PRMT4; Protein arginine methyltransferase; Protein arginine N methyltransferase 4; Protein arginine N-methyltransferase 4.
WB, IP
Human, Mouse
CARM1 Antibody (YA5184) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CARM1. It can be applicated for WB, IP assays, in the background of human, mouse.
Cdk 5; Cdk5; CDK5_human; Cell division protein kinase 5; Crk6; Cyclin dependent kinase 5; Cyclin-dependent kinase 5; Protein kinase CDK5 splicing; PSSALRE; Serine threonine protein kinase PSSALRE; Serine/threonine-protein kinase PSSALRE; Tau protein kinase II catalytic subunit; TPKII catalytic subunit.
WB, ICC
Human, Mouse, Rat, Monkey
CDK5(N-term) Antibody (YA5225) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CDK5 (N-term). It can be applicated for WB, ICC assays, in the background of human, mouse, rat, monkey.
MDA-9; MDA9; Melanoma differentiation-associated protein 9; Pro-TGF-alpha cytoplasmic domain-interacting protein 18; Scaffold protein Pbp1; SDCB1_human; Sdcbp; SDCBP; ST1; SYCL; Syndecan binding protein; syntenin; Syndecan binding protein 1; Syndecan-binding protein 1; Syntenin 1; Syntenin-1; TACIP18.
WB
Human
Syntenin-1 Antibody (YA5231) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Syntenin. It can be applicated for WB assays, in the background of human.
beta Arrestin 1 Antibody (YA5236) is a mouse-derived and non-conjugated monoclonal antibody, targeting to β-Arrestin 1. It can be applicated for WB assays, in the background of mouse, rat, human.
HRES 1 / RAB4; Oncogene RAB4; OTTHUMP00000042824; Rab 4; RAB 4A; RAB4 member RAS oncogene family; RAB4A; RAB4A member RAS oncogene family; RAB4A_human; Ras related protein Rab 4A; Ras related protein Rab4A; Ras-related protein Rab-4A.
WB
Human, Mouse, Rat, Monkey
Rab4 Antibody (YA5249) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RAB4A. It can be applicated for WB assays, in the background of human, mouse, rat, monkey.
AKT 1; AKT; AKT1; AKT1_human; C AKT; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha; Protein kinase B; Proto-oncogene c-Akt; RAC Alpha; RAC; RAC PK Alpha; RAC Serine/Threonine Protein Kinase; RAC-alpha serine/threonine-protein kinase; RAC-PK-alpha; vAKT Murine Thymoma Viral Oncogene Homolog 1
WB
Mouse, Transfected
AKT1 Antibody (YA5253) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Akt1. It can be applicated for WB assays for mouse background or exogenous protein in transfected cells.
CBR1 Antibody (YA5259) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CBR1. It can be applicated for WB, ICC assays, in the background of human.
Annexin VI Antibody (YA5267) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Annexin VI. It can be applicated for WB assays, in the background of human.
RBBP 5; RBBP-5; RBBP5; RBBP5_human; RBQ 3; RBQ3; Retinoblastoma binding protein 5; Retinoblastoma binding protein RBQ3; Retinoblastoma binding protein5; Retinoblastoma-binding protein 5; Retinoblastoma-binding protein RBQ-3; SWD1; SWD1, Set1c WD40 repeat protein, homolog.
WB, ICC/IF
Human, Mouse, Rat
RbBP5 Antibody (YA5309) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RBBP5. It can be applicated for WB, ICC/IF assays, in the background of human, mouse, rat.
Glypican 3 Antibody (YA5609) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Glypican-3. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
MAGE-C1 Antibody (YA5624) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to MAGE-C1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Deafness; Deafness X-linked 7; DFN7; FAEES3; Fatty Acid Ethyl Ester Synthase III; Glutathione S Transferase 3; Glutathione S Transferase Pi; Glutathione S-transferase P; Glutathione S-transferase pi 1; GST class-pi; GST3; GSTP; Gstp1; GSTP1-1; GSTP1_human; PI; X linked 7
IHC-P, WB, ICC/IF, ELISA
Human, Mouse,
GST-Pi Antibody (YA5627) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to GST-Pi. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
Glypican 3 Antibody (YA5632) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Glypican-3. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
MAGE-C1 Antibody (YA5633) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MAGE-C1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
MUC6 Antibody (YA5667) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MUC6. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.
UCHL1 / PGP9.5; UCHL1; B220; CD 45; CD45; cd45 antigen; ec3.1.3.48; GP 180; GP180; human homolog of severe combined immunodeficiency due to PTPRC deficiency; L CA; L-CA; lca; Leukocyte common antigen; LY 5; LY5; Protein tyrosine phosphatase receptor type
WB, IHC-P, IHC-F, ICC/IF, IP
Human, Mouse, Rat
PGP9.5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to PGP9.5. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.
Muscarinic Acetylcholine receptor M3 Antibody is an unconjugated, approximately 66 kDa, rabbit-derived, anti-Muscarinic Acetylcholine receptor M3 monoclonal antibody. Muscarinic Acetylcholine receptor M3 Antibody can be used for: WB expriments in human background without labeling.
GLP-1R Antibody is an unconjugated, approximately 51 kDa, rabbit-derived, anti-GLP-1R polyclonal antibody. GLP-1R Antibody can be used for: WB, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, and predicted: dog background without labeling.
GADD153; CHOP; Growth arrest and DNA damage-inducible 153; C/EBP homologous protein; C/EBP Homology Protein; CEBPZ; CHOP10; DDIT 3; DNA Damage Inducible Transcript 3; GADD 153; Growth Arrest and DNA Damage Inducible Protein 153; Growth arrest and DNA damage inducible protein GADD153; MGC4154; DDIT3_human.
WB, IHC-P, ICC/IF
Human, Mouse, Rat
DDIT3 Antibody is an unconjugated, approximately 19 kDa, rabbit-derived, anti-DDIT3 polyclonal antibody. DDIT3 Antibody can be used for: WB, IHC-P, IF expriments in human, mouse, rat background without labeling.
CK 7; CK-7; ck7; Cytokeratin 7; Cytokeratin-7; Cytokeratin7; D15Wsu77e; K2C7; K2C7_human; K7; Keratin 55k type ii cytoskeletal; Keratin 7; Keratin simple epithelial type 1 k7; Keratin type II cytoskeletal 7
WB, ICC/IF
Human
Cytokeratin 7 Antibody (YA950) is a mouse-derived non-conjugated IgG2b antibody (Clone NO.: YA950), targeting Cytokeratin 7, with a predicted molecular weight of 51 kDa (observed band size: 55 kDa). Cytokeratin 7 Antibody (YA950) can be used for WB, ICC/IF experiment in human background.
CK 7; CK-7; ck7; Cytokeratin 7; Cytokeratin-7; Cytokeratin7; D15Wsu77e; K2C7; K2C7_human; K7; Keratin 55k type ii cytoskeletal; Keratin 7; Keratin simple epithelial type 1 k7; Keratin type II cytoskeletal 7
WB, IHC-F, IHC-P, ICC/IF, IP
Human, Mouse, Rat
Cytokeratin 7 Antibody (YA951) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA951), targeting Cytokeratin 7, with a predicted molecular weight of 51 kDa (observed band size: 54 kDa). Cytokeratin 7 Antibody (YA951) can be used for WB, IHC-F, IHC-P, ICC/IF, IP experiment in human, mouse, rat background.
CK 7; CK-7; ck7; Cytokeratin 7; Cytokeratin-7; Cytokeratin7; D15Wsu77e; K2C7; K2C7_human; K7; Keratin 55k type ii cytoskeletal; Keratin 7; Keratin simple epithelial type 1 k7; Keratin type II cytoskeletal 7
WB, ICC/IF, IP
Human
Cytokeratin 7 Antibody (YA952) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA952), targeting Cytokeratin 7, with a predicted molecular weight of 51 kDa (observed band size: 51 kDa). Cytokeratin 7 Antibody (YA952) can be used for WB, ICC/IF, IP experiment in human background.
FOXO1(C-term) Antibody (YA5217) is a mouse-derived and non-conjugated monoclonal antibody, targeting to FOXO1 (C-term). It can be applicated for WB assays, in the background of human.
C SRC; C SRC kinase; C src Tyrosine Kinase; C-SRC kinase; c-src tyrosine kinase; Csk A; CSK; CSK_human; CYTOPLASMIC TYROSINE KINASE; MGC112926; MGC117393; MGC154049; P60 Src; Protein tyrosine kinase CYL; Protein-tyrosine kinase CYL; Proto oncogene tyrosine protein kinase; Tyrosine protein kinase CSK; Tyrosine protein kinase CSK; Tyrosine-protein kinase CSK; zgc:154049.
WB, ICC
Human, Rat
CSK Antibody (YA5238) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CSK. It can be applicated for WB, ICC assays, in the background of human, rat.
Claudin 7 Antibody (YA5490) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Claudin 7. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CK 4; CK-4; CK4; CYK4; Cytokeratin 4; CytokeRatin-4; CytokeRatin4; FLJ31692; K2C4_human; K4; KeRatin 4; KeRatin; KeRatin type II cytoskeletal 4; KeRatin-4; KeRatin4; KRT 4; Krt4; type II cytoskeletal 4; Type-II keRatin Kb4
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 4 Antibody (YA5598) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 4. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Claudin 7 Antibody (YA5600) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Claudin 7. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
p57 Kip2 Antibody (YA5616) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to p57kip2. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
p57 Kip2 Antibody (YA5656) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to p57kip2. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Claudin 7 Antibody (YA5688) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Claudin 7. It can be applicated for IHC-P, ELISA assays, in the background of human.
Claudin 7 Antibody (YA5722) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Claudin 7. It can be applicated for IHC-P, ELISA assays, in the background of human, mouse, rat.
p57 Kip2 Antibody (YA5751) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to p57kip2. It can be applicated for IHC-P, ELISA assays, in the background of human, mouse, rat.
Antigen NY-CO-13; BCC7; Cellular tumor antigen p53; FLJ92943; LFS1; Mutant tumor protein 53; p53; p53 tumor suppressor; P53_human; Phosphoprotein p53; Tp53; Transformation related protein 53; TRP53; tumor antigen p55; Tumor protein 53; Tumor protein p53; Tumor suppressor p53;
WB, IHC-P, ICC/IF, IP, ELISA
Human
p53 Antibody (YA5861) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p53. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.
PCNA Antibody (YA6226) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PCNA. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Alkaline phosphatase Antibody (YA6345) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Alkaline phosphatase. It can be applicated for WB assays, in the background of human, mouse, rat.
ABC20; ABCB1; ATP binding cassette, sub family B(MDR/TAP), member 1; ATP-binding cassette sub-family B member 1; CD243; CLCS; Colchicin sensitivity; Doxorubicin resistance; GP170; MDR1; MDR1_human; Multidrug resistance 1; Multidrug resistance protein 1; P glycoprotein 1; P gp; PGY1.
IHC-P, IF-Tissue, IHC-F, WB
Human, Mouse, Rat
P Glycoprotein Antibody (YA6354) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to P Glycoprotein. It can be applicated for IHC-P, IF-Tissue, IHC-F, WB assays, in the background of human, mouse, rat.
Cytokeratin 14; CK 14; Cytokeratin14; Cytokeratin-14; Dowling Meara; ebs3; Epidermolysis bullosa simplex; k14; Keratin 14; Keratin type I cytoskeletal 14; Keratin14; Koebner; Krt 14; krt14; EBS3; EBS4; NFJ; Keratin, type I cytoskeletal 14; K1C14_human.
IHC-P, IHC-F, IF-Tissue
Human, Mouse, Rat
Cytokeratin 14 Antibody (YA6355) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 14. It can be applicated for IHC-P, IHC-F, IF-Tissue assays, in the background of human, mouse, rat.
30 kDa adipocyte complement related protein; ACDC; ACRP 30; ACRP30; ADIPO_human; Adipocyte; AdipoQ; Adipose most abundant gene transcript 1; Adipose specific collagen like factor; ADIPQTL1; ADPN; APM 1; apM-1; ApM1; C1q and collagen domain-containing protein; GBP 28; GBP28; Gelatin binding protein; Gelatin binding protein 28; Gelatin-binding protein.
WB, ICC/IF, IHC-P
Mouse
Adiponectin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 27 kDa, targeting to Adiponectin. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Mouse.
Cdk7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 39 kDa, targeting to Cdk7. It can be used for WB assays with tag free, in the background of Human.
Connexin 43; Connexin-43; Cx 43; Cx43; CXA1_human; DFNB38; Gap junction 43 kDa heart protein; Gap junction alpha-1 protein; Gap junction protein alpha 1 43kDa (connexin 43); Gap junction protein alpha 1 43kDa; Gap junction protein alpha like; GJA 1; Gja1
WB, IHC-F, IHC-P, ICC/IF, ELISA
Human, Mouse, Rat
Connexin 43 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 43 kDa, targeting to Connexin 43. It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat.
Advanced glycosylation end product specific receptor; Advanced glycosylation end product-specific receptor; AGER; EC 2.7.11.22; LE 9211 A antigen; LE-9211-A antigen; MGC22357; MOK; RAGE 1; RAGE1; MOK protein kinase; Receptor for advanced glycation endproducts; Renal tumor antigen 1; Renal tumor antigen; Renal cell carcinoma antigen (MOK protein kinase); Renal tumor antigen 1; RAGE_human.
WB, IHC-P, FC
Human, Mouse, Rat,
RAGE Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-RAGE polyclonal antibody. RAGE Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, background without labeling.
IGF1 Receptor Antibody is an unconjugated, approximately 7.7/21 kDa, rabbit-derived, anti-IGF 1 polyclonal antibody. IGF1 Receptor Antibody can be used for: WB, IHC-P, IHC-F, IF, ELISA expriments in human, mouse, rat, dog, and predicted: pig, cow, rabbit, sheep background without labeling.
CXC-chemokine receptor 2; CD 182; CD182; CD182 antigen; CDw128b; Chemokine (CXC) receptor 2; CMKAR2; CXCR 2; CXC R2; CXC-R2; CXCR2_human; C-X-C chemokine receptor type 2; CXCR-2; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8R B; IL-8 receptor type 2.
WB, IHC-P, ELISA
Human
CXCR2 Antibody is an unconjugated, approximately 41 kDa, rabbit-derived, anti-CXCR2 polyclonal antibody. CXCR2 Antibody can be used for: WB,IHC-P ELISA expriments in human background without labeling.
CD56 Antibody (YA4690) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD56. It can be applicated for ELISA, FC assays, in the background of human.
9330148M11Rik; C80220; GTP binding protein; LHX; OTTMUSP00000004796; RAB2; RAB2 member RAS oncogene family; RAB2A; RAB2A, member RAS oncogene family; RAB2A_human; Ras related protein Rab 2A; RAS-associated protein RAB2; Ras-related protein Rab-2A; RP23-183L6.1; Small GTP binding protein RAB2A.
WB, ICC
Human
Rab2 Antibody (YA5218) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Rab2. It can be applicated for WB, ICC assays, in the background of human.
CDK4 Antibody (YA5223) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CDK4. It can be applicated for WB assays, in the background of human, mouse, rat.
ALDH2 Antibody (YA5273) is a mouse-derived and non-conjugated monoclonal antibody, targeting to ALDH2. It can be applicated for WB assays, in the background of human, mouse, rat, monkey, hamster.
4E-BP2; 4EBP2; 4EBP2_human; eIF4E binding protein 2; eIF4E-binding protein 2; Eif4ebp2; Eukaryotic translation initiation factor 4E binding protein 1; Eukaryotic translation initiation factor 4E-binding protein 2; PHASII; phosphorylated, heat and acid stable regulated by insulin protein II.
WB
Transfected
eIF4EBP2 Antibody (YA5314) is a mouse-derived and non-conjugated monoclonal antibody, targeting to 4E-BP2. It can be applicated for WB assays for exogenous protein in transfected cells.
47 kDa cytokeRatin; CK-13; CK13; Cytokeratin 13; CytokeRatin-13; K13; K1C13_human; Ka13; KeRatin 13; KeRatin; keRatin type I cytoskeletal 13; KeRatin-13; Krt-1.13; Krt1-13; KRT13; MGC161462; MGC3781; type I cytoskeletal 13; Type I keRatin Ka13; WSN2
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 13 Antibody (YA5592) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 13. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Antigen LB39 AA; Antigen LB39-AA; Antigen SK29 AA; Antigen SK29-AA; MAR1_human; MART 1; MART-1; MART1; Melan A; Melan A protein; Melanoma antigen recognized by T cells 1; Melanoma antigen recognized by T-cells 1; MLAN A; MLANA; OTTHUMP00000021036; OTTHUMP00000021037; OTTHUMP00000021038; Protein Melan-A
IHC-P, WB, ICC/IF, ELISA
Human
Melan-A Antibody (YA5610) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Melan-A. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
MUM1 Antibody (YA5612) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MUM1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CD56 Antibody (YA5643) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD56. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
beta Granin; betagranin; N-terminal fragment of chromogranin A; catestatin; CgA; CHG A; Chga; chromofungin; Chromogranin A; Chromogranin A parathyroid secretory protein 1; Chromogranin A precursor; ChromograninA; CMGA_human; ER-37; Pancreastatin; Parastatin; Parathyroid secretory protein 1; Pituitary secretory protein I; Secretory protein I; SP I; SP-I; SP1; SPI; vasostatin 2; Vasostatin; Vasostatin I; Vasostatin II; vasostatin-2
IHC-P, ELISA
Human, Mouse,
Chromogranin A Antibody (YA5678) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Chromogranin A. It can be applicated for IHC-P, ELISA assays, in the background of human, mouse.
NEF; Protein S100 B; Protein S100-B; S 100 calcium binding protein beta chain; S 100 protein beta chain; S-100 protein beta chain; S-100 protein subunit beta; S100; S100 calcium binding protein beta (neural); S100 calcium-binding protein B; S100 protein beta chain; S100B; S100B_human; S100beta
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
S100B Antibody (YA6064) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to S100B. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
beta Granin; betagranin; N-terminal fragment of chromogranin A; catestatin; CgA; CHG A; Chga; chromofungin; Chromogranin A; Chromogranin A parathyroid secretory protein 1; Chromogranin A precursor; ChromograninA; CMGA_human; ER-37; Pancreastatin; Parastatin; Parathyroid secretory protein 1; Pituitary secretory protein I; Secretory protein I; SP I; SP-I; SP1; SPI; vasostatin 2; Vasostatin; Vasostatin I; Vasostatin II; vasostatin-2
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Chromogranin A Antibody (YA6219) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Chromogranin A. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
PDGFR alpha Antibody (YA6353) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDGFR-α. It can be applicated for WB assays, in the background of human, mouse, rat.
Nrf2 Antibody (YA6356) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Nrf2. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue, FC, ICC/IF assays, in the background of human, mouse, rat.
EC 2.7.11.1; FLJ11330; NAK; NF kappa B activating kinase; NF kB activating kinase; NF-kappa-B-activating kinase; Serine/threonine protein kinase TBK 1; Serine/threonine protein kinase TBK1; Serine/threonine-protein kinase TBK1; T2K; TANK binding kinase 1; TANK-binding kinase 1; TBK 1; TBK1_human.
WB, IHC-P, IHC-F, IF-Tissue
Human, Rat, Mouse
TBK1 Antibody (YA6366) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of human, rat, mouse.
STAT3(phospho Y705); p-STAT3(phospho Y705); phospho-Stat3(pTyr705); STAT3(phospho-Tyr705); p-STAT3(Tyr705); phosphorylated Stat3(pTyr705); p-Stat3; Acute Phase Response Factor; APRF; DNA binding protein APRF; FLJ20882; MGC16063; Signal Transductor and Activator of Transcription 3; STAT 3; STAT3_human.
IHC-P, IHC-F, IF-Tissue
Human, Rat
phospho-STAT3 (Tyr705) Antibody (YA6429) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to STAT3 (Tyr705). It can be applicated for IHC-P, IHC-F, IF-Tissue assays, in the background of human, rat.
B220; CD 45; CD-45; cd45 antigen; ec3.1.3.48; CD45R; GP180; GP180; GP 180; L CA; LCA; L-CA; Leukocyte common antigen; LY5; Ly-5 glycoprotein; Protein tyrosine phosphatase receptor type C; Protein tyrosine phosphatase receptor type c polypeptide; protein tyrosine phosphatase, receptor type, C; Receptor-type tyrosine-protein phosphatase C; PTPRC; PTPRC_human; SCID due to PTPRC deficiency; T200; T200 glycoprotein; T200 leukocyte common antigen; human homolog of severe combined immunodeficiency due to PTPRC deficiency.
WB, IHC-P, IHC-F, IF-Tissue
Human
CD45 Antibody (YA6369) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD45. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of human.
DHS Fam38a Family with sequence similarity 38 member A KIAA0233 Membrane protein induced by beta-amyloid treatment Mib PIEZ1_human Piezo-type mechanosensitive ion channel component 1 PIEZO1 Protein FAM38A DHS Fam38a Family with sequence similarity 38 member A KIAA0233 Membrane protein induced by beta-amyloid treatment Mib PIEZ1_human Piezo-type mechanosensitive ion channel component 1 PIEZO1 Protein FAM38A Protein FAM38B Protein PIEZO1
Cancer/testis antigen 98; CT98; DKFZp686F1078; hKOC; IF2B3_human; IGF II mRNA binding protein 3; IGF-II mRNA-binding protein 3; IGF2 mRNA binding protein 3; IGF2 mRNA-binding protein 3; IGF2BP3; IMP 3; IMP-3; Insulin like growth factor 2 mRNA binding prot
WB, ICC/IF, IP, FC
Human, Mouse, Rat
IMP3 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 64 kDa, targeting to IMP3. It can be used for WB,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.
Clgi; Collagenase inhibitor; EPA; EPO; Erythroid Potentiating Activity; Fibroblast collagenase inhibitor; FLJ90373; HC; human Collagenase Inhibitor; Metalloproteinase inhibitor 1; Metalloproteinase inhibitor 1 precursor; OTTHUMP00000023214; TIMP 1; TIMP; TIMP metallopeptidase inhibitor 1; TIMP1 protein; Tissue Inhibitor of Metalloproteinase 1; Tissue inhibitor of metalloproteinases; Ttissue inhibitor of metalloproteinase 1 erythroid potentiating activity collagenase inhibitor.
WB, IHC-P, ICC/IF
Human
TIMP-1 Antibody is an unconjugated, approximately 21 kDa, rabbit-derived, anti-TIMP-1 monoclonal antibody. TIMP-1 Antibody can be used for: WB, IHC-P, ICC/IF expriments in human background without labeling.
CD8 antigen, alpha polypeptide (p32); CD8a; CD8a antigen; CD8a molecule; CD8A_MOUSE; CD8A_human; Leu2; Leu2 T lymphocyte antigen; MAL; OKT8 T cell antigen; p32; T cell antigen Leu2; T cell co receptor; T-cell surface glycoprotein CD8 alpha chain; T-lymphocyte differentiation antigen T8/Leu-2; T8 T cell antigen.
WB, IHC-P, ICC/IF
Mouse
CD8 Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-CD8 polyclonal antibody. CD8 Antibody can be used for: WB, IHC-P, IHC-F, IF expriments in mouse, background without labeling.
interleukin-1 alpha; Hematopoietin 1; IL 1 alpha; IL1 alpha; IL 1; IL 1A; Il-1a; IL1; IL1A; IL1F1; ilia; Interleukin 1 alpha; Interleukin 1 alpha precursor; Interleukin1 alpha; Preinterleukin 1 alpha; Pro interleukin 1 alpha; Prointerleukin 1 alpha; IL1A_human.
WB, ELISA, IHC-P, IHC-F, FC, ICC/IF
Human, Mouse
IL-1 alpha Antibody is a rabbit-derived non-conjugated IgG antibody, targeting IL-1 alpha, with a predicted molecular weight of 31 kDa. IL-1 alpha Antibody can be used for WB, ELISA, IHC-P, IHC-F, FC, ICC/IF experiments in human, mouse backgrounds.
422 protein; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_human; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3
ELISA
Human
FABP3 Antibody (YA968) is a mouse-derived non-conjugated IgG2b antibody (Clone NO.: YA968), targeting FABP3. FABP3 Antibody (YA968) can be used for ELISA experiment in human background.
422 protein; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_human; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3
ELISA
Human
FABP3 Antibody (YA969) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA969), targeting FABP3. FABP3 Antibody (YA969) can be used for ELISA experiment in human background.
422 protein; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_human; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3
WB, IHC-P
Human, Mouse, Rat
FABP3 Antibody (YA970) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA970), targeting FABP3, with a predicted molecular weight of 15 kDa (observed band size: 15 kDa). FABP3 Antibody (YA970) can be used for WB, IHC-P experiment in human, mouse, rat background.
GSDMD Antibody is an unconjugated, approximately 53 kDa, rabbit-derived, anti-GSDMD monoclonal antibody. GSDMD Antibody can be used for: WB expriments in human background without labeling.
Advanced glycosylation end product specific receptor; Advanced glycosylation end product-specific receptor; AGER; EC 2.7.11.22; LE 9211 A antigen; LE-9211-A antigen; MGC22357; MOK; RAGE 1; RAGE1; MOK protein kinase; Receptor for advanced glycation endproducts; Renal tumor antigen 1; Renal tumor antigen; Renal cell carcinoma antigen (MOK protein kinase); Renal tumor antigen 1; RAGE_human.
WB, IHC-P, ICC/IF
Human, Mouse, Rat
RAGE Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-RAGE monoclonal antibody. RAGE Antibody can be used for: WB, IHC-P, IF-Tissue, mIHC expriments in human, mouse, rat, background without labeling.
Histone methyltransferase SMYD2; HSKM B; HSKM-B; HSKMB; KMT3C; Lysine N-methyltransferase 3C; MGC119305; N lysine methyltransferase SMYD2; N-lysine methyltransferase SMYD2; SET and MYND domain containing 2; SET and MYND domain containing protein 2; SET and MYND domain-containing protein 2; Smyd2; SMYD2_human; Zinc finger MYND domain containing 14; ZMYND14.
WB
Human, Mouse
SMYD2 Antibody (YA5183) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SMYD2. It can be applicated for WB assays, in the background of human, mouse.
CBX 3; CBX3; CBX3_human; Chromobox homolog 3; HP1 gamma homolog, Drosophila; Chromobox homolog 3; Chromobox protein homolog 3; GAMMA; HECH; Heterochromatin like protein 1; Heterochromatin protein 1 homolog gamma; Heterochromatin protein HP1 gamma; HP1 gamma; HP1 gamma homolog; HP1Hs gamma; Modifier 2 protein.
WB, ICC/IF, IP, IHC-P
Mouse, Human, Monkey, Hamster, Rat
HP1 gamma Antibody (YA5185) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HP1-γ. It can be applicated for WB, ICC/IF, IP, IHC-P assays, in the background of mouse, human, monkey, hamster, rat.
Pyruvate Dehydrogenase E1 alpha Antibody (YA5196) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PDHA1. It can be applicated for WB, ICC assays, in the background of human, mouse.
ADR; AKR1B 1; Akr1b1; Aldehyde reductase 1; Aldehyde reductase; Aldo keto reductase family 1, member B1; Aldo-keto reductase family 1 member B1; aldo-keto reductase family 1, member B1; aldose reductase; Aldose reductase; aldr 1; ALDR_human; ALDR1; ALR2; AR; Lii5 2 CTCL tumor antigen; Low Km aldose reductase; MGC1804.
WB
Human, Mouse, Rat
Aldose Reductase Antibody (YA5250) is a mouse-derived and non-conjugated monoclonal antibody, targeting to AKR1B1. It can be applicated for WB assays, in the background of human, mouse, rat.
ATP dependent helicase CHD4; ATP-dependent helicase CHD4; CHD 4; CHD-4; CHD4; CHD4_human; Chromodomain helicase DNA binding protein 4; Chromodomain-helicase-DNA-binding protein 4; DKFZp686E06161; Mi 2 autoantigen 218 kDa protein; Mi 2b; Mi-2 autoantigen 218 kDa protein; Mi2 beta; Mi2-beta.
WB, IP
Human
CHD4 Antibody (YA5264) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CHD4. It can be applicated for WB, IP assays, in the background of human.
WDR77 Antibody (YA5281) is a mouse-derived and non-conjugated monoclonal antibody, targeting to WDR77. It can be applicated for WB, ICC assays, in the background of human, mouse, rat.
Actin smooth muscle (SMA) Antibody (YA5519) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to smooth muscle actin (SMA). It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Caldesmon Antibody (YA5529) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to caldesmon. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CD7; CD7 antigen; p41; CD7 antigen; CD7 molecule; CD7_human; GP40; LEU 9; LEU9; p41 protein; T cell antigen CD7; T cell leukemia antigen; T cell surface antigen Leu 9; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; Tp 40; Tp40; TP41
IHC-P, WB, ICC/IF, ELISA
Human
CD7 Antibody (YA5589) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD7. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CD279; CD279 antigen; hPD 1; hPD l; hPD-1; hSLE1; PD 1; PD-1; PD1; PDCD 1; PDCD1; PDCD1_human; Programmed cell death 1; Programmed cell death 1 protein; Programmed cell death protein 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2
IHC-P, WB, ICC/IF, ELISA
Human
PD-1 Antibody (YA5617) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PD1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
alpha isozyme; ATP hydrolyzing DNA topoisomerase II alfa; DNA gyrase; DNA topoisomerase; ATP hydrolyzing; DNA topoisomerase 2 alpha; DNA topoisomerase 2-alpha; DNA topoisomerase II 170 kD; DNA topoisomerase II alpha isozyme; DNA topoisomerase II; DNA Topoisomerase2; TOP 2A; TOP2; TOP2A; TOP2A_human; Topoisomerase DNA II alpha 170 kDa; TP2A
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Topoisomerase II alpha Antibody (YA5621) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Topoisomerase IIα. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
ABC20; ABCB1; ATP binding cassette, sub family B; MDR/TAP; , member 1; ATP-binding cassette sub-family B member 1; CD243; CLCS; Colchicin sensitivity; Doxorubicin resistance; GP170; MDR1; MDR1_human; Multidrug resistance 1; Multidrug resistance protein 1; P glycoprotein 1; P gp; P-glycoprotein 1; PGY1
IHC-P, WB, ICC/IF, ELISA
Human, Mouse,
P Glycoprotein Antibody (YA5626) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MDR1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
ABC20; ABCB1; ATP binding cassette, sub family B; MDR/TAP; , member 1; ATP-binding cassette sub-family B member 1; CD243; CLCS; Colchicin sensitivity; Doxorubicin resistance; GP170; MDR1; MDR1_human; Multidrug resistance 1; Multidrug resistance protein 1; P glycoprotein 1; P gp; P-glycoprotein 1; PGY1
IHC-P, ELISA
Human, Mouse,
P Glycoprotein Antibody (YA5747) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MDR1. It can be applicated for IHC-P, ELISA assays, in the background of human, mouse.
ABC20; ABCB1; ATP binding cassette, sub family B; MDR/TAP; , member 1; ATP-binding cassette sub-family B member 1; CD243; CLCS; Colchicin sensitivity; Doxorubicin resistance; GP170; MDR1; MDR1_human; Multidrug resistance 1; Multidrug resistance protein 1; P glycoprotein 1; P gp; P-glycoprotein 1; PGY1
WB, IHC-P, ICC/IF, IP, ELISA
Human
P Glycoprotein Antibody (YA6028) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MDR1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.
FAP Antibody (YA6365) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FAP. It can be applicated for WB assays, in the background of human.
Fbx32; 4833442G10Rik; AI430017; Atrogin 1; Atrogin-1; ATROGIN1; Atrophy gene 1; F box only protein 32; F-box only protein 32; F-box protein 32; FBX32_human; fbxo25; FBXO32; FLJ32424; MAFbx; MGC108443; MGC137646; MGC33610; Muscle atrophy F box; Muscle atrophy F box protein; Muscle atrophy F-box protein.
WB; ICC/IF
Human, Mouse, Rat
Fbx32 Antibody (YA919) is an unconjugated, approximately 42 kDa, rabbit-derived, anti-Fbx32 (YA919) monoclonal antibody. Fbx32 Antibody (YA919) can be used for: WB, IF-Cell expriments in mouse, rat, and human background without labeling.
DA transporter; DAT 1; DAT; DAT1; SC6A3_human; SLC6A3; Sodium dependent dopamine transporter; Sodium-dependent dopamine transporter; Solute carrier family 6 (neurotransmitter transporter dopamine), member 3; Solute carrier family 6 member 3; Variable number tandem repeat (VNTR); dopamine transporter; ADAT 1; Adenosine deaminase tRNA specific 1; HADAT1; tRNA specific adenosine deaminase 1.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse, Rat
Dopamine Transporter Antibody is an unconjugated, approximately 68 kDa, rabbit-derived, anti-Dopamine Transporter polyclonal antibody. Dopamine Transporter Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: dog, cow background without labeling.
LOX 1 Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, IF-Cell, IHC-P, FC expriments in human, mouse background without labeling.
ACS3; B-HLH DNA binding protein; bHLHa38; BPES2; BPES3; Class A basic helix-loop-helix protein 38; CRS1; H-twist; OTTHUMP00000116043; SCS; Twist basic helix loop helix transcription factor 1; Twist homolog 1 (Drosophila); Twist homolog 1; TWIST homolog of drosophila; Twist related protein 1; Twist-related protein 1; Twist1; TWST1_human.
WB, IHC-P, ICC/IF, FC
Human, Mouse
TWIST1 Antibody (YA3398) is an unconjugated, approximately 23 kDa, mouse-derived, anti-TWIST monoclonal antibody. TWIST1 Antibody (YA3398) can be used for: WB, IHC-P, ICC/IF, FC expriments in human, mouse background without labeling.
40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_human; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd.
WB, ELISA, IHC-P, IHC-F, FC, ICC/IF
Human
Cytokeratin 19 Antibody is an unconjugated, approximately 44 kDa, rabbit-derived, anti-Cytokeratin 19 polyclonal antibody. Cytokeratin 19 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human and predicted: mouse, rat, chicken, dog, pig, cow, horse, rabbit background without labeling.
HAVCR; HAVCR 1; HA; Vcr-1; hepatitis A virus cellular receptor 1; HKIM-1; Kidney Injury Molecule1; KIM1; KIM 1; KIM-1; TIM-1; TIMD 1; TIMD1; KM-1; TIMD1_human; T cell immunoglobin domain and mucin domain protein 1; T-cell immunoglobulin and mucin domain-containing protein 1; T-cell membrane protein 1. 肾脏损伤分子1
WB
Human, Mouse, Rat
TIM 1 Antibody is an unconjugated, approximately 39 kDa, rabbit-derived, anti-TIM 1 monoclonal antibody. TIM 1 Antibody can be used for: WB expriments in human, mouse, and rat background without labeling.
JMJD6(N-term) Antibody (YA5177) is a mouse-derived and non-conjugated monoclonal antibody, targeting to JMJD6 (N-term). It can be applicated for WB, ICC assays, in the background of human.
EG5; HKSP; KIF11; KIF11_human; kinesin family member 11; Kinesin like protein 1; Kinesin like spindle protein HKSP; Kinesin-like protein 1; Kinesin-like protein KIF11; Kinesin-like spindle protein HKSP; Kinesin-related motor protein Eg5; KNSL1; MCLMR; Thyroid receptor interacting protein 5; Thyroid receptor-interacting protein 5; TR-interacting protein 5; TRIP-5; TRIP5.
WB, IP, ICC
Human
Eg5 Antibody (YA5181) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Eg5. It can be applicated for WB, IP, ICC assays, in the background of human.
ANM6_human; Chromobox protein homolog 7; FLJ10559; FLJ51477; Heterogeneous nuclear ribonucleoprotein methyltransferase like protein 6; Heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 6; Histone-arginine N-methyltransferase PRMT6; HMT1 hnRNP methyltransferase like 6.; HRMT1L6; OTTHUMP00000012633; PRMT 6; prmt6; Protein arginine methyltransferase 6; Protein arginine N methyltransferase 6; Protein arginine N-methyltransferase 6.
WB, IHC-P, ICC
Human
PRMT6 Antibody (YA5188) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PRMT6. It can be applicated for WB, IHC-P, ICC assays, in the background of human.
PP X; PP-X; PP4; PP4C; PP4C; PP4C_human; PPH3; PPP4; ppp4c; PPX; protein phosphatase 4; formerly X; , catalytic subunit; Protein phosphatase 4 catalytic subunit; Protein phosphatase X; Protein phosphatase X; protein phosphatase X, catalytic subunit; Serine/threonine protein phosphatase 4 catalytic subunit; Serine/threonine-protein phosphatase 4 catalytic subunit.
WB, IHC-P, ICC
Human
Protein Phosphatase 4C Antibody (YA5192) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Protein Phosphatase 4C. It can be applicated for WB, IHC-P, ICC assays, in the background of human.
AMPK beta 1 Antibody (YA5270) is a mouse-derived and non-conjugated monoclonal antibody, targeting to AMPKβ1. It can be applicated for WB, ICC/IF, IP, IHC-P assays, in the background of human, mouse, rat, monkey.
DNA repair protein XRCC1; RCC; X ray repair complementing defective repair in chinese hamster; X ray repair complementing defective repair in chinese hamster cells 1; X ray Repair Complementing Defective Repair in Chinese Hamster Cells; X ray repair cross complementing protein 1; X ray repair, complementing defective, repair in Chinese hamster; X-ray repair cross-complementing protein 1; XRCC 1; Xrcc1; XRCC1_human.
WB
Human
XRCC1 Antibody (YA5297) is a mouse-derived and non-conjugated monoclonal antibody, targeting to XRCC1. It can be applicated for WB assays, in the background of human.
Antigen identified by monoclonal Ki 67; Antigen identified by monoclonal Ki-67; Antigen KI-67; Antigen KI67; Antigen Ki67; KI67_human; KIA; Marker of prolifeRation Ki-67; MIB 1; MIB; MKI67; PPP1R105; ProlifeRation marker protein Ki-67; ProlifeRation related Ki 67 antigen; Protein phosphatase 1 regulatory subunit 105; RP11-380J17.2
IHC-P, WB, ICC/IF, ELISA
Human
Ki67 Antibody (YA5351) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Ki-67. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CD79a Antibody (YA5591) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD79a. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, rat.
CD20; CK 20; CK-20; CK20; CytokeRatin-20; CytokeRatin20; K1C20_human; K20; KA20; KeRatin 20; keRatin 20, type I; keRatin 21, Rat, homolog of; KeRatin; KeRatin type I cytoskeletal 20; KeRatin-20; KeRatin20; KRT 20; KRT 21; KRT20; KRT21; MGC35423; OTTHUMP00000164518; Protein IT; type I cytoskeletal 20
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Cytokeratin 20 Antibody (YA5597) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 20. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Stathmin 1 Antibody (YA5629) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Stathmin 1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
40 kDa keRatin intermediate filament; CK 19; CK-19; CK19; Cytokeratin 19; CytokeRatin-19; K19; K1C19_human; K1CS; KeRatin 19; KeRatin type I 40 kD; KeRatin type I 40kD; KeRatin type I cytoskeletal 19; KeRatin, type I cytoskeletal 19; KeRatin, type I, 40 kd; KeRatin-19; KRT19; MGC15366
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 19/10 Antibody (YA5635) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 19/10. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Antigen identified by monoclonal Ki 67; Antigen identified by monoclonal Ki-67; Antigen KI-67; Antigen KI67; Antigen Ki67; KI67_human; KIA; Marker of prolifeRation Ki-67; MIB 1; MIB; MKI67; PPP1R105; ProlifeRation marker protein Ki-67; ProlifeRation related Ki 67 antigen; Protein phosphatase 1 regulatory subunit 105; RP11-380J17.2
IHC-P, WB, ELISA
Human
Ki67 Antibody (YA5753) is a rabbit-derived and non-conjugated IgG1 monoclonal antibody, targeting to Ki-67. It can be applicated for IHC-P, WB, ELISA assays, in the background of human.
Phospho-BTK(Y223) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 76 kDa, targeting to Phospho-BTK(Y223). It can be used for WB, IP assays with tag free, in the background of Human.
CD90/Thy-1 Antibody is an unconjugated, approximately 18 kDa, rabbit-derived, anti-CD90/Thy-1 monoclonal antibody. CD90/Thy-1 Antibody can be used for: WB,IHC-P,ICC/IF expriments in human background without labeling.
Alpha-ENaC Antibody is an unconjugated, approximately 76 kDa, rabbit-derived, anti-Alpha-ENaC polyclonal antibody. Alpha-ENaC Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: dog, pig, cow, horse, sheep background without labeling.
DGAT1 Antibody is a rabbit-derived non-conjugated IgG antibody, targeting DGAT1, with a predicted molecular weight of 55 kDa (observed band size: 55 kDa). DGAT1 Antibody can be used for WB,IHC-P,IP experiments in human backgrounds.
40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_human; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd
WB, IHC-P, IHC-F, ICC/IF
Human
Cytokeratin 19 Antibody is an unconjugated, approximately 44 kDa, mouse-derived, anti-Cytokeratin 19 monoclonal antibody. Cytokeratin 19 Antibody can be used for: WB,IHC-F,IHC-P,ICC/IF expriments in human background without labeling.
Alpha isoform serine threonine protein phosphatase PP1alpha 1 catalytic subunit; Catalytic subunit; PP1A; PP1A_human; PP1alpha; PP2C ALPHA; PP2CA; Ppp1ca; Protein Phosphatase 2C Alpha Isoform; Serine threonine protein phosphatase PP1 alpha catalytic subunit; Serine threonine protein phosphatase PP1 alpha catalytic subunit protein phosphatase 1; Serine/threonine-protein phosphatase PP1-alpha catalytic subunit.
WB, IHC-F, IHC-P, ICC/IF
Human
PP1C alpha Antibody (YA1040) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1040), targeting PP1C alpha, with a predicted molecular weight of 38 kDa (observed band size: 38 kDa). PP1C alpha Antibody (YA1040) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human background.
Alpha isoform serine threonine protein phosphatase PP1alpha 1 catalytic subunit; Catalytic subunit; PP1A; PP1A_human; PP1alpha; PP2C ALPHA; PP2CA; Ppp1ca; Protein Phosphatase 2C Alpha Isoform; Serine threonine protein phosphatase PP1 alpha catalytic subunit; Serine threonine protein phosphatase PP1 alpha catalytic subunit protein phosphatase 1; Serine/threonine-protein phosphatase PP1-alpha catalytic subunit.
WB, ICC/IF
Human
PP1C alpha Antibody (YA1041) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1041), targeting PP1C alpha, with a predicted molecular weight of 38 kDa (observed band size: 38 kDa). PP1C alpha Antibody (YA1041) can be used for WB, ICC/IF experiment in human background.
40 kDa keratin intermediate filament; CK 19; ck19; CK19; CK-19; KRT19; Cytokeratin19; Cytokeratin-19; k19; k1cs; Keratin 19; Keratin-19; Keratin type I 40 kD; Keratin type i 40kD; Keratin type I cytoskeletal 19; krt19; mgc15366; K1C19_human; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd.
WB, IHC-P, IHC-F, ICC/IF, FC, ELISA
Human, Mouse
Cytokeratin 19 Antibody is an unconjugated, approximately 44 kDa, rabbit-derived, anti-Cytokeratin 19 polyclonal antibody. Cytokeratin 19 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, chicken, dog, pig, cow, horse, rabbit background without labeling.
Caudal type homeo box 2; Caudal type homeo box transcription factor 2; Caudal type homeobox 2; Caudal type homeobox protein 2; caudal type homeobox transcription factor 2; Caudal-type homeobox protein 2; CDX 2; CDX 3; CDX-3; Cdx2; CDX2_human; CDX3; Homeobox protein CDX 2; Homeobox protein CDX-2; Homeobox protein CDX2.
WB, IP, ICC
Human, Monkey
CDX2 Antibody (YA5261) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CDX2. It can be applicated for WB, IP, ICC assays, in the background of human, monkey.
BAG1 Antibody (YA5299) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Bag1. It can be applicated for WB assays, in the background of human, mouse.
CK 16; CK-16; CK16; Cytokeratin 16; CytokeRatin-16; CytokeRatin16; FNEPPK; Focal non epidermolytic palmoplantar keRatoderma; K 16; K16; K1C16_human; K1CP; KeRatin 1 type I; KeRatin 16; KeRatin; KeRatin type I cytoskeletal 16; KeRatin-16; KeRatin16; KRT 16; Krt16; KRT16A; NEPPK; PC1; type I cytoskeletal 16
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 16 Antibody (YA5594) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 16. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
DNA mismatch repair protein Msh6; G/T mismatch binding protein; G/T mismatch-binding protein; GTBP; GTMBP; hMSH6; HNPCC 5; HNPCC5; HSAP; MSH 6; MSH6; MSH6_human; mutS; E. coli; homolog 6; MutS alpha 160 kDa subunit; MutS homolog 6; E. coli; mutS homolog 6; MutS-alpha 160 kDa subunit; p160; Sperm associated protein
IHC-P, WB, ICC/IF, ELISA
Human
MSH6 Antibody (YA5611) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MSH6. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
TRAP Antibody (YA5670) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to TRAP. It can be applicated for IHC-P, ICC/IF, ELISA assays, in the background of human.
CARD2; CK 8; CK-8; CK8; CYK8; CYKER; Cytokeratin endo A; Cytokeratin-8; DreK8; EndoA; K2C8; K2C8_human; K8; Keratin 8; Keratin type II cytoskeletal 8; Keratin, type II cytoskeletal 8; Keratin-8; KO; Krt 2.8; KRT8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keratin Kb8
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Cytokeratin 8 Antibody (YA6196) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 8. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
BNSP; Bone sialoprotein 1; BSP I; BSPI; Early T lymphocyte activation 1; ETA 1; ETA1; MGC110940; Nephropontin; OPN; osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein; OSTP_human; secreted phosphoprotein 1(osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); Secreted phosphoprotein 1; SPP 1; SPP-1; SPP1; SPP1/CALPHA1 fusion; Urinary stone protein; Uropontin.
IHC-P, WB, IHC-F, IF-Tissue
Human
Osteopontin Antibody (YA6362) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Osteopontin. It can be applicated for IHC-P, WB, IHC-F, IF-Tissue assays, in the background of human.
ACE2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 92 kDa, targeting to ACE2. It can be used for WB,ICC,IHC-P,IP assays with tag free, in the background of Human, Mouse, Hamster.
COX2/Cyclooxygenase 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 69 kDa, targeting to COX2/Cyclooxygenase 2. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Rat.
Mannose Receptor; C-type lectin domain family 13 member D; CD 206; CD206; CD206 antigen; CLEC13D; CLEC13DL; Macrophage mannose receptor; Mannose receptor C type 1; MMR; MRC 1; MRC-1; MRC1_human; Macrophage mannose receptor 1; MRC1L1; C-type lectin domain family 13 member D-like; Macrophage mannose receptor 1-like protein 1.
WB
Human, Rat
MRC1 Antibody is an unconjugated, approximately 160 kDa, rabbit-derived, anti-MRC1 monoclonal antibody. MRC1 Antibody can be used for: WB expriments in human and rat background without labeling.
PP 1G; PP-1G; PP1G; PP1G_human; PP1gamma; PPP 1G; PPP1CC; PPP1CC protein; PPP1G; Protein phosphatase 1 catalytic subunit gamma isoform; Protein phosphatase 1C catalytic subunit; Protein phosphatase 1C subunit; Protein phosphatase 2C gamma isoform; Serine/threonine phosphatase 1 gamma; Serine/threonine protein phosphatase PP1 gamma catalytic subunit; Serine/threonine-protein phosphatase PP1-gamma catalytic subunit.
WB
Human
PP1C gamma Antibody (YA1068) is a non-conjugated IgG2b antibody, targeting PP1C gamma, with a predicted molecular weight of 37 kDa (observed band size: 37 kDa). PP1C gamma Antibody (YA1068) can be used for WB experiment in human background.
Alpha isoform serine threonine protein phosphatase PP1alpha 1 catalytic subunit; Catalytic subunit; PP1A; PP1A_human; PP1alpha; PP2C ALPHA; PP2CA; Ppp1ca; Protein Phosphatase 2C Alpha Isoform; Serine threonine protein phosphatase PP1 alpha catalytic subunit; Serine threonine protein phosphatase PP1 alpha catalytic subunit protein phosphatase 1; Serine/threonine-protein phosphatase PP1-alpha catalytic subunit.
WB, IHC-P, IP
Human, Mouse, Rat
PP1C alpha/beta Antibody (YA1700) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1700), targeting PP1C alpha/beta, with a predicted molecular weight of 38 kDa (observed band size: 38 kDa). PP1C alpha/beta Antibody (YA1700) can be used for WB, IHC-P, IP experiment in human, mouse, rat background.
GTF2H1 Antibody (YA5206) is a mouse-derived and non-conjugated monoclonal antibody, targeting to GTF2H1. It can be applicated for WB, IP, ICC assays, in the background of human.
ATIC Antibody (YA5245) is a mouse-derived and non-conjugated monoclonal antibody, targeting to ATIC. It can be applicated for WB assays, in the background of human, mouse, rat.
39.1; CK 17; CK-17; CytokeRatin-17; K17; K1C17_human; KeRatin 17; keRatin 17 epitope S1; keRatin 17 epitope S2; keRatin 17 epitope S4; KeRatin 17, type I; KeRatin; KeRatin type I cytoskeletal 17; keRatin, type i cytoskeletal 17 [version 1]; KeRatin-17; KRT17; PC; PC2; PCHC1; type I cytoskeletal 17
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Cytokeratin 17 Antibody (YA5595) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 17. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
bA525O21.1; coagulation factor XIII, A1 polypeptide; Coagulation factor XIII A chain; Coagulation factor XIII A1 polypeptide; Coagulation factor XIII A1 subunit; Coagulation factor XIII, A polypeptide; Coagulation factor XIIIa; F13A; F13A_human; F13a1; Factor XIIIA; Fibrin stabilizing factor, A subunit; Fibrinoligase; FSF, A subunit; Protein glutamine gamma glutamyltransferase A chain; Protein-glutamine gamma-glutamyltransferase A chain; TGase; Transglutaminase A chain; Transglutaminase, plasma; Transglutaminase. plasma
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Factor XIIIa Antibody (YA5604) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Factor XIIIa. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
class 2; Lymphoid restricted immunoglobulin octamer binding protein; Lymphoid-restricted immunoglobulin octamer-binding protein NF-A2; NF A2; Oct 2; Oct-2; Octamer binding transcription factor 2; Octamer-binding protein 2; Octamer-binding transcription factor 2; OTF-2; OTF2; PO2F2_human; POU domain; POU domain class 2 transcription factor 2; POU2F2; transcription factor 2
IHC-P, WB, ICC/IF, ELISA
Human, Mouse,
Oct-2 Antibody (YA5615) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to OCT2. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
BCEI; Breast cancer estrogen inducible protein; Breast cancer estrogen inducible sequence; Breast cancer estrogen-inducible protein; D21S21; Gastrointestinal trefoil protein; Gastrointestinal trefoil protein pS2; hP1.A; HP1A; HPS 2; HPS2; pNR 2; PNR-2; pNR2; Polypeptide P1.A; Protein pS2; PS 2; pS2; pS2 protein; TFF 1; TFF1; TFF1_human; Trefoil factor 1
IHC-P, WB, ICC/IF, ELISA
Human
Estrogen Inducible Protein pS2 Antibody (YA5628) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to pS2. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
F4/80 (mouse); Adhesion G protein-coupled receptor E1; Cell surface glycoprotein EMR1; Cell surface glycoprotein F4/80; DD7A5 7; Egf like module containing mucin like hormone receptor like 1; Egf like module containing mucin like hormone receptor like sequence 1; EGF like module receptor 1; EGF TM7; EGF-like module receptor 1; EGF-like module-containing mucin-like hormone receptor-like 1; EGFTM7; EMR 1; EMR1; EMR-1; EMR1 hormone receptor; EMR1_human; AGRE1_human; Gpf480; Ly71; Lymphocyte antigen 71; TM7LN3.
WB, IHC-P, IHC-F, ICC/IF
Mouse, Rat
F4/80 Antibody (YA920) is an unconjugated, approximately 102 kDa, rabbit-derived, anti-ADGRE1 (F4/80) (YA920) monoclonal antibody. F4/80 Antibody (YA920) can be used for: WB, IHC-P, IF-Tissue, IHC-Fr expriments in mouse, rat background without labeling.
2-oxoglutarate dehydrogenase complex component E2; Dihydrolipoamide S succinyltransferase (E2 component of 2 oxo glutarate complex); Dihydrolipoamide S succinyltransferase; Dihydrolipoamide succinyltransferase component of 2 oxoglutarate dehydrogenase complex; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex; Dihydrolipoyllysine residue succinyltransferase component of 2 oxoglutarate dehydrogenase complex; Dihydrolipoyllysine residue succinyltransferase component of 2 oxoglutarate dehydrogenase complex mitochondrial; Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex; Dlst; DLTS; E2; E2K; mitochondrial; ODO2_human; OGDC-E2.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse
DLST Antibody is an unconjugated, approximately 41 kDa, rabbit-derived, anti-DLST polyclonal antibody. DLST Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF, expriments in mouse and predicted: human, rat, dog, pig, cow, horse, rabbit, sheep background without labeling.
Toll-like receptor 2; Toll like receptor 2; Toll like receptor 2 precursor; Toll-like receptor 2; TLR 2; TLR-2; Toll/interleukin-1 receptor-like protein 4; CD282 antigen; CD282; TIL 4; TIL4; TLR2_human; Toll/interleukin 1 receptor like 4; Toll/interleukin 1 receptor like protein 4; Toll/interleukin receptor like protein 4.
WB, ICC/IF, FC
Human, Mouse, Rat
TLR2 Antibody is an unconjugated, approximately 84 kDa, rabbit-derived, anti-TLR2 monoclonal antibody. TLR2 Antibody can be used for: WB, FC, IF-Cell expriments in human, mouse, rat background without labeling.
troponin I type 3 (cardiac); Cardiac troponin I; Troponin I, cardiac muscle; Cardiomyopathy, familial hypertrophic, 7, included; CMD1FF; CMD2A; CMH7; cTnI; Familial hypertrophic cardiomyopathy 7; MGC116817; RCM1; Tn1; Tni; TNN I3; TNNC 1; TNNC-1; TNNC1; TNNI3; Troponin I cardiac; Troponin I cardiac muscle; Troponin I cardiac muscle isoform; Troponin I type 3 cardiac; troponin I, cardiac 3; TroponinI; Troponin I; TNNI3_human.
WB, IHC-P, ICC/IF, IP
Human
Cardiac Troponin I Antibody (YA3484) is an unconjugated, approximately 23 kDa, rabbit-derived, anti-Cardiac Troponin I/TNNC1 monoclonal antibody. Cardiac Troponin I Antibody (YA3484) can be used for:WB,IHC-P,ICC/IF,IP expriments in human background without labeling.
AMCFII; C-X-C motif chemokine 5; Cxcl5; CXCL5_human; ENA-78(1-78); ENA-78(9-78); ENA78; Epithelial derived neutrophil activating peptide 78; Epithelial derived neutrophil activating protein 78; Epithelial-derived neutrophil-activating protein 78; GCP2; LIX; Neutrophil activating peptide ENA 78; Neutrophil-activating peptide ENA-78; SCYB5; Scyb6; Small inducible cytokine B5; Small inducible cytokine subfamily B member 5; Small-inducible cytokine B5.
WB, ICC/IF, IP
Human
CXCL5 Antibody is an unconjugated, approximately 10 kDa, rabbit-derived, anti-CXCL5 monoclonal antibody. CXCL5 Antibody can be used for: WB,ICC/IF,IP expriments in human background without labeling.
CD80 Antibody is an unconjugated, approximately 30 kDa, mouse-derived, anti-CD80 monoclonal antibody. CD80 Antibody can be used for: WB, IHC-P,FC ICC expriments in mouse,human, and predicted: rat background without labeling.
Phospho-eNOS (Ser1177) Antibody is an unconjugated, approximately 133 kDa, rabbit-derived, anti-eNOS (Ser1177) polyclonal antibody. Phospho-eNOS (Ser1177) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, dog, pig, cow, rabbit, sheep, guinea pig background without labeling.
NOX2 Antibody is an unconjugated, approximately 65 kDa, rabbit-derived, anti-NOX2 polyclonal antibody. NOX2 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, rabbit background without labeling.
Collagen type I; Alpha 1 type I collagen; Alpha 2 type I collagen; COL1A1; COL1A2; Collagen I alpha 1 polypeptide; Collagen I alpha 2 polypeptide; Collagen Of Skin Tendon And Bone; Collagen Type 1; Collagen type I alpha 1; Collagen type I alpha 2; OI4; Osteogenesis Imperfecta Type IV; Pro alpha 1(I) collagen; Type I procollagen; CO1A1_human.
WB, IHC-P
Human, Mouse, Rat, Rabbit
Collagen I Antibody is an unconjugated, approximately 130 kDa, rabbit-derived, anti-Collagen I polyclonal antibody. Collagen I Antibody can be used for: WB, IHC-P expriments in human, mouse, rat, rabbit, and predicted: chicken, dog, cow, sheep background without labeling.
CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_human; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.
WB, IP
Human
Ikaros Antibody (YA987) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA987), targeting Ikaros, with a predicted molecular weight of 58 kDa (observed band size: 58 kDa). Ikaros Antibody (YA987) can be used for WB, IP experiment in human background.
CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros (zinc finger protein); IKAROS; IKAROS family zinc finger 1 (Ikaros); Ikaros family zinc finger protein 1; Ikzf1; IKZF1_human; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1 (Ikaros); zinc finger protein subfamily 1A 1; Zinc finger protein; subfamily 1A; member 1; ZNFN1A1.
IHC-P
Human
Ikaros Antibody (YA988) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA988), targeting Ikaros. Ikaros Antibody (YA988) can be used for IHC-P experiment in human background.
B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_human; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.
WB, ICC/IF
Human, Mouse, Rat
RanBP9 Antibody (YA1995) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1995), targeting RanBP9, with a predicted molecular weight of 78 kDa (observed band size: 91 kDa). RanBP9 Antibody (YA1995) can be used for WB, ICC/IF experiment in human, mouse, rat background.
PP1C alpha Antibody (YA5191) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PPP1A. It can be applicated for WB, IHC-P, ICC assays, in the background of human.
PP2A beta; PP2A-beta; PP2AB_human; PP2Abeta; PP2CB; Ppp2cb; Protein phosphatase 2; formerly 2A; , catalytic subunit, beta isoform; Protein phosphatase 2 catalytic subunit beta isozyme; Protein phosphatase 2, catalytic subunit, beta isoform; Protein phosphatase 2A catalytic subunit beta isoform; Protein phosphatase type 2A catalytic subunit; Serine/threonine protein phosphatase 2A catalytic subunit beta; Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform.
WB, IP
Human, Mouse, Rat
PP2A alpha + beta Antibody (YA5209) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PP2A α and β. It can be applicated for WB, IP assays, in the background of human, mouse, rat.
PP1C gamma Antibody (YA5210) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PP1C. It can be applicated for WB assays, in the background of human.
ACE Antibody (YA5212) is a mouse-derived and non-conjugated monoclonal antibody, targeting to ACE. It can be applicated for WB assays, in the background of mouse.
BRCA1/BRCA2 containing complex, subunit 5; BRCC 5; BRCC5; DNA repair protein RAD51 homolog 1; DNA repair protein rhp51; HRAD51; HsRad51; HsT16930; MRMV2; Rad 51; RAD51; RAD51 homolog; RecA homolog, E. coli; S. cerevisiae; RAD51 homolog A; RAD51 homolog; RAD51 recombinase; RAD51, S. cerevisiae, homolog of; RAD51_human; RAD51A; RECA; RecA like protein; RecA, E. coli, homolog of; Recombination protein A.
WB
Human, Mouse, Rat, Monkey
Rad51 Antibody (YA5219) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RAD51. It can be applicated for WB assays, in the background of human, mouse, rat, monkey.
GRK2 Antibody (YA5226) is a mouse-derived and non-conjugated monoclonal antibody, targeting to GRK 2. It can be applicated for WB assays, in the background of human.
B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_human; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.
WB, ICC/IF, IP
Human
RanBP9 Antibody (YA5234) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RanBP9. It can be applicated for WB, ICC/IF, IP assays, in the background of human.
C syn protooncogene; Fyn; FYN oncogene related to SRC FGR YES; FYN_human; MGC45350; OKT3 induced calcium influx regulator; P59 FYN; p59-Fyn; Protein tyrosine kinase fyn; Proto oncogene tyrosine protein kinase fyn; Proto-oncogene c-Fyn; Proto-oncogene Syn; Protooncogene Syn; SLK; Src like kinase; Src yes related novel gene; Src-like kinase; Src/yes related novel; Src/yes related novel gene; SYN; Tyrosine kinase p59fyn T; Tyrosine kinase p59fyn; T; Tyrosine-protein kinase Fyn.
WB, ICC
Human, Monkey, Rat, Mouse
Fyn Antibody (YA5237) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Fyn. It can be applicated for WB, ICC assays, in the background of human, monkey, rat, mouse.
High temperature requirement protein A2; HTRA 2; HtrA like serine protease; HtrA serine peptidase 2; HtrA, E. coli, homolog of, 2; HtrA2; HTRA2_human; mitochondrial; Omi stress regulated endoprotease; Omi stress-regulated endoprotease; PARK 13; PARK13; Protease serine 25; PRSS 25; PRSS25; Serine protease 25; Serine protease HTRA2; Serine protease HTRA2 mitochondrial; Serine protease htra2 mitochondrial precursor; Serine protease omi; Serine proteinase OMI.
WB
Mouse, Hamster
HtrA5/Omi Antibody (YA5333) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HtrA2/Omi. It can be applicated for WB assays, in the background of mouse, hamster.
CD2 Antibody (YA5540) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD2. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
C3 binding protein; C3b/C4b receptor; C3BR; C4BR; CD 35; CD35; CD35 antigen; complement component; 3b/4b; receptor 1; Knops blood group; complement component; 3b/4b; receptor 1 including Knops blood group system; Complement component receptor 1; Complement receptor 1; Complement receptor type 1; CR 1; CR1; CR1_human; KN; Knops blood group antigen
IHC-P, WB, ICC/IF, ELISA
Human
CD35 Antibody (YA5586) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD35. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
B220; CD 45; CD45; CD45 antigen; CD45R; GP180; L-CA; LCA; Leukocyte common antigen; loc; Ly-5; LY5; Ly5, homolog of; Lyt-4; OTTHUMP00000033813; OTTHUMP00000033816; OTTHUMP00000033817; OTTHUMP00000038574; Protein tyrosine phosphatase receptor type c polypeptide; Protein tyrosine phosphatase, receptor type C; protein tyrosine phosphatase, receptor type, C; Protein tyrosine phosphatase, receptor type, c polypeptide; Ptprc; PTPRC_human; Receptor-type tyrosine-protein phosphatase C; T200; T200 glycoprotein; T200 leukocyte common antigen
IHC-P, WB, ICC/IF, ELISA
Human
CD45 Antibody (YA5587) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD45. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
AI528832; CK 15; CK-15; CK15; CytokeRatin-15; CytokeRatin15; K15; K1C15_human; K1CO; Ka15; KeRatin 15; KeRatin 15 basic; KeRatin 15 beta; KeRatin; KeRatin complex 1 acidic gene 15; KeRatin type I cytoskeletal 15; KeRatin-15; KeRatin15; KRT 15; Krt1-15; KRT15; KRTB; KRTL15; Type I cytoskeletal 15; Type I keRatin Ka15
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 15 Antibody (YA5593) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 15. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Anti TCL1A; Lymphoma/leukemia, T-cell; Oncogene TCL-1; Oncogene TCL1; P14 TCL1; P14 TCL1 protein; Protein p14 TCL1; T cell leukemia 1; T cell lymphoma 1; T cell lymphoma 1A; T-cell leukemia/lymphoma 1A; T-cell leukemia/lymphoma protein 1A; TCL 1 protein; TCL1; TCL1 oncogene; TCL1 PEN; Tcl1a; TCL1A; TCL1A_human
IHC-P, WB, ICC/IF, ELISA
Human
T Cell Leukemia/Lymphoma Protein 1A Antibody (YA5620) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to TCL1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
SMARCB1 Antibody (YA5649) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to INI-1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
C7orf1; Claudin-3; Claudin3; CLD3_human; CLDN 3; Cldn3; Clostridium perfringens enterotoxin receptor 2; CPE R2; CPE receptor 2; CPE-R 2; CPE-receptor 2; CPETR 2; CPETR2; HRVP 1; HRVP1; Rat ventral prostate 1 like protein; Rat ventral prostate.1 protein homolog; RVP1; Ventral prostate.1 like protein; Ventral prostate.1 protein homolog
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Claudin 3 Antibody (YA5783) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Claudin 3. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
B220; CD 45; CD45; CD45 antigen; CD45R; GP180; L-CA; LCA; Leukocyte common antigen; loc; Ly-5; LY5; Ly5, homolog of; Lyt-4; OTTHUMP00000033813; OTTHUMP00000033816; OTTHUMP00000033817; OTTHUMP00000038574; Protein tyrosine phosphatase receptor type c polypeptide; Protein tyrosine phosphatase, receptor type C; protein tyrosine phosphatase, receptor type, C; Protein tyrosine phosphatase, receptor type, c polypeptide; Ptprc; PTPRC_human; Receptor-type tyrosine-protein phosphatase C; T200; T200 glycoprotein; T200 leukocyte common antigen
WB, IHC-P, ICC/IF, IP, ELISA
Human
CD45 Antibody (YA6135) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD45. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.
Toll-like receptor 2; Toll like receptor 2; Toll like receptor 2 precursor; Toll-like receptor 2; TLR 2; TLR-2; Toll/interleukin-1 receptor-like protein 4; CD282 antigen; CD282; TIL 4; TIL4; TLR2_human; Toll/interleukin 1 receptor like 4; Toll/interleukin 1 receptor like protein 4; Toll/interleukin receptor like protein 4.
WB, FC
Human, Mouse
TLR2 Antibody (YA6351) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TLR2. It can be applicated for WB, FC assays, in the background of human, mouse.
Dmrpa1; Drosophila Replication Protein A; DRPA; DSSB; HSSB; human single stranded DNA binding protein; MST075; MSTP075; p70; REPA 1; REPA1; Replication factor A; Replication factor A protein 1; Replication protein A 70 kDa DNA-binding subunit; Replication protein A 70kDa DNA binding subunit; Replication protein A1; 70kD; Replication protein A1; 70kD; Replication protein A1 70kDa; Replication protein A1; RF A; RF-A protein 1; RFA; RFA1_human; RP A; RP-A p70; RPA 1; RPA 70; RPA; RPA1; Single stranded binding protein 70; Single stranded DNA binding protein; Single-stranded DNA-binding protein; Ssb70.
WB, ICC/IF, IP
Human, Monkey, Mouse, Rat
RPA70 Antibody (YA5280) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RPA70. It can be applicated for WB, ICC/IF, IP assays, in the background of human, monkey, mouse, rat.
CARD2; CK 8; CK-8; CK8; CYK8; CYKER; Cytokeratin endo A; CytokeRatin-8; DreK8; EndoA; K2C8; K2C8_human; K8; KeRatin 8; KeRatin type II cytoskeletal 8; KeRatin, type II cytoskeletal 8; KeRatin-8; KO; Krt 2.8; KRT8; MGC118110; MGC174782; MGC53564; MGC85764; sb:cb186; Type-II keRatin Kb8; CK 18; CK-18; CK18; CYK18; Cytokeratin 18; Cytokeratin endo B; CytokeRatin-18; K 18; K18; K1C18_human; KA18; KeRatin 18; KeRatin 18, type I; KeRatin D; keRatin, type I cytoskeletal 18; KeRatin-18; Krt18
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Cytokeratin 8/18 Antibody (YA5596) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Cytokeratin 8/18. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
PP2A A; PP2A alpha; PP2A B; PP2A beta; PP2A-alpha; PP2A-beta; PP2AA_human; PP2Aalpha; PP2AB_human; PP2Abeta; PP2Ac; PP2CA; PP2Calpha; PP2CB; PPP2CA; PPP2CB; Protein phosphatase 2 catalytic subunit alpha isoform; Protein phosphatase 2 catalytic subunit beta isoform; Protein phosphatase type 2A catalytic subunit; Replication protein C; RP C; RP-C; RPC; Serine/threonine protein phosphatase 2A catalytic subunit alpha isoform; Serine/threonine protein phosphatase 2A catalytic subunit beta isoform; Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform;
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
PP2A alpha/beta Antibody (YA6103) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PP2A alpha/beta. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Cytokeratin 5 Antibody is an unconjugated, approximately 62 kDa, rabbit-derived, anti-Cytokeratin 5 monoclonal antibody. Cytokeratin 5 Antibody can be used for: WB, IHC-P, IF-Tissue, IF-Cell, FC expriments in human, mouse, rat background without labeling.
COL 3A1; COL3A1; Collagen alpha 1(III) chain; Collagen III alpha 1 chain precursor; Collagen III alpha 1 polypeptide; Collagen type III alpha 1 (Ehlers Danlos syndrome type IV autosomal dominant); Collagen type III alpha 1; Collagen type III alpha; EDS4A; Ehlers Danlos syndrome type IV, autosomal dominant; Fetal collagen; Type III collagen; CO3A1_human; Collagen alpha-1(III) chain; Type III collagen; type III preprocollagen alpha 1 chain.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Dog, Rabbit
Collagen III Antibody is an unconjugated, approximately 117 kDa, rabbit-derived, anti-Collagen III polyclonal antibody. Collagen III Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, dog, rabbit, and predicted: mouse, rat, chicken, cow background without labeling.
CCN 2; CCN-2; CCN2; Connective Tissue Growth Factor; Hcs 24; Hcs24; Hypertrophic chondrocyte specific protein 24; Hypertrophic chondrocyte-specific gene product 24; Insulin-like Growth Factor-Binding Protein 8; MGC102839; NOV 2; NOV2; Connective tissue growth factor; CCN family member 2; Hypertrophic chondrocyte-specific protein 24; Insulin-like growth-binding protein 8; IBP-8; IGF-binding protein 8; IGFBP8; IGFBP-8; connective tissue growth factor precursor; CTGF_human.
WB, ELISA
Mouse, Rat
CTGF Antibody is an unconjugated, approximately 36 kDa, rabbit-derived, anti-CTGF polyclonal antibody. CTGF Antibody can be used for: WB, ELISA expriments in mouse, rat, and predicted: human,chicken, dog, pig, cow background without labeling.
CXCR3_human; Interferon-inducible protein 10 receptor; IP-10 receptor; C-X-C chemokine receptor type 3; CD 183; CD183; CD183 antigen; G protein-coupled receptor 9; G Protein Coupled Receptor 9; Chemokine (C X C motif) receptor 3; Chemokine (C X C) receptor 3; C-X-C Chemokine receptor; CXC Motif Receptor 3; Chemokine CXC Motif Receptor 3; CKRL2; CKR L2; CKR-L2; GPR9; CXC-R3; CXCR-3; IP10 receptor.
WB
Human, Mouse, Rat
CXCR3 Antibody is an unconjugated, approximately 40 kDa, rabbit-derived, anti-CXCR3 polyclonal antibody. CXCR3 Antibody can be used for: WB expriments in human, mouse, rat, and predicted: dog, pig, cow, rabbit, guinea pig background without labeling.
LATS1 +LATS2 (phospho T1079 + T1041); Serine/threonine protein kinase LATS2; KPM; Large tumor supressor, homolog 1; LATS, large tumor suppressor, homolog 1 (Drosophila); LATS, large tumor suppressor, homolog 2 (Drosophila); LATS1 +LATS2 (phospho T1079 + T1041); p-LATS1 +LATS2(Thr1079 +Thr1041); RGD1564085; Serine/threonine protein kinase LATS1; WARTS; WARTS protein kinase; wts; 4932411G09Rik; AV277261; AW208599; AW228608; FLJ13161; LATS1_human.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse
phospho-LATS1+LATS2 (Thr1079 +Thr1041) Antibody is an unconjugated, approximately 124 kDa, rabbit-derived, anti-phospho-LATS1+LATS2 (Thr1079 +Thr1041) polyclonal antibody. phospho-LATS1+LATS2 (Thr1079 +Thr1041) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, chicken, dog, pig, cow, horse, rabbit background without labeling.
CXCR3_human; Interferon-inducible protein 10 receptor; IP-10 receptor; C-X-C chemokine receptor type 3; CD 183; CD183; CD183 antigen; G protein-coupled receptor 9; G Protein Coupled Receptor 9; Chemokine (C X C motif) receptor 3; Chemokine (C X C) receptor 3; C-X-C Chemokine receptor; CXC Motif Receptor 3; Chemokine CXC Motif Receptor 3; CKRL2; CKR L2; CKR-L2; GPR9; CXC-R3; CXCR-3; IP10 receptor.
WB, ICC/IF, IP
Human
CXCR3 Antibody is an unconjugated, approximately 41 kDa, rabbit-derived, anti-CXCR3 monoclonal antibody. CXCR3 Antibody can be used for: WB expriments in human background without labeling.
Dynactin 1(N-term) Antibody (YA5180) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Dynactin 1 (N-term). It can be applicated for WB, IP assays, in the background of human.
Chromosome segregation protein SmcB; DXS423E; KIAA0178; MGC138332; Sb1.8; Segregation of mitotic chromosomes 1; SMC protein 1A; SMC-1-alpha; SMC-1A; SMC1; structural maintenance of chromosomes 1 yeast; like 1; SMC1; SMC1 structural maintenance of chromosomes 1 like 1; SMC1A; SMC1A_human; SMC1alpha; SMC1L1; SMCB; Structural maintenance of chromosomes 1A; Structural maintenance of chromosomes protein 1A.
WB, IHC-P, FC
Human
SMC1A(N-term) Antibody (YA5194) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SMC1A (N-term). It can be applicated for WB, IHC-P, FC assays, in the background of human.
Chromosome segregation protein SmcB; DXS423E; KIAA0178; MGC138332; Sb1.8; Segregation of mitotic chromosomes 1; SMC protein 1A; SMC-1-alpha; SMC-1A; SMC1; structural maintenance of chromosomes 1 yeast; like 1; SMC1; SMC1 structural maintenance of chromosomes 1 like 1; SMC1A; SMC1A_human; SMC1alpha; SMC1L1; SMCB; Structural maintenance of chromosomes 1A; Structural maintenance of chromosomes protein 1A.
WB, ICC
Human
SMC1A(C-term) Antibody (YA5195) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SMC1A (C-term). It can be applicated for WB, ICC assays, in the background of human.
CLL associated antigen KW 6; DNA-binding protein Ikaros; hIk 1; hIk-1; Hs.54452; IK1; Ikaros; zinc finger protein; IKAROS; IKAROS family zinc finger 1; Ikaros; Ikaros family zinc finger protein 1; Ikzf1; IKZF1_human; LYF1; Lymphoid transcription factor LyF-1; PRO0758; Zinc finger protein subfamily 1A 1; Ikaros; zinc finger protein subfamily 1A 1; Zinc finger protein, subfamily 1A, member 1; ZNFN1A1.
WB, IP
Human
Ikaros(C-term) Antibody (YA5216) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Ikaros (C-term). It can be applicated for WB, IP assays, in the background of human.
Abundant SRC homology; Adapter protein GRB2; ASH; Ash protein; EGFRBP GRB2; Epidermal growth factor receptor binding protein; Epidermal growth factor receptor binding protein GRB2; GRB 2; GRB2 adapter protein; Grb2; GRB2_human; Grb3 3; Growth factor receptor bound protein 2; Growth factor receptor bound protein 3; Growth factor receptor-bound protein 2; HT027; MST084; MSTP084; NCKAP2; OTTHUMP00000166096; OTTHUMP00000166097; OTTHUMP00000166098; Protein ASH; SEM5; SH2/SH3 adapter GRB2.
WB
Human, Mouse, Rat
GRB2 Antibody (YA5228) is a mouse-derived and non-conjugated monoclonal antibody, targeting to GRB2. It can be applicated for WB assays, in the background of human, mouse, rat.
EGFR Antibody (YA5292) is a mouse-derived and non-conjugated monoclonal antibody, targeting to EGFR. It can be applicated for WB, IHC-P, ICC/IF, IP assays, in the background of human, monkey.
GOT2 Antibody (YA5322) is a mouse-derived and non-conjugated monoclonal antibody, targeting to GOT2. It can be applicated for WB assays, in the background of human, mouse.
B cell Oct binding protein 1; B cell specific coactivator OBF 1; B cell specific coactivator OBF1; B-cell-specific coactivator OBF-1; BOB 1; BOB-1; OBF 1; OBF1; OBF1_human; OCA B; OCA-B; OCAB; OCT binding factor 1; OCT-binding factor 1; POU class 2 associating factor 1; POU domain class 2 associating factor 1; POU domain class 2-associating factor 1; Pou2af1
IHC-P, WB, ICC/IF, ELISA
Human, Mouse,
BOB1 Antibody (YA5521) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to BOB.1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
Alpha 1 collagen type I; Alpha 1 type I collagen; Alpha 1 type I procollagen; Alpha 1; I; collagen; Alpha 1; I; procollagen; Alpha-1 type I collagen; CO1A1_human; COL1A1; Collagen alpha 1; I; chain; Collagen alpha-1; I; chain; Collagen I alpha 1 polypeptide; Collagen of skin tendon and bone alpha 1 chain; Collagen type I alpha 1
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
Collagen I Antibody (YA5601) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Collagen Type I A1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Alpha 1 collagen type I; Alpha 1 type I collagen; Alpha 1 type I procollagen; Alpha 1; I; collagen; Alpha 1; I; procollagen; Alpha-1 type I collagen; CO1A1_human; COL1A1; Collagen alpha 1; I; chain; Collagen alpha-1; I; chain; Collagen I alpha 1 polypeptide; Collagen of skin tendon and bone alpha 1 chain; Collagen type I alpha 1
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Collagen I Antibody (YA5793) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Collagen I. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
CK 7; CK-7; CK7; Cytokeratin 7; Cytokeratin-7; D15Wsu77e; K2C7; K2C7_human; K7; Keratin 7; Keratin 7, type II; Keratin type II cytoskeletal 7; Keratin, 55K type II cytoskeletal; Keratin, simple epithelial; Keratin, simple epithelial type I, K7; Keratin, type II cytoskeletal 7; Keratin-7; Krt2-7; KRT7; MGC11625; MGC129731; MGC3625; Sarcolectin; SCL; Type II mesothelial keratin K7; Type-II keratin Kb7
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
Cytokeratin 7 Antibody (YA6177) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 7. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
PRKACA/PRKACB; PRKACA + PRKACB; PKA alpha + beta; PKA alpha; PKA beta; cAMP dependent protein kinase alpha catalytic subunit; cAMP dependent protein kinase beta catalytic subunit; cAMP dependent protein kinase catalytic subunit alpha; cAMP dependent protein kinase catalytic subunit beta; DKFZp781I2452; MGC102831; MGC41879; MGC48865; MGC9320; PKA C alpha; PKA C beta; PKACA; PKACB; PRKACA; PRKACB; Protein kinase A catalytic subunit alpha; Protein kinase A catalytic subunit; Protein kinase A catalytic subunit beta; Protein kinase cAMP dependent catalytic alpha; Protein kinase cAMP dependent catalytic beta; cAMP dependent protein kinase catalytic subunit alpha isoform 1; cAMP-dependent protein kinase catalytic subunit alpha; KAPCA_human; KAPCB_human; PKA C alpha; PKA C-alpha; PKACA; PRKACA; Protein kinase A catalytic subunit; Protein kinase cAMP dependent catalytic alpha.
WB, ELISA, IHC-P, IHC-F, ICC/IF
Human, Mouse
PKA C-alpha Antibody is an unconjugated, approximately 40 kDa, rabbit-derived, anti-PKA alpha + beta polyclonal antibody. PKA C-alpha Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, and predicted: rat background without labeling.
Collagen II alpha 1; COL2A1; COL2A1 protein; collagen, type II, alpha 1; collagen alpha-1(II); type II collagen; alpha-1 type II collagen; alpha1 type II collagen; Col2a1; AOM; Cartilage collagen; Chondrocalcin; COL11A3; Collagen alpha 1(II) chain precursor; Collagen II alpha 1 polypeptide; Collagen type II alpha 1 (primary osteoarthritis spondyloepiphyseal dysplasia congenital); MGC131516; SEDC; Collagen alpha-1(II) chain; Alpha-1 type II collagen; CO2A1_human.; CollagenII
WB, ELISA, IHC-P, ICC/IF
Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit, Guinea Pig
Collagen II Antibody is an unconjugated, approximately 117 KDa, rabbit-derived, anti-Collagen II polyclonal antibody. Collagen II Antibody can be used for: WB, ELISA, IHC-P, IF expriments in human, mouse, rat, chicken, dog, pig, cow, rabbit, guinea pig background without labeling.
CD 152; CD152; CD152 antigen; Celiac disease 3; CELIAC3; CTLA 4; CTLA-4; Cytotoxic T cell associated 4; Cytotoxic T lymphocyte associated 4; Cytotoxic T lymphocyte associated antigen 4; Cytotoxic T lymphocyte associated protein 4; Cytotoxic T lymphocyte associated serine esterase 4; Cytotoxic T lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; Cytotoxic T-lymphocyte-associated protein 4; GSE; IDDM12; CD152 isoform; CTLA4_human; GRD4; ICOS; Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4.
WB, ICC/IF
Human, Mouse, Rat
CTLA4 Antibody is a rabbit-derived non-conjugated IgG antibody, targeting CTLA4, with a predicted molecular weight of 25 kDa. CTLA4 Antibody can be used for WB,ICC/IF experiments in human, mouse, rat backgrounds.
ACE Antibody is an unconjugated, approximately 150 kDa, rabbit-derived, anti-ACE monoclonal antibody. ACE Antibody can be used for: WB,IHC-P,FC expriments in human, mouse background without labeling.
Caspase-1 Antibody is an unconjugated, approximately 46 kDa, rabbit-derived, anti-Caspase-1 polyclonal antibody. Caspase-1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, background without labeling.
CASP4 Antibody is a non-conjugated IgG antibody, targeting CASP4, with a predicted molecular weight of 43 kDa. CASP4 Antibody can be used for WB, ELISA experiment in human and rat background.
C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/HDAC3 complex subunit; Nuclear receptor corepressor/HDAC3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_human; TBL1XR1; Transducin (beta) like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.
WB, IHC-F, IHC-P, ICC/IF
Human, Mouse
TBLR1 Antibody (YA1052) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1052), targeting TBL1XR1, with a predicted molecular weight of 56 kDa (observed band size: 60 kDa). TBLR1 Antibody (YA1052) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human, mouse background.
C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/HDAC3 complex subunit; Nuclear receptor corepressor/HDAC3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_human; TBL1XR1; Transducin (beta) like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.
WB, IHC-P, ICC/IF
Human, Mouse, Rat
TBLR1 Antibody (YA1053) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1053), targeting TBL1XR1, with a predicted molecular weight of 56 kDa (observed band size: 56 kDa). TBLR1 Antibody (YA1053) can be used for WB, IHC-P, ICC/IF experiment in human, mouse, rat background.
C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/HDAC3 complex subunit; Nuclear receptor corepressor/HDAC3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_human; TBL1XR1; Transducin (beta) like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.
WB, IHC-P, ICC/IF
Human, Monkey
TBLR1 Antibody (YA1084) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1084), targeting TBLR1, with a predicted molecular weight of 56 kDa (observed band size: 60 kDa). TBLR1 Antibody (YA1084) can be used for WB, IHC-P, ICC/IF experiment in human, monkey background.
DKFZp781C1895; DKFZp781O1323; Dwfc; hSmad 5; hSmad5; JV5 1; JV5-1; MAD homolog 5; MAD mothers against decapentaplegic homolog 5; MAD; mothers against decapentaplegic homolog 5; MADH 5; MADH5; Mothers against decapentaplegic homolog 5; Mothers against DPP homolog 5; MusMLP; SMA and MAD related protein 5; SMAD 5; SMAD family member 5; SMAD mothers against DPP homolog 5; Smad5; Smad5; SMAD5_human.
WB, IHC-P, ICC/IF
Human, Mouse, Rat
Phospho-Smad5 (Ser463/465) Antibody (YA2838) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2838), targeting Phospho-Smad5 (Ser463/465), with a predicted molecular weight of 52 kDa (observed band size: 58 kDa). Phospho-Smad5 (Ser463/465) Antibody (YA2838) can be used for WB, IHC-P, ICC/IF experiment in human, mouse, rat background.
Collagen II alpha 1; COL2A1; COL2A1 protein; collagen, type II, alpha 1; collagen alpha-1(II); type II collagen; alpha-1 type II collagen; alpha1 type II collagen; Col2a1; AOM; Cartilage collagen; Chondrocalcin; COL11A3; Collagen alpha 1(II) chain precursor; Collagen II alpha 1 polypeptide; Collagen type II alpha 1 (primary osteoarthritis spondyloepiphyseal dysplasia congenital); MGC131516; SEDC; Collagen alpha-1(II) chain; Alpha-1 type II collagen; CO2A1_human.; CollagenII;
WB, IHC-P, ICC/IF
Human, Mouse, Rat
Collagen II Antibody is an unconjugated, approximately 117 KDa, rabbit-derived, anti-Collagen II monoclonal antibody. Collagen II Antibody can be used for: WB, IHC-P, IF-Tissue expriments in human, mouse, rat background without labeling.
DXS1272E; Histone demethylase JARID1C; JARID1C; JmjC domain containing protein SMCX; Jumonji AT rich interactive domain 1C; Jumonji, AT rich interactive domain 1C; RBP2 like; Jumonji/ARID domain-containing protein 1C; KDM5C; KDM5C_human; Lysine; K; specific demethylase 5C; Lysine-specific demethylase 5C; MRXJ; MRXSCJ; MRXSJ; Protein SmcX; Protein Xe169; rbp2 like protein; Selected cDNA on X; SMCX; Smcx homolog X chromosome; SmcX protein; SmcX protein; Smcy homolog X linked; XE169; Xe169 protein; Xe169 protein.
WB, ICC
Human
KDM5C/Jarid1C/SMCX Antibody (YA5174) is a mouse-derived and non-conjugated monoclonal antibody, targeting to KDM5C/Jarid1C/SMCX. It can be applicated for WB, ICC assays, in the background of human.
Amine oxidase; flavin containing; domain 2; AOF2; BHC110; BRAF35 HDAC complex protein BHC110; BRAF35-HDAC complex protein BHC110; FAD binding protein BRAF35 HDAC complex, 110 kDa subunit; Flavin-containing amine oxidase domain-containing protein 2; KDM 1; KDM1; Kdm1a; KDM1A_human; LSD 1; LSD1; Lysine; K; specific demethylase 1; Lysine; K; specific demethylase 1A; Lysine specific histone demethylase 1; Lysine specific histone demethylase 1A; Lysine-specific histone demethylase 1A.
WB, ICC/IF, IP
Human, Monkey
KDM1/LSD1 Antibody (YA5176) is a mouse-derived and non-conjugated monoclonal antibody, targeting to KDM1/LSD1. It can be applicated for WB, ICC/IF, IP assays, in the background of human, monkey.
EBI; F box like/WD repeat protein TBL1X; F-box-like/WD repeat-containing protein TBL1X; SMAP 55; SMAP55; TBL 1; TBL 1X; TBL1; TBL1X; TBL1X_human; Transducin; beta; like 1; Transducin; beta; like 1 X linked; Transducin; beta; like 1X linked; Transducin beta like 1 X linked; Transducin beta like 1X; Transducin beta like 1X protein; Transducin beta like protein 1, X linked; Transducin beta-like protein 1X; Transducin-beta-like protein 1; X-linked.
WB, ICC
Human
TBL1X Antibody (YA5178) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TBL1. It can be applicated for WB, ICC assays, in the background of human.
AL024441; COX 4; COX IV 1; COX IV; COX IV-1; Cox4; COX41_human; Cox4a; COX4B; COX4I1; COX4I2; COX4L2; COXIV; Cytochrome c oxidase polypeptide IV; Cytochrome c oxidase subunit 4 isoform 1 mitochondrial; Cytochrome c oxidase subunit 4 isoform 1, mitochondrial; Cytochrome C Oxidase subunit IV; Cytochrome c oxidase subunit IV isoform 1; Cytochrome c oxidase subunit IV isoform 2; lung; Cytochrome c oxydase subunit; dJ857M17.2; MGC105470; MGC72016.
WB, FC, ICC/IF, IP, IHC-P
Human, Mouse, Rat, Hamster, Goat, Monkey
COX IV Antibody (YA5187) is a mouse-derived and non-conjugated monoclonal antibody, targeting to COX IV. It can be applicated for WB, FC, ICC/IF, IP, IHC-P assays, in the background of human, mouse, rat, hamster, goat, monkey.
C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/HDAC3 complex subunit; Nuclear receptor corepressor/HDAC3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_human; TBL1XR1; Transducin; beta; like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.
WB, IHC-P, ICC
Human, Mouse
TBLR1 Antibody (YA5202) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TBLR1. It can be applicated for WB, IHC-P, ICC assays, in the background of human, mouse.
NFIC Antibody (YA5203) is a mouse-derived and non-conjugated monoclonal antibody, targeting to NFIC. It can be applicated for WB, ICC assays, in the background of human.
Brain Ca; 2; calmodulin dependent protein kinase type 4; Brain Ca; 2; calmodulin dependent protein kinase type IV; Brain Ca -calmodulin dependent protein kinase type IV; Calcium / calmodulin dependent protein kinase type 4 catalytic chain; Calcium / calmodulin dependent protein kinase type IV catalytic chain; Calcium/calmodulin dependent protein kinase IV; Calcium/calmodulin dependent protein kinase type IV; Calcium/calmodulin-dependent protein kinase type IV; CAM kinase 4; CAM kinase GR; CAM kinase IV; CAM kinase-GR; CaMK 4; CAMK GR; CaMK IV; CaMK4; CaMKGR; IV; KCC4_human; MGC36771.
WB
Human
CaMKIV Antibody (YA5229) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CaMKIV. It can be applicated for WB assays, in the background of human.
LCK; Lck p56; LCK_human; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell specific protein tyrosine kinase; Lymphocyte cell-specific protein-tyrosine kinase; Lymphocyte Specific Protein Tyrosine Kinase; Membrane associated protein tyrosine kinase; Oncogene lck; P56 LCK; p56; LSTRA; protein tyrosine kinase; p56-LCK; p56lck; pp58 lck; pp58lck; Protein YT16; Proto oncogene tyrosine protein kinase LCK; Proto-oncogene Lck; Protooncogene tyrosine protein kinase LCK; T cell specific protein tyrosine kinase; T cell-specific protein-tyrosine kinase; T lymphocyte specific protein tyrosine kinase p56lck; Tyrosine-protein kinase Lck; YT 16; YT16.
WB
Human
Lck Antibody (YA5247) is a mouse-derived and non-conjugated monoclonal antibody, targeting to LCK. It can be applicated for WB assays, in the background of human.
70 kDa zeta associated protein; 70 kDa zeta-associated protein; FLJ17670; FLJ17679; Selective T cell defect; SRK; STD; Syk related tyrosine kinase; Syk-related tyrosine kinase; Truncated ZAP kinase; Tyrosine protein kinase ZAP70; Tyrosine-protein kinase ZAP-70; TZK; ZAP 70; ZAP-70; ZAP70; ZAP70_human; Zeta chain associated protein kinase 70kD; Zeta chain associated protein kinase 70kDa; Zeta chain associated protein kinase 70kDa isoform 1; Zeta chain associated protein kinase 70kDa isoform 2; Zeta chain TCR associated protein kinase 70kD; Zeta chain TCR associated protein kinase 70kDa.
WB, IP
Human
ZAP70 Antibody (YA5284) is a mouse-derived and non-conjugated monoclonal antibody, targeting to ZAP-70. It can be applicated for WB, IP assays, in the background of human.
Adapter protein GRID; GADS; GADS protein; GRAP-2; Grap2; GRAP2_human; GRB-2-like protein; GRB2-related adapter protein 2; GRB2-related adaptor protein 2; GRB2-related protein with insert domain; GRB2L; GRBLG; GRBX; Grf-40; Grf40 adapter protein; Grf40; GRID; Growth factor receptor-binding protein; Growth factor receptor-bound protein 2-related adaptor protein 2; GRPL; Hema; Hematopoietic cell-associated adapter protein GrpL; Hematopoietic cell-associated adaptor protein GRPL; Mona; p38; Protein GADS; SH3-SH2-SH3 adapter Mona; SH3-SH2-SH3 adaptor molecule.
WB
Human
GRAP2 Antibody (YA5313) is a mouse-derived and non-conjugated monoclonal antibody, targeting to GRAP2. It can be applicated for WB assays, in the background of human.
18A2; 42A; calcium Placental protein; Calvasculin; CAPL; Fibroblast specific protein 1; Fibroblast specific protein; FSP1; Leukemia multidrug resistance associated protein; Malignant transformation suppression 1; Metastasin; MTS1; OTTHUMP00000015467; OTTHUMP00000015468; P9KA; PEL98; Placental calcium-binding protein; Protein Mts1; Protein S100 A4; Protein S100-A4; S100 calcium binding protein A4; calcium protein, calvasculin, metastasin, murine placental homolog; S100 calcium binding protein A4; S100 calcium-binding protein A4; S100a4; S10A4_human.
WB
Human
S100A4 Antibody (YA5318) is a mouse-derived and non-conjugated monoclonal antibody, targeting to S100A4. It can be applicated for WB assays, in the background of human.
Galectin-3 Antibody (YA5606) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Galectin-3. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
CD 152; CD152; CD152 antigen; Celiac disease 3; CELIAC3; CTLA 4; CTLA-4; Cytotoxic T cell associated 4; Cytotoxic T lymphocyte associated 4; Cytotoxic T lymphocyte associated antigen 4; Cytotoxic T lymphocyte associated protein 4; Cytotoxic T lymphocyte associated serine esterase 4; Cytotoxic T lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; Cytotoxic T-lymphocyte-associated protein 4; GSE; IDDM12; CD152 isoform; CTLA4_human; GRD4; ICOS; Ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4.
IHC-P, mIHC
Human, Mouse
CTLA4 Antibody is a rabbit-derived non-conjugated IgG antibody, targeting CTLA4, with a predicted molecular weight of 25 kDa. CTLA4 Antibody can be used for IHC-P, mIHC experiments in human, mouse backgrounds.
Basic domain helix loop helix protein class B 1; Basic helix loop helix protein class B 1; BHLHB; bHLHB1; bHLHe19; Class B basic helix loop helix protein 1; Class B basic helix-loop-helix protein 1; class E basic helix loop helix protein 19; Class E basic helix-loop-helix protein 19; human protein kinase C binding protein RACK17; Olig2; OLIG2_human; Oligo2; Oligodendrocyte lineage transcription factor 2; Oligodendrocyte specific bHLH transcription factor 2; Oligodendrocyte transcription factor 2; OTTHUMP00000067569; OTTHUMP00000067570; PRKCBP2; Protein kinase C binding protein 2; Protein kinase C binding protein RACK17; Protein kinase C-binding protein 2; Protein kinase C-binding protein RACK17; RACK17.
WB, ICC/IF, ELISA
Human, Mouse,
Olig2 Antibody (YA5279) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to OLIG2. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human, mouse.
HSD3B1 Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-HSD3B1 monoclonal antibody. HSD3B1 Antibody can be used for: WB,ICC/IF expriments in human background without labeling.
Arresten; Canstatin; COL4A1; HANAC; ICH; POREN1; Collagen Alpha 1(IV) Chain; Collagen IV Alpha 1 Polypeptide; Collagen Of Basement Membrane Alpha 1 Chain; Collagen Of Basement Membrane Alpha 2 Chain; Collagen Type IV Alpha 1; DKFZp686I14213; FLJ22259; collagen alpha-1(IV) chain preproprotein; collagen alpha-1(IV) chain preproprotein; Col4a1 protein; collagen of basement membrane, alpha-1 chain; collagen IV, alpha-1 polypeptide; collagen alpha-1(IV) chain; COL4A1 NC1 domain; CO4A1_human; Collagen Ⅳ; Collagen Type Ⅳ.
ELISA, IHC-P, IHC-F, FC, ICC/IF
Human, Mouse, Rat
Collagen IV Antibody is an unconjugated, approximately 165 kDa, rabbit-derived, anti-Collagen IV polyclonal antibody. Collagen IV Antibody can be used for: ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, rabbit background without labeling.
PKM2 Antibody (YA5243) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PKM2. It can be applicated for WB, ICC/IF, IP assays, in the background of human, mouse, monkey.
PKM2 Antibody (YA5244) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PKM2. It can be applicated for WB, ICC/IF assays, in the background of human, mouse, rat, monkey.
70 kDa mitochondrial autoantigen of primary biliary cirrhosis; anti DLAT; Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex; Dihydrolipoamide; Dihydrolipoamide S Acetyltransferase; Dihydrolipoamide S-acetyltransferase; E2 component of pyruvate dehydrogenase complex; Dihydrolipoamide S-Acetyltransferase; Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex mitochondrial; DLAT; DLAT; DLTA; E2; E2 component of pyruvate dehydrogenase complex; M2 antigen complex 70 kDa subunit; M2 Antigen Complex 70kD Subunit; mitochondrial; ODP2_human; PBC; PDC E2; PDC-E2; PDCE2; Pyruvate dehydrogenase complex component E2; Pyruvate dehydrogenase complex E2 subunit; S acetyltransferase component of pyruvate dehydrogenase complex.
WB, ICC/IF, IP
Human, Mouse
Pyruvate Dehydrogenase E2 Antibody (YA5248) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Pyruvate Dehydrogenase E2. It can be applicated for WB, ICC/IF, IP assays, in the background of human, mouse.
Cytochrome P450 17A1 Antibody (YA5258) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CYP17A1. It can be applicated for WB assays, in the background of human.
HSP90AB1; 90 kda heat shock protein beta HSP90 beta; D6S182; FLJ26984; Heat shock 84 kDa; Heat shock 90kD protein 1, beta; Heat shock 90kDa protein 1 beta; Heat shock protein 90kDa alpha; cytosolic; class B member 1; Heat shock protein beta; Heat shock protein HSP 90 beta; Heat shock protein HSP 90-beta; HS90B_human; HSP 84; HSP 90; HSP 90 b; HSP 90b; HSP84; HSP90 BETA; hsp90ab1; HSP90B; HSPC2; HSPCB.
WB, ICC/IF, IP
Human, Mouse, Rat, Monkey, Hamster
Hsp90 beta Antibody (YA5288) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HSP90B. It can be applicated for WB, ICC/IF, IP assays, in the background of human, mouse, rat, monkey, hamster.
ATP dependent RNA helicase DDX3X; ATP-dependent RNA helicase DDX3X; CAP Rf; DBX; DDX14; DDX3X; DDX3X_human; DEAD; Asp Glu Ala Asp; box polypeptide 3 X linked; DEAD box; DEAD box protein 3; DEAD box protein 3 X-chromosomal; DEAD box X isoform; DEAD/H; Asp Glu Ala Asp/His; box polypeptide 3; DEAD/H box 3; DEAD/H box 3, X-linked; Fibroblast Growth Factor Inducible 14; Fin14; Helicase like protein 2; Helicase-like protein 2; HLP2; X isoform; X-chromosomal.
WB, IP, ICC
Human, Rat, Mouse, Monkey
DDX3 Antibody (YA5296) is a mouse-derived and non-conjugated monoclonal antibody, targeting to DDX3. It can be applicated for WB, IP, ICC assays, in the background of human, rat, mouse, monkey.
Fascin Antibody (YA5605) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Fascin. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Epididymis luminal protein 117; Epididymis secretory protein Li 53; HEL 117; HEL S 53; NDGOA; Neuron cytoplasmic protein 9.5; OTTHUMP00000218137; OTTHUMP00000218139; OTTHUMP00000218140; OTTHUMP00000218141; Park 5; PARK5; PGP 9.5; PGP9.5; PGP95; Protein gene product 9.5; Ubiquitin C terminal esterase L1; Ubiquitin C terminal hydrolase; Ubiquitin C terminal hydrolase L1; Ubiquitin carboxyl terminal esterase L1; Ubiquitin carboxyl terminal hydrolase isozyme L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin thioesterase L1; Ubiquitin thiolesterase; Ubiquitin thiolesterase L1; UCH-L1; UCHL1; UCHL1_human
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
PGP9.5 Antibody (YA5618) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PGP9.5. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
C Kit; CD 117; CD117; CD117 antigen; KIT; KIT_human; Mast/stem cell growth factor receptor; Mast/stem cell growth factor receptor Kit; p145 c-kit; PBT; Piebald trait protein; Proto oncogene c Kit; Proto oncogene tyrosine protein kinase Kit; Proto-oncogene c-Kit; SCF Receptor; SCFR; soluble KIT variant 1; Stem cell factor receptor; tyrosine protein kinase Kit; Tyrosine-protein kinase Kit; v kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog; v kit Hardy Zuckerman 4 feline sarcoma viral oncogene like protein; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog.
WB, IHC-P, IHC-F, IF-Tissue
Human
c-Kit Antibody (YA6347) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to c-Kit. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of human.
IL-4 Antibody (YA6361) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-4. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of human.
E3 SUMO protein ligase TRIM28; E3 SUMO-protein ligase TRIM28; FLJ29029; KAP 1; KAP-1; KRAB associated protein 1; KRAB interacting protein 1; KRAB-associated protein 1; KRAB-interacting protein 1; KRIP 1; KRIP-1; KRIP1; Nuclear corepressor KAP 1; Nuclear corepressor KAP-1; RING finger protein 96; RNF96; TF1B; TIF1 beta; TIF1-beta; TIF1B; TIF1B_human; Transcription intermediary factor 1 beta; Transcription intermediary factor 1-beta; TRIM28; Tripartite motif containing 28; tripartite motif containing protein 28; Tripartite motif-containing protein 28.
WB, ICC/IF, IHC-P, IP
Human
KAP1 Antibody (YA5197) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TIF1β. It can be applicated for WB, ICC/IF, IHC-P, IP assays, in the background of human.
BRAF Antibody (YA5221) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Raf-B. It can be applicated for WB assays, in the background of human, mouse.
Cancer/testis antigen 98; CT98; DKFZp686F1078; hKOC; IF2B3_human; IGF II mRNA binding protein 3; IGF-II mRNA-binding protein 3; IGF2 mRNA binding protein 3; IGF2 mRNA-binding protein 3; IGF2BP3; IMP 3; IMP-3; Insulin like growth factor 2 mRNA binding protein 3; Insulin-like growth factor 2 mRNA-binding protein 3; KH domain containing protein overexpressed in cancer; KH domain-containing protein overexpressed in cancer; KOC 1; KOC1; VICKZ 3; VICKZ family member 3; VICKZ3.
IHC-P, WB, ICC/IF, ELISA
Human, Mouse,
IMP3 Antibody (YA5275) is a mouse-derived and non-conjugated IgG monoclonal antibody, targeting to IMP3. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
FADK 1; FADK; FAK 1; FAK 1; FAK related non kinase polypeptide; FAK1; FAK1_human; Focal adhesion kinase 1; Focal adhesion kinase 1; Focal adhesion Kinase; Focal adhesion kinase isoform FAK Del33; Focal adhesion kinase related nonkinase; FRNK; p125FAK; pp125FAK; pp125FAK; PPP1R71; Protein phosphatase 1 regulatory subunit 71; Protein tyrosine kinase 2; Protein Tyrosine Kinase Cytoplasmic; Protein Tyrosine Kinase Cytoplasmic; Protein-tyrosine kinase 2; PTK 2; PTK 2; PTK2; PTK2 protein tyrosine kinase 2; PTK2 protein tyrosine kinase 2.
WB, ICC/IF
Human
FAK Antibody (YA5276) is a mouse-derived and non-conjugated monoclonal antibody, targeting to FAK. It can be applicated for WB, ICC/IF assays, in the background of human.
hHR 23b; hHR23B; HR 23B; HR23B; mHR 23B; mHR23B; P58; RAD 23B; RAD23; S. cerevisiae; homolog B; RAD23 homolog B; S. cerevisiae; RAD23 homolog B; RAD23 yeast homolog of B; RAD23B; RD23B_human; UV excision repair protein RAD23 homolog B; XP C repair complementing complex 58 kDa; XP C repair complementing complex 58 kDa protein; XP C repair complementing protein; XP-C repair-complementing complex 58 kDa protein; XPC repair complementing complex 58 kDa; XPC repair complementing complex 58 kDa protein; XPC repair complementing protein.
WB, ICC/IF, IHC-P
Human, Mouse, Rat, Monkey, Hamster
Rad23B Antibody (YA5286) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Rad23B. It can be applicated for WB, ICC/IF, IHC-P assays, in the background of human, mouse, rat, monkey, hamster.
70 kda SHP1L protein; 70Z-SHP; HCP; HCPH; Hematopoietic cell phosphatase; Hematopoietic cell protein tyrosine phosphatase; Hematopoietic cell protein-tyrosine phosphatase; HPTP1C; Protein tyrosine phosphatase 1C; Protein tyrosine phosphatase non receptor type 6; Protein tyrosine phosphatase SHP1; Protein-tyrosine phosphatase 1C; protein-tyrosine phosphatase SHP 1; Protein-tyrosine phosphatase SHP-1; PTN6_human; PTP 1C; PTP-1C; PTP1C; PTPN6; SH PTP 1; SH PTP1; SH-PTP1; SHP 1; SHP 1L; SHP1; SHP1L; tyrosine protein phosphatase non receptor type 6; Tyrosine-protein phosphatase non-receptor type 6.
WB, IP
Human
SHP1 Antibody (YA5316) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SHP-1. It can be applicated for WB, IP assays, in the background of human.
C Kit; c-Kit; c-Kit Ligand; CD117; Kit; Kit Ligand; KIT oncogene; KIT proto oncogene receptor tyrosine kinase; KIT_human; Mast cell growth factor receptor; Mast/stem cell growth factor receptor Kit; MGF; p145 c-kit; PBT; Piebald trait protein; Proto oncogene c Kit; Proto oncogene tyrosine protein kinase Kit; Proto-oncogene c-Kit; SCF Receptor; SCFR; soluble KIT variant 1; Steel Factor Receptor; Stem cell factor receptor; tyrosine protein kinase Kit; Tyrosine-protein kinase Kit; v kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog; v kit Hardy Zuckerman 4 feline sarcoma viral oncogene like protein; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
IHC-P, WB, ICC/IF, ELISA
Human
c-Kit Antibody (YA5533) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to c-Kit/CD117. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Iba 1 Antibody (YA5582) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Iba 1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
Iba1 Antibody (YA6228) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Iba1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Matrix metalloproteinase-9 precursor; MMP-9; MMP9; MMP 9; 92 kDa type IV; Collagenase; 92 kDa gelatinase; Gelatinase B; GELB; MMP9_human; 82 kDa matrix metalloproteinase-9; 92 kDa type IV collagenase; CLG 4B; CLG-4B; CLG4B; Collagenase Type 4 beta; Collagenase Type-4 beta; Collagenase type IV 92 KD; Collagenase type IV 92 KD; EC 3.4.24.35; Gelatinase 92 KD; Gelatinase 92 KD; Gelatinase beta; Gelatinase-beta; GelatinaseB; GELB; Macrophage gelatinase; MANDP2; Matrix metallopeptidase 9(gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase); Matrix Metalloproteinase 9; Type V collagenase.
WB, IHC-P, IHC-F, IF-Tissue
Human, Mouse, Rat
MMP-9 Antibody (YA6348) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MMP9. It can be applicated for WB, IHC-P, IHC-F, IF-Tissue assays, in the background of human, mouse, rat.
Alpha CaMKII; Calcium calmodulin dependent protein kinase II; Calcium/calmodulin dependent protein kinase II alpha B subunit; Calcium/calmodulin dependent protein kinase type II alpha chain; Calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha; Calcium/calmodulin-dependent protein kinase II alpha; Calcium/calmodulin-dependent protein kinase II-alpha; Calcium/calmodulin-dependent protein kinase type II subunit alpha; Calcium/calmodulin-dependent protein kinase type IIA; CaM kinase II alpha chain; CaM kinase II alpha subunit; CaM kinase II subunit alpha; CaMK II alpha subunit; CaMK-II subunit alpha; Camk2a; CAMKA; CaMKII; CaMKIINalpha; EC2.7.11.17; KCC2A_human; KIAA0968; MGC123320; MGC139375; MGC155201; mKIAA0968; PK2CDD; PKCCD; R74975; zgc:112538; zgc:123320
WB, IP, FC, IHC-P
Human, Mouse, Rat
CaMKII alpha Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to CaMKII alpha. It can be used for WB,IP,FC,IHC-P assays with tag free, in the background of Human, Mouse, Rat.
TRIM33 Antibody (YA5201) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TIF1γ. It can be applicated for WB assays, in the background of human.
PEG10 Antibody (YA5265) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PEG10. It can be applicated for WB, IP assays, in the background of human.
70 kDa zeta associated protein; 70 kDa zeta-associated protein; FLJ17670; FLJ17679; Selective T cell defect; SRK; STD; Syk related tyrosine kinase; Syk-related tyrosine kinase; Truncated ZAP kinase; Tyrosine protein kinase ZAP70; Tyrosine-protein kinase ZAP-70; TZK; ZAP 70; ZAP70; ZAP70_human; Zeta chain associated protein kinase 70kD; Zeta chain associated protein kinase 70 kDa; Zeta chain associated protein kinase 70 kDa isoform 1; Zeta chain associated protein kinase 70 kDa isoform 2; Zeta chain of T cell receptor associated protein kinase 70; Zeta chain TCR associated protein kinase 70kD; Zeta chain TCR associated protein kinase 70 kDa
IHC-P, WB, ICC/IF, ELISA
Human, Mouse,
ZAP70 Antibody (YA5523) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ZAP-70. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
Arresten; BSVD; CO4A1_human; COL4A1; COL4A1 NC1 domain; COL4A2; COL4A3; COL4A4; COL4A5; collagen alpha-1; IV; chain; Collagen IV Alpha 1 Polypeptide; Collagen IV Alpha 2 Polypeptide; Collagen Of Basement Membrane Alpha 1 Chain; Collagen Of Basement Membrane Alpha 2 Chain; Collagen Type IV Alpha 1; collagen type IV alpha 1 chain; Collagen Type IV Alpha 2; Collagen Type IV Alpha 3; Collagen Type IV Alpha 4; Collagen Type IV Alpha 5; RatOR
WB, IHC-P, ICC/IF, IP, ELISA
Human
Collagen IV Antibody (YA6331) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Collagen IV. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.
Immunoglobulin kappa variable 1D-16 Ig kappa chain V-I region HK146 Ig kappa chain V-I region HK189 Immunoglobulin kappa constant Ig kappa chain C regionCurated Ig kappa chain C region AG Ig kappa chain C region CUM Ig kappa chain C region EU Ig kappa chain C region OU Ig kappa chain C region ROY Immunoglobulin kappa variable 1D-16 Ig kappa chain V-I region HK146 Ig kappa chain V-I region HK189 Immunoglobulin kappa constant Ig kappa chain C regionCurated Ig kappa chain C region AG Ig kappa chain C region CUM Ig kappa chain C region EU Ig kappa chain C region OU Ig kappa chain C region ROY Ig kappa chain C region TI
Galectin 3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 26 kDa, targeting to Galectin 3. It can be used for WB,ICC/IF,FC,IHC-P assays with tag free, in the background of Human, Mouse.
CCR7_human; BLR 2; BLR2; C C chemokine receptor type 7; C C CKR 7; CC chemokine receptor 7; CC chemokine receptor type 7; CC CKR 7; CCCKR7; CCR 7; CD 197; CD197; CD197 antigen; CDW197; Chemokine C C motif receptor 7; Chemokine C C receptor 7; Chemokine receptor 7-like protein; EBI 1; EBI1; Ebi1h; EBV Induced G Protein Coupled Receptor 1; Epstein Barr virus induced G protein coupled receptor; Epstein Barr virus induced gene 1; EVI 1; EVI1; Lymphocyte Specific G Protein Coupled Peptide Receptor; MGC108519; MIP 3 beta receptor; MIP3 Beta Receptor.
WB, IHC-P, ICC/IF, ELISA
Human, Mouse, Rat
CCR7 Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-CCR7 polyclonal antibody. CCR7 Antibody can be used for: WB, ELISA, IHC-P, ICC, IF expriments in human, mouse, rat, and predicted: dog background without labeling.
Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_human; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; Hypoxia inducible factor 2 alpha; Hypoxia inducible factor 2 alpha subunit; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.
WB, IHC-P, FC
Human, Mouse, Rat
HIF-2 alpha Antibody (YA3517) is an unconjugated, approximately 96 kDa, rabbit-derived, anti-HIF 2 alpha monoclonal antibody. HIF 2 alpha Antibody can be used for:WB, IHC-P, FC expriments in human, mouse, rat background without labeling.
PIK3CA Antibody is an unconjugated, approximately 110 kDa, rabbit-derived, anti-PIK3CA monoclonal antibody. PIK3CA Antibody can be used for: WB, ICC/IF, IP expriments in human, mouse, rat background without labeling.
PIK3CA Antibody is an unconjugated, approximately 110 kDa, rabbit-derived, anti-PIK3CA monoclonal antibody. PIK3CA Antibody can be used for: WB, ICC/IF, IP expriments in human, mouse, rat background without labeling.
Hsp70(C-term) Antibody (YA5200) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Hsp70 (C-term). It can be applicated for WB, IP assays, in the background of human.
Damage specific DNA binding protein 1; Damage-specific DNA-binding protein 1; DDB 1; DDB p127 subunit; Ddb1; DDB1_human; DDBa; DNA damage binding protein 1; DNA damage-binding protein 1; DNA damage-binding protein a; HBV X-associated protein 1; UV damaged DNA binding factor; UV damaged DNA binding protein 1; UV DDB 1; UV DDB1; UV-damaged DNA-binding factor; UV-damaged DNA-binding protein 1; UV-DDB 1; UV-DDB1; X associated protein 1; XAP 1; XAP-1; XAP1; Xeroderma pigmentosum group E complementing protein; Xeroderma pigmentosum group E-complementing protein; XPCE; XPE; XPE BF; XPE binding factor; XPE-BF; XPE-binding factor.
WB
Human, Mouse, Rat, Monkey
DDB1 Antibody (YA5274) is a mouse-derived and non-conjugated monoclonal antibody, targeting to DDB1. It can be applicated for WB assays, in the background of human, mouse, rat, monkey.
AI849689; c Jun N terminal kinase 1; C-JUN kinase 1; c-Jun N-terminal kinase 1; JAK 1A; JAK1A; JNK 1; JNK 46; JNK; JNK-46; JNK1A2; JNK21B1/2; MAP kinase 8; MAPK 8; MAPK8; Mitogen activated protein kinase 8; Mitogen-activated protein kinase 8; MK08_human; p54 gamma; PRKM 8; PRKM8; Protein kinase JNK1; Protein kinase, mitogen-activated, 8; SAPK 1; SAPK gamma; SAPK1; Stress activated protein kinase JNK1; Stress-activated protein kinase 1; Stress-activated protein kinase JNK1; Tyrosine protein kinase JAK1 .
WB, ICC/IF
Human, Mouse, Rat
JNK1 Antibody (YA5290) is a mouse-derived and non-conjugated monoclonal antibody, targeting to JNK1. It can be applicated for WB, ICC/IF assays, in the background of human, mouse, rat.
FADD; FADD protein; FADD_human; Fas; TNFRSF6; associated via death domain; Fas associated via death domain; Fas associating death domain containing protein; Fas associating death domain containing protein; Fas associating protein; Fas associating protein with death domain; Fas associating protein with death domain; Fas TNFRSF6 associated via death domain; FAS-associated death domain protein; FAS-associating death domain-containing protein; FasTNFRSF6 associated via death domain; FasTNFRSF6 associated via death domain; GIG 3; GIG3; Growth inhibiting gene 3 protein; Growth-inhibiting gene 3 protein; H sapiens mRNA for mediator of receptor induced toxicity; H sapiens mRNA for mediator of receptor induced toxicity; Mediator of receptor induced toxicity; Mediator of receptor induced toxicity; MGC8528; MGC8528; MORT 1; MORT1; MORT1; Protein FADD.
WB
Human
FADD Antibody (YA5328) is a mouse-derived and non-conjugated monoclonal antibody, targeting to FADD. It can be applicated for WB assays, in the background of human.
AV026640; BCH; Benign chorea; BHC; Homeobox protein NK 2 homolog A; Homeobox protein NK-2 homolog A; Homeobox protein Nkx 2.1; Homeobox protein Nkx-2.1; Homeobox protein Nkx2.1; NK 2; NK 2 homolog A; NK2; NK2 homeobox 1; NK2, drosophila, homolog of, A; NK2.1, Mouse, homolog of; Nkx 2 1; NKX 2.1; NKX 2A; NKX2 1; Nkx2-1; NKX2.1; NKX21_human; NKX2A; T EBP; T/EBP; TEBP; Thyroid nuclear factor 1; Thyroid nuclear factor; Thyroid specific enhancer binding protein; Thyroid transcription factor 1; Tin man; Tinman; TITF 1; TITF1; TTF 1; TTF-1; TTF1
IHC-P, WB, ICC/IF, ELISA
Human, Mouse, Rat
TTF-1 Antibody (YA5637) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TTF-1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.
AV026640; BCH; Benign chorea; BHC; Homeobox protein NK 2 homolog A; Homeobox protein NK-2 homolog A; Homeobox protein Nkx 2.1; Homeobox protein Nkx-2.1; Homeobox protein Nkx2.1; NK 2; NK 2 homolog A; NK2; NK2 homeobox 1; NK2, drosophila, homolog of, A; NK2.1, Mouse, homolog of; Nkx 2 1; NKX 2.1; NKX 2A; NKX2 1; Nkx2-1; NKX2.1; NKX21_human; NKX2A; T EBP; T/EBP; TEBP; Thyroid nuclear factor 1; Thyroid nuclear factor; Thyroid specific enhancer binding protein; Thyroid transcription factor 1; Tin man; Tinman; TITF 1; TITF1; TTF 1; TTF-1; TTF1
WB, IHC-P, ICC/IF, IP, ELISA
Human, Mouse, Rat
TTF-1 Antibody (YA5847) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TTF1. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
alpha smooth muscle Actin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 42 kDa, targeting to alpha smooth muscle Actin. It can be used for WB,IHC-P,FC,IP assays with tag free, in the background of Human, Mouse.
MCP-1/CCL2; C-C motif chemokine 2; CCL 2; CCL2; CCL2_human; Chemokine (C C motif) ligand 2; Chemokine C C motif ligand 2; Chemokine CC Motif Ligand 2; GDCF 2; GDCF 2 HC11; GDCF-2; GDCF2; HC11; HSMCR30; HSMCR30; JE; MCAF; MCP 1; MCP-1; MGC9434; Monocyte chemoattractant protein 1; Monocyte chemotactic and activating factor; Monocyte chemotactic protein 1; Monocyte secretory protein JE; SCYA2; Small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig je); Small inducible cytokine A2; Small inducible cytokine subfamily A (Cys Cys), member 2; Small inducible cytokine subfamily A Cys Cys member 2; Small-inducible cytokine A2; SMC CF; SMC-CF; SMCCF.
WB, ELISA, IHC-P, IHC-F, FC, ICC/IF
Human, Rat
MCP1 Antibody is an unconjugated, approximately 11 kDa, rabbit-derived, anti-MCP1 polyclonal antibody. MCP1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, rat, and predicted: mouse, dog, pig, horse, rabbit background without labeling.
alpha smooth muscle Actin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 42 kDa, targeting to alpha smooth muscle Actin. It can be used for WB, IF-Cell, IF-Tissue, IHC-P, FC, mIHC assays with tag free, in the background of Human, Mouse,Rat.
HAUSP/USP7 Antibody (YA5204) is a mouse-derived and non-conjugated monoclonal antibody, targeting to HAUSP/USP7. It can be applicated for WB assays, in the background of human.
Fas(C-term) Antibody (YA5207) is a mouse-derived and non-conjugated monoclonal antibody, targeting to FAS (C-term). It can be applicated for WB assays, in the background of human.
FLJ35621; FLJ37491; NAD dependent deacetylase sirtuin 2; NAD-dependent deacetylase sirtuin-2; NAD-dependent protein deacetylase sirtuin-2; Regulatory protein SIR2 homolog 2; Silencing information regulator 2 like; Silent information regulator 2; Silent mating type information regulation 2; Silent mating type information regulation 2 homolog; SIR 2; SIR2; SIR2 like; SIR2 like protein 2; Sir2 related protein type 2; SIR2, S. cerevisiae, homolog-loke 2; SIR2-like protein 2; SIR2L; SIR2L2; SIRT 2; SIRT2; SIRT2_human; Sirtuin; silent mating type information regulation 2 homolog; 2; S.cerevisiae; Sirtuin 2; Sirtuin type 2; Sirtuin2.
WB, ICC/IF
Human, Mouse, Rat
SirT2 Antibody (YA5213) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SirT2. It can be applicated for WB, ICC/IF assays, in the background of human, mouse, rat.
2310012M03Rik; 3'-Tab1; MAP3K7IP 1; MAP3K7IP1; MGC57664; Mitogen activated protein kinase kinase kinase 7 interacting protein 1; Mitogen-activated protein kinase kinase kinase 7-interacting protein 1; TAB 1; TAB1; TAB1_human; TAK1 binding protein 1; TAK1-binding protein 1; TGF beta activated kinase 1 binding protein 1; TGF-beta activated kinase 1/MAP3K7 binding protein 1; TGF-beta-activated kinase 1 and MAP3K7-binding protein 1; TGF-beta-activated kinase 1-binding protein 1; Transforming growth factor beta activated kinase binding protein 1.
WB
Human
TAB1(N-term) Antibody (YA5232) is a mouse-derived and non-conjugated monoclonal antibody, targeting to TAB1 (N-term). It can be applicated for WB assays, in the background of human.
AIP 1; AIP1; API 2; API2; API2; Apoptosis inhibitor 2; Baculoviral IAP repeat containing 3; Baculoviral IAP repeat containing protein 3; Baculoviral IAP repeat-containing protein 3; BIRC 3; BIRC3; BIRC3; BIRC3_human; C IAP2; C-IAP2; CIAP 2; CIAP 2; CIAP2; HAIP 1; HAIP1; HAIP1; HIAP 1; HIAP-1; HIAP1; IAP homolog C; IAP-1; Inhibitor of apoptosis protein 1; Inhibitor of apoptosis protein 1; MALT 2; MALT2; Mammalian IAP homolog C; MIHC; MIHC; RING finger protein 49; RNF49; TNFR2 TRAF signaling complex protein 1; TNFR2 TRAF signalling complex protein; TNFR2-TRAF-signaling complex protein 1.
WB
Human, Monkey
cIAP2 Antibody (YA5260) is a mouse-derived and non-conjugated monoclonal antibody, targeting to cIAP2. It can be applicated for WB assays, in the background of human, monkey.
DKFZp686C01211; DNA binding factor KBF1; DNA binding factor KBF1 EBP1; DNA-binding factor KBF1; EBP 1; EBP-1; EBP1; KBF1; MGC54151; NF kappa B; NF kappaB; NF kappabeta; NF kB1; NFkappaB; NFKB 1; NFKB p105; NFKB p50; Nfkb1; NFKB1_human; Nuclear factor kappa B DNA binding subunit; Nuclear factor kappa-B, subunit 1; Nuclear factor NF kappa B p105 subunit; Nuclear factor NF kappa B p50 subunit; Nuclear factor NF-kappa-B p50 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; p105; p50; p84/NF-kappa-B1 p98.
WB
Human
NF-KB p105/p50 Antibody (YA5331) is a mouse-derived and non-conjugated monoclonal antibody, targeting to NFKB1. It can be applicated for WB assays, in the background of human.
CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_human; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12
IHC-P, WB, ICC/IF, ELISA
Human
Cytokeratin 6 Antibody (YA5518) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 6. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
Melanoma gp100 Antibody (YA5625) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HMB45. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse.
CK 6A; CK 6B; CK 6C; CK 6D; CK 6E; CK-6B; CK-6C; CK-6E; Cytokeratin 6a; Cytokeratin 6B; Cytokeratin 6C; Cytokeratin 6D; Cytokeratin 6E; Cytokeratin-6B; Cytokeratin-6C; Cytokeratin-6E; K2C6C_human; K6a keratin; K6b keratin; K6C; K6c keratin; K6d keratin; K6e keratin; Keratin; Keratin K6h; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; Keratin type II cytoskeletal 6C; Keratin type II cytoskeletal 6D; Keratin type II cytoskeletal 6E; Keratin-6C; KRT6A; KRT6B; KRT6C; KRT6D; KRT6E; type II cytoskeletal 6C; Type-II keratin Kb12
IHC-P, ELISA
Human
Cytokeratin 6 Antibody (YA5682) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Cytokeratin 6. It can be applicated for IHC-P, ELISA assays, in the background of human.
Melanoma gp100 Antibody (YA5749) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HMB45. It can be applicated for IHC-P, ELISA assays, in the background of human, mouse.
Histone H3 (tri methyl K9) Antibody is a non-conjugated and Mouse origined monoclonal antibody about 15 kDa, targeting to Histone H3 (tri methyl K9). It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse, Rat.
I kappa B kinase 2; I kappa B kinase beta; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK 2; IKK B; IKK beta; IKK-B; IKK-beta; IKK2; IKKB; IKKB_human; IMD15; Inhibitor of kappa light chain gene enhancer in B cells; Inhibitor of kappa light polypeptide gene enhancer in B cells; Inhibitor of kappa light polypeptide gene enhancer in B cells kinase beta; Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta; Inhibitor of nuclear factor kappa B kinase beta subunit; Inhibitor of nuclear factor kappa B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit beta; MGC131801; NFKBIKB; Nuclear factor NF kappa B inhibitor kinase beta; Nuclear factor NF-kappa-B inhibitor kinase beta; Nuclear factor of kappa light chain gene enhancer in B cells inhibitor.
WB
Human, Rat
IKK beta Antibody (YA5222) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IKKβ. It can be applicated for WB assays, in the background of human, rat.
SMARCC1 Antibody (YA5256) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SMARCC1. It can be applicated for WB assays, in the background of human.
422 protein; Cardiac Fatty Acid Binding Protein; FABP 11; FABP 3; FABP11; FABP3; FABPH_human; fatty acid binding protein 11; Fatty acid binding protein 3; Fatty acid binding protein 3 muscle and heart; Fatty acid binding protein 3 muscle and heart mammary derived growth inhibitor; Fatty acid binding protein 3 muscle; Fatty acid binding protein 3, muscle and heart; mammary derived growth inhibitor; Fatty acid binding protein 3, muscle; Fatty acid binding protein heart; Fatty acid binding protein, heart; Fatty acid binding protein, muscle and heart; Fatty acid binding protein, skeletal muscle; Fatty acid-binding protein 3; Fatty acid-binding protein; H FABP; H-FABP; heart; Heart type fatty acid binding protein; Heart-type fatty acid-binding protein; M FABP; M-FABP; mammary derived growth inhibitor; Mammary-derived growth inhibitor; MDGI; Muscle fatty acid binding protein; Muscle fatty acid-binding protein; mylein protein P2 homolog; O FABP; OTTHUMP00000003898; P2 adopocyte protein.
ELISA
Human
FABP3 Antibody (YA5307) is a mouse-derived and non-conjugated monoclonal antibody, targeting to H-FABP. It can be applicated for sELISA, Detector assays, in the background of human.
Sodium Potassium ATPase Antibody (YA6357) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Sodium Potassium ATPase. It can be applicated for WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC assays, in the background of human, mouse, rat.
ERK2 Antibody (YA6346) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ERK1/2. It can be applicated for WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, FC assays, in the background of human, mouse, rat.
phospho-PI3 Kinase p110 beta (Ser1070) Antibody is an unconjugated, approximately 110-123 kDa, rabbit-derived, anti-phospho-PI3 Kinase p110 beta (Ser1070) polyclonal antibody. phospho-PI3 Kinase p110 beta (Ser1070) Antibody can be used for: WB, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, guinea pig background without labeling.
Phospho-NF-KB p65 (Ser536) ;
NF-kB p65 (phospho S536); p-NF-κB p65(Phospho-Ser536); RELA(phospho S536); NF kB P65; NF-kB p65; NFKBp65; NF-κBp65; p65 NF kappaB; p65 NFkB; NFKBp65; RELA; Transcription Factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A; p65NFKB; Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NFKB 3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells; TF65_human. NFκB-p65; NFκB p65; NF κB-p65; NFκBp65
WB, IHC-P, FC
Human, Mouse, Rat
Phospho-NF-κB p65 (Ser536) Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Phospho-NF-κB p65 (Ser536), with a predicted molecular weight of 61 kDa. Phospho-NF-κB p65 (Ser536) Antibody can be used for WB, IHC-P, FC experiments in human, mouse, rat backgrounds.
60S acidic ribosomal protein P1; AA409079; AI325195; AU020965; HSSB; ik:tdsubc_2g1; M(2)21C; MGC137236; OTTHUMP00000004008; p32; p34; RCJMB04_6d17 replication protein A2; 32kDa; REPA 2; REPA1; REPA2; Replication factor A protein 2; Replication protein A 32 kDa subunit; Replication protein A 32kDa subunit; Replication protein A 34 kDa subunit; Replication protein A; replication protein A1 (70kD); Replication Protein A2 (32kDa); Replication protein A2 32kD; Replication protein A2 32kDa; Replication protein A2; Replication protein A2; 32kDa; RF A; RF-A protein 2; Rf-A2; RFA; RFA2_human; RP A; RP-A p32; RP-A p34; RP21C; RPA 2; RPA 32; RPA; RPA2; RPA32; RPA34; RPA70; RpLP1; RpP2; xx:tdsubc_2g1; zgc:109822.
WB, IP
Human, Mouse, Rat
Phospho-RPA32/RPA2 (Thr21) Antibody (YA2720) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2720), targeting Phospho-RPA2 (Thr21), with a predicted molecular weight of 29 kDa (observed band size: 32 kDa). Phospho-RPA32/RPA2 (Thr21) Antibody (YA2720) can be used for WB, IP experiment in human, mouse, rat background.
Ac2-121; AL022808; E3 ubiquitin-protein ligase UHRF1; FLJ21925; Hnp95 Huhrf1; HuNp95; ICBP90; Inverted CCAAT box binding protein of 90 kDa; Inverted CCAAT box binding protein, 90-Kd; Inverted CCAAT box-binding protein of 90 kDa; Liver regeneration-related protein LRRG126; MGC138707; NP95; Nuclear phosphoprotein, 95-KD; Nuclear protein 95; Nuclear zinc finger protein Np95; RING finger protein 106; RNF106; Transcription factor ICBP90; Ubiquitin like containing PHD and RING finger domains protein 1; Ubiquitin like PHD and RING finger domain containing protein 1; Ubiquitin-like PHD and RING finger domain-containing protein 1; Ubiquitin-like protein containing PHD and RING finger domains 1; Ubiquitin-like with PHD and ring finger domains 1; Ubiquitin-like, containing PHD and RING finger domains, 1; Ubiquitin-like-containing PHD and RING finger domains protein 1; UHRF1; UHRF1_human.
WB
Human, Mouse
UHRF1(N-term) Antibody (YA5175) is a mouse-derived and non-conjugated monoclonal antibody, targeting to UHRF1 (N-term). It can be applicated for WB assays, in the background of human, mouse.
MEK1 Antibody (YA5208) is a mouse-derived and non-conjugated monoclonal antibody, targeting to MEK1. It can be applicated for WB assays, in the background of human.
60S acidic ribosomal protein P1; AA409079; AI325195; AU020965; HSSB; ik:tdsubc_2g1; M; 2; 21C; MGC137236; OTTHUMP00000004008; p32; p34; RCJMB04_6d17 replication protein A2, 32kDa; REPA 2; REPA1; REPA2; Replication factor A protein 2; Replication protein A 32 kDa subunit; Replication protein A 32kDa subunit; Replication protein A 34 kDa subunit; Replication protein A; replication protein A1; 70kD; Replication Protein A2; 32kDa; Replication protein A2 32kD; Replication protein A2 32kDa; Replication protein A2; Replication protein A2, 32kDa; RF A; RF-A protein 2; Rf-A2; RFA; RFA2_human; RP A; RP-A p32; RP-A p34; RP21C; RPA 2; RPA 32; RPA; RPA2; RPA32; RPA34; RPA70; RpLP1; RpP2; xx:tdsubc_2g1; zgc:109822.
WB, IP, ICC
Human
RPA32/RPA2 Antibody (YA5283) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RFA2. It can be applicated for WB, IP, ICC assays, in the background of human.
E2F-1 Antibody (YA5305) is a mouse-derived and non-conjugated monoclonal antibody, targeting to E2F-1. It can be applicated for WB, ICC/IF, IP assays, in the background of human, rat.
EIF2S1 Antibody (YA5308) is a mouse-derived and non-conjugated monoclonal antibody, targeting to eIF2α. It can be applicated for WB, ICC/IF, IP assays, in the background of human, mouse, rat.
COX2 Antibody (YA5631) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to COX2. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
MEK3 Antibody (YA3214) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3214), targeting MEK3, with a predicted molecular weight of 39 kDa (observed band size: 38-40 kDa). MEK3 Antibody (YA3214) can be used for WB, ICC/IF,IP experiment in human, mouse, rat background.
p38 (phospho T180 + Y182); p-p38 (phospho T180 + Y182); p38 (phospho T180/Y182); CSAID Binding Protein 1; CSAID binding protein; CSAID-binding protein; Csaids binding protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB 1; CSPB1; Cytokine suppressive anti inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; EXIP; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAPK14; MAX interacting protein 2; MAX-interacting protein 2; Mitogen Activated Protein Kinase 14; Mitogen activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38 alpha; MK14_human; Mxi 2; Mxi2; p38 ALPHA; p38; p38 MAP kinase; p38 MAPK; p38 mitogen activated protein kinase; p38ALPHA; p38alpha Exip; PRKM14; PRKM15; RK; SAPK 2A; SAPK2A; Stress Activated Protein Kinase 2A.
WB, IHC-P, FC, ICC/IF, ELISA
Human, Mouse
Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody is a rabbit-derived non-conjugated IgG antibody, targeting Phospho-p38 (Thr180+Tyr182), with a predicted molecular weight of 41 kDa . Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody can be used for WB, IHC-P, FC, ICC/IF, ELISA experiments in human, mouse backgrounds.
Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD 262; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death domain containing receptor for TRAIL/Apo2L; Death receptor 5; DR 5; DR5; Fas like protein precursor; KILLER; KILLER/DR5; OTTHUMP00000123492; OTTHUMP00000123493; p53 regulated DNA damage inducible cell death receptor; killer; p53 regulated DNA damage inducible cell death receptor; killer; TNF related apoptosis inducing ligand receptor 2; TNF related apoptosis inducing ligand receptor 2; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TR10B_human; TRAIL R2; TRAIL receptor 2; TRAIL-R2; TRAILR2; TRANCER; TRICK2; TRICK2A; TRICK2B; TRICKB; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor superfamily member 10b; Tumor necrosis factor receptor superfamily, member 10b; ZTNFR9.
WB, ICC
Human, Mouse
DR5 Antibody (YA5269) is a mouse-derived and non-conjugated monoclonal antibody, targeting to DR5. It can be applicated for WB, ICC assays, in the background of human, mouse.
ATP dependent DNA helicase II 80 kDa subunit; ATP dependent DNA helicase II 86 Kd subunit; ATP dependent DNA helicase II; ATP-dependent DNA helicase 2 subunit 2; ATP-dependent DNA helicase II 80 kDa subunit; CTC box binding factor 85 kDa; CTC box-binding factor 85 kDa subunit; CTC85; CTCBF; DNA repair protein XRCC5; Double strand break rejoining; FLJ39089; G22P2; KARP 1; KARP1; Ku 80; Ku autoantigen 80kDa; Ku80; Ku86; Ku86 autoantigen related protein 1; KUB 2; KUB2; Lupus Ku autoantigen protein p86; NFIV; Nuclear factor IV; Thyroid lupus autoantigen; Thyroid-lupus autoantigen; TLAA; X ray repair complementing defective repair in Chinese hamster cells 5; double strand break rejoining; X-ray repair complementing defective repair in Chinese hamster cells 5; double-strand-break rejoining; X-ray repair cross-complementing protein 5; Xray repair complementing defective repair in Chinese hamster cells 5; XRCC 5; XRCC5; XRCC5_human.
WB, ICC/IF, IP
Human, Monkey
Ku80 Antibody (YA5291) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Ku-80. It can be applicated for WB, ICC/IF, IP assays, in the background of human, monkey.
ATP dependent helicase SMARCA4; ATP-dependent helicase SMARCA4; BAF 190; BAF190; BAF190A; Brahma protein homolog 1; Brahma protein like 1; BRG1; BRG1 associated factor 190A; BRG1 protein; BRG1-associated factor 190A; BRM/SWI2 related gene 1; Global transcription activator homologous sequence; global transcription activator snf2l4; Homeotic gene regulator; hSNF2b; Mitotic growth and transcription activator; MRD16; Nuclear protein GRB1; Protein brahma homolog 1; Protein BRG-1; Protein BRG1; RTPS2; SMARC A4; SMARCA4; SMCA4_human; SNF2; SNF2 beta; SNF2 like 4; SNF2-beta; SNF2B; SNF2L4; SNF2LB; Sucrose nonfermenting like 4; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 4; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4; SWI2; Transcription activator BRG1.
WB, ICC/IF, IP
Human, Mouse
BRG1 Antibody (YA5293) is a mouse-derived and non-conjugated monoclonal antibody, targeting to BRG1. It can be applicated for WB, ICC/IF, IP assays, in the background of human, mouse.
Histone H3 Antibody (YA6364) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Histone H3. It can be applicated for IHC-P, IHC-F, IF-Tissue, WB, FC, ICC/IF assays, in the background of human, rat, mouse.
5''-deoxyribose-5-phosphate lyase Ku70; 5''-dRP lyase Ku70; 70 kDa subunit of Ku antigen; ATP dependent DNA helicase 2 subunit 1; ATP dependent DNA helicase II 70 kDa subunit; ATP-dependent DNA helicase 2 subunit 1; ATP-dependent DNA helicase II 70 kDa subunit; CTC box binding factor 75 kDa subunit; CTC box-binding factor 75 kDa subunit; CTC75; CTCBF; CTCBF; DNA repair protein XRCC6; G22P1; Ku 70; Ku autoantigen 70kDa; Ku autoantigen p70 subunit; Ku autoantigen, 70kDa; Ku p70; Ku70; Ku70 DNA binding component of DNA-dependent proteinkinase complex; thyroid autoantigen 70 kDa; Kup70; Lupus Ku autoantigen protein p70; ML8; Thyroid autoantigen 70kD; Ku antigen; Thyroid autoantigen; Thyroid lupus autoantigen; Thyroid lupus autoantigen; Thyroid lupus autoantigen p70; Thyroid-lupus autoantigen; TLAA; TLAA; X ray repair complementing defective repair in Chinese hamster cells 6; X-ray repair complementing defective repair in Chinese hamster cells 6; X-ray repair cross-complementing protein 6; XRCC 6; XRCC6; XRCC6_human.
WB, ICC/IF, IP
Human, Monkey
Ku70 Antibody (YA5289) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Ku70/XRCC6. It can be applicated for WB, ICC/IF, IP assays, in the background of human, monkey.
Mucin 1 Antibody (YA5526) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mucin 1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.
PI3 Kinase p110 alpha/PIK3CA Antibody (YA5770) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PI3K(p110α). It can be applicated for WB, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
PI3 Kinase p85 beta Antibody (YA5277) is a mouse-derived and non-conjugated monoclonal antibody, targeting to PI3K(p85β). It can be applicated for WB assays, in the background of human, mouse, rat.
Ala-IL-8; 77; Ser-IL-8; 72; 3 10C; 310C; AMCF 1; AMCF1; b ENAP; Bbeta thromboglobulin like protein; Beta thromboglobulin like protein; C-X-C motif chemokine 8; CXC chemokine ligand 8; CXCL 8; CXCL8; Emoctakin; GCP 1; GCP-1; GCP/IL-8 protein I; GCP/IL-8 protein II; GCP/IL-8 protein III; GCP/IL-8 protein IV; GCP/IL-8 protein V; GCP/IL-8 protein VI; GCP1; Granulocyte chemotactic protein 1; IL 8; IL-8; IL-8; 1-77; IL-8; 9-77; IL8; IL8/NAP1 form I; IL8/NAP1 form II; IL8/NAP1 form III; IL8/NAP1 form IV; IL8/NAP1 form V; IL8/NAP1 form VI; IL8_human; Inteleukin 8; Interleukin8; K 60; K60; LECT; LUCT; Lymphocyte derived neutrophil activating factor; Lymphocyte-derived neutrophil-activating factor; LYNAP; MDNCF; MDNCF-b; MDNCF-c; MONAP; Monocyte derived neutrophil activating peptide; Monocyte derived neutrophil activating protein; Monocyte derived neutrophil chemotactic factor; Monocyte-derived neutrophil chemotactic factor; Monocyte-derived neutrophil-activating peptide; NAF; NAP 1; NAP-1; NAP1; Neutrophil activating factor; Neutrophil activating peptide 1; Neutrophil activating protein 1; Neutrophil-activating factor; Neutrophil-activating protein 1; Protein 3 10C; Protein 3-10C; SCYB 8; SCYB8; Small inducible cytokine subfamily B member 8; T cell chemotactic factor; T-cell chemotactic factor; TSG 1; TSG1;
WB, ELISA
Human
IL-8/CXCL8 Antibody (YA5190) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IL-8. It can be applicated for WB, ELISA assays, in the background of human.
Human IL10 mRNA encodes the human interleukin 10 (IL10) protein, a cytokine that produces primarily by monocytes and to a lesser extent by lymphocytes. IL10 has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II Ags, and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production.
Inquiry Online
Your information is safe with us. * Required Fields.
